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Background: Diagnosis of lung cancer frequently occurs in its later stages. Low-dose computed
tomography (LDCT) could detect lung cancer early.
Objectives: To estimate the clinical effectiveness and cost-effectiveness of LDCT lung cancer screening in
high-risk populations.
Data sources: Bibliographic sources included MEDLINE, EMBASE, Web of Science and The
Cochrane Library.
Methods: Clinical effectiveness – a systematic review of randomised controlled trials (RCTs) comparing
LDCT screening programmes with usual care (no screening) or other imaging screening programmes
[such as chest X-ray (CXR)] was conducted. Bibliographic sources included MEDLINE, EMBASE, Web of
Science and The Cochrane Library. Meta-analyses, including network meta-analyses, were performed.
Cost-effectiveness – an independent economic model employing discrete event simulation and using a
natural history model calibrated to results from a large RCT was developed. There were 12 different
population eligibility criteria and four intervention frequencies [(1) single screen, (2) triple screen, (3) annual
screening and (4) biennial screening] and a no-screening control arm.
Results: Clinical effectiveness – 12 RCTs were included, four of which currently contribute evidence
on mortality. Meta-analysis of these demonstrated that LDCT, with ≤ 9.80 years of follow-up, was
associated with a non-statistically significant decrease in lung cancer mortality (pooled relative risk 0.94,
95% confidence interval 0.74 to 1.19). The findings also showed that LDCT screening demonstrated a
non-statistically significant increase in all-cause mortality. Given the considerable heterogeneity detected
between studies for both outcomes, the results should be treated with caution. Network meta-analysis,
including six RCTs, was performed to assess the relative clinical effectiveness of LDCT, CXR and usual care.
The results showed that LDCT was ranked as the best screening strategy in terms of lung cancer mortality
reduction. CXR had a 99.7% probability of being the worst intervention and usual care was ranked second.
Cost-effectiveness – screening programmes are predicted to be more effective than no screening, reduce lung
cancer mortality and result in more lung cancer diagnoses. Screening programmes also increase costs.
Screening for lung cancer is unlikely to be cost-effective at a threshold of £20,000/quality-adjusted life-year
(QALY), but may be cost-effective at a threshold of £30,000/QALY. The incremental cost-effectiveness ratio
for a single screen in smokers aged 60–75 years with at least a 3% risk of lung cancer is £28,169 per QALY.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
v
ABSTRACT
viSensitivity and scenario analyses were conducted. Screening was only cost-effective at a threshold of
£20,000/QALY in only a minority of analyses.
Limitations: Clinical effectiveness – the largest of the included RCTs compared LDCT with CXR screening
rather than no screening. Cost-effectiveness – a representative cost to the NHS of lung cancer has not
been recently estimated according to key variables such as stage at diagnosis. Certain costs associated with
running a screening programme have not been included.
Conclusions: LDCT screening may be clinically effective in reducing lung cancer mortality, but there is
considerable uncertainty. There is evidence that a single round of screening could be considered
cost-effective at conventional thresholds, but there is significant uncertainty about the effect on costs
and the magnitude of benefits.
Future work: Clinical effectiveness and cost-effectiveness estimates should be updated with the
anticipated results from several ongoing RCTs [particularly the NEderlands Leuvens Longkanker Screenings
ONderzoek (NELSON) screening trial].
Study registration: This study is registered as PROSPERO CRD42016048530.
Funding: The National Institute for Health Research Health Technology Assessment programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Absorbed dose The physical amount of radiation absorbed by matter or tissue, without accounting for
the biological impact of the radiation.
Attenuation characteristics X-rays are normally fired from the source to the detectors. Each individual
placed between the source and the detectors absorbs X-rays differently. The number of X-rays that finally
reach the detectors affects the resultant images.
Automatic tube current modulation The computed tomography machine changes the output of tube
current based on the individual biological make-up (e.g. anteroposterior diameter of the thorax).
Axial (non-helical/non-spiral) acquisition This technique is also known as the ‘step-and-shoot’ or
‘scan–move–scan’ technique. All data are collected in the z-axis direction of each slice before moving to the
next position. There is a correlation between the z position, where data are collected, and reconstructed slices.
Background radiation The combined ionising radiation from both natural and artificial sources. Some
areas might have higher background radiation owing to environmental factors (e.g. radon-affected areas
in Cornwall, UK).
Baseline screening The first time screening is conducted in a population (it gives an estimate of the
prevalence of the disease), also known as prevalence screening.
Breathing artefact Imaging of the lung is susceptible to movement artefact due to respiration. The part
of the lung near the diaphragm produces more movement artefact than the lung apices.
Collimation In single-slice computed tomography, the X-ray beam collimation is the z-axis width of the
X-ray beam at the centre of the gantry rotation, which is the same as slice thickness. This relationship is
not true for multislice computed tomography. For dosimetry purpose, multislice computed tomography is
assumed to behave like single-slice computed tomography.
Computed tomography An imaging technology, usually based on X-rays, that reconstructs the density
of cross-sectional slices of an object from a number of projections obtained from different angles.
Confidence interval A range generated from a sample with a specified probability of containing the
population statistic of interest (e.g. 95% of 95% confidence intervals for the mean are expected to
contain the population mean).
Conversion factor Tissue weighting factor is a measure of the stochastic risk of ionising radiation. It
varies among different tissue and organs. Conversion factor is body-part specific and accounts for the
variable radiosensitivities.
Cost-effective An intervention is cost-effective compared with a comparator if it provides more health at
an acceptable cost (according to a threshold) or provides significant savings with an acceptable loss of
health; an intervention is cost-effective in a fully incremental analysis if it is cost-effective compared with
all comparators.
Credible interval A Bayesian equivalent of the confidence interval, which is a range containing the
specified proportion of the probability mass of the posterior distribution.
Dominated An intervention is dominated by a comparator if it is more costly and less effective.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
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GLOSSARY
xxDose length product An output of computed tomography radiation dose from a computed tomography
machine. This is calculated using the volume of computed tomography dose index multiplied by scan
length (slice thickness multiplied by number of slices) in centimetres.
Effective dose A measure of the health effect of ionising radiation that accounts for the different health
effects of different types of radiation and different tissues (if the whole body is not being uniformly irradiated).
Equivalent dose A measure of the health effect of ionising radiation that accounts for the different
health effects of different types of radiation, but not the variation of health effect according to the tissue
being irradiated.
Extendedly dominated An intervention is extendedly dominated by two comparators if it would be
dominated by a linear combination of the two comparators.
False-negative (test result) A negative test result when the disease was in fact present.
False-positive (test result) A positive test result (leading to further testing or treatment) when the
disease was in fact absent.
Fixed-tube current The tube current is not adjusted according to biological factors for all individuals.
Gray The SI-derived unit for the absorption of radiation energy; 1 gray = 1 joule of radiation energy per
kilogram of matter.
Helical/spiral acquisition Rotation and table movement occur at the same time with continuous data
acquisition. In contrast to axial acquisition, there is no correlation between z positions, where the data are
collected, and reconstructed slices.
Image noise Computed tomography image noise depends on the number of X-rays contributing to the
image. Low image noise enables the ability to resolve low-contrast structures.
Incidence The rate at which members of a population are newly diagnosed with a disease, or newly
develop a disease.
Incidence screening Subsequent rounds of screening within a population; if the time between screening
rounds is fixed, this can give an estimate of the incidence.
Indeterminate When the test is unable to classify the disease as being present or absent, usually resulting
in further testing in the future.
Intention to treat A method of statistical analysis in which the groups for statistical comparison are
defined by the intended (often randomised) treatment, even if a different treatment or no treatment
was actually received.
Interval cancer A cancer that is diagnosed after one or more screening rounds and before a scheduled
screening round, but not as a consequence of screening.
Lead-time bias Screening tends to diagnose disease earlier, which can appear to result in prolonged
survival (or prolonged time to some event of interest), although the actual date of the event has not
been delayed by screening.
Length bias Screening tends to diagnose slower progressing, less aggressive disease, which leads to
greater apparent survival compared with non-screen-detected disease.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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(sophisticated averages).
Multislice Other names include multidetector row computed tomography and multirow computed
tomography. The design of the detector is in contrast to single-slice technology (see Single-slice computed
tomography), where a long element is divided into several smaller detectors in the z-axis direction.
Negative predictive value The probability that an individual does not have the target condition, given
that the test is negative.
Net monetary benefit The value of an intervention, estimated by valuing outcomes according to the
willingness to pay and subtracting the costs of the intervention.
Network meta-analysis Meta-analysis methods that can combine results from studies with different sets
of interventions and comparators.
Over-diagnosis When a disease is detected by screening that would not have clinically presented prior to
death from other causes in the absence of screening (an extreme form of lead-time and length bias).
Pack-year A composite measure of smoking history including the duration and intensity of smoking;
one pack-year = one pack (20 cigarettes) per day for 1 year.
Pitch (in axial scanning) Also known as detector pitch. This is the distance that the table travels in one
full gantry rotation divided by beam collimation.
Pitch (in helical scanning) Also known as beam pitch. Helical pitch is calculated as the movement of the
table per rotation divided by slice thickness. Pitches of < 1 mean that X-ray beams overlap/double irradiation,
whereas pitches of > 1 mean that there are gaps between the X-ray beams.
Positive predictive value The probability that an individual has the target condition, given that the test
result is positive.
Prevalence The proportion of people in a population who have a disease.
Prevalence screening See Baseline screening.
Probabilistic sensitivity analysis A method for exploring the impact of parameter uncertainty, across all
parameters, on decision uncertainty.
Radiosensitivity The harmful effect of ionising radiation depends on the relative susceptibility of tissues
and organs.
Randomised controlled trial An experiment in which people are randomly assigned to receive one of
two or more interventions, and are then followed up to see the effects of the treatment.
Sensitivity The probability that a test conducted in an individual with the target condition will be positive.
Sievert The SI-derived unit for the health effect of ionising radiation, the unit for equivalent dose and
effective dose.
Single-slice computed tomography Other names include single-detector computed tomography and
single row computed tomography. The design of the detector array contains one long element in the
z-axis direction.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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xxiiSlice thickness In multislice computed tomography, slice thickness is based on the detector configuration.
In single-slice computed tomography, slice thickness is determined by beam collimators.
Specificity The probability that a test conducted in an individual without the target condition will
be negative.
Test failure When a test is not completed as planned (e.g. as a result of operator failure or
equipment failure).
Tube current (in helical scanning) Indicates the number of electrons flowing from the cathode to
anode. Milliamperes is the unit of measurement.
Tube current time product (in helical scanning) The product of tube current and exposure time.
Milliamperes-second (mAs) is the unit of measurement.
Volumetric analysis Lung nodule on computed tomography thorax was traditionally measured axially to
produce a two-dimensional measurement that subsequently served as the reference point for subsequent
investigations. Different companies designed software to incorporate three-dimensional information to
produce a volume measurement. Specifically, the doubling of volume measurement is being proposed as
the indicator of significant change.
Willingness to pay The rate at which the decision-maker is prepared to pay for some outcome, which
may be related to the ability of the health service to disinvest from current technologies.
z-axis resolution (in helical scanning) The z-axis is the longitudinal axis in helical computed
tomography. Between the start and the end position of the data acquisition, the raw data can be
reconstructed retrospectively at short or at longer intervals. A number of factors affect the resolution,
including pitch, slice thickness and method of reconstruction.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69List of abbreviations© Q
Hea
jour
be a
ParkACRIN American College of Radiology
Imaging Network
BMI body mass index
CDSR Cochrane Database of Systematic
Reviews
CENTRAL Cochrane Central Register of
Controlled Trials
CHEC Consensus on Health Economic
Criteria
CI confidence interval
CINAHL Cumulative Index to Nursing and
Allied Health Literature
COPD chronic obstructive pulmonary
disease
COS-LC consequences of screening
lung cancer
CPCI-S Conference Proceedings Citation
Index – Science
CrI credible interval
CT computed tomography
CXR chest X-ray
DANTE Detection and Screening of Early
Lung Cancer with Novel Imaging
Technology and Molecular Essays
DES discrete event simulation
DLCST Danish Lung Cancer
Screening Trial
ELCAP Early Lung Cancer Action Project
EQ-5D EuroQoL 5-Dimensions
EU European Union
[18F]FDG-PET fludeoxyglucose (18F) positron
emission tomography
FEV1 forced expiratory volume in
1 second
GP general practitioner
HMIC Health Management Information
Consortium
HR hazard ratioueen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et a
lth and Social Care. This issue may be freely reproduced for the purposes of private rese
nals provided that suitable acknowledgement is made and the reproduction is not assoc
ddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Tr
, Southampton SO16 7NS, UK.HRG Healthcare Resource Group
HRQoL health-related quality of life
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
IES impact of event scale
INMB incremental net monetary benefit
ISRCTN International Standard Randomised
Controlled Trial Number
ITALUNG Italian lung cancer screening
LCNEC large cell neuroendocrine carcinoma
LDCT low-dose computed tomography
LLPv2 Liverpool Lung Project version 2
MCMC Markov chain Monte Carlo
MDT multidisciplinary team
MILD Multicentric Italian Lung Detection
MRI magnetic resonance imaging
NELSON NEderlands Leuvens Longkanker
Screenings ONderzoek
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NLST National Lung Screening Trial
NMB net monetary benefit
NNS number needed to screen
NSC National Screening Committee
NSCLC non-small cell lung cancer
OR odds ratio
PenPIG Peninsula Public Involvement Group
PenTAG Peninsula Technology Assessment
Group
PET-CT positron emission tomography–
computerised tomography
PLuSS Pittsburgh Lung Screening Study
PPI patient and public involvementl. under the terms of a commissioning contract issued by the Secretary of State for
arch and study and extracts (or indeed, the full report) may be included in professional
iated with any form of advertising. Applications for commercial reproduction should
ials and Studies Coordinating Centre, Alpha House, University of Southampton Science
xxiii
LIST OF ABBREVIATIONS
NIH
xxivPRISMA Preferred Reporting Items for
Systematic reviews and
Meta-Analyses
PSA probabilistic sensitivity analysis
PSS Personal Social Services
QALY quality-adjusted life-year
QoL quality of life
RCT randomised controlled trial
RR relative risk
SCI Science Citation Index
SCLC small cell lung cancer
SD standard deviationR Journals Library www.journalslibrary.nihr.ac.ukSES socioeconomic status
SF-12 Short Form questionnaire-12 items
SF-36 Short Form questionnaire-36 items
SF-6D Short Form questionnaire-6
Dimensions
STAI-6 Spielberger State–Trait Anxiety
Inventory, six-item Short Form
TNM tumour, node, metastasis
TTO time trade-off
UKLS UK Lung Cancer Screening Trial
VAS visual analogue scale
WHO World Health Organization
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Plain English summary
Lung cancer is a leading cause of death among smokers in the UK. Many people each year arediagnosed with lung cancer and experience poor outcomes because it is usually diagnosed in later
stages of the disease when cure is unlikely. If lung cancer can be found earlier it may reduce the number
of people dying from lung cancer and give people with lung cancer better outcomes.
Computed tomography (CT) is a technique that uses X-rays to produce images of cross-sections through a
person’s body, and this can show up lung cancers. Repeated exposure to X-ray radiation could be harmful.
Low-dose CT (LDCT) reduces the amount of radiation to the point that it may, on balance, be safe to receive
as a screening test, that is, a test to be used in people who may not have any symptoms of lung cancer.
We searched for high-quality trials [randomised controlled trials (RCTs)] of LDCT as a screening test for
lung cancer. We found 12 RCTs, but only six of these currently provide evidence on key patient outcomes.
More will do so in the future. We found some evidence that LDCT could reduce deaths from lung cancer,
but this evidence was mixed and no firm conclusion could be reached.
We estimated whether or not screening for lung cancer with LDCT could be a good use of NHS resources,
assuming that there is a reduction in death from lung cancer. It may or may not be cost-effective to screen
once for lung cancer in people aged 60–75 years with a high risk of lung cancer, depending on the
threshold used by policy-makers.
There are trials of lung cancer screening expected to publish results within the next few years, and these
might make the evidence on clinical effectiveness and cost-effectiveness clearer.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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Approximately 46,400 cases of lung cancer were diagnosed in the UK in 2014, representing 13% of the
total number of cancer cases. Diagnosis of lung cancer frequently occurs in its later stages. Low-dose
computed tomography (LDCT) could detect lung cancer in its early stages, but its clinical effectiveness and
cost-effectiveness in a UK national screening setting are uncertain.Objectives
This assessment aims to evaluate the clinical effectiveness and cost-effectiveness of using LDCT in
screening programmes for lung cancers in high-risk populations.Methods
Clinical effectiveness
For the systematic review, a range of bibliographic databases including MEDLINE (via Ovid), MEDLINE
In-Process & Other Non-Indexed Citations (via Ovid), EMBASE (via Ovid), PsycINFO (via Ovid), Web of Science
(via Clarivate Analytics), CDSR (Cochrane Database of Systematic Reviews), CENTRAL (Cochrane Central
Register of Controlled Trials) and CINAHL (Cumulative Index to Nursing and Allied Health Literature) were
searched from January 2004 to January 2017. Both published and unpublished literature were identified
from systematic searches of electronic sources, consultation with experts in the field and reference checking
of relevant systematic reviews.
We included randomised controlled trials (RCTs) involving populations at high risk of lung cancer. Any
definitions of high-risk populations were eligible. LDCT screening programmes included both single and
multiple rounds. The eligible comparators were no screening or other imaging technology screening
programmes [such as chest X-ray (CXR)]. The key outcomes included lung cancer mortality, all-cause
mortality, numbers of lung cancers and their stages, health-related quality of life (HRQoL) and smoking
behaviour.
Two researchers independently screened the titles and abstracts of all reports identified by the search
strategy and full-text papers were subsequently obtained for assessment. Data extraction and quality
assessment were undertaken by one researcher and checked by a second. The risk of bias of included
studies was assessed using the Cochrane Risk of Bias tool.
Data were tabulated and primarily considered in a narrative review. When appropriate, DerSimonian and
Laird random-effects meta-analyses were performed to pool the estimates of effect. A random-effects
approach was prespecified as part of the protocol development process; a fixed approach was not
favoured as it was thought highly unlikely that only random variation would account for differences
between the results of included studies. Statistical heterogeneity was assessed using the I2-statistic.
We considered the following factors for the exploration of heterogeneity: quality of trials, nature of
interventions (e.g. frequency of LDCT screening) and nature of control groups (e.g. best available care
such as CXR screening or usual care).
Network meta-analysis was performed to assess the relative effectiveness of three screening strategies
(LDCT, usual care and CXR). We estimated the relative ranking probability of each intervention and© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
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xxviiiobtained the treatment hierarchy of competing interventions using rankogram, surface under the
cumulative ranking curve and mean ranks.
Cost-effectiveness
A systematic review of economic evaluations of LDCT screening for lung cancer was undertaken, including
a narrative synthesis.
A decision-analytic model was built in Microsoft Excel® 2013 (Microsoft Corporation, Redmond, WA, USA)
using a decision tree and discrete event simulation approach. A lifetime time horizon was used, costs
(2016 prices) were included from a NHS and Personal Social Services perspective and discounted at 3.5%
per year. Health effects on targeted individuals were included and discounted at 3.5% per year.
A natural history model for lung cancer was developed including seven substages of lung cancer
development, with progressively worsening survival. The rates of incidence, preclinical progression and
clinical presentation were estimated by calibrating the natural history model to data from a large RCT of
LDCT screening and to English cancer incidence statistics. LDCT screening was assumed to have imperfect
diagnostic performance (i.e. some lung cancers would not be detected) and some individuals without lung
cancer would receive further tests.
A risk prediction component was incorporated, so that each individual’s short-term risk of lung cancer
would be estimated and would be used to decide whether or not the individual was eligible for LDCT
screening.
Twelve combinations of age limits and risk thresholds were considered, as were four frequencies of
screening: (1) single screen (S), (2) triple screen (T), (3) annual screening (A) and (4) biennial screening (B).
Forty-eight screening programmes were evaluated in total and were compared with current practice
(no screening).
Costs were estimated from English cost data sets or from the published literature. Health state utility values
were estimated from the published literature.
The primary outcome for each strategy was the fully incremental cost-effectiveness ratio (ICER), which is
defined for strategies on the cost-effectiveness frontier (strategies that are optimal for some cost-effectiveness
threshold) as the ratio of incremental costs to incremental benefits relative to the next worse strategy.
Benefits were measured in quality-adjusted life-years (QALYs).
Patient and public involvement
We collected views about the possible impact of a lung cancer screening programme in the UK. We
conducted three workshop meetings in which we elicited views from a range of patient and public
members, with a particular focus on smokers/former smokers currently without symptoms of lung cancer
who would be the target group for any UK national lung cancer screening programme.Results
Clinical effectiveness
Twelve RCTs were included in the systematic review of clinical effectiveness. Six of these contributed to
the key outcomes. Most studies were conducted in European countries but some studies were conducted
in the USA, including by far the largest, National Lung Screening Trial (NLST), with > 50,000 participants.
One trial, the UK Lung Cancer Screening Trial (UKLS), was conducted in the UK. Most RCTs started between
2001 and 2010, so many are just maturing. The majority of included trials were judged to be of moderate
to high quality, but two trials were judged to be of poor quality, including one that contributed mortality
data. There was variation between the LDCT programmes, but typically they involved 3–5 rounds ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
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participants also varied but was usually defined in terms of age and current and past smoking. Of the trials,
NLST stands apart, not just in terms of size, but by comparing LDCT to CXR screening rather than
no screening.
Concerning mortality, only four of the RCTs, including NLST, currently contribute. Meta-analysis of these
showed that LDCT screening was associated with a non-statistically significant decrease in lung cancer
mortality [pooled relative risk (RR) 0.94, 95% confidence interval (CI) 0.74 to 1.19] with up to 9.80 years of
follow-up when compared with controls (usual care/best available care). A moderate level of heterogeneity
was observed (I2 = 43.3%); therefore, the results should be treated with caution.
A range of potential sources for heterogeneity was investigated. When removing the poor-quality trial
[Multicentric Italian Lung Detection (MILD)], sensitivity analysis demonstrated a statistically significant
decrease in lung cancer mortality (pooled RR 0.85, 95% CI 0.74 to 0.98) in favour of LDCT screening with
considerable reduction in heterogeneity (I2 = 6.9%).
For all-cause mortality, the review showed a non-statistically significant increase (pooled RR 1.01, 95% CI
0.87 to 1.16) for LDCT screening. Again, given the substantial heterogeneity (I2 = 57.0%), this pooled
estimate should be treated with caution. In the investigation of heterogeneity, removing the low-quality
trial (MILD) showed a non-statistically significant decrease in all-cause mortality (pooled RR 0.95, 95% CI
0.89 to 1.00) with considerable reduction in heterogeneity (I2 = 0%).
Network meta-analysis (including six RCTs) was performed to assess the relative clinical effectiveness of
LDCT, usual care and CXR screening. The results showed that LDCT was ranked as the best screening
strategy, with a 74.8% probability of being the best intervention in terms of lung cancer mortality
reduction. Usual care (no screening) had a 74.7% probability of being the second best strategy and CXR
screening a 99.7% probability of being the worst strategy. Both consistency and inconsistency models
were fit for lung cancer mortality data. By applying the design-by-treatment model, we did not find any
evidence of inconsistency. The global test for inconsistency gives a p-value of 0.29, indicating no evidence
of inconsistency.
Concerning numbers of lung cancers detected, compared with controls (usual care/best available care),
LDCT screening was associated with a statistically significant increase (pooled RR 1.38, 95% CI 1.02 to
1.86) with at least 5 years’ follow-up. Although there was heterogeneity (I2 = 79.7%), all included studies
individually showed statistically significant increases in the number of cancers detected in the LDCT group.
Our findings further demonstrated a shift due to LDCT screening on the stage distribution towards earlier
stages for detection of lung cancers. LDCT screening was associated with a statistically significant increase
in early-stage (I and II) cancer detection (pooled RR 1.73, 95% CI 1.27 to 2.37) with a corresponding
statistically significant decrease in late-stage (III and IV) cancer. There was a statistically significant reduction
in the absolute risk of late-stage lung cancer, indicating that there is an element of actual stage shift
(pooled RR 0.85, 95% CI 0.73 to 1.00).
Based on the randomised data from four included trials, there were consistently no statistically significant
differences in HRQoL or psychological consequences between the LDCT screening groups and control
groups during the trials.
The data from three included trials (one reported as two subcomponents) showed mixed results with
regard to the effect of a LDCT screening programme on participants’ smoking behaviours. The data within
trial arms sometimes indicated positive associations between smoking cessation and the presence of an
abnormality on LDCT. However, this is inconsistent with the evidence comparing trial arms that did not
show a consistent pattern favouring LDCT’s effect on smoking behaviour.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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xxxCost-effectiveness
Existing economic evaluations of LDCT screening for lung cancer have produced markedly variable
estimates of the cost-effectiveness of screening. Nineteen studies were identified, with variable quality, and
with ICERs ranging from low thousands of US dollars per QALY to in excess of US$100,000 per QALY.
In the independent economic evaluation (base-case analysis), it was estimated that it would not be
cost-effective to screen for lung cancer by LDCT at a cost-effectiveness threshold of £20,000 per QALY,
whereas it was estimated that a single screen for individuals aged 60–75 years with at least a 3% risk
of lung cancer (S–60–75–3%) would be cost-effective at a cost-effectiveness threshold of £30,000
per QALY (ICER approximately £28,000 per QALY). Three other screening programmes were on the
cost-effectiveness frontier; these all used a 3% risk threshold, two were single screens and one was a
triple screen. The ICERs for these programmes were > £30,000 per QALY and, therefore, would not be
considered cost-effective at commonly used thresholds in the UK. Additionally, annual and biennial
screening programmes were not predicted to be cost-effective at any cost-effectiveness threshold.
Screening was predicted to improve the stage distribution and survival of lung cancer, but also to result in
overdiagnosis (diagnosis of lung cancers that never would have clinically presented).
A single screen was predicted to reduce lung cancer mortality by 4.2%, and triple screening was predicted
to reduce mortality by 4.4%.
A probabilistic sensitivity analysis (PSA) produced similar results to the base-case analysis, although the
ICER for S–60–75–3% was higher (approximately £36,000 per QALY). Results from the PSA are typically
preferred as they capture non-linear associations between inputs and outcomes.
One-way sensitivity analyses showed that the results were sensitive to the natural history of lung cancer,
the cost of lung cancer and the cost of LDCT screening.
Scenario analyses showed that cost-effectiveness was worsened when the natural history model included
heterogeneity in the rate of lung cancer progression, and when the mortality effect from screening was
attenuated or eliminated. Cost-effectiveness was improved if there was no negative impact on HRQoL
from false-positive or indeterminate results.
Patient and public involvement
An explanatory model was constructed detailing the key associations and core dynamics arising from our
patient and public involvement meetings. The model details views around decisions to attend a national
lung cancer screening programme, together with views on the broader cultural and societal influences that
may affect such decisions. The potential impact of wider societal and cultural contexts on decisions to
attend lung cancer screening were discussed. Poor public awareness about potentially effective treatments
for lung cancer and survival benefits resulting from early detection was acknowledged, as was a culture of
stigma and blame associated with smoking.Conclusions
Low-dose computed tomography screening may be clinically effective in reducing lung cancer mortality but
there is considerable uncertainty. This arises from the imprecision of pooled estimates, the heterogeneity
between the results of the included studies, the fact that the key RCT compares LDCT with CXR screening
and the finding from our network meta-analysis that screening with CXR may be associated with worse
outcomes than no screening.
Beyond mortality, the review confirms the theoretical basis of LDCT by showing that more lung cancers are
diagnosed in the earlier stages and fewer in the later stages. However, it also confirms that more lungNIHR Journals Library www.journalslibrary.nihr.ac.uk
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indicating an element of overdiagnosis.
It seems unlikely that LDCT screening leads to major differences in psychological consequences and
HRQoL, and the effect on smoking behaviour continues to be uncertain.
Evidence from economic modelling suggests that LDCT screening for lung cancer may not be cost-effective,
depending on the cost-effectiveness threshold used. Thresholds of £20,000 to £30,000 per QALY are
commonly used in the UK, and screening is estimated to be cost-effective with the higher threshold (when
using mean values for inputs), but not with the lower. When the probable range of inputs is considered in a
PSA, it is estimated that screening is not cost-effective with either threshold.
It is estimated that a national screening programme could result in up to half a million additional computed
tomography (CT) screens a year, compared with 2 million CT screens currently conducted each year
(in England). It is unlikely such an increase in the burden on radiography services would be accommodated
without significant recruitment and/or service reconfiguration.Recommendations for research
Clinical effectiveness and cost-effectiveness estimates should be updated with the anticipated results from
several ongoing RCTs [particularly the NEderlands Leuvens Longkanker Screenings ONderzoek (NELSON)
screening trial]. This is likely to resolve many current uncertainties within a reasonable time.
In the longer term, another large trial of lung cancer screening is currently being conducted in Asia that
will further explore the generalisability of the initial trial results to populations with different ethnicities.
Further investigation of the quality of currently included trials needs to be conducted to confirm whether
they were all truly RCTs or not. If not, they would be appropriately excluded in future systematic reviews
on the effectiveness of LDCT.
Further research on why the results of economic evaluations of lung cancer screening vary might enable
model selection and model averaging to obtain best estimates of cost-effectiveness while also reflecting
structural uncertainty. In addition, certain key costs for the generalisation of economic evaluation results
(e.g. the cost of lung cancer) should be estimated from high-quality, representative and recently
collected data.Registration
This study is registered as PROSPERO CRD42016048530.Funding
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Lung cancer is malignant growth of cells in the lung. It typically affects older people1 who smoke or
smoked in the past. Men are more likely than women to get lung cancer and are more likely to die from
lung cancer.1 Lung cancer is the leading cause of cancer death in men and women and is responsible for
22% of deaths from cancer.1
Risk factors
Smoking
The main cause of lung cancer is smoking (mainly cigarettes). It is estimated that 85% of lung cancer is
attributable to smoking.2 Smoking cigars, pipes or waterpipes is also associated with lung cancer, as well
as other health problems.3,4
Smoking cessation leads to reduced risk of lung cancer, but the risk still remains higher than for those who
have never smoked if there is a significant smoking history.5 Generally, the risk of lung cancer increases
with the number of cigarettes smoked and the duration of smoking, with the pack-year a commonly used
measure for smoking history. One pack-year is the equivalent of smoking one pack (20 cigarettes) per day
for 1 year (around 7300 cigarettes). Duration of smoking appears to be a more important factor than
smoking intensity (the number of cigarettes per day), such that it is worse to smoke one pack per day for
40 years than two packs per day for 20 years.6
Smoking rates have declined substantially and steadily over the previous 40 years, but there remains a
significant proportion of adults who continue to smoke and who have quit smoking but remain at high
risk of lung cancer. Since 2005, at least half of the people who were ever regular cigarette smokers
have quit.7
Cigarette smoking rates vary geographically within the UK.8 Compared with other European Union (EU)
countries in 2014, the UK had the second lowest rate of current smokers (17.3%), higher only than
Sweden (16.7%). The UK also had a gender gap in the smoking rate of 3.1%, which was significantly
below the EU average (9.2%).9
Smoking is also strongly correlated with income and socioeconomic status (SES). Individuals with a gross
personal income of < £20,000 are twice as likely to be current smokers compared with individuals with a
gross personal income of ≥ £40,000 (22% vs. 11%). Employment is also significant: 36% of unemployed
adults smoke compared with 20% of employed adults, and 15% of economically inactive adults (e.g.
pensioners and students).7
Efforts in the UK to reduce smoking include direct taxation of smoking (tobacco duty),10 smoking cessation
services and campaigns (e.g. Smokefree,11 Stoptober12), standardised (plain) packaging (compulsory from
May 2017)13 and restrictions on advertising.14
Passive smoking
Passive smoking is when a person does not smoke themselves, but spends time in an environment where
smoking occurs. Passive smoking causes lung cancer and other diseases, including respiratory infections
and asthma. For example, women who never smoked but were exposed to second-hand smoke from
their spouse face a 27% higher risk of lung cancer than similar women not exposed to second-hand
spousal smoke.15© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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BACKGROUND
2Environmental risk factors
In addition to smoking, there are other environmental risk factors that, following exposure, have
demonstrated an increased risk of lung cancer. These risk factors include asbestos, radon gas and air
pollution. When these environmental risk factors are combined with smoking, the overall risk of lung
cancer is exacerbated.16
Pathology
Lung cancer is the term for a malignant neoplasm originating in the lung, typically developing from cells of
the respiratory epithelium.17
Lung cancer cell type
Lung cancer can be divided into two broad categories: (1) small cell lung cancer (SCLC) and (2) non-small
cell lung cancer (NSCLC). SCLC is a highly malignant tumour accounting for 11% of all lung cancer cases
in the UK, and is derived from cells exhibiting neuroendocrine characteristics.18 NSCLC accounts for 88%
of all lung cancer cases in the UK. NSCLC can further be divided into three major pathologic subtypes:
(1) adenocarcinoma, (2) squamous cell carcinoma and (3) large cell carcinoma. Statistics from the
National Lung Cancer Audit Annual Report 201618 report the distribution of NSCLC in the UK as follows:
adenocarcinoma 36%, squamous 22%, other 11% and no pathology 31%.18
Neuroendocrine tumours account for around one-quarter of primary lung neoplasms, including SCLC
(20%), large cell neuroendocrine carcinoma (LCNEC) (a subtype of large cell carcinoma; 3%) and carcinoid
tumours (typical and atypical carcinoid; 2%).19 Lung neuroendocrine tumours arise from cells of the diffuse
neuroendocrine system in the bronchial mucosa.20
The World Health Organization (WHO) classification of lung tumours21 now recommends (2015 classification)
greater restriction on the diagnosis of large cell carcinoma (former subtypes now reclassified), reclassification
of adenocarcinoma subtypes, reclassification of squamous cell carcinoma subtypes and a number of
smaller changes.21
Grade
Grading of lung cancer for NSCLC distinguishes lung cancer cells into groups based on the cell’s
appearance:22l
l
l
l
l
l
NIHRGrade 1 – cells look normal, will grow slowly and are less likely to spread (may also be called ‘low
grade’ or ‘well differentiated’).
Grade 2 – cells look abnormal and are more likely to spread (may also be called ‘moderate grade’ or
‘moderately well differentiated’).
Grades 3 and 4 – cells look very abnormal, will grow quickly and are more likely to spread (may also be
called ‘high grade’ or ‘poorly differentiated’).Neuroendocrine tumours are also graded:19low grade (typical carcinoid)
intermediate grade (atypical carcinoid)
high grade (SCLC and LCNEC).Stage
The stage of the lung cancer relates to the extent of the cancer and is currently classified by the NHS in the
UK according to the international tumour, node, metastasis (TNM) system (Seventh Edition).23,24 The Eighth
Edition of the TNM system has been recently published25 and is due to be adopted in the UK. There areJournals Library www.journalslibrary.nihr.ac.uk
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tumour (diameter in greatest dimension; TX, T0–T4), (2) whether or not it has spread to the lymph nodes
(NX, N0–N3) and (3) whether or not it has distant metastasis (MX, M0, M1).26 In the UK, the following
percentages of cases recorded postoperatively by stage were reported by the National Lung Cancer Audit
Annual Report 2016:18l
l
l
l
l
l
l
l
l
l
l
l
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stage IB, 7%
stage IIA, 4%
stage IIB, 4%
stage IIIA, 12%
stage IIIB, 9%
stage IV, 53%.Note that, at present, there is no national lung cancer screening programme, so the vast majority of these
cases are either clinically presenting or incidental findings.
Diagnosis
Presentation
Diagnosis of lung cancer generally follows symptomatic presentation of (typically late-stage) lung cancer,
but it can also be an incidental finding during other investigations.
Of the 73,063 lung cancer cases diagnosed in England (2012–13), 25,668 presented as an emergency,
20,420 were referred by a general practitioner (GP) through the 2-week wait pathway and 15,525 were
otherwise referred by a GP.27 The remaining cases presented through some other route or were identified
only through a death certificate. Stages I–III were most often diagnosed following GP referral, whereas
stage IV and unstaged cancers were most often diagnosed following emergency presentation.27
The National Institute for Health and Care Excellence (NICE) guidelines on suspected cancer referral28
identify a number of key symptoms and findings that should prompt an urgent referral or chest X-ray
(CXR), which include (not an exhaustive list):unexplained haemoptysis (coughing blood or blood-stained mucus)
respiratory symptoms (cough, shortness of breath)
chest symptoms and signs (chest pain, persistent or recurring chest infection)
general symptoms and signs (fatigue, weight loss, appetite loss)
finger clubbing.In addition, there are decision aids for GPs that can help to identify the significance of combinations
of symptoms.29
Investigation
The 2011 NICE guidelines on lung cancer diagnosis and management30 recommend an investigative pathway
for suspected lung cancer that includes contrast-enhanced chest computed tomography (CT) to further the
diagnosis and contribute to staging the disease. Positron emission tomography–computerised tomography
(PET-CT) is recommended for patients who are potentially suitable for treatment with curative intent. Other
investigations are recommended according to the location and spread of the disease; many of these are
invasive and involve endoscopy (including bronchoscopy) and biopsy.een’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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4Prognosis
Overall, the prognosis for long-term survival with lung cancer is poor. Net survival for adults (aged 15–99 years)
in England and Wales in 2010–11 was predicted as follows: 1-year survival, 32.1%; 5-year survival, 9.5%; and
10-year survival, 4.9%.31 The 10-year survival for lung cancer ranks second lowest out of 20 common cancers
in England and Wales.31 However, prognosis is variable depending on a multitude of factors including:l
l
l
l
l
l
NIHRtype of lung cancer – survival is lower for those with SCLC than for those with NSCLC32
age – the prognosis for long-term survival with lung-cancer deteriorates with age32
stage – the higher the stage, the poorer the prognosis (e.g. the 1-year survival rate is > 80% when
lung cancer is diagnosed in stage I, but < 20% when diagnosed in stage IV32)
sex – the prognosis for women is better than for men32
route of diagnosis – those presenting through the 2-week wait referral route have a better prognosis
than those with emergency presentation33
geographical location.34Epidemiology
Incidence
Lung cancer is the most common cancer in the world, with 1.8 million new cases diagnosed in 2012.35
In the UK in 2014, 46,400 new cases of lung cancer were diagnosed (130 new cases per day on average).
Lung cancer is the third most common cancer in the UK and, in 2014, it accounted for 13% of all new
cases of cancer in the UK. The directly age-standardised rates of lung cancer incidence in England (2014)
were 91.6 and 65.2 per 100,000 person-years for men and women, respectively, but the incidence rate
climbs with age.1
The incidence of lung cancer has declined for men compared with historical levels, but has climbed
for women.1 Men continue to be at a higher risk of lung cancer than women. Across the UK, the
age-standardised rate of lung cancer decreased from 2012 to 2014, to approximately 2006 levels.
Mortality
Lung cancer is the most common cause of deaths from cancer in the EU (20.8% of all cancer-related
deaths).36 Lung cancer accounted for 5.4% of the total number of deaths in the EU (2013), equating to
more than one-quarter of a million people (268,744 people) or 55.2 deaths per 100,000 inhabitants.36
There were 35,895 lung cancer deaths in the UK in 2014,37–39 accounting for 22% of all cancer deaths;
lung cancer is the most common cause of cancer death. Crude mortality rates indicate that there are
62 lung cancer deaths for every 100,000 males and 50 for every 100,000 females.37–40 In England in 2014,
15,856 men and 12,993 women died from lung cancer (19,563 and 16,332, respectively, for the UK).37–39
Prevalence
The prevalence of lung cancer (i.e. the proportion of people previously diagnosed with lung cancer who
are still alive at a given time) is relatively low because survival is generally poor. Worldwide, the overall
ratio of mortality to incidence is 0.87, because of the high fatality rate associated with lung cancer.
In 2006, it was estimated that 38,141 people were alive in the UK who had been diagnosed with lung
cancer within the previous 10 years, 15,802 of whom had been diagnosed within the previous year.41Journals Library www.journalslibrary.nihr.ac.uk
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Significance for lung cancer patients
The prognosis for those diagnosed with lung cancer is disappointing despite recent advances in oncology
and surgery. This is because lung cancer is typically diagnosed when the cancer is in the later stages,
and in older people, who often have concomitant diseases that subsequently limit therapeutic options.
For individuals with NSCLC, the primary symptoms (or most frequent) are appetite loss (98%), fatigue
(98%), shortness of breath (94%), cough (93%), pain (90%) and blood in sputum (70%). From the
literature, it appears that fatigue is the primary symptom that has an impact on daily living for those with
lung cancer, followed by pain (chest pain/pain swallowing).42 Quality-of-life (QoL) scores deteriorate as the
number of chemotherapy cycles increases (i.e. the longer the treatment lasts, the lower the QoL).42 Being
treated for lung cancer also has a detrimental impact on an individual’s social life, family life and ability
to work.42
Significance for the NHS
Luengo-Fernandez et al.43 estimated that lung cancer had the highest economic cost of any cancer in
the UK, but health-care costs are greater for colorectal cancer and breast cancer (lung cancer leads to
significantly more productivity losses).
Measurement of disease
Treatment for lung cancer depends on where the cancer is within the lung, the tumour size, whether or
not, and how far, it has spread, and the general health and fitness of the individual presenting. The main
treatment options are chemotherapy, radiotherapy, surgery, chemoradiotherapy, control of symptoms and
palliative care. These treatments may be offered in combination or in sequence. Typically, if the stage is
low (I or II) and a patient is fit for surgery, this will generally be the treatment option. This may be followed
by chemotherapy and radiotherapy depending on whether or not the patient has lymph node metastases.
The intent will usually be curative. If the stage is high (III or IV), the intent of further treatment is typically
palliative although it may be, in some cases, long-term survival.
Whether or not treatment is effective is measured by the following means:l
l
l
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The size of the tumour (diameter, volume). With the intention of slowing progression of growth of the
tumour, reducing it in size or removing it entirely. Typically, the RECIST 1.1 treatment response criteria44
can be used to assess this outcome.
Health-related quality of life (HRQoL). This can be measured using a variety of condition-specific tools
including –¢
¢
¢
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SouthEuropean Organisation for Research and Treatment of Cancer (EORTC) QLQ (Quality of Life
Questionnaire)-C3045 (a 30-item patient questionnaire for use in cancer trials, including multi-item
scales such as physical and role function, a global HRQoL scale and a number of single items) and
QLQ-LC1346 (a 13-item patient module primarily consisting of symptoms of lung cancer and lung
cancer treatments)
Lung Cancer Symptom Scale (LCSS)47 [a nine-item patient questionnaire using visual analogue
scales (VASs), focusing particularly on physical and functional QoL]
Functional Assessment of Cancer Therapy – General (FACT-G)48 (a 27-item patient questionnaire
for patients receiving cancer therapy covering physical, social/family, emotional and functional
well-being) and Functional Assessment of Cancer Therapy – Lung (FACT-L)49 (a nine-item patient
module primarily consisting of symptoms of lung cancer and lung cancer treatments).eIn addition, generic, preference-based measures were used to measure treatment effectiveness, such as
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6Current service provision
Management of disease
The normal clinical pathway in the absence of screening is that people will present with symptoms such
as persistent cough, haemoptysis or persistent breathlessness that will then be investigated with CXR,
CT, bronchoscopy and biopsy. The investigations not only potentially confirm lung cancer, but are also
used for staging. Occasionally individuals will have a CXR or CT scan for another clinical investigation in
which lung cancer is noted as an unexpected finding without any symptoms.
The National Lung Cancer Audit Annual Report 201618 reported that, in the UK, the following treatments were
given for 20,323 males and 17,946 females: any anticancer treatment in 60% of males and 60% of females,
surgery in 15% of males and 18% of females, chemotherapy in 32% of males and 31% of females and
radiotherapy in 35% of males and 32% of females.
Current service cost
In 2009, it was estimated that cancer costs the EU €126B, of which €18.8B (or 15%) was specifically for
lung cancer.43 The total costs for lung cancer in the EU were made up from €4.23B for health-care costs,
€9.92B from mortality losses, €8M from morbidity losses and €3.82B in informal care costs.43 The same study
reported that the proportion of health-care costs in 2009 for the EU were 12% on medicine, 68% on
inpatient care, 1% on accident and emergency services, 13% on outpatient care and 6% on primary care.43
Costs are generally concentrated around the time of diagnosis (when treatment is likely to be initiated) and
the time of death (when significant palliative care and medical management costs accrue). The following
estimates were obtained for the health economic model, and details of sources are given in Chapter 6,
Resources and costs:l
l
l
NIHRCosts in the first year following diagnosis range from approximately £8000 to £13,000 (depending on
the stage).
Costs in subsequent years range from around £1000 to £1600.
The estimated cost at the end of life is approximately £4600.Variation in services and/or uncertainty about best practice
It is evident that there is a variation in service across the UK. The National Lung Cancer Audit Annual
Report 201618 reports the following ranges for different treatments: percentage of people who received
any anticancer treatment ranged from 54% on the south-east coast to 64% in the London Cancer
Alliance, surgery ranged from 13% on the south-east coast to 21% in the London Cancer Alliance,
chemotherapy for NSCLC ranged from 58% in Cheshire and Merseyside to 78% in the London Cancer
Alliance, and chemotherapy for SCLC ranged from 57% on the south-east coast to 78% in Wessex.
Relevant national guidelines, including National Service Frameworks
There are many potential relevant guidelines for the diagnosis, treatment and management of lung cancer.
NICE has produced a significant amount of guidance through various programmes. The British Thoracic
Society has also produced two relevant guidelines.50,51Description of technology under assessment
Over several decades, a number of potential screening tests for lung cancer have been investigated, including
CXRs and sputum cytology. Neither of these has been found to be effective in randomised controlled trials
(RCTs). As CT scanning has developed and offered progressively improved images at lower radiation dosage,
so it has become the test offering the greatest potential for clinically effective and cost-effective screening for
lung cancer, with much research devoted to investigating whether or not this is the case.52Journals Library www.journalslibrary.nihr.ac.uk
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Computed tomography scanning makes use of computer-processed combinations of many X-ray images
taken from different angles to produce cross-sectional (tomographic) images (virtual ‘slices’) of specific
areas of a scanned object, allowing the user to see inside without cutting. CT scanning has developed in a
number of ways, notably the number of detectors, the speed with which data can be acquired and the
sophistication of the computer reconstruction techniques. The amount of radiation required to provide
an acceptable image for initial diagnostic purposes has also reduced, so that a low-dose computed
tomography (LDCT) scan requires an effective radiation dose of ≤ 1.6 mSv. In the UK, the average annual
exposure, including background and medical applications, is about 2.7 mSv of radiation per year.53
Training and quality control are critical in achieving high-quality images while minimising X-ray exposure.
Lung CT scans detect discrete pulmonary nodules as the most common abnormality that may be
suggestive of malignancy, but abnormal scarring and ground glass opacities may also be seen as worrying
features and potentially recognised as malignant changes. Nodules suspicious of malignancy are often
referred to as non-calcified nodules, but calcification is not a guarantee that the nodule is not cancerous.
Size is also important in determining the likelihood that a non-calcified nodule is malignant, and large
lesions are more likely to be malignant than small ones.54
An important issue is that LDCT screening for lung cancer is not a homogenous technology, so careful
attention needs to be paid to the exact nature of the device being used, the protocol being used and
precise criteria being employed to define an abnormality as potentially malignant, benign or indeterminate.
In a screening programme, this needs to take into account the possibility that screening scans may be
repeated and stability of abnormalities over time may be part of the criteria indicating a possible cancer.
The further management of each category, particularly further investigation, also needs to be specified as
part of the definition of the technology.
A major challenge in all screening is that virtually no test is completely accurate. As a consequence, the
benefits flowing from earlier identification and treatment of disease in some individuals will need to be
offset by the likelihood that there will be some who may be falsely reassured by false-negative results
and a number found to be false positives who will require further investigations and possibly experience
additional anxiety relative to the situation in which no screening takes place. The problem of false positives
is frequently magnified in screening because the incidence of the cancer being detected is often still low in
the screened population, so apparently accurate tests, particularly in terms of their specificity, generate
large absolute numbers of false positives.
Some recent lung cancer screening trials [the UK Lung Cancer Screening Trial (UKLS)55 and the Dutch–Belgian
Lung Cancer Screening trial, NEderlands Leuvens Longkanker Screenings ONderzoek (NELSON)56,57] have
discriminated between positive and indeterminate findings, whereby positive findings require follow-up
with technology other than LDCT, while indeterminate findings can be managed purely by LDCT follow-up.
From an intention-to-diagnose perspective (for calculating measures of diagnostic accuracy), these are both
counted as positive findings (and false positive if lung cancer is not actually present), although it is likely that
management purely by LDCT follow-up will be less invasive and lead to less radiation exposure, [although
other harms (e.g. anxiety) may not be lessened by an indeterminate classification].
Identification of important subgroups
The following subgroups present with variable risk profiles associated with the incidence of lung cancer:l
l
l
l
l
l
l
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8Consideration as to how these subgroup risk profiles affect lung cancer risk will need to be considered for
any screening programme.
Current usage in the NHS
In the UK, population-level lung cancer screening is currently not implemented by the NHS. This was based
on the findings of the UK National Screening Committee (NSC) in July 2006 when they last assessed
whether or not lung cancer screening should be recommended for adult cigarette smokers. They concluded
that it should not be recommended but should be reviewed in 2015/16, which prompted the commissioning
of this review.
Some screening pilots have gone ahead at local levels (without control arms), such as the Macmillan
Cancer Improvement Partnership pilot in Manchester.58
Anticipated costs associated with intervention
If a lung cancer screening programme is to be implemented, there are a multitude of costs that will need
to be considered. These can be broadly categorised in accordance with the phase of implementation
(setup, running, evaluation) and dependency on volume (fixed and variable costs). It is also likely that
implementation would proceed initially with pilots before rollout, with pilots having their own evaluation
costs. Furthermore, there would likely be societal costs and benefits of a screening programme, and
impacts on other areas of government spending, though these would often not be considered by NHS
policy-makers, such as NICE.
If lung cancer screening significantly has an impact on smoking behaviour, or if it is implemented with
attached smoking cessation interventions, there could be significant impacts on the NHS, the government
and society more widely.Challenges of screening programmes
Implementation
When implementing a screening programme, of any nature, there will always be challenges in executing
its delivery effectively. Predominantly all of these challenges fall around communication. First, how to
identify and communicate with the target population so that they are eligible for the screening programme.
Identification could be through GP records, questionnaires or self-referral, and they all come with their own
limitations. For example, how accurate the GP records are, how honest will individuals be at responding to a
questionnaire, would self-referral predominantly identify only the worried-well. Once the target population
has been identified, the response to invitation needs to be considered. Again, will it disproportionately be
the worried-well who respond and attend screening. Whether SES or income factors affect attendance and
also whether or not the invitation itself causes a detrimental increase in anxiety for the individual invited
need consideration. Communication regarding making and rescheduling appointments along with follow-up
of missed appointments will all require careful administration along with the communication of results and
any follow-up appointments required.
Value
Understanding the added value that a screening programme can offer will also be a challenge. Ensuring
that public attitudes are acceptable and amenable to the implementation and value of the screening
programme will be paramount. Also of importance will be ensuring that the value of the screening
programme is understood by those selected for participation (individuals to be screened) and placating
concerns surrounding whether or not accepting screening has an impact on health insurance. Beyond the
added value of reducing costs of treating lung cancer early and improving outcomes for an individual, a
screening programme can furthermore benefit individuals by prompting/motivating smoking cessation, give
individuals with a lung cancer diagnosis more time with their loved ones and also give them time to put
their affairs in order.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Finally, when implementing a screening programme, there will be challenges in assessing whether or not the
screening programme is clinically effective. Primarily these challenges hinge on the lack of an appropriate
gold standard to compare against, particularly for negative results but also accounting for overdiagnosis,
lead-time bias, length bias and other forms of bias such as differential efforts to achieve smoking cessation.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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The purpose of this work was to provide the NSC with the most up-to-date clinical effectiveness andcost-effectiveness evidence for the screening of lung cancer in the UK by LDCT.
Decision problem
Population
People identified as being at ‘high’ risk of lung cancer.
Intervention
Low-dose CT screening.
Comparators
No screening was set by the scope as the primary comparator. We have also included alternative screening
programmes (e.g. CXR) for comparative purposes.
Outcomes
From the scope, the outcomes suggested were potential effect on mortality, QoL and cost-effectiveness.
Additional outcomes that were deemed relevant following consultation with our advisory committee
included lung cancer incidence, stage and morphology of lung cancer, follow-up investigations and
treatments, smoking cessation, adherence to screening, diagnostic accuracy, radiation dose of screening
and adverse psychological impacts.Overall aims and objectives of assessment
In order to assess the clinical effectiveness and cost-effectiveness of lung cancer screening in a high-risk
population using LDCT screening, the following key objectives were performed:l
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Identification of studies
The literature search aimed to systematically identify studies relating to the clinical effectiveness and
cost-effectiveness of LDCT screening programmes in high-risk populations. For the identification of
studies for clinical effectiveness, the following bibliographic databases were searched:l
l
l
l
l
l
l
l
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Park,MEDLINE (via Ovid)
MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
EMBASE (via Ovid)
Health Management Information Consortium (via Ovid)
PsycINFO (via Ovid)
Web of Science (via Clarivate Analytics)
Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL)
and Health Technology Assessment (HTA) (all via The Cochrane Library)
Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost).The search strategies were developed by an information specialist (SR) and were carried out in two stages.
The first searches, from 2004 to January 2012, were intended to update the HTA by the Aberdeen HTA
Group in 200654 and to supplement the Cochrane systematic review of 2013.52 These comprised
population terms for lung cancer and intervention terms for LDCT screening. Filters for diagnostic studies
were not used to limit the study designs retrieved as these have not been found to be effective. Search
results were limited to RCTs and English-language studies and were run in January 2017.
The second searches, from 2012 to January 2017, were more comprehensive in scope. These searches
comprised population terms for lung cancer and intervention terms for CT screening (not restricted to
low dose) and for CXR as a comparator. Searches were limited to RCTs and English-language studies.
The search results were exported to EndNote X7 [Clarivate Analytics (formerly) Thomson Reuters,
Philadelphia, PA, USA] and deduplicated using automatic and manual checking.
Systematic reviews identified by further bibliographic database searches were used to source other relevant
studies. Items included after full-text screening were backward-citation chased using Scopus (via Elsevier)
in order to identify additional relevant studies. A search for ongoing clinical trials was carried out in
February 2017 in clinicaltrials.gov, the WHO registry, the EU clinical trials registry and the International
Standard Randomised Controlled Trial Number (ISRCTN).
Reference lists of relevant systematic reviews were checked. We defined systematic reviews as those
reviews in which systematic and reproducible search strategies were used, a well-defined research question
(with clear inclusion and exclusion criteria) was addressed and either a Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram or a sufficient description of the flow of
studies that allows the construction of the flow diagram was included. A full search strategy for each
database can be found in Appendix 1.een’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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14Inclusion and exclusion criteria
Inclusion criteria
Population
The eligible population was individuals at high risk of lung cancer. Any definitions of high-risk populations
were eligible in order to facilitate exploration of risk as a particular feature by which clinical effectiveness
and cost-effectiveness might vary.
Intervention(s)
Low-dose CT screening programmes, including both single and multiple rounds, were eligible for inclusion.
We carefully investigated variations in the screening programme, not only in the techniques used to do the
initial screen, but also the criteria used to define positive tests and how positive and indeterminate tests
(when applicable) were followed up.
Comparator(s)
The eligible comparators were usual care (no screening) or other imaging technology screening
programmes (such as CXR), including both single and multiple screening rounds.
Study design
The eligible study design was RCTs. The following types of report were excluded: editorials and opinions,
case reports and reports focusing on only technical aspects of the CT technology (such as technical
descriptions of the CT technology).
Outcomes
The following outcomes were included:l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
NIHRlung cancer mortality
all-cause mortality
stage distributions of lung cancers
number of lung cancers detected
number and type of follow-up investigations
number of patients who were more amenable to surgical treatment
surgical resection rate
any HRQoL
smoking cessation and patients’ smoking behaviour change
adherence rate to screening
diagnostic accuracy outcomes (including indeterminate results)
overdiagnosis
complications in those who underwent an invasive procedure
radiation dose of screening
radiation-related patient outcomes
adverse psychological impact.Exclusion criteria
Studies were excluded if they did not match the inclusion criteria. In addition, certain studies were not
considered, particularly:animal models
preclinical and biological studies
non-systematic reviews, editorials, opinions
non-English language papers
reports published as meeting abstracts only, as there is unlikely to be sufficient methodological details
to allow critical appraisal of study quality.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69At least two reviewers independently screened the titles and abstracts (if available) of all reports identified
by the search strategy. Full-text copies of all studies deemed to be potentially relevant were obtained and
two reviewers independently assessed them for inclusion. Any disagreements were resolved by consensus
or by a third reviewer.
Data abstraction strategy
We selected the most recent or most complete report in cases of multiple reports for a given study or
when the possibility of overlapping populations could not be excluded.
The data extraction forms were developed and piloted. One reviewer independently extracted details from
full-text studies of study design, participants, intervention, comparator and outcome data. The data
extraction was checked by another reviewer. Any disagreements were resolved by consensus or by a
third reviewer.
For studies reporting clinical outcomes, we extracted data on these as numbers of patients experiencing
the specified outcome. Mean differences, relative risks (RRs) or odds ratios (ORs) [with 95% confidence
intervals (CIs)] were extracted, when reported.
Critical appraisal strategy
One reviewer independently assessed the quality of all included studies using the Cochrane Risk of Bias
tool. Other risks of bias include the following two items: (1) underpowered sample size for important
outcomes and (2) significant baseline differences between study arms on important characteristics. The
quality assessment was checked by another reviewer. Any disagreements were resolved by consensus or
by a third reviewer if necessary.
Methods of data synthesis
All data were tabulated and primarily considered in a narrative review. When appropriate, DerSimonian
and Laird random-effects models59 were performed to pool the estimates of effect size of clinical
effectiveness data from included trials. A random-effects approach was prespecified as part of the protocol
development process; a fixed approach was not favoured as it was thought highly unlikely that only
random variation would account for differences between the results of included studies.
Statistical heterogeneity was assessed using the I2-statistic: 30–50% was considered as moderate
heterogeneity and > 50% as substantial heterogeneity. We performed only statistical pooling of data for
both lung cancer mortality and all-cause mortality with ≥ 5 years’ follow-up. The statistical analyses were
performed in Stata® 14 (StataCorp LP, College Station, TX, USA).
We closely took into account any heterogeneity observed between studies. Particularly, we considered the
following factors for the exploration of heterogeneity:l
l
l
l
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Park,quality of trials (focusing on adequacy of randomisation to define the criteria)
characteristics of populations (e.g. different level of risk status of participants at baseline)
nature of interventions (e.g. frequency of LDCT screening)
characteristics of control groups (such as CXR screening or usual care).Sensitivity analyses and subgroup analyses based on the above factors were performed to explore the
potential sources of heterogeneity.
Changes to protocol
The methods for this review differ from the protocol prospectively registered on PROSPERO as described
below.een’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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16Decision problem
The set of outcomes was expanded to include the following, after consultation with clinical experts:l
l
l
l
l
l
l
l
l
l
l
l
NIHRnumber of patients who were more amenable to surgical treatment
surgical resection rate
smoking cessation and patients’ smoking behaviour change
adherence rate to screening
overdiagnosis
complications in those who underwent an invasive procedure
radiation dose of screening
radiation-related patient outcomes
adverse psychological impact.Search methods
The following resources were not searched:National Research Register
Food and Drug Administration website
European Medicines Agency website.In addition, the WHO trial registry was searched.
Subgroups
The prospectively registered protocol indicated that heterogeneity would be explored through
consideration of the study populations, methods and interventions. In the review, heterogeneity was
specifically explored through consideration of study quality, which relates to study methods, but was
not explicitly listed in the protocol.Results
Quantity and quality of research available
The literature searches of bibliographic databases identified 7496 references. After initial screening of titles
and abstracts, 380 were considered to be potentially relevant and were ordered for full-paper screening.
In total, 12 RCTs were included for the systematic review of clinical effectiveness of lung cancer screening
by LDCT scanning. All the included trials with linked citations are presented in Appendix 2. Figure 1 shows a
flow diagram outlining the screening process with reasons for exclusion of full-text papers.
Most trials were reported in multiple papers and abstracts, with considerable overlaps in data and
reporting. We selected the paper with the most up-to-date and complete data for the data extraction.
A list of full-text papers that were excluded along with the reasons for their exclusions is given in Appendix 3.
These papers were excluded because they failed to meet one or more of the inclusion criteria in terms of the
type of study design, participants, interventions or outcomes reported.
Assessment of clinical effectiveness
Characteristics of included studies
Table 1 presents the summary information of characteristics of included trials for the systematic review of
clinical effectiveness. All of the included studies were RCTs. Nine studies were conducted in European
countries and three studies were conducted in the USA. Two trials (one of which was a pilot trial) were
conducted in the UK. Only a minority of included trials contributed to important comparative outcomes.Journals Library www.journalslibrary.nihr.ac.uk
Records identified through
database searching
• 2012 – 17, n = 6473
• 2004 – 11, n = 823
• information specialist (SR)
   search, n = 1088
• Study design, n = 181
• Comparator, n = 11
• Outcome, n = 12
• Language, n = 4
• Intervention, n = 5
• Population, n = 12
• Unobtainable, n = 5
Additional records identified
through other sources
• Backward citations, n = 1246
• Cross-referencing with HTAs, 
   n = 25
Total records identified
(n = 9655)
Records after duplicates removed and 
the total number of records screened
(n = 7496)
Records excluded
(n = 7102)
Full-text articles excluded
(n = 230)
Full-text articles assessed for
eligibility
(n = 394)
Systematic reviews screened
for included studies
(n = 18)
Studies included in direct
meta-analysis
(n = 4, studies from 18 citations)
Studies included in qualitative
synthesis
(n = 12, studies from 128 citations)
Studies included in network
meta-analysis
(n = 7, studies from 85 citations;
n = 6 for the main analysis, 
n = 1 for the sensitivity analysis)
FIGURE 1 The PRISMA flow diagram for systematic review of clinical effectiveness. SR, systematic review. Adapted
from Moher et al.60 © 2009 Moher et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Low-dose CT screening was a key component of the screening programmes. Most of the included trials
used usual care as a comparator, whereas three trials used CXR as a comparator. The sample size of
included trials ranged from 190 to 53,434. The included trials recruited participants with age ranging from
47 to 80 years. The number of screening rounds ranged from 1 to 10. Most trials adopted 1-year interval
screening. However, one trial [Multicentric Italian Lung Detection (MILD)]69 used both annual and biennial
screening and the NELSON trial56 performed screening at baseline, 1 year, 3 years and 5.5 years of follow-up.
When reported, the duration of follow-up ranged from 2 to 9.53 years.
All included trials recruited high-risk populations. The characteristics of study populations are shown in
Appendix 4. The percentage of male participants ranged from 32% to 100%. All the studies recruited
current smokers and former smokers. Most trials recruited participants through targeted mailings of
questionnaires via GPs and family doctors, media, internet and newspaper advertisements. The
characteristics of recruitment methods are shown in Appendix 4.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
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TABLE 1 Summary of included trials
Study
identifier Country Recruitment time Screening programme Comparator Sample size (n)
Age range,
years
(recruitment
protocol)
Number of
screening
rounds
Screening times and
interval (years)
Duration of
follow-up
(mean/median)
DANTE61 Italy March 2001 to February
2006
LDCT, medical examination
and one CXR
No screening, medical
examination and one CXR
2811
(2400 planned)
60–74 5 T0, T1, T2, T3, T4
(1-year interval)
At December 2012,
median 6 years
3.5 months
Depiscan62 France NR LDCT CXR 830 47–76
(protocol 50–75)
3 T0, T1, T2 (1-year
interval)
NR
DLCST63 Denmark October 2004 to March
2006
LDCT No screening 4104 50–70 5 T0, T1, T2, T3, T4
(1-year interval)
Median: 9.47 years
vs. 9.53 years
(planned 10 years)
Garg et al.64 USA January 2001 to October
2001
LDCT No screening 190
(400 planned)
50–80 2 T0, T1 (1-year interval) NR (planned 2 years)
ITALUNG65 Italy NR LDCT, smoking cessation
programme
No screening, smoking
cessation programme
3206 55 –59 4 T0, T1, T2, T3 (1-year
interval)
NR
LSS-PLCO66 USA Randomisation from
September 2000 to
November 2000 or January
2001 (depending on source)
LDCT CXR 3318
(3000 planned)
55–74 1 T0, T1 (1-year interval) NR
LungSEARCH67 UK August 2007 to March
2011
Sputum surveillance, if
abnormal sputum, LDCT
and AFB
CXR at 5 years 1568
(1300 planned)
Mean 63 5 T0, T1, T2, T3, T4
(1-year interval)
NR (planned 5 years)
LUSI68 Germany September 2007 to
April 2011
LDCT, smoking counselling No screening, smoking
counselling
4052
(4000 planned)
50–69 5 T0, T1, T2, T3, T4
(1-year interval)
NR
MILD69 Italy September 2005 to
September 2011
LDCT (annual and biannual),
smoking cessation,
pulmonary function test,
blood sample
No screening, smoking
cessation, pulmonary
function test, blood sample
4099
(10,000 planned)
> 49 10 T0, T1, T2, T3, T4, T5,
T6, T7, T8, T9, (1-year
interval) vs. T0, T2, T4,
T6, T8 (2-year interval)
Median 7.3 years
NELSON56,57 The
Netherlands/
Belgium
Second half of 2003 to
December 2006
LDCT No screening 15,822 50–75 4 T0, T1, T2, T3,
T0 to T1, 1 year; T0 to
T2, 3 years;
T0 to T3, 5.5 years
NR (planned
10 years)
NLST70,71 USA August 2002 to
April 2004
LDCT CXR 53,454 55–74 3 T0, T1, T2 (1-year
interval)
Median 6.5 years
UKLS55 UK August 2011 to
August 2012
LDCT No screening 4061
(4000 planned)
50–75 1 T0 NR (planned
10 years)
AFB, autofluorescence bronchoscopy; DANTE, Detection and Screening of Early Lung Cancer with Novel Imaging Technology and Molecular Essays; DLCST, Danish Lung Cancer Screening Trial; ITALUNG, Italian lung cancer
screening; LSS-PLCO, Lung Screening Study as part of the Prostate, Lung, Colorectal and Ovarian cancer screening trial; LUSI, German lung cancer screening intervention; NLST, National Lung Screening Trial; NR, not reported.
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69As seen from this table, there were wide variations in definitions of high risk between trials. For example, the
National Lung Screening Trial (NLST)71 (which was conducted in the USA) used two variables (age and smoking
history) to define high risk:l
l
l
l
l
l
l
l
l
l
l
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Park,aged 55–74 years
current smokers with at least a 30 pack-year smoking history
former smokers (who had quit within the previous 15 years) with at least a 30 pack-year
smoking history.However, UKLS55 used the Liverpool Lung Project lung cancer risk prediction algorithm to predict high risk.
This risk prediction rule has been validated in three independent studies from Europe and North America
and demonstrated its predictive benefit. The following variables were included in this risk prediction model:age
sex
prior diagnosis of pneumonia
family history of lung cancer
smoking duration
prior diagnosis of malignant tumour
personal history of other cancer and non-malignant lung diseases
early onset (< 60 years of age) family history of lung cancer.In this trial,55 participants were selected based on the prediction result (i.e. ≥ 5% risk of developing lung
cancer in the next 5 years). It should be noted that such variations in the definition of ‘high-risk’ participants
can lead to different prevalences of lung cancer being detected at baseline between different trials.
Furthermore, the Detection and Screening of Early Lung Cancer with Novel Imaging Technology and
Molecular Essays (DANTE) trial61 defined high-risk participants as those smokers or former smokers (aged
60–74 years) of at least 20 pack-years who had quit < 10 years before recruitment. Similar criteria were
adopted by the Italian lung cancer screening (ITALUNG) trial.72 The Despiscan trial62 defined high-risk patients
as those aged 50–75 years who were current or former smokers (having quit < 15 years from enrolment)
with cigarette consumption of ≥ 15 cigarettes per day for ≥ 20 years. The Danish Lung Cancer Screening
Trial (DLCST)63 defined high-risk participants as those current or previous smokers (aged 50–70 years) with
≥ 20 pack-years of smoking. Previous smokers had to have quit after the age of 50 years and < 10 years
prior to the start of the study. Patients had to be able to climb 36 steps without pause. In this trial, forced
expiratory volume in 1 second (FEV1) had to be at least 30% of predicted normal at baseline. It should be
noted that the MILD trial69 recruited younger participants (≥ 49 years) who were current or former smokers
(having quit smoking within 10 years of recruitment) with ≥ 20 pack-years of smoking.69
The DANTE trial61 recruited only male participants, whereas most trials recruited both male and female
participants. The NELSON trial57 recruited at first only men, and later also women (aged 50–75 years),
who were current and former smokers with ≤ 10 years of cessation, who smoked > 15 cigarettes per day
for > 25 years or > 10 cigarettes per day for > 30 years.
The characteristics of screening programmes are shown in Appendix 4. Most studies compared LDCT
screening with usual care (no screening), whereas three studies compared LDCT screening with CXR
screening. As seen in Appendix 4, Table 43, the definitions of a positive scan varied across studies in terms
of nodule sizes. For example, the NELSON trial57 defined positive CT scans as those non-calcified nodules
that had a solid component of > 500 mm3 (> 9.8-mm diameter) or volume-doubling time of < 400 days.
If the volume of largest solid nodule or the solid component of a partially solid nodule was 50–500 mm3
(4.6–9.8 mm in diameter) or > 8 mm in diameter for non-solid nodules or volume-doubling time was
400–600 days, these results were treated as indeterminate test results. In NLST,71 any non-calcified nodule
measuring ≥ 4 mm in any diameter and radiographic images were classified as positive, suspicious for lungeen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
h and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
als provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
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20cancer. Other abnormalities (e.g. adenopathy or effusion) could be positive or suspicious. As per the
protocol, abnormal findings suspicious for lung cancer that were stable across the three screening rounds
were classified as minor abnormalities rather than positive findings.
There were variations in imaging evaluation and interpretation strategy across included trials. When reported,
two radiologists independently interpreted and reported the results in most trials. If there was disagreement,
final interpretation was based on joint consensus.
The diagnostic follow-up strategies for suspicious abnormality findings varied between studies.
When reported, most studies used further diagnostic imaging {e.g. high-resolution CT or chest
fludeoxyglucose (18F) positron emission tomography ([18F] FDG-PET)} and/or invasive biopsy with rapid
on-site examination.
Computed tomography parameters
The key CT technical specifications of the included studies are presented in Tables 2 and 3 (see the
Glossary for definitions of CT parameters). Given the selective reporting of CT vendors, the available
information suggests that the trials transition from single (single bank of detectors) to multislice (multiple
banks of detectors) technology during a time of rapid CT development. The DANTE,61 Garg et al.,64
ITALUNG72 and German Lung Cancer Screening Intervention (LUSI)68 trials have incorporated single-slice
technology. The advantages of multislice over single-slice technology mainly include the same acquisition
in shorter time, better z-axis resolution and the capacity to scan larger volumes in the same time. Specific
to CT of the thorax, multislice technology allows for quicker scanning, resulting in reduced breathing
artefact and better quantification of thoracic lesions where present.
In general, the slice thickness ranges between 1 and 3 mm. These are generally considered ‘thin’ slices and
were considered superior to ‘thick’ slices. Reconstructed slice thickness (which includes the consideration
of pitch and collimation) is complicated in helical multidetector compared with single-detector scanning.
In helical scanning, reducing slice thickness increases z-axis resolution but this results in a trade-off with
increased image noise and possibly dose. The DANTE trial61 adopted a slice thickness of 5 mm, which is at
odds with the other trials.
In the last decade, the development of multislice technology expanded the applications of CT, leading to
the increased number of examinations and radiation exposure. Given the concern about the rise of medical
radiation, automatic tube current modulation was designed to achieve the same image quality for individuals
with different biological make-up/patient attenuation characteristics, reducing radiation exposure. In the
setting of LDCT screening, there are two broad strategies in performing CT thorax, either (1) tube current
modulation (as described) or (2) a fixed-tube current approach. In this report, three main strategies of dose
reduction have been identified:
1. fixed-tube current and voltage regardless of the body mass index (BMI)
2. fixed-tube current and voltage depending on the BMI
3. automatic tube current and voltage depending on the BMI.
Considering the selective reporting, each LDCT thorax strategy results in different radiation output but the
reported doses are generally lower than the doses of standard CT thorax in the literature.
Some trials conducted volumetric analysis using software mostly developed by the CT vendors. DLCST63 used
semiautomated software designed by Philips, whereas MILD,69 NELSON56,57 and UKLS55 used semiautomated
software made by Siemens. LUSI68 used computer-aided detection software made by MEDIAN. The
comparability of volumetric measurements using different software is not known.
Estimation of radiation dose is achieved by multiplying the dose length product by a conversion factor;
none of the studies reported whether or not the commonly used conversion factor (0.014) was used inNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 2 Computed tomography parameters for LDCT vs. usual care
Study
identifier
CT technology (vendor CT
scanner)
Multi or single
detector Voltage (kV)
Tube current-
time product
(mAs)
Slice
thickness
(mm) Volumetric analysis Pitch
Estimated
average
effective dose
(mSv)
DANTE61 NR Multi after 2003 and
single before 2003
140 40 5 NR 1.25 NR
DLCST63 Philips Mx 8000 (Philips Medical
Systems, Eindhoven, the
Netherlands)
Multi (16 slice) 120 40 1–1.5 Philips evaluation
semiautomated software
1.5 1
Garg et al.64 NR Single 120 50 NR NR 2 : 1 NR
ITALUNG65 NR 1 × single and
4 ×multi
120–140 20–43 1–1.25 for
multislice
NR 1–2 NR
LungSEARCH67 NR NR NR NR NR NR NR NR
LUSI68 Unspecified Toshiba and Siemens
scanners, (switch of technology at
2010)
Multi (16 and 128
slice) after 2010 and
single before 2010
NR NR 1 Computer-aided detection
(MEDIAN Technologies,
Valbonne, France) with
volumetric software
NR 1.6–2
MILD69 Somatom Sensation 16, Siemens
(Siemens Medical Solutions,
Forchheim, Germany)
Multi (16 slice) 120 30 1 LungCare, Siemens,
semi-automated software
(Siemens Healthcare,
Forchheim, Germany)
1.5 NR
NELSON56,57 M×8000 IDT (Philips Medical
Systems, Cleveland, OH, USA) or
Brilliance 16P, Philips (Philips
Medical Systems, Cleveland, OH,
USA), or Sensation-16, Siemens
(Siemens Medical Solutions,
Forchheim, Germany)
Multi (16 slice) 80–90 (< 50 kg)
100 (< 60 kg)
120 (60–80 kg)
140 (> 80 kg)
20 1 LungCare, Siemens,
semi-automated software
1.5 < 0.4 (< 60 kg)
< 0.8 (60–80 kg)
< 1.6 (> 80 kg)
UKLS55 Unspecified Siemens and Philips
Brilliance 64 (Philips Medical
Systems, Cleveland, OH, USA)
Multi (128 and 64
slice)
Automated
based on BMI
Automated
based on BMI
1 Siemens syngo LungCare,
version Somaris/5 VB 10A,
(Siemens Medical
Solutions, Forchheim,
Germany)
0.9–1.1 NR
BMI, body mass index; LUSI, German Lung Cancer Screening Intervention; NR, not reported.
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TABLE 3 Computed tomography parameters for LDCT vs. CXR
Study
CT technology
(vendor CT scanner) Multi or single detector Voltage (kV)
Tube current-time
product (mAs)
Slice
thickness
(mm)
Volumetric
analysis Pitch
Estimated average
effective dose (mSv)
Depiscan62 NR Multi 100–140 automated
based on BMI
20–100 automated
based on BMI
1.25–3 NR NR NR
LSS-PLCO66 Variable and not
specified
Multi (inclusion criteria
said must have a history
of a spiral/helical CT scan)
120–140 60 NR NR 2 NR
NLST70,71 97 different scanners Multi > 4 slices 120–140 40–80 automated
based on BMI
1–2.5 NR 1.25–2
(typically 1.5)
1.5
BMI, body mass index; LSS-PLCO, Lung Screening Study as part of the Prostate, Lung, Colorectal and Ovarian cancer screening trial; NR, not reported.
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69estimating the average radiation dose. However, all studies used radiation doses that would be considered
low by CT standards and are less than annual background radiation exposure. Image quality has not been
considered as an outcome in the trials, which is influenced by patient demographics.
Ongoing studies
A total of 125 ongoing trials were identified in the search and investigated further. Of these, only two
were considered relevant to this review. One is the MILD trial69 (NCT02837809), which is already included,
and the second is a RCT based in China (NCT02898441), which is due for completion by December 2018.
This study compares LDCT screening for lung cancer with usual care. The anticipated recruitment is 6000
participants and the primary outcome is lung cancer incidence. The 5-year follow-up is planned for lung
cancer incidence, lung cancer mortality and all-cause mortality.
Outcome measures in included trials
In order to demonstrate the variability of reporting in the included trials, Table 4 displays which outcome is
measured and whether or not it includes ≥ 5 years of follow-up. Additional information, when available, is
given on whether or not the outcome was predefined in a protocol and, if so, whether it was categorised
as a primary or secondary outcome.
Of the 12 included studies, predefined outcomes could not be verified for five studies.61,62,64,66,68 Only the
ITALUNG trial65 had a full protocol published,65 whereas the remaining trials listed outcomes in relevant
clinical trials registries.55,57,63,67,69,70 Five studies62,64,66–68 have no data on the outcomes of interest. A sixth
trial (ITALUNG65) has recently reported results for several outcomes; however, as they were published after
the inclusion date for the current review, these results were not incorporated in the analyses.
Lung cancer mortality, all-cause mortality and cancer incidence with > 5 years’ follow-up are reported
in four studies.61,63,69,70 When lung cancer mortality is cited as a primary outcome, data for two studies57,65
were not identified. However, one of these is the ITALUNG trial,65 as previously mentioned, and the second
is the more recent NELSON trial,57 for which results may be published imminently. As a secondary outcome
in the LungSEARCH trial,67 data for lung cancer mortality remain unreported.
Cancer incidence is defined as a secondary outcome for three studies, with results available for two
studies63,70 in this review and the third being the ITALUNG trial.65
Data for stage distribution are provided for three studies61,63,70 with ≥ 5 years’ follow-up. Although the
LungSEARCH trial67 has stage distribution defined as a primary outcome, no results were available.
Complete resection is the least reported outcome, with only two studies61,70 providing data for ≥ 5 years.
Smoking cessation was reported in three studies,56,61,63 with a fourth study defining this as a secondary
outcome; however, the results have not been published.69
With regard to HRQoL, this is reported for four studies;55,57,63,70 however, the follow-up is < 5 years and
actually < 1 year for the NLST trial. Furthermore, the NELSON trial57 included only a subsample of
participants for this outcome.
Risk of bias of included studies
All the studies were assessed for risk of bias using the Cochrane Risk of Bias tool.76 However, as indicated
in Table 4, only a minority of the included studies contributed data to the consideration of the main
outcome measures assessed through a comparison of the intervention arm with the control. Thus, the
reporting of quality focuses on the risk of bias for the studies contributing results of the main outcomes,
particularly separating mortality, psychological consequences/HRQoL and smoking cessation, as we noted
that not only were there different included studies for these outcomes, but also differing threats to validity
depending on the outcome. This stemmed from variation in the objectivity of the outcome and different
losses to follow-up between outcomes within a trial.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
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Park, Southampton SO16 7NS, UK.
23
TABLE 4 Outcomes measured in screening and control arms
Study identifier
(recruitment period)
Number of
randomised
participants
Mortality
Cancer
incidence
Stage
distribution
Complete
resection HRQoL
Smoking
cessation Additional informationLung cancer All-cause
DANTE61,73 (March 2001
to February 2006)
2450 ≥ 5 years ≥ 5 years ≥ 5 years ≥ 5 years ≥ 5 years NR ≥ 5 years NCT00420862
l No protocol found
l Update (May 2017) combined
with MILD69
Depiscan62 (October 2002
to December 2004)
830 NR NR NR NR NR NR NR Pilot
l No protocol found
DLCST63 (October 2004
to March 2006)
4104 ≥ 5 years, 1°,
10 years
≥ 5 years ≥ 5 years, 2°,
5 years
≥ 5 years, 2°,
5 years
NR COS-LC 1–5 years Annual smoking
status 1–5 years
NCT00496977
l Details in ClinicalTrials.gov
Garg et al.64 (January
2001 to October 2001)
190 NR NR NR NR NR NR NR Feasibility study
l No protocol found
ITALUNG65 [March 2004
to September 2010 (end
of last intervention scan
at year 4)]
3206 NR, 1°, 8 years NR, 2°, 8 years NR, 2°, 8 yearsa NR NR NR NR NCT02777996
l Details in ClinicalTrials.gov
l Results > 5 years recently
published but, after inclusion
date for this review
LSS-PLCO66 (September
2000 to November 2000
or January 2001)b
3318 NR NR NR NR NR NR NR NCT00006382
l No protocol found
l Feasibility study for NSLT
LungSEARCH67 (August
2007 to March 2011)
1568 NR, 1°,
15 years
NR NR NR, 2°, 5 years NR NR NR NCT00512746
l Details in ClinicalTrials.gov
LUSI68 (September 2007
to April 2011)
4052 NR NR NR NR NR NR NR l No protocol found
l Conference abstract 2016
indicates that results imminent
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Study identifier
(recruitment period)
Number of
randomised
participants
Mortality
Cancer
incidence
Stage
distribution
Complete
resection HRQoL
Smoking
cessation Additional informationLung cancer All-cause
MILD69 (September 2005
to September 2011)
4099 ≥ 5 years, 1°,
10 years
≥ 5 years ≥ 5 years NR NR NR NR, 2°, 10 years NCT02837809
l Details in ClinicalTrials.gov
l Update (May 2017) combined
with DANTE
NELSON56,57 (January 2004
to December 2006)
15,822 NR, 10 NR NR NR NR < 5 yearsc 2° < 5 yearsc ISRCTN63545820
l Details in ISRCTN entry
NLST70,71,74 (August 2002
to April 2004)
53,454 ≥ 5 years,d 1° ≥ 5 years,d 2° ≥ 5 years,d 2° ≥ 5 years ≥ 5 years < 1 years NR NCT00047385
l Details in ClinicalTrials.gov
UKLS55 (August 2011 to
August 2012)
4061 NR NR NR NR NR < 5 years NR ISRCTN78513845
l Stated intention to combine
mortality and incidence data
with NELSON
1°, primary outcome; 2°, secondary outcome; COS-LC, consequences of screening lung cancer; LSS-PLCO, Lung Screening Study as part of the Prostate, Lung, Colorectal and Ovarian cancer
screening trial; NR, not reported.
a Including overdiagnosis.
b Recruitment period varies according to source.
c Subsample of participants.
d Prespecified – all events to 31 December 2009.
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26Risk of bias for lung cancer and overall mortality
There were four contributing included studies to mortality outcomes. As indicated in Table 5, according to
the standard criteria for risk of bias, all but one of these trials were well conducted. All performed power
calculations and met their sample size targets, but it should be noted that the anticipated effect on mortality
was much more modest in NLST71 and, hence, the trial very much larger, with > 10 times the number of
participants of DANTE61 and DLCST.63 The only quality assessment issues identified for DANTE,61 DLCST63
and NLST71 were lack of demonstration of allocation concealment of randomisation and failure to blind
study participants to allocation. Although allocation concealment is the most sensitive indicator of trial
quality, it should be noted that failure to demonstrate allocation concealment is still common in trials, more
so with RCTs designed several years ago. The great practical difficulty of achieving blinding in DANTE,61
DLCST63 and NLST71 was not felt to introduce bias in view of the relative objectivity of the outcome. This
would have been reinforced further in the NLST trial because it employed an active control arm.
Relative to the other trials measuring mortality, MILD69 appeared to be considerably more open to bias than
DANTE, DLCST or NLST.61,63,71 Like the other trials it did blind assessment of outcome, achieve complete
follow-up and avoid selective reporting. Again, like the other trials, it did not achieve allocation concealment
or blind participants. However, there were considerably greater concerns about the randomisation process,
which were not true of the other trials. First, there was lack of detail about the process of randomisation.
Second, there were marked differences in three of the baseline characteristics (participant sex, current
smoking status and FEV1). This greatly challenges the assumption that randomisation achieved equivalence
between the CT screening arm and the control arm, which is the fundamental premise of all RCTs. The
comparison between the two intervention arms may not have been as badly affected.
An additional table illustrates the size of the imbalance in baseline characteristics between the four trials
contributing results on mortality (Table 6).
In the MILD trial,69 percentage of male participants and smoking history were similar at baseline. However,
there were more current smokers in the usual-care group (90%) than in the annual (69%) and biennial
(68%) screening groups. There were more participants aged < 55 years in the usual-care group (38%)
than in the annual (33%) and biennial (32%) screening groups. Furthermore, it should be noted that
fewer participants in the usual-care group (19%) had FEV1 per cent predicted that was < 90%, compared
with both the annual screening (28%) and biennial screening groups (28%). This indicated that the overall
lung functions of patients in both annual and biennial screening groups were worse at baseline compared
with the usual-care group, which could threaten the validity of the results.
The baseline imbalances in the other trials, DANTE,61 DLCST63 and NLST71 were much less common and,
when they did occur, were much less marked in size.
Risk of bias for psychological consequences and health-related quality of life
Four included trials contributed information on psychological consequences and HRQoL. Two were
common to mortality outcomes (DLCST and NLST)63,71 and two were trials which currently did not
contribute evidence on mortality but are likely to do so in the future (NELSON and UKLS).55,57 The risks of
bias in the four RCTs, DLCST,63 NELSON,56,57 NLST71 and UKLS,55 contributing evidence on psychological
consequences and HRQoL are shown in the Table 7.
The most important feature is that, relative to mortality, the risk of bias for psychological consequences
and HRQoL is much higher. This arises both because the outcomes are more subjective and, hence,
susceptible to the lack of blinding that occurs across all the included trials, but also because losses to
follow-up were often in excess of 10% and unequal between CT screening arms and the controls.
The UKLS was the only trial that demonstrated both good allocation sequence and allocation concealment.55NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 5 Risk of bias of included studies for lung cancer and overall mortality
Study
identifier
(country)
Criteria
Random-
sequence
generation
(selection
bias)
Allocation
concealment
(selection
bias)
Blinding of
participants
and personnel
(performance
bias)
Blinding
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition
bias)
Selective
reporting
(reporting
bias)
Other risk of
bias
DANTE (Italy)61 Low Unclear Low Low Low Low Low and low
DLCST
(Denmark)63
Low Unclear Low Low Low Low Low and low
MILD (Italy)69 Unclear Unclear Low Low Low Low Inadequate and
inadequate
NLST (USA)71 Low Unclear Low Low Low Low Low and low
low, low risk of bias; unclear, unclear risk of bias.
Notes
Other potential sources of risks: underpowered sample size for important outcomes, and significant baseline differences
between study arms on important characteristics.
DANTE61
Random-sequence generation: ‘Subjects were randomised by a 1 : 1 scheme in blocks of four and stratified by centre
according to a computer-generated list supplied by the data centre each week before the enrolment sessions’.61
No blinding but the assessment of mortality was not felt likely to be influenced by this. ‘A panel blinded to patient’s
assignment reviewed the clinical cases whenever several competing causes of death were possible’.61
Loss to follow-up unlikely as ‘Life status data and death certificates were requested for the entire study population from
local health registries’.61
Outcome prespecified.
Met sample size target, but power calculation based on mortality reduction of 50%.
Baseline equivalence demonstrated with the exception of respiratory comorbidity: LDCT 35%, control 31%; p = 0.0321.
DLCST63
Random-sequence generation. ‘Participants were randomized by a computer program (random permuted blocks of 10
participants) to either annual screening by low-dose computed tomography (the screening group) or the control group,
which was not offered CT screening’.63
No blinding, but the assessment of mortality was not felt likely to be influenced by this. Outcome assessment blinded
‘An international independent death review board will be established’.63
Loss to follow-up unlikely as Danish Civil Registration System checked annually.
Outcome prespecified.
Met target sample size (n= 4000). Designed to be adequately powered in combination with NELSON (n= 16,000) to detect
25% reduction in mortality at 10 years.
Baseline equivalence demonstrated.
MILD69
Random-sequence generation. No detail on method of randomisation. Control group referred to as ‘. . . observational
control arm’ in the discussion section of main paper reporting results.69
No blinding, but the assessment of mortality was not felt likely to be influenced by this. Outcome assessment blinded
‘. . . Cancer Registry Office database of Lombardy which traced the vital status of all participants blindly, without knowing
the random allocation’.69
Loss to follow-up unlikely because of use of death and cancer registries.
Outcome prespecified.
Failed to meet sample target size (n= 10,000) which was powered to detect a 30% reduction in lung cancer mortality after
10 years. Single centre results rather than the originally planned multicentre study.
Pronounced imbalances in baseline characteristics in three important characteristics (sex, current smoking status and
predicted FEV1).
NLST71
Random-sequence generation. ‘Randomization occurred after data co-ordinating centres confirmed that eligibility criteria
had been met for a given individual; participants were then assigned to either the computerized tomography arm or chest
radiograph arm in a 1 : 1 ratio, stratifying by site, sex, and 5-year age group. Stratified randomization was accomplished
by use of a block size of six or eight, with block size chosen at random’.75 Allocation concealment seems likely but not
explicitly stated, thus categorised as unclear.
No blinding, but the assessment of mortality was not felt likely to be influenced by this. Outcome assessment blinded
‘An endpoint verification team determined whether the cause of death was lung cancer . . . members of the team were not
aware of the group assignments’.70
Loss to follow-up unlikely because of use of National Death Index.77
Outcome prespecified.
Met target sample size (n= 50,000). Powered to achieve a 20% reduction in lung cancer mortality. Baseline equivalence
demonstrated.
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TABLE 6 Imbalance in baseline characteristics between the four trials reporting mortality
Study characteristics
Study (number of participants)
DANTE78 (n= 2450) DLSCT63 (n= 4104) MILD69 (n= 4099) NLST71 (n= 53,456)
Trial arm LDCT Control LDCT Control
LDCT
(biennial)
LDCT
(annual) Control LDCT Control
n (%) 1264 (51.6) 1186 (48.4) 2052 (50) 2052 (50) 1186 (28.9) 1190 (29.0) 1723 (42.0) 26723 (50) 26733 (50)
Sex (% of n male) NR NR 55.9a 54.6a 68.5 68.4 63.3 59.0 59.0
Age (years), mean 64.6 64.6 57.9a 57.9a 58.2a 58.3a 57.6a 61.6a 61.6a
Occupational exposure (%) 31.3 34.1 NR NR NR NR NR 27.9 28.3
Smoking
Current smokers (%) 56.5 57.4 75.3a 76.9a 68.3 68.9 89.7 48.2 48.3
Pack-years (mean) 47.3 47.2 NR NR 39b 39b 38b 56.0 55.9
Smoking duration (years), mean NR NR 38.5a 38.6a 38.4a 38.3a 38.5a 43.1 43.1
Cigarettes/day (mean) NR NR 19.2a 18.6a 26.3a 26.8a 25.2a 28.5 28.4
Duration smoking cessation in former smokers
(years), mean
NR NR 4.2a 4.4a NR NR NR 7.7a 7.7a
Comorbidities, n
Respiratory 35.3 31.2 NR NR NR NR NR NR NR
Chronic bronchitis, emphysema or COPD NR NR NR NR NR NR NR 17.5 17.4
Hypertension 36.1 37.7 NR NR NR NR NR 35.1 35.7
Cardiac 12.6 13.9 NR NR NR NR NR NR NR
Heart disease or heart attack NR NR NR NR NR NR NR 12.9 12.5
Stroke NR NR NR NR NR NR NR 2.8 2.8
PVD 10.3 9.0 NR NR NR NR NR NR NR
Diabetes 8.3 8.4 NR NR NR NR NR 9.7 9.7
Malignancies NR NR NR NR NR NR NR 4.0 4.5
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Study characteristics
Study (number of participants)
DANTE78 (n= 2450) DLSCT63 (n= 4104) MILD69 (n= 4099) NLST71 (n= 53,456)
Trial arm LDCT Control LDCT Control
LDCT
(biennial)
LDCT
(annual) Control LDCT Control
Lung function
FEV1 (litres) NR NR 2.9 2.9 NR NR NR NR NR
FEV1 < 90% predicted NR NR NR NR 27.7 28.2 19.2 NR NR
Other data available Social status Paper indicates that only ‘selected
baseline characteristics’ were reported
Race; education; marital
status; BMI categories
NR, not reported; PenTAG, Peninsula Technology Assessment Group; PVD, peripheral vascular disease.
a Calculated by PenTAG.
b Median rather than mean.
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TABLE 7 Risk of bias of included studies for psychological consequences and HRQoL
Study
identifier
(country)
Criteria
Random-
sequence
generation
(selection
bias)
Allocation
concealment
(selection
bias)
Blinding of
participants
and personnel
(performance
bias)
Blinding
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition
bias)
Selective
reporting
(reporting
bias)
Other risk
of bias
DLCST
(Denmark)63
Low Unclear High High High Low Unclear and
low
NELSON
(Dutch-Belgian
trial)57
Unclear Unclear High High High Low Unclear and
low
NLST (USA)71 Unclear Unclear High High High Low Unclear and
unclear
UKLS (UK)55 Low Low High High High Low Unclear and
low
ACRIN, American College of Radiology Imaging Network; high, high risk of bias; low, low risk of bias; unclear, unclear risk of bias.
Notes
Other potential sources of risks: underpowered sample size for important outcomes, significant baseline differences
between study arms on important characteristics.
DLCST63
Random-sequence generation. ‘Participants were randomised by use of an in-house computer program developed by
Asger Dirksen, M.D.,D.Msc. (random permuted blocks of 10 participants) to either annual screening by low-dose computed
tomography (the screening group) or the control group, which was not offered CT screening’.79
Outcome assessment high risk because it is self-reported and reporters are unblinded.
Losses to follow-up > 10%, particularly in control arm.
Consequences of screening tool prespecified and reported.
No comment on power to detect differences in psychological consequences. Baseline equivalence demonstrated.
NELSON56,57
No details on methods of randomisation found. Minimal details on how sample from all those recruited into the main trial
was achieved. Sampling was done to obtain subset of all trial entrants taking part in HRQoL part of trial. The control arm
was further sampled to obtain follow-up questionnaire data. Sampling said to be random.
Outcome assessment high risk because it is self-reported and reporters are unblinded.
> 10% loss to follow-up at 2 years with much higher loss in control arm.
HRQoL prespecified as a secondary outcome.
No power calculation provided. Baseline equivalence demonstrated.
NLST71
Participants were randomised 1 : 1 to LDCT or CXR following confirmation of eligibility. Permuted block randomisation with
randomly selected block size (six or eight) was used with stratification by site, sex and age group (5 years).75
Assume adequate randomisation for all NLST can be extended to ACRIN substudy. Unclear how participants were sampled
and whether or not this would break randomisation.
Outcome assessment high risk because it is self-reported and reporters are unblinded.
Losses to follow-up of > 10%. No information on loss to follow-up in each arm.
HRQoL and psychological consequences prespecified in protocol attached to main study report.70
Power calculation not provided. Baseline equivalence not demonstrated.
UKLS55
‘Following attendance at a research clinic, recruits were randomised by computer into the intervention arm (LDCT scan,
screen group) or the control arm (usual care, non-screen group) at a ratio of 1 : 1’.55 How allocation concealment was
achieved is also detailed in this source.
Outcome assessment high risk because it is self-reported and reporters are unblinded.
Losses to follow-up of > 10% particularly in control arm.
Prespecified as secondary outcome measure.
Power calculation not provided. Baseline equivalence demonstrated at T0 and T1.
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69None of the included trials was clear about whether or not it was adequately powered to assess the
outcomes in question, which was often further complicated by the fact that samples of the whole-trial
population were used to measure the effectiveness of screening on psychological consequences and
HRQoL. UKLS was the largest study with respect to these outcomes, even though it was a pilot study.55
There were no risk-of-bias issues with respect to baseline equivalence as there were for mortality. NLST did
not demonstrate baseline equivalence, but it may be reasonable to assume this from the demonstration
of baseline equivalence for the whole trial and that the sample of participants used for assessment of
psychological consequences and HRQoL appeared to be random.71
Risk of bias for smoking behaviour
Three included trials contributed information on smoking behaviour. Two were common to mortality
outcomes (DLCST and NLST),63,71 and one was a trial that currently does not contribute evidence on
mortality but is likely to do so in the future (NELSON).57 The NLST reported its findings on smoking in two
parts: one for each of its two contributing research networks, Lung Screening Study (LSS) and American
College of Radiology Imaging Network (ACRIN). The risk of bias for each substudy was the same (Table 8).
Evidence on smoking behaviour from the UKLS study was in press at time of writing, but has subsequently
been published.80 The risks of bias for the three RCTs, DLCST,63 NELSON56,57 and NLST71 contributing
evidence on smoking behaviour are shown in Table 8.
As for psychological consequences and HRQoL, the most important feature is that, relative to mortality, the
risk of bias for smoking behaviour is much higher. This mainly arises because the outcomes are more
subjective and, hence, susceptible to the lack of blinding that occurs across all the included trials, but also
because of losses to follow-up, which were often > 10% and unequal between CT screening arms and
the control arms. NLST performed best with respect to loss to follow-up, with levels well below 10%, but
it did not report whether or not the levels were similar in both the CT screening and CXR screening arms.71
However, despite this, it was categorised as being at a low risk of bias with respect to attrition bias. The
risk of bias for NLST71 arising from lack of blinding may have been less than DLCST63 and NELSON57
because it had an active control arm rather than usual care. Across all trials, smoking behaviour was
generally based on participant self-report with little or no confirmation of true smoking status using
measurements such as exhaled carbon monoxide.
None of the included trials was clear about whether or not it was adequately powered to assess smoking
behaviour. Given the nature and frequency of smoking behaviour, it seems likely that DLCST and NLST
were adequately powered to assess it.63,71 However, the smoking behaviour study for NELSON was
undertaken on a very small subsample of the whole trial.57 A power calculation was done to confirm that
the sample size was sufficient to detect a 7% difference in quit rate.
There were no risk-of-bias issues with respect to baseline equivalence as there were for mortality.
Risk of bias for assessments of characteristics based on a single arm of a randomised
controlled trial
Many studies provided information on outcomes measured in one arm of the study only, usually the
intervention arm. These are not randomised comparisons and are hence open to the same biases as
case series, particularly confounding. The data were summarised in the results sections for completeness.
However, it should be clearly noted that they do not provide the same robustness of evidence as the
randomised comparisons even though they are derived from RCTs, and they are clearly separated from the
randomised comparisons in the results section as a consequence. The results from single arms of the RCTs
have not been formally quality assessed, beyond noting that they are at very high risk of bias when
making comparisons.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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TABLE 8 Risk of bias of included studies reporting smoking behaviour
Study
identifier
(country)
Criteria
Random-
sequence
generation
(selection
bias)
Allocation
concealment
(selection
bias)
Blinding of
participants
and personnel
(performance
bias)
Blinding
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition
bias)
Selective
reporting
(reporting
bias)
Other risk
of bias
DLCST
(Denmark)63
Low Unclear High High High Unclear Unclear and
low
NELSON
(Dutch-Belgian
trial)57
Unclear Unclear High High High Low Low risk and
low
NLST – LSS
(USA)71
Low Unclear High High Low Unclear Unclear and
low
NLST – ACRIN
(USA)70
Low Unclear High High Low Unclear Unclear and
low
high, high risk of bias; ITT, intention to treat; low, low risk of bias; unclear, unclear risk of bias.
Notes
Other potential sources of risks: underpowered sample size for important outcomes; significant baseline differences
between study arms on important characteristics.
DLCST63
Random-sequence generation. Participants were randomised 1 : 1 to annual LDCT (screening group) or no CT screening
(control group). Permuted block randomisation with fixed block size (10) was used.79
Outcome assessment high risk because it is self-reported and reporters are unblinded. Somewhat mitigated by verification
of smoking status using exhaled carbon monoxide (CO) measurement in some participants.
> 10% loss to follow-up at 5 years with much higher loss in control arm. Somewhat mitigated by use of ITT analyses.
Smoking as an outcome not prespecified; no definition of which measures of smoking cessation would be used.
No comment on power to detect differences in smoking cessation. Baseline equivalence demonstrated.
NELSON57
No details on methods of randomisation found. Minimal details on how sample from all those recruited into the main trial
was achieved: ‘. . . . conducted in a random subgroup of current male smokers randomised to the screen (n= 641) or
control (n= 643) arm of the NELSON trial during the first recruitment period . . .’.81
Outcome assessment high risk because it is self-reported and reporters are unblinded. No verification of smoking status
using exhaled CO measurement.
> 10% loss to follow-up at 2 years with much higher loss in control arm. Somewhat mitigated by use of ITT analyses.
Smoking prespecified as a secondary outcome.
Power calculation provided. ‘Power analysis indicated that a sample of 480 participants in the screen arm and 240
participants in the control arm would have 80% power to detect an expected difference in quit rates of 14% in the screen
arm and 7% in the control arm’.81
Baseline equivalence demonstrated.
NLST70,71
Participants were randomised 1 : 1 to LDCT or CXR following confirmation of eligibility. Permuted block randomisation with
randomly selected block size (six or eight) was used with stratification by site, sex and age group (5 years).75
Assume adequate randomisation for all NLST can be extended to two substudies.
Outcome assessment high risk because it is self-reported and reporters are unblinded. No verification of smoking status
using exhaled CO measurement. Active control group may improve objectivity of outcome.
LSS: 94.7% completion of data. Not subdivided by allocated group.
ACRIN: 93.9% completion of data. Not subdivided by allocated group.
Smoking not prespecified as an outcome.
Power calculation not provided.
Baseline equivalence demonstrated for combined trial.
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Comparative outcomes
Lung cancer mortality
Four RCTs (DANTE, DLCST, MILD and NLST) assessed the effects of LDCT screening compared with either
usual care (no screening) or the best available care (CXR screening), and reported lung cancer mortality at
long-term follow-up.61,63,69,71 Over the long-term follow-up, it was likely that CXR could be an element thatNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69constituted usual care for the early detection of lung cancer in a high-risk population. Therefore, usual care in
this context was not dissimilar to the best available care when CXR was used in early detection of lung cancer.
For this reason, we performed statistical pooling of all the four RCTs on mortality outcomes. All trials were
conducted in participants at high risk for lung cancer. We only performed statistical pooling for trials that
reported lung cancer mortality data with ≥ 5 years of follow-up, using the random-effects model.
Figure 2 shows the overall pooled result of four RCTs comparing LDCT screening with controls. When
compared with controls (usual care/best available care), LDCT screening was associated with a non-statistically
significant reduction in lung cancer mortality (pooled RR 0.94, 95% CI 0.74 to 1.19) with up to 9.80 years of
follow-up. There was moderate heterogeneity in the magnitude of effects (I2 = 43.3%).
It is important to note that, given the moderate heterogeneity observed with this outcome (I2 = 43.3%),
the pooled non-statistically significant decrease in lung cancer mortality (pooled RR 0.94, 95% CI 0.74 to
1.19) should be treated with caution.
Exploration of heterogeneity
The quality of trials Among these four RCTs, the MILD trial69 was judged to be of poor quality, whereas
the remaining trials were judged to be of moderate to high quality (see Risk of bias for lung cancer and
overall mortality).55 We explored the impact of trial quality on the robustness of overall results.
Figure 3 presents the sensitivity analysis by excluding the poor-quality trial (MILD69). The results of the
sensitivity analysis showed that, compared with controls (usual care/best available care), LDCT screening
demonstrated a statistically significant reduction in lung cancer mortality (pooled RR 0.85, 95% CI 0.74 to
0.98). The level of heterogeneity was considerably reduced (I2 = 6.9%). This suggests that variation in trial
quality could be a potential source of heterogeneity.
Annual low-dose computed tomography screening versus usual care We further explored the
heterogeneity on the basis of frequency of screening interventions (e.g. annual screening or biennial
screening). We conducted a subgroup analysis based on the annual LDCT screening compared with usual
care only. Figure 4 presents the pooled results of this subgroup analysis. When compared with usual care
(no screening), LDCT screening programme demonstrated a non-statistically significant increase in lung
cancer mortality outcome, with a pooled RR of 1.15 (95% CI 0.79 to 1.67) from three RCTs. The level of
heterogeneity was reduced (I2 = 38.9%).Overall (I 2 = 43.3%; p = 0.152)
DLCST63
NLST71
DANTE61
MILD69
Study identifier
Relative risk
0.94 (0.74 to 1.19)
1.03 (0.66 to 1.60)
0.80 (0.70 to 0.92)
RR (95% CI)
1.01 (0.70 to 1.44)
1.86 (0.78 to 4.45)
100.00
19.29
49.06
Weight (%)
25.07
6.58
10.1 10
FIGURE 2 Lung cancer mortality: overall results.
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FIGURE 4 Lung cancer mortality subgroup analysis: annual LDCT screening vs. usual care (no screening).
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FIGURE 3 Lung cancer mortality: sensitivity analysis by excluding the low-quality trial (MILD69).
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34All-cause mortality
Four RCTs (DANTE, DLCST, MILD and NLST) assessed the effects of LDCT screening compared with either
usual care (no screening) or the best available care (CXR screening), and reported all-cause mortality
outcome with ≥ 5 years of follow-up (see Appendix 4).61,63,69,71 Likewise, considering that CXR could be an
element that constituted usual care for the early detection of lung cancer in high-risk populations, we
performed statistical pooling of all these four RCTs on all-cause mortality outcome in a similar fashion.
Figure 5 shows the overall pooled result of four RCTs comparing LDCT screening with controls. When
compared with controls (usual care/best available care), LDCT screening demonstrated no statistically
significant difference in all-cause mortality outcome (pooled RR 1.00, 95% CI 0.87 to 1.16) with up to
9.80 years of follow-up. There was substantial heterogeneity associated with this outcome (I2 = 57.0%).
Sensitivity analysis and subgroup analysis were also performed to explore the potential sources of
heterogeneity.
Given the substantial heterogeneity detected between studies, the results from this pooled analysis should
be treated with caution.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 5 All-cause mortality: overall results.
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The quality of trials We assessed the impact of trial quality on the robustness of overall results as a
means to explore heterogeneity. The details of trial quality are presented in Quantity and quality of research
available, and Figure 6 shows the results of removing the low-quality trial (MILD).55 Based on the pooled
data, the LDCT screening programme demonstrated a non-statistically significant decrease in all-cause
mortality (pooled RR 0.95, 95% CI 0.89 to 1.00) compared with controls (usual care/best available care).
It should be noted that the level of heterogeneity was considerably reduced (I2 = 0%), suggesting that
variation in trial quality could be a potential source of heterogeneity between studies.
Annual low-dose computed tomography screening versus usual care A subgroup analysis are
performed on the basis of annual LDCT screening compared with usual care. Three trials evaluated the
effect of annual LDCT screening versus usual care (no screening).Overall (I 2 = 0.0%, p = 0.783)
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FIGURE 6 All-cause mortality: sensitivity analysis by excluding the low-quality trial (MILD69).
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36The pooled results of this subgroup analysis are shown in Figure 7. Annual LDCT screening showed a
non-statistically significant increase in all-cause mortality compared with usual care, with a pooled RR of
1.15 (95% CI 0.84 to 1.58). There was substantial heterogeneity (I2 = 75.2%) observed in this outcome.
Cancer detection
We performed meta-analyses for three studies providing comparative cancer incidence data (with a control
group) with ≥ 5-years’ follow-up, as this was judged sufficiently long to obtain mature data.61,63,71
Compared with controls (usual care/best available care), LDCT screening was associated with a statistically
significant increase in lung cancer detection rate (pooled RR 1.38, 95% CI 1.02 to 1.86; I2 = 79.7%) with
≥ 5 years’ follow-up (Figure 8). When compared with usual care (no screening) only, the sensitivity analysis
demonstrated a consistent result (pooled RR 1.58, 95% CI 1.15 to 2.19) over 5 years after last screening,
with a reduction in the level of heterogeneity (I2 = 54.6%).
Stage distribution
We performed meta-analyses for trials that provided relevant data for ≥ 5 years’ follow-up as this was judged
sufficiently long to obtain mature data. Figure 9 illustrates the change of lung cancer stage distribution
between LDCT screening and control arms. When pooling data from three trials with ≤ 6 years’ follow-up,Overall (I 2 = 79.7%, p = 0.007)
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FIGURE 8 Cancer detection difference between LDCT and controls: overall results.
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FIGURE 7 All-cause mortality subgroup analysis: annual screening LDCT vs. usual care.
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FIGURE 9 Early cancer stage (stage I and II) distribution between LDCT screening and control arms. M–H, Mantel–Haenszel.
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ASSESSMENT OF CLINICAL EFFECTIVENESS
38lung cancers detected in the LDCT screening arms (including interval cancers and cancers diagnosed after the
final screening round) were more likely to be early stage (I and II) than those in the control arm, and this was
statistically significant (RR 1.73, 95% CI 1.27 to 2.37, I2 = 61%). Correspondingly, these cancers were less
likely to be late stage (RR 0.67, 97% CI 0.60 to 0.75, I2 = 22%).
We performed sensitivity analyses to explore the potential sources of heterogeneity. When pooling data
of two trials comparing LDCT screening with usual care (no screening) only as part of investigation of
heterogeneity, LDCT screening was associated with a statistically significant increase in early stage (I and II)
cancer detection (RR 2.09, 95% CI 1.34 to 3.24) with ≤ 5 years’ follow-up. The level of heterogeneity was
considerably reduced (from I2 of 61% to 39.1%).
The change in stage distribution in these analyses could arise through two mechanisms: (1) cancers that
would have presented clinically as late stage are instead detected at the earlier stages (stage shift) and
(2) cancers that would never have presented clinically are instead detected at the earlier stages (overdiagnosis).
Figure 10 shows the impact of screening on the risk of late-stage lung cancer diagnosis. This is minimally
affected by overdiagnosis because late-stage lung cancers are associated with poor survival. The results from
three studies indicate that, on average, there is a risk reduction of 15% associated with LDCT screening,
which is just statistically significant (RR 0.85, 95% CI 0.73 to 1.00; I2 = 17%).
A sensitivity analysis comparing LDCT screening with usual care (no screening), that is, excluding NLST,71
indicated no statistically significant evidence of an impact on the late-stage lung cancer risk (RR 1.00, 95% CI
0.75 to 1.34; I2 = 0%).
Health-related quality of life and psychological consequences
Four trials (NELSON, NLST, DLCST and UKLS) evaluated the psychological consequences on patients of
LDCT screening and patients’ HRQoL (Table 9).55,57,63,71 Two trials (NELSON and NLST) assessed the impact
of LDCT screening on patients’ HRQoL measures.57,71 Both NELSON and NLST trials assessed this HRQoL
outcome at short- and long-term follow-up. Four trials (DLCST, NELSON, UKLS and NLST) assessed adverse
psychological impact associated with LDCT screening.55,57,63,71
All included studies suffered from additional challenges to their validity relative to mortality outcomes,
resulting from subjectivity of outcomes in trials that were not blinded and loss to follow-up. Three studies
(NLST, NELSON and DLSCT) evaluated these outcomes in subsamples of their whole-trial populations.
Hence, the size of the whole trial is not a good guide to quantity of evidence provided by each study on
these outcomes. The sample size of each study was UKLS (n = 4061), DLSCT (n = 3929), NLST (n = 2812)
and NELSON (n = 1466).
As a general comment, when normal values for psychological consequences and HRQoL were provided,
the levels encountered were generally well outside the scale values, indicating marked psychological
distress or QoL outside that which would be expected in the normal population.
UK Lung Cancer Screening Trial
The UKLS evaluated the psychological consequences on patients of LDCT screening and patients’ HRQoL in
4061 participants.55 This trial assessed participants’ distress using the lung cancer distress (Cancer Worry
Scale), assessed participants’ anxiety using the Hospital Anxiety and Depression Scale and assessed
participants’ depression using the Hospital Anxiety and Depression Scale. Decision satisfaction was also
assessed in this trial. The assessments were performed at baseline (T0), the 2-week post-scan result (T1)
and the 2-year follow-up (T2).
At T1, distress scores were statistically significantly higher in the LDCT screening group (LDCT 8.54 vs.
control 8.26; p ≤ 0.001), with a very small effect size. However, there was no statistically significant
difference in the distress scores between the two groups at the 2-year follow-up (LDCT 8.15 vs. control 8.10).NIHR Journals Library www.journalslibrary.nihr.ac.uk
Study identifier Events Total Events Total Weight (%)
DANTE61
DLCST63
NLST71
Total (95% CI)
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FIGURE 10 Late-stage lung cancer risk between LDCT screening and control arms. M–H, Mantel–Haenszel.
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TABLE 9 Psychological consequences and HRQoL
Study
identifier
Number of
participants
randomised to
LDCT/control Measures
Number of
(LDCT/control);
response rates
Result LDCT; mean
(SD or 95% CI) Result control Difference Notes
DLCST82,83 4104
(205/2052)
COS; COS-LC
(results not
included in this
table)
Prevalence round (Y1)
COS – high scores worse
2052/1873 A: 1.48 (2.20)
B: 0.72 (1.78)
D: 1.21 (1.99)
S: 0.63 (1.56)
A: 1.61 (2.31)
B: 0.84 (2.08)
D: 1.37 (2.17)
S :0.70 (1.72)
Prevalence round (Y1):
reduced psychological
consequences for LDCT.
p-values: 0.07, 0.05,
0.03 and 0.20,
respectively
Screen positives (n= 179)
not included in analysis
Only results of four scales
in COS reported in this
table: ‘anxiety’ [A]
(0–18), ‘negative impact
on behaviour’ [B] (0–21),
‘sense of dejection’ [D]
(0–18) and ‘negative
impact on sleep’ [S]
(0–12)
Worsening psychological
consequences noted in
both groups between Y1
and Y2. The increases in
the LDCT and control
groups were not
statistically significantly
different in size
Incidence round (prior to second screening round)
1884/1817 A: 1.50 (2.52)
B: 1.76 (2.85)
D: 1.61 (2.71)
S: 1.64 (2.47)
A: 1.71 (2.79)
B: 2.02 (3.04)
D: 1.88 (2.98)
S: 1.79 (2.57)
Incidence round (Y2):
reduced psychological
consequences for LDCT.
p-values: 0.03, 0.01,
0.01 and 0.10,
respectively
Y5a
1825/1374 (some
variation depending
on outcomes)
A: –0.26 (–0.39 to –0.13)
B: 0.77 (0.63 to 0.91)
D: 0.09 (0.04 to 0.22)
S: 0.83 (0.71 to 0.95)
A: 0.25 (0.04 to 0.46)
B: 1.37 (1.13 to 1.60)
D: 0.67 (0.44 to 0.90)
S: 1.53 (1.31 to 1.74)
Less worsening of
psychological
consequences in LDCT
vs. control
Same pattern of results
at Y5
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Study
identifier
Number of
participants
randomised to
LDCT/control Measures
Number of
(LDCT/control);
response rates
Result LDCT; mean
(SD or 95% CI) Result control Difference Notes
NELSON84,85 15,822 Generic HRQoL
(SF-12 and EQ-5D)
Generic anxiety
short form
Spielberger STAI-6
(20–80; high
scores indicating
more anxiety)
Lung-cancer-
specific distress IES
(0–75; higher score
indicates worse
distress)
Baseline
Randomised
733/733
658 (89.8%)/630
(85.9%)
EQ-5D – high scores better
79.19 (78.02 to 80.36) 78.50 (77.15 to 79.85)
STAI-6 – high scores worse
33.27 (32.51 to 34.03) 33.75 (32.87 to 34.62)
IES total – high scores worse
4.05 (3.45 to 4.65) 4.02 (3.33 to 4.71)
Y2 (6 months post second CT scan in LDCT group)
609 (89.3%)/322
(64.7%)
EQ-5D – high scores better
79.53 (78.35 to 80.71) 77.45 (75.95 to 78.95)
STAI-6 – high scores worse
32.67 (31.91 to 33.43) 33.42 (32.44 to 34.39)
IES total – high scores worse
3.72 (3.12 to 4.32) 4.03 (3.24 to 4.81)
No statistically significant
differences were found
in in any HRQoL scores
or psychological
consequence over time
between the screen and
control groups
Study conducted on
circa 10% random
sample of whole-trial
cohort
Y2 questionnaire further
restricted to random
sample of original
random sample in
control group
Only results for EQ-5D,
STAI-6 and total IES
included in this table to
illustrate general findings
Further questionnaire
data in LDCT arm after
baseline scan.
Longitudinal trends
available in HRQoL
comparing indeterminate
with negative screen
findings. Results not
included as not a
randomised comparison
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TABLE 9 Psychological consequences and HRQoL (continued )
Study
identifier
Number of
participants
randomised to
LDCT/control Measures
Number of
(LDCT/control);
response rates
Result LDCT; mean
(SD or 95% CI) Result control Difference Notes
NLST74 53,454 Generic HRQoL
(SF-36)
Generic anxiety
short form
Spielberger
STAI-Y1 (20–80;
high scores
indicating more
anxiety; median
norm for working
adults aged 50–69
years is 34.51 for
men and 32.20 for
women)
Baseline
2812 SF-36 physical – high scores better
48.07 48.89
STAI-Y1 – high scores worse
NR NR
1 month
2317
(82.4%)
SF-36 physical – high scores better
47.58 48.49
STAI-Y1 – high scores worse
33.59 33.02
6 months
1990
(70.8%)
SF-36 physical – high scores better
47.32 47.78
STAI-Y1 – high scores worse
33.33 33.11
No statistically significant
differences between
LDCT and CXR for any of
the outcomes
Study conducted on
sample of whole-trial
cohort
Only results on physical
subscale of SF-36 and
STAI included in this
table to illustrate results
pattern
Weighted average
calculated from data in
paper
Comparison of trends
over time in different
screen categories
(negative, significant
incidental finding, false
positives and true
positives) also analysed
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Study
identifier
Number of
participants
randomised to
LDCT/control Measures
Number of
(LDCT/control);
response rates
Result LDCT; mean
(SD or 95% CI) Result control Difference Notes
UKLS55,86 4061
(2028/2027)
Lung cancer
distress (CWS);
6–24, > 12.5
indicates distress);
Anxiety (HADS;
0–21 8–10 ‘mild’)
Depression (HADS;
0–21 8–10 ‘mild’)
Decision
satisfaction; % very
satisfied
Baseline (T0)
2018 (99.5%)/2019
(99.6%)
CWS – high scores worse
8.75 8.74
HADS (anxiety) – high score worse
3.72 3.67
HADS (depression) – high score worse
2.66 2.61
Satisfaction – high score better
39% 42%
Only results for T0 scorers
of < 12.5 included in
table
Results T0> 12.5 were
326/3225 at T1
Differences in all
outcomes between TP, FP,
Incidental and TN also
examined
Size of differences noted
to be small relative to
clinically important
changes in score
2-week post scan result (T1)
1653 (84.1%)/1579
(78.3%)
CWS – high scores worse
8.54 (8.44 to 8.64) 8.26 (8.16 to 8.36)
HADS (anxiety) – high score worse
3.67 (3.54 to 3.80) 3.78 (3.64 to 3.92)
HADS (depression) – high score worse
2.53 (2.42 to 2.63) 2.81 (2.70 to 2.92)
Satisfaction – high score better
42% 34%
More distress in LDCT
p≤ 0.001
Less anxiety in LDCT, NS
Less depression in LDCT
p≤ 0.001
More satisfaction in
LDCT p≤ 0.001
continued
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TABLE 9 Psychological consequences and HRQoL (continued )
Study
identifier
Number of
participants
randomised to
LDCT/control Measures
Number of
(LDCT/control);
response rates
Result LDCT; mean
(SD or 95% CI) Result control Difference Notes
2 year (T2)
1553 (82.3%)/1302
(65.3%)
CWS – high scores worse
8.15 (8.05 to 8.25) 8.10 (7.99 to 8.25)
HADS (anxiety) – high score worse
3.66 (3.52 to 3.80) 4.02 (3.86 to 4.19)
HADS (depression) – high score worse
2.77 (2.67 to 2.89) 3.01 (2.89 to 3.14)
Satisfaction – high score better
40% 26%
More distress in control,
NS
Less anxiety in LDCT
p≤ 0.001
Less depression in LDCT
p≤ 0.01
More satisfaction in
LDCT p≤ 0.001
COS, consequences of screening; COS-LC, consequences of screening lung cancer; CWS, Cancer Worry Scale; HADS, Hospital Anxiety and Depression Scale; IES, impact of event scale;
SD, standard deviation; SF-12, Short Form questionnaire-12 items; SF-36, Short Form questionnaire-36 items; STAI, State–Trait Anxiety Inventory; STAI-6, Spielberger State–Trait Anxiety
Inventory, six-item Short Form; Y1, year 1; Y2, year 2; Y5, year 5.
a Reported as change from year 1 to year 5.
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Participants in the LDCT screening group had less anxiety compared with the control group at T1 (LDCT
3.67 vs. control 3.78), although this difference did not reach statistical significance. At the 2-year follow-up,
participants in the LDCT screening group had statistically significantly less anxiety compared with the control
group (LDCT 3.66 vs. control 4.02; p ≤ 0.001).
Furthermore, participants in the LDCT screening group had statistically significantly less depression than
those in the control group at T1 (LDCT 2.53 vs. control 2.81; p ≤ 0.001) and at T2 (LDCT 2.77 vs. control
3.01, p ≤ 0.01).
At both T1 and T2, participants in the LDCT screening group had a statistically significantly higher satisfaction
rate than the control group (T1: LDCT 42% vs. control 34%; T2: LDCT 40% vs. control 26%).
Danish Lung Cancer Screening Trial
In the DLCST,82 participants in the LDCT screening and usual-care groups were invited annually to the
screening clinic to complete the validated lung cancer-specific questionnaire: consequences of screening
lung cancer (COS-LC). In this questionnaire, higher scores indicate worse outcomes. COS-LC consists of two
parts, but Part II is applicable only after a final diagnosis and was not used in the study. Part I contains nine
psychosocial scales (anxiety, behavior, sense of dejection, negative impact on sleep, self-blame, focus on
airway symptoms, stigmatization, introvert and harm of smoking) and two single items (busy to take mind
off things and less interest in sex). In total, 4104 participants were randomised to either the LDCT screening
arm or the control group. The completion rates for COS-LC for the LDCT group and usual-care group were
95.5% and 73.6%, respectively.
At the prevalence round, there was an effect of reduced psychological consequences in the LDCT screening
arm compared with the control group (anxiety: LDCT 1.48 vs. control 1.61; negative impact on behaviour:
LDCT 0.72 vs. control 0.84; sense of dejection: LDCT 1.21 vs. control 1.37; and negative impact on sleep:
LDCT 0.63 vs. control 0.70). Of these, only the difference in sense of dejection between the two groups
reached statistical significance (p = 0.03).
At the incidence round (prior to the second screening), an effect of reduced psychological consequences
in the LDCT arm was also observed (anxiety: LDCT 1.50 vs. control 1.71; negative impact on behaviour:
LDCT 1.76 vs. control 2.02; sense of dejection: LDCT 1.61 vs. control 1.88; and negative impact on sleep:
LDCT 1.64 vs. control 1.79). The differences in anxiety, negative impact on behaviour and sense of dejection
between the two groups reached statistical significance (p = 0.03, p = 0.01 and p = 0.01, respectively).
The results from the DLCST trial82 also showed a statistically significant increase in negative psychosocial
consequences from baseline through rounds 2 to 5 for both the LDCT screening group and the control
group (p< 0.0001 for three of four possible scales). It should be noted that, during rounds 2 to 5, participants
in the control group experienced statistically significantly more negative psychosocial consequences in seven
of nine scales than the LDCT screening group (p< 0.03). When evaluating the change from year 1 to 5, the
data from Table 7 showed less worsening of psychological consequences in the LDCT screening group than in
the control group. The differences seen were small and not likely to be clinically important.
National Lung Screening Trial
The NLST74 assessed the impact of LDCT screening on the HRQoL [Short Form questionnaire-36 items (SF-36)]
measure in a sample of 2812 participants. A total of 2812 participants at 16 of 23 ACRIN sites who had
completed baseline HRQoL assessments were asked to complete SF-36 questionnaires. There were no
statistically significant differences in SF-36 (physical component score) between the LDCT screening and the
CXR screening groups at baseline (LDCT 48.07 vs. CXR 48.89) or at the 1-month follow-up (LDCT 47.58 vs.
CXR 48.49) or 6-month follow-up (LDCT 47.32 vs. CXR 47.78).
The NLST74 also assessed patients’ anxiety associated with screening using the Spielberger State–Trait
Anxiety Inventory, (STAI-Y1) (20–80; high scores indicating more anxiety). The results showed no© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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46statistically significant differences between the LDCT and CXR screening groups for this outcome at the
1-month follow-up (LDCT 33.59 vs. CXR 33.02) or 6-month follow-up (LDCT 33.33 vs. CXR 33.11).
NEderlands Leuvens Longkanker Screenings ONderzoek
The NELSON trial84 investigated whether or not HRQoL differed between groups in a random sample
of 733 participants in each arm. A patient’s QoL in the NELSON trial84 was measured using the Short
Form questionnaire-12 items (SF-12) and the EQ-5D questionnaire. Participants were asked to rate their
own health on the VAS of EQ-5D, which ranged from 0 (worst imaginable health status) to 100 (best
imaginable health status). The NELSON trial84 also assessed patients’ anxiety associated with screening
using the STAI-6 and patients’ distress associated with screening using the lung cancer-specific distress
impact of event scale (IES) (0–75; with higher scores indicating worse distress). The participants received
questionnaires before randomisation (T0), 2 months after baseline screening (CT screen group only; T1)
and at the 2-year follow-up (T2).
At baseline, there were no statistically significant differences in HRQoL measures and psychological
consequences between the LDCT screening and control groups in terms of the mean scores of EQ-5D
(LDCT 79.19 vs. control 78.50), STAI-6 (LDCT 33.27 vs. control 33.75) and IES (LDCT 4.05 vs. control 4.02)
(see Table 9).
At the 2-year follow-up, as seen in Table 9, no statistically significant differences were found in mean
EQ-5D scores over time between the LDCT screening group and the control group (LDCT 79.53 vs.
control 77.45), indicating that there were no clinically relevant changes over time for the scores on EQ-5D.
Likewise, there were no statistically significant differences in mean scores of STAI-6 over time between
the LDCT screening group and the control group (LDCT 32.67 vs. control 33.43). Again, no statistically
significant difference was observed in mean scores of IES over time at the 2-year follow-up between the
LDCT screening group and the control group (LDCT 3.72 vs. control 4.03). The evidence from single-study
arms for this outcome is presented in Appendix 4.
Conclusion
Overall, based on the randomised evidence from included trials, the majority of the data showed that there
were no statistically significant differences in HRQoL or psychological consequences between the LDCT
screening group and control group at any point in time. When there were statistically significant differences,
these were generally of a size unlikely to be clinically important and were more commonly in a direction
favouring LDCT screening rather than no screening.
Change in smoking behaviour
Lung cancer screening may have a potential impact on participants’ smoking behaviour, for example,
providing a new opportunity for attempts to quit smoking. One potential drawback of lung cancer
screening is that it may reduce smokers’ motivation to quit smoking by inducing a sense of assurance,
thereby delaying smoking cessation. Three trials (DLCST, NELSON and NLST) reported relevant data on
patients’ behaviour change in smoking within the trial period (Table 10).57,63,71
The NLST71 and DLCST63 provided randomised evidence on all participants randomised (n = 4104 and
n = 53,456, respectively). Evidence from NLST was reported for each of the two contributing research
networks, LSS and ACRIN. The evidence for NELSON was on a much smaller scale (n = 1284) based on a
sample of the whole trial. Additional evidence from UKLS is reported to be in the process of publication.
The randomised evidence for smoking behaviour was more open to bias than evidence on mortality. The
absence of blinding would have influenced the validity of self-reported smoking status relative to more
objectives. In addition, DLCST63 and NELSON56,57 were open to further bias through loss to follow-up, although
this was greater in the no-screening arm. The fact that NLST71 was compared with an active intervention,
CXR, rather than no screening in DLCST63 and NELSON56,57 is also noteworthy.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 10 Smoking status and smoking cessation
Study (balanced?)
LDCT
smokers/
ex-smokers Missing
Control
smokers/
ex-smokers Missing
Difference LDCT vs.
control Time Other results Notes
Number
randomised
DLCST87
Yes [five annual visits
including brief
(< 5 minutes) smoking
cessation advice in
both trial arms]
1545/507 0 1579/473
No screening
0 Ex-smoker rate: 25% vs.
23% (p= 0.21)
Baseline 4104 (2052/2052)
1335/596
(calculated)
121 1274/540
(calculated)
238 Quit rate: 11.3% vs.
10.4% (p= 0.47)
1 year Restart rates also noted to be
similar
ITT analysis assuming missing info
did not quit
1051/806 195 937/713 402 Ex-smoker rate: 42% vs.
40% (p= 0.075)
5 years 2-, 3-, 4-year results; similar
results
Last observation carried forward
used for missing data
MILD69 NR NR NR NR NR NR NR NR. Smoking a prespecified
secondary outcome. Marked
baseline imbalance in current
smoker status likely to compromise
results if published
4099
NELSON81,88
Yes (standard brochure
or a questionnaire by
which people could
ask for tailored
smoking cessation
information sent to
both trial arms)
NR NR NR
No screening
NR Ex-smoker rate:
circa 45%
Baseline
(all)
Within those screened, there
was a positive relationship
between indeterminate test
result (as opposed to normal
test result) and smoking
cessation, but not statistically
significant
Analysis on sample of participants
who smoked at baseline. 641 and
643 in LDCT and control groups,
respectively. 581 (90.6%) and 503
(78.2%) responded in the LDCT
and control groups, respectively
Further analysis restricted to those
screened, 550 testing negative and
440 with one or more indeterminate
test results. Response rates 90.1%
and 93.6%, respectively
15,822 (7915/7453)
641/0 0 643/0 0 Baseline
(sample)
493/88 60 404/99 140 Quit rate (ITT non-
responders assumed as
continued smokers):
13.7% vs. 15.5%
(p= 0.38)
2 years
NLST89
Yes (just literature
offered in both arms.
No organised smoking
cessation programmes)
12,869/13,854 0 12,910/13,823
CXR screening
0 Ex-smoker rate: 51.8%
vs. 51.7%
Quit rate: 23.8%
vs. 23.2% (p= 0.38)
Baseline
(all)
Smoking cessation strongly
associated with presence of
abnormality at last scan
Analysis restricted to LSS centres.
Analysis restricted to smokers at
baseline who did not develop lung
cancer (n= 15,489). Complete
data available on 14661 (94.7%)
(data from table used rather than
paper text)
53,456
(26,723/26,733)
5618/1757 NR 5595/1691 NR Y3 LSS 34,612
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TABLE 10 Smoking status and smoking cessation (continued )
Study (balanced?)
LDCT
smokers/
ex-smokers Missing
Control
smokers/
ex-smokers Missing
Difference LDCT vs.
control Time Other results Notes
Number
randomised
NLST90
Yes (just literature
offered in both arms.
No organised smoking
cessation programmes)
12,869/13,854 0 12,910/13,823
CXR screening
0 Ex-smoker rate: 51.8%
vs. 51.7%
HR of point abstinence in
smokers: 1.07 (95% CI
1.00 to 1.15)
HR of relapse in long-
term abstinent former
smokers: 0.96 (95% CI
0.79 to 1.11)
Baseline
(all)
Smoking cessation (point and
sustained) associated with
(false) positive result
Analysis restricted to ACRIN
centres. Analysis restricted to those
who did not develop lung cancer
(n= 18,066). Complete data
available on 16,964 (3.9%)
53,456
(26,723/26,733)
NR NR NR NR Y5 ACRIN 18840
UKLS55 NR NR No screening NR NR NR NR Results reported to be in press
(Professor David Baldwin,
Nottingham University Hospitals,
2017, personal communication)
4061
HR, hazard ratio; ITT, intention to treat; NR, not reported in the identified study reports.
Notes
The table identifies the effect of screening on smoking status or smoking cessation.
Balanced refers to whether or not there were any differences in support for smoking cessation between LDCT screening and comparison arms.
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The LSS centres of the NLST78 assessed the effect of LDCT screening on smoking cessation compared with
CXR screening. There was no organised smoking cessation programme in either groups. At baseline, there
was no statistically significant difference in ex-smoker rate between the two groups (LDCT 51.8% vs. CXR
51.7%). At the 3-year follow-up, no statistically significant difference in quit rate between the two groups
was observed (LDCT 23.8% vs. CXR 23.2%; p = 0.38). Smoking cessation was strongly associated with the
presence of abnormality at last scan.
The ACRIN centres of the NLST79 also reported that, at 5-year follow-up, there was borderline significance
in point abstinence in smokers [hazard ratio (HR) 1.07, 95% CI 1.00 to 1.15] between the LDCT and CXR
screening groups. Likewise, there was also no statistically significant difference in relapse among long-term
abstinent former smokers (HR 0.96, 95% CI 0.79 to 1.11) between the two screening groups.
Danish Lung Cancer Screening Trial
The DLCST87 reported the effect of LDCT screening on smoking status and smoking cessation. There was
a balance in support for smoking cessation between LDCT screening and control arms: five annual visits
including < 5-minute brief for cessation advice in both trial arms. This trial reported that there was no
statistically significant difference in ex-smoker rate at baseline between the screening group (25%) and the
control group (no screening) (23%); p = 0.21. At the 1-year follow-up, no statistically significant difference
in quit rate between the screening group (11.3%) and the control group (10.4%) was observed (p = 0.47).
At the 5-year follow-up, there was no statistically significant difference in ex-smoker rate between the two
groups (screening group 42% vs. control group 40%; p = 0.075). Similar results were observed at the 2-,
3- and 4-year follow-ups. The findings from the DLCST73 showed that screening with LDCT had no additional
effect on participants’ smoking status compared with the control group (no screening).
NEderlands Leuvens Longkanker Screenings ONderzoek
The NELSON trial84 investigated the effect of lung cancer screening on smoking abstinence in two random
samples of male smokers in the screening (n = 641) and control arm (no screening) (n = 643). In this trial,
standard brochure or a questionnaire by which participants could ask for tailored smoking cessation
information was sent to both trial arms. The point prevalence of smoking abstinence was 15.1% for the
CT screening arm and 19.8% for the control arm (no screening). After 2 years’ trial participation, the
findings showed that CT screening was associated with a lower prolonged abstinence rate (14.5%) than
the control (no screening) (19.1%). However, there was no statistically significant difference in quit rate
between the two groups at the 2-year follow-up (screening group 13.7% vs. control group 15.5%; p= 0.38).
The NELSON trial81,88 also reported that, within those who were screened, there was a positive relationship
between indeterminate test results (as opposed to negative test results) and smoking cessation, but this
not statistically significant. The results showed that the continued smoking abstinence rate was 8.9%
among those with negative results; however, the continued smoking abstinence rate was higher among
those with indeterminate results (11.5%).
In conclusion, the results on smoking behaviour are mixed but, on balance, slightly favour a positive effect
on smoking cessation by virtue of a borderline statistically significant result in the largest of the three
included studies, NLST (ACRIN). Uncertainty on this outcome may be resolved through ongoing studies in
the process of publication.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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50Non-comparative outcomes
Nodule detection and lung cancer detection rate
Four trials57,61,63,71 reported the number of participants with non-calcified lung nodules identified on screening
over the study period. Figure 11 presents the rate of participants with non-calcified lung nodules over the
study threshold in the LDCT arm. As shown in this figure, there were wide variations in the percentages of
participants with non-calcified lung nodules over the study threshold in the LDCT arm. It ranged from 11%
to 69%, indicating that all these trials may have used different criteria to define a positive LDCT scan.
Diagnostic follow-up evaluations There were variations in the diagnostic methods used to follow nodules
that were identified as ‘positive’ scans. Most positive scans were resolved by comparison with prior scans
or further diagnostic imaging. Figure 12 presents the proportions of participants with additional diagnostic
CT scans in the CT screening arm. It ranged from 5% to 52%. It should be noted that both NELSON and
NLST trials had similar proportions (33% to 34%) of participants with additional diagnostic CT scans in theDANTE61
DLCST63
NELSON56,57
NLST71
Study identifier
0.24 (0.21 to 0.26)
0.68 (0.66 to 0.70)
0.11 (0.10 to 0.11)
0.69 (0.68 to 0.70)
Effect size (95% CI)
– 0.5 0 0.5
Positive scans detected
1
FIGURE 11 Positive scans detected in the LDCT screening arm.
DANTE61
ITALUNG65
NELSON56,57
UKLS55
NLST71
Study identifier
0.10 (0.09 to 0.12)
0.52 (0.50 to 0.55)
0.34 (0.33 to 0.35)
0.05 (0.04 to 0.06)
0.33 (0.33 to 0.34)
Effect size (95% CI)
– 0.2 0 0.2 0.4
Proportion of patients
0.6 0.8
FIGURE 12 Proportion of participants with additional diagnostic CT scan.
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further diagnostic CT scans. This reflects the effective nodule management protocols being used in the
UK setting.
Figure 13 presents the proportions of participants who underwent surgical biopsy or procedures for diagnosis
in the CT screening arm. It ranged from 2% to 4%. This figure appears to be consistent across these trials.
Lung cancer detection rate Figure 14 shows the lung cancer prevalence rate at baseline. The lung
cancer prevalence rate ranged from 1% to 2% across different trials, indicating that included trials usedDANTE61
DLCST63
ITALUNG65
NELSON56,57
UKLS55
NLST71
Study identifier
0.04 (0.03 to 0.05)
0.02 (0.02 to 0.03)
0.02 (0.01 to 0.03)
0.03 (0.02 to 0.03)
0.02 (0.01 to 0.02)
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Effect size (95% CI)
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FIGURE 13 Proportion of patients undergoing surgical biopsy or procedures for diagnosis.
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FIGURE 14 Lung cancer prevalence rate at baseline.
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52different definitions of high-risk populations. For example, UKLS55 used a risk prediction model to define
‘high risk’, whereas both the NLST70 and the NELSON56 trial used only two variables (age and smoking
status) to define ‘high risk’. We discuss this further in Discussion.
Figure 15 presents the cumulative lung cancer detection rates for LDCT screening. Six trials reported the
cumulative lung cancer detection rates of all the screening rounds.57,61,63,65,69,71 The cumulative lung cancer
detection rate ranged from 1.7% to 5.2% for the LDCT screening arms.
As seen in the figure, the NELSON trial reported that the cumulative lung cancer detection rate of the three
screening rounds was 2.6%. There was a relatively stable detection rate of lung cancer across the three
screening rounds. NLST reported a detection rate of 2.5% across all three screening rounds. DLCST63
reported a detection rate of 3.4%. The ITALUNG trial65 reported that the cumulative lung cancer detection
rate was 2.7%. The MILD trial69 reported that the cumulative lung cancer detection rate was 2.4% for
annual screening and 1.7% for biannual screening. UKLS reported that the cumulative lung cancer
detection rate was 2.1% for the pilot trial period. The DANTE trial61 reported that cumulative lung cancer
detection rate was 5.2%.
Interval cancer findings Two trials reported interval cancer findings (i.e. those cancers were detected
during the two rounds of screenings). One large US-based trial70 reported that, in the LDCT screening
group, among 1060 total lung cancer cases detected, there were 367 (35%) participants who either
missed the screening or received the diagnosis after their trial screening phase. In the CXR group, among
941 total lung cancer cases detected, there were 525 (56%) participants who either missed the screening
or received the diagnosis after their trial screening phase.
Another large trial (NELSON) also reported that, among 200 total lung cancer cases detected, 52 (26%)
cancers were detected between two different screening rounds (i.e. received the diagnosis of lung
cancer after their trial screening phase).56 The NELSON trial56 defined interval cancers as (1) lung cancers
diagnosed after negative screening results, (2) lung cancers diagnosed after indeterminate screening resultsNELSON56,57
DANTE61
DLCST63
ITALUNG65
MILD-169
MILD-269
UKLS55
NLST71
Study
0.026 (0.023 to 0.030)
0.052 (0.041 to 0.066)
0.034 (0.027 to 0.042)
0.027 (0.020 to 0.037)
0.024 (0.017 to 0.035)
0.017 (0.011 to 0.026)
0.021 (0.016 to 0.028)
0.025 (0.023 to 0.027)
Effect size (95% CI)
−0.05 0 0.05 0.1
FIGURE 15 Cumulative lung cancer detection rate in CT screening.
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cancers diagnosed after a positive screening test if the diagnostic investigation on the positive screening
result did not lead to a diagnosis of lung cancer at that stage but a confirmed diagnosis was made later as
patients’ symptoms triggered further diagnostic work-up that resulted in a diagnosis of lung cancer.
Number of participants who were more amenable to surgical treatment and surgical
resection rate
No trials reported the number of participants who were more amenable to surgical treatment. The ITALUNG
trial65 reported that 17 cancers in 16 subjects (81%) were surgically resected and one surgical resection was
performed on a benign lesion. The LUSI trial68 reported that 19 out of 22 cancers were surgically resected.
The NELSON trial91 reported 215 participants who had surgical work-up for treatment. The MILD trial69
reported that the rate of resectability was 84% overall and the vast majority of participants were treated
with lobectomy. Similarly, the UKLS reported that 35 out of 42 participants (83.3%) who were diagnosed
with lung cancer underwent surgical resection as their primary treatment.55
False positives
False positives are one of the key outcomes for the evaluation of important adverse effects associated
with LDCT screening for early detection of lung cancers. For those patients with positive scans, further
evaluations often involve more non-invasive evaluations (e.g. imaging scans) and more invasive procedures
(e.g. bronchoscopy, fine-needle biopsy and/or surgery). It is important to note that for patients with false
positives, these further evaluations may be even harmful as a result of serious complications (e.g. serious
infections and postoperative deaths associated with surgery).
Five trials55,57,61,63,69 reported the percentage of scans in the screening arm performed over the trial period that
had a false positive result, ranging from 1.2% to 23% (Figure 16). It should be noted that such variations
could be because of differences in the definition of a positive scan among included trials (e.g. different
thresholds of lung nodule sizes being categorised as a positive scan).
One large trial57 (NELSON with a total of 24,354 CT scans) reported that 59.4% (293 out of 493; 95% CI
54.8% to 63.9%) of positive screen results were false positive for a follow-up period of 5.5 years. The
NELSON trial reported that the positive screenings had a predictive value of 40.6%. This trial reported that
55% to 65% of positive screen results were false positive across four screening arounds. A total of 493
positive results across three rounds of the NELSON trial led to a diagnosis of lung cancer in 200 patients.DANTE61
DLCST63
MILD-169
MILD-269
NELSON56,57
UKLS55
Study identifier
0.229 (0.206 to 0.253)
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FIGURE 16 Proportion of scans in the screening arm with a false-positive result.
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54In the NELSON trial,57 around 24.5% (n = 67) of those participants with false-positive screen results
underwent an invasive procedure in the diagnostic work-up. A total of 91% (n = 61) of these invasive
procedures were surgeries (including thoracotomies, mediastinoscopies, sternotomy and video-assisted
thoracoscopies) and the remaining six procedures were transthoracic biopsies.
In NLST, across the three rounds, 96% of the positive scans in the LDCT group and 95% of those in the
radiography group were false positive. These percentages differed little by screening round. The sensitivity
of LDCT screening varied from 93% to 94%, whereas the sensitivity of CXR screening varied from 64% to
74% across three rounds. The specificity of LDCT screening varied from 73% to 84%, whereas the specificity
of CXR screening varied from 91% to 95% across three rounds. The NLST reported complications from
diagnostic procedures used to evaluate a positive LDCT scan. In this trial, around 1.4% of participants had
at least one complication in the CT screening group and 1.6% in the CXR screening group.
However, the high positive rate in NLST reflects the fact that there was no distinction being made for those
indeterminate findings or interval imaging findings from false positives.
It is important to note that recent trials (such as NELSON and UKLS) have made a distinction of the
definitions of indeterminate findings or interval imaging rate from false positives. For example, in the
NELSON trial, the LDCT screening result was indeterminate in 10.8% (2629 out of 24,354) of the all scans
across three rounds of CT screening. A CT scan in the NELSON trial was considered indeterminate if the
volume of the largest solid nodule or the solid component of a partially solid nodule was 50–500 mm3 or
> 8 mm in diameter for non-solid nodule. Indeterminate results led to invitations for a repeat scan (after
6–8 weeks or after 12 months, depending on the nodule size and screening round) in order to determine
the final result as positive or negative.
In UKLS,55 a false positive was counted if a participant did not have lung cancer but was referred to the
multidisciplinary team (MDT) and/or was subjected to repeated imaging scans before 12 months had
elapsed. The UKLS reported that the interval imaging rate for the category 3 (larger, potentially malignant)
nodules was 23.2%.
False negatives
Another concern of using CT screening for lung cancer is the potential adverse effect associated with
false-negative results. Four trials (DANTE,78 MILD,92 NLST93 and NELSON94) reported that the sensitivity of
CT screening for the detection of lung cancer ranged from 69% to 94%. The data indicated that the
false-negative examination rates ranged from 6% to 21%. Three trials57,61,69 reported the percentage of scans
in the low-dose screening arm that had a false-negative result, ranging from 0.1% to 1.3% (Figure 17).DANTE61
MILD-169
MILD-269
NELSON56,57
Study identifier
0.013 (0.008 to 0.021)
0.003 (0.002 to 0.004)
0.002 (0.001 to 0.004)
0.001 (0.001 to 0.001)
Effect size (95% CI)
– 0.01 0 0.01 0.02 0.03 0.04
FIGURE 17 Proportion of scans in the screening arm with a false-negative result.
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were no studies evaluating the potential harm associated with false-negative examinations. One potential
adverse effect associated with false reassurance of patients is that it can cause delayed examinations of
future suspicious symptoms in patients. Given this consideration, participants should be aware of the
importance of reporting symptoms (such as cough, haemoptysis or weight loss) even if they have a
negative screening scan.
Overdiagnosis
Overdiagnosis is a common issue for all screening trials of cancer, and can lead to overtreatment. The
treatment of an ‘overdiagnosed’ lung cancer would not extend a patient’s life, either because the disease
itself would not have progressed or would have resolved spontaneously. Although we investigated this
issue, most included trials did not report relevant data of overdiagnosed lung cancers attributable to
screening. Overdiagnosis associated with LDCT screening was estimated at 18.5% (95% CI 5.4% to
30.6%) on the basis of detected cancers in NLST.95
Adherence rate to screening
Ten trials report the adherence rate for LDCT screening,55,57,61–63,65,66,68–70 with four trials also reporting
results for the control arm (DANTE, Depsican, ITALUNG and LUSI)61,63,65,68 and three trials reporting
adherence to CXR [Depsican, Lung Screening Study as part of the Prostate, Lung, Colorectal and Ovarian
cancer screening trial (LSS-PLCO) and NLST] (Table 11).62,66,70
At baseline, the adherence rate for screening across the studies ranges from 85.7% to 99.9% for LDCT,
from 76.6% to 97.4% for CXR and from 93.5% to 100% for the control arms.
The DLCST and LUSI trials provide data for five rounds of screening.63,68 For the DLCST trial, the intervention
group received annual LDCT screening and an invitation to a hospital screening clinic, where participants
were offered spirometry and smoking counselling. Although the control group did not undergo LDCT
screening, they did receive a similar invitation to the screening clinic. At baseline, adherence was 99.8% for
the intervention group and 100% for the control group. At screening round 5, this decreased to 90.2%
and 68.9%, respectively, indicating a high adherence rate for LDCT.63 With regard to the LUSI trial,68 the
control group were not offered additional spirometry or counselling. A slight decline in adherence is seen
for both arms over time, with 99.9% adherence at baseline for both groups, falling to 94.5% for the LDCT
group and 91.1% for the control group at screening round 5. The results from these two trials for LDCT
screening are supported by the remaining studies, although with fewer screening rounds, in which the
overall decrease in adherence is < 10%.57,65,66,68,70
Three studies report adherence rates for LDCT and CXR (Depsican, LSS-PLCO and NLST).62,66,70 In all cases
and at all time points (maximum of three screening rounds), adherence rates were greater for those
receiving LDCT, with a difference between arms ranging from 1.1% at baseline for NLST to 9.1% at
baseline for the Depsican trial.70
The Depsican trial reports the lowest adherence at baseline (LDCT, 85.7%; CXR, 76.6%) with 19% of
participants overall refusing to participate after randomisation.62 No clear explanation is given for this by
the authors, other than a possible association with the motivation of GPs and trial participants.
Complications and postoperative deaths in those who underwent an invasive
diagnostic procedure
Four trials (DANTE, DLCST, NELSON and NLST)56,57,61,63,70,71 reported major complications in those who
underwent a surgical or other invasive diagnostic work-up procedure, although only two of these trials
(DANTE and NLST)61,70,71 provided data for both the LDCT screening arm and the control arm. Two of the
four trials also reported data on postoperative deaths (DLCST and NLST).63,70,71 One of these trials (NLST)
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TABLE 11 Adherence to CT screening and control arms
Study identifier
(country)
Time point, n/N (%)
Across all data
points, n/N (%)Baseline Round 2 Round 3 Round 4 Round 5
DANTE (Italy)61 LDCT:
1264/1300 (97.2)
Control:
1186/1232
(96.3)
NR NR NR NR LDCT:
1184/1264a
(93.7)
Depiscan (France)62 LDCT:
330/385 (85.7)
CXR:
291/380 (76.6)
NR NR NR NR NR
DLCST (Denmark)63,82 LDCT:
2047/2052 (99.8)
Control:
2052/2052
(100)
LDCT:
1976/2052
(96.3)
Control:
1516/2052
(73.9)
LDCT:
1944/2052
(94.7)
Control:
1388/2052
(67.6)
LDCT:
1982/2052
(96.6)
Control:
1179/2052
(57.5)
LDCT:
1851/2052
(90.2)
Control:
1414/2052
(68.9)
NRb
ITALUNG (Italy)65 LDCT:
1406/1613 (87.2)
Control:
1593/1593
(100)
LDCT:
1356/1593
(85.1)
LDCT:
1308/1589
(82.3)
LDCT:
1263/1581
(79.8)
NA LDCT: (79.0)c
LSS-PLCO (USA)66 LDCT:
1586/1660 (95.5)
CXR:
1550/1658
(93.5)
LDCT:
1398/1629
(85.8)
CXR:
1317/1648
(79.9)
NA NA NA NR
LUSI (Germany)68,96 LDCT:
2028/2029 (99.9)
Control:
2022/2023
(99.9)
LDCT:
1892/2000
(94.6)
Control:
1847/2018
(91.5)
LDCT:
1849/1978
(93.4)
Control:
1897/2005
(94.5)
LDCT:
1826/1958
(93.1)
Control:
1898/1988
(95.5)
LDCT:
1565/1656
(94.5)
Control:
1515/1599
(91.1)
NRd
MILD (Italy)69 NR NR NR NR NR Annual: 96.1e
Biennial: 95.1e
NELSON (The
Netherlands and
Belgium)56,57
LDCT:
7582/7915 (95.8)f
LDCT:
7557/7915
(95.5)f
LDCT:
7295/7845
(93.0)f
LDCT:
6922/7790
(88.9)f
NR NR
NLST (USA)70,71 LDCT:
26,309/26,715 (98.5)
CXR:
26,035/26,724
(97.4)
LDCT:
24,715/26,285
(94.0)
CXR:
24,089/26,410
(91.2)
LDCT:
24,102/25,942
(92.9)
CXR:
23,346/26,110
(89.4)
NR NR NR
g
UKLS (UK)55 LDCT:
1994/2028 (98.3)
NR NR NR NR NR
NR, not reported.
a Of those who completed baseline screening.
b Mean participation rates across all rounds reported as 95.5% in the LDCT arm and 93.0% in the control arm.
c Reported in the text, but n/N not reported.
d Text reports that almost 90% at time of latest publication had completed four rounds, and 60% so far had completed five rounds.
e Reported in the text, but n/N not reported, also unclear whether these data relate to adherence at baseline or adherence over the course of the study.
f These data are reported differently across publications.
g Text reports that across the study compliance exceeded 90% in each group, but it is not clear if those data are based on interim results.
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major complications following invasive procedures ranged from 10.7% in the NELSON trial56,57 to 37.5%
in DLCST.63 It should be noted that, for DLCST, this was based on major complications following thoracotomy,
and data were also provided following video-assisted thoracic surgery.63 It is also important to note that NLST
also reported a much smaller proportion of major complications following invasive diagnostic procedures
among participants who did not have lung cancer confirmed (2.4%).70,71
In both the DANTE trial61 and the NLST, there was a higher proportion of participants in the LDCT screening arm
than in the control group who had major complications following invasive procedures [Table 12; DANTE trial,61
28.6% in the LDCT group, 19.3% in the usual-care group; NLST trial (among those with confirmed lung
cancer), 12.0% in the LDCT group, 9.0% in the CXR group; NLST trial (among those with lung cancer not
confirmed), 2.4% in the LDCT group, 0.9% in the CXR group].61,70,71
In NLST, similar proportions of people experiencing major complications after non-invasive procedures
(e.g. biopsy) were reported in the LDCT screening arm and the CXR arm (among those with confirmed
lung cancer, 6.5% in the LDCT group and 6.7% in the CXR group; among those with lung cancer not
confirmed, < 0.1% in the LDCT group and 0.1% in the CXR group).70,71 It is important to note that, across
groups, the number of people experiencing major complications after non-invasive procedures was very
low (see Table 12).
With regard to postoperative deaths associated with surgery or an invasive diagnostic procedure (see Table 12),
DLCST63 reported that, although one person died following surgical treatment for lung cancer, nobody died
within 30 days of diagnostic surgery. The NLST reported that, of those with lung cancer confirmed, there
were 10 participants (1.5%) in the CT screening arm and 11 participants (3.9%) in the CXR arm who died
within 60 days of an invasive diagnostic procedure, and, of those with lung cancer not confirmed, there were
11 participants (0.1%) in the CT screening arm and three participants (0.1%) in the CXR arm who died within
60 days after an invasive diagnostic procedure.70,71TABLE 12 Deaths and major complications following diagnostic work-up
Study identifier
Major complications following
Postoperative deaths
following diagnostic
work-up
Surgical/invasive diagnostic
work-up Non-surgical work-up
DANTE61 LDCT: 22/77 (28.6%)
Usual care: 6/31 (19.3%)
NR NR
DLCST63 LDCT: 3/8 (37.5%);a 3/41 (7.3%)b NR 0c
NELSON56,57 LDCT: 20/187 (10.7%) NR NR
NLST70,71 LDCT:d 73/618 (12.0%)
CXR:d 23/264 (9.0%)
LDCT:f 11/457 (2.4%)
CXR:f 1/115 (0.9%)
LDCT:d 2/31 (6.5%)
CXR:d 1/15 (6.7%)
LDCT:f 1/16,596 (< 0.1%)
CXR:f 3/4559 (0.1%)
LDCT:d,e 10/649 (1.5%)
CXR:d,e 11/279 (3.9%)
LDCT:e,f 11/17,053 (0.1%)
CXR:e,f 3/4674 (0.1%)
NR, not reported.
a Following thoracotomy.
b Following video-assisted thoracic surgery.
c Within 30 days.
d Among participants with confirmed lung cancer.
e Within 60 days.
f Among participants with lung cancer not confirmed.
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58Radiation dose/radiation exposure level for participants
Three trials (UKLS,55 ITALUNG65 and NLST71) reported radiation dose associated with LDCT screening.
The ITALUNG trial reported that the mean collective effective dose among 1406 participants ranged from
8.75 to 9.36 mSv. This trial also reported that the mean effective dose to the single subject over 4 years’
follow-up was between 6.2 and 6.8 mSv (range 1.7–21.5 mSv) based on the cranial–caudal length of the
LDCT volume. It was estimated that 77% of the radiation dose was attributable to annual LDCT scan and
23% of the radiation dose was attributable to further imaging investigations, including follow-up LDCT
and FDG-PET scans.
A large US trial (NLST)97,98 reported that an average effective radiation dose was 1.4 mSv in the LDCT arm
and 0.052 mSv in the CXR arm. The UKLS55 reported that the median radiation dose for baseline CT scans
was 1.62 mGy (range 0.54–3.93 mGy). However, none of these studies reported radiation-related patient
outcome (e.g. radiation-induced lung cancer) at long-term follow-up.
It should be noted that the radiation doses being measured in different trials were not comparable as the
numbers of screening rounds were different. For example, the UKLS55 used one single-screening round but
other trials, such as NLST, used multiple screening rounds. In addition, the collective effective dose from
the ITALUNG trial was based on both LDCT scans and follow-up imaging investigations (including further
LDCT and PDG-PET scans); however, other trials may not take into account the radiation exposure from
further follow-up imaging investigations.Discussion
Summary of findings
Twelve RCTs evaluated the clinical effectiveness of LDCT screening compared with no screening or CXR.
The sample size of included trials ranged from 190 to 53,434.
The majority of included trials were judged to be of moderate to high quality; however, two trials (MILD69
and Garg et al.64) were judged to be of poor quality. There were substantial differences between the
LDCT screening and usual-care groups at baseline in both trials, raising concerns about the adequacy of
randomisation. Both trials were also underpowered.
Key outcomes
Mortality
The LDCT screening was associated with a non-statistically significant decrease in lung cancer mortality
(pooled RR 0.94, 95% CI 0.74 to 1.19) with up to 9.80 years of follow-up. However, there was moderate
heterogeneity in the magnitude of effects (I2 = 43.3%).
We assessed the impact of trial quality on the robustness of overall results by excluding the poor quality
trial (MILD69). The results demonstrated a statistically significant decrease in lung cancer mortality (pooled
RR 0.85, 95% CI 0.74 to 0.98) in favour of LDCT screening. The statistical heterogeneity was considerably
reduced (I2 = 6.9%), suggesting that variation in trial quality could be a potential source of heterogeneity.
A sensitivity analysis was performed including only annual LDCT screening. The result showed that LDCT
screening demonstrated no statistically significant increase in lung cancer mortality compared with usual
care. This result was generally consistent with the overall result.
The findings from this review also showed that, compared with controls (usual care/best available care),
LDCT screening demonstrated no statistically significant increase on all-cause mortality outcome (pooled RR
1.01, 95% CI 0.87 to 1.16) with up to 9.80 years of follow-up. Similarly, given the substantial heterogeneity
(I2 = 57.0%) detected between studies, the results from this pooled analysis should be treated with caution.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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sensitivity analysis showed that LDCT screening demonstrated a non-statistically significant decrease in
all-cause mortality (pooled RR 0.95, 95% CI 0.89 to 1.00) compared with controls. The level of heterogeneity
was also considerably reduced (I2 = 0%), suggesting that variation in trial quality could be a potential source
of heterogeneity between studies.
Number of lung cancers and their stage distribution
The LDCT screening was associated with a statistically significantly increase in lung cancer detection rate
(pooled RR 1.38, 95% CI 1.02 to 1.86) with ≥ 5 years’ follow-up. Although there was heterogeneity
(I2 = 79.7%), all included studies individually showed statistically significant increases in the numbers of
cancers detected in the LDCT group relative to the control group. This has implications for the possibility
of overdiagnosis.
A shift in cancer stage distribution towards earlier stages is often considered as one of clinical benefits
associated with LDCT screening. We assessed the results of lung cancer distribution difference between
the screening and control arms with ≤ 6 years of follow-up. The results showed that LDCT screening was
associated with statistically significantly increases in early stage (I and II) cancer detection (RR 1.73, 95% CI
1.27 to 2.37; I2 = 61%). When pooling data of trials comparing LDCT screening with no-screening only,
the results were consistent with the overall results and the degrees of heterogeneities were also
substantially reduced.
The LDCT screening was also associated with a statistically significant reduction in the risk of late-stage
lung cancer compared with controls (RR 0.85, 95% CI 0.73 to 1.00), although this effect was not observed
when only trials comparing LDCT to no screening were included (RR 1.00, 95% CI 0.75 to 1.34), despite
these trials still finding an increased probability of lung cancers being early stage. This is consistent with
overdiagnosis being a significant factor in the trials.
Psychological consequences and health-related quality of life
Based on the randomised evidence from four included trials (NELSON, NLST, DLCST and UKLS), the
majority of the data demonstrated that there were no statistically significant differences in HRQoL or
psychological consequences between the LDCT screening group and control group at any point in
time.55,57,63,71 When there were statistically significant differences between the two groups, these were
generally of an effect size unlikely to be clinically important and were more commonly in a direction
favouring LDCT screening rather than no screening. However, the validities of results from these outcomes
were compromised by lack of blinding, loss to follow-up and the limitation of self-report data.
Impact on smoking behaviour
Lung cancer screening may have a potential impact on participants’ smoking behaviour as it can offer
an opportunity for attempts to quit smoking because of increased awareness of risk associated with
smoking. We found that the results on smoking behaviour were mixed. Overall, the results suggest that
an introduction of LDCT screening in high-risk populations may have a positive impact on participants’
smoking behaviour change, given the borderline statistically significant result in the largest of the three
included studies, NLST (ACRIN). Uncertainty on this effect may be resolved through ongoing studies in the
process of publication.
Other outcomes
Lung cancer detection
The lung cancer prevalence rate ranged from 1% to 2% across included trials. This suggests that the different
definitions for high risk of lung cancer (eligibility criteria) in different trials led to different included populations.
It should be noted that not all lung cancers were detected at the screening rounds and some lung cancers
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60reported interval cancers that were detected between two different screening rounds. NLST70 reported that
there were 367 (35%) participants who either missed the screening or received the diagnosis after their
trial screening phase in the LDCT arm, and there were 525 (56%) participants who either missed the
screening or received the diagnosis after their trial screening phase in the CXR group.70 The NELSON trial
reported that 52 (26%) lung cancers were detected between two different screening rounds (i.e. received
a diagnosis of lung cancer after their trial screening phase).57 These data suggest that a small proportion
of lung cancers cannot be detected at any particular screening round or develop too fast to be identified
through screening.
Positive scans and follow-up investigations
Positive scan findings at screening were high, and most patients who tested positive required further
follow-up investigations including repeat CT scans, PET-CT scans, invasive biopsy or surgical procedures.
Our findings showed wide variations in the percentages of patients with non-calcified lung nodules over
the study threshold. The included trials used different criteria to define a positive CT scan.
In terms of follow-up investigations for ‘positive’ nodules, although the diagnostic methods used differed
between included trials, further diagnostic imaging was commonly used. There were considerable
differences in the proportions of patients with additional diagnostic CT scans (5% to 52%). It should be
noted that in both large trials (NELSON and NLST), similar proportions (33% to 34%) of participants
undergoing additional diagnostic CT scans were observed.57,71 This suggests that both trials may have used
similar imaging follow-up protocols to resolve these scans that were identified as ‘positive’. In contrast,
the proportions of patients undergoing surgical biopsy or procedures for diagnosis in the screening arm
appeared to be low (ranging from 2% to 4%).
False-positive scans are one of the key concerns associated with the evaluation of adverse effects of
screening, as they may be associated with an increased level of costs and more complications attributable
to follow-up invasive investigations. The percentage of scans in the screening arm performed over the trial
period that had a false-positive result ranged from 1.2% to 23%. The NELSON trial reported that 59.4%
of positive screen results were false positive for a follow-up period of 5.5 years.57 In particular, around
24.5% of those participants with false-positive screen results underwent an invasive procedure in the
diagnostic work-up. Around 91% of these invasive procedures were surgeries (including thoracotomies,
mediastinoscopies, sternotomy, video-assisted thoracoscopies), which were associated with risks of
complications. The UKLS reported that, for further follow-up invasive investigations, only four participants
had surgical biopsies or resections for benign disease.55
The data from our review showed that a high proportion (96%) of positive CT screen results were false
positives for the NLST trial, which required further investigations that may be harmful.71 However, the
high positive rate in NLST reflects the fact that there was no distinction being made for those indeterminate
findings or interval imaging findings from false positives. It is important to note that more recent trials such
as NELSON and UKLS have made such distinctions in their screening protocols in order to achieve better
nodule detection management.55,57 Limited data showed that a small proportion of participants who
underwent invasive surgery procedures experienced major complications. For example, the NELSON trial
reported that there were 187 participants who underwent thoracotomy in the screening arm. Among these
participants, only 10.7% of participants who underwent surgical procedures had major complications.57
Overdiagnosis
Overdiagnosis in lung cancer is one potential adverse effect associate with screening. Apart from detecting
aggressive cancers, screening would also detect indolent tumours that may not cause clinical symptoms.
In particular, slow-growing tumours are likely to be overdiagnosed. Therefore, it is plausible that there
may be some harm to patients of identifying lung cancer nodules that are overdiagnosed, which would
then lead to overtreatment (such as surgery). We found no direct data on the harms associated with
overdiagnosis. Overdiagnosis associated with LDCT screening was estimated at 18.5% (95% CI 5.4% toNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 6930.6%) on the basis of detected cancers in NLST.95 However, the magnitude of overdiagnosed lung
cancers attributable to screening is unknown, largely because the optimum duration of follow-up for
measuring overdiagnosed lung cancers is not known. It should be noted that the adequate length of
follow-up is of particular importance for quantifying the degree of overdiagnosis in cancer screening.99
Radiation exposure
None of included studies reported radiation-related patient outcomes such as radiation-related lung cancer
at long-term follow-up. It has been estimated that the lifetime attributable risk of major cancers due to
LDCT screening ranged from 2.6 to 8.1 major cancers per 10,000 participants based on participants’ age
and sex.100
Based on a recent publication conducted in Plymouth (UK), approximately 1.5 mSv of additional radiation
was given to subjects taking part in a low-dose chest CT diagnostic accuracy study.101 This equates to an
approximate 20% increase in radiation exposure when the consented individuals received the standard of
care chest CT (4 mSv) and two low-dose chest CTs (0.9 and 0.48 mSv, respectively) at enrolment. This is
equivalent to about 6 months of background radiation in the south-west of the UK (part of the region
is designated a radon-affected area). The approximate lifetime risk for patients from 16 to 69 years old to
develop fatal cancer as a result of receiving this additional radiation dose would be approximately 1 in
13,000. These risk levels represent very small additions to the 1 in 3 chance of developing cancer in the
general population. Alternatively, the additional radiation exposure is the equivalent of receiving 15 extra
chest radiographs.101
Reliability of evidence
It is worth noting that the evidence for outcomes such as lung cancer and all-cause mortality is highly
reliable, as such evidence is based on comparative data from RCTs. However, the evidence for other
outcomes from single study arms such as positive scans and follow-up evaluations is less reliable, as this
is not based on comparative data but primarily relying on data from a single arm of screening. Therefore,
this limitation compromised the reliability of these findings.
Our results from this systematic review were consistent with recent systematic reviews on the effectiveness
of LDCT screening. An overview of relevant systematic reviews is presented in Appendix 6. As seen in
this appendix, most systematic reviews suggested that the evidence of effectiveness of LDCT was not
yet conclusive. In our review, we have extended the analysis of the randomised evidence on HRQoL,
psychological consequences and smoking behaviour. Our review appears to be the first review to notice
the issues raised by quality assessment, particularly in relation to the MILD trial.
Generalisability of the results
Given that all included trials recruited high-risk participants, the findings from this review are generalisable
to populations who are at high risk of lung cancer, despite variations in its definitions across trials.
However, the generalisability of findings to those populations who are at low risk of lung cancer is very
limited. The findings based on a large US-based trial (NLST) have limited generalisability to other settings
(e.g. the UK setting) because of variations in health policies and differences in baseline risk profiles in the
populations. In NLST, there is also concern about whether or not comparing LDCT screening with CXR
screening gives a true indication of the effect of introducing LDCT where there is currently no screening.71
This requires acceptance that CXR screening has similar effectiveness to no screening, an issue that is
examined in more detail in the next chapter of the report.
It should be further noted that there were variations in the CT parameters and technology used between
NLST and the European trials. For example, NLST did not use volumetric analysis but relied on utilising the
CT nodule diameter in the measurement of positive nodules.71 However, both NELSON and UKLS trials
used volumetric analysis in their nodule measurement to minimise false-positive examinations.55,57 Given
this consideration, there is limited generalisability of NLST findings to the UK setting where volumetric
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screening randomised controlled trials
The relative effectiveness of three screening strategies (LDCT, CXR and usual care) is unclear. To addressthis uncertainty, we performed a network meta-analysis for the primary outcome of lung cancer
mortality to establish the relative effectiveness of different screening strategies between LDCT, CXR and
usual care. The methods and results of the network meta-analysis are presented in this section.Methods
Search strategy and selection criteria
The eligible population was individuals at high risk of lung cancer. Any definitions of high-risk populations
were eligible for inclusion. RCTs comparing LDCT screening with usual care or CXRs were eligible for
inclusion. In particular, RCTs comparing CXR with usual care were included in order to explore the possibility
of network meta-analysis. RCTs that provided lung cancer mortality data were included. The search strategy
has been described in Chapter 3, Identification of studies. A full search strategy can be found in Appendix 1.
Network meta-analysis methods
A network meta-analysis was performed to estimate the relative efficacy between different interventions
among included trials. The relative efficacy in lung cancer mortality outcome was estimated between LDCT
screening, CXR screening and usual care. We performed network meta-analysis in Stata® 14 (StataCorp LP,
College Station, TX, USA).
We estimated the relative ranking probability of each intervention and obtained the treatment hierarchy of
competing interventions using rankogram, surface under the cumulative ranking curve and mean ranks.102
The probability was estimated using a Bayesian model with flat priors, under the assumption that the
posterior distribution of the parameter estimates was approximated by a normal distribution with mean
and variance equal to the frequentist estimates and variance–covariance matrix.103
In order to assess the presence of inconsistency, both consistency and inconsistency models were fitted to
data. We used the design-by-treatment model by Higgins et al.104 to check the assumption of consistency
in the entire network. This design-by-treatment model provides a robust approach to assess the
consistency of the network being constructed.Results
Characteristics of included studies
We identified six studies for the network meta-analysis. This network meta-analysis includes the following
trials: three trials (DANTE,61 DLSCT63 and MILD69) comparing LDCT vs. usual care, one trial (NLST) comparing
LDCT vs. CXR) and two trials105,106 comparing CXR vs. usual care. The characteristics of trial population and
interventions for trials of LDCT screening have been described in Chapter 3,Characteristics of included
studies. Figure 1 shows the flow of inclusion and exclusion of relevant trials.
Table 13 presents the summary information of characteristics for trials of CXRs for the network meta-analysis.
Two trials105,106 assessing the effect of CXR screening compared with usual care were identified. The trial by
Kubík and Haerting105 was conducted in the Czech Republic and the Mayo Clinic trial was conducted in the
USA. The sample size ranged from 6346 to 10,933. The length of follow-up of included trials ranged from
6 to 15 years.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
TABLE 13 Summary of included trials and the trials for sensitivity analysis of mixed treatment comparison
Study
identifier Country Recruitment time
Screening
programme Comparator Sample size
Eligible age
range per
protocol (years)
Number of
screening
rounds
Screening times and
interval (years)
Duration of
follow-up
Kubík and
Haerting105
Czech
Republic
June 1976 to
June 1977
CXR Usual care n= 6364 40–64 Frequently = 9
vs. less
frequently= 5
Frequently: every 6 months
for 3 years then once in
years 4, 5 and 6 vs. less
frequently: prior to
randomisation, at 3, 4, 5
and 6 years
15 years
Mayo106 USA August 1971 to NR
(screening ended
July 1976)
CXR, sputum
cytology
Usual care
(recommendation
for an annual
CXR and sputum
cytology)
n= 11,001 (planned
10,000)a
> 45 18 4 months 6 years
PLCO (for
sensitivity
analysis
only)107
USA 1993 to 2001 CXR No screening n= 154,901 (NLST
eligible subgroup,
n= 30,321)
55–74 4 Annually 6 years (for NLST
eligible subgroup)
NR, not reported; PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial.
a Fontana et al.108 and Marcus et al.106 report; n = 10,933.
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Both trials recruited high-risk populations. The characteristics of the study populations are shown in Appendix 5.
The percentage of current smokers was 100% in the trial by Kubík and Haerting105 and 90% in the Mayo
trial.106 The percentage of former smokers was 10% in the Mayo trial. The percentage of males in both trials
was 100%. The characteristics of the recruitment methods are shown in Appendix 5. The trial by Kubík and
Haerting105 recruited participants from a general health preventative examination of the middle-aged male
population. The Mayo trial106 recruited participants who underwent general medical examinations as
outpatients at the Mayo Clinic.
There were some variations in the definitions of high risk between trials, but both trials mainly used age
and smoking history to define high risk. For example, the trial by Kubík and Haerting105 used the following
criteria to define high risk: (1) aged 40–64 years, (2) current smokers with an approximate lifetime
consumption of ≥ 150,000 cigarettes and (3) participants who were smoking at time of enrolment with
unknown pulmonary disease visible on the chest roentgenogram. The Mayo trial used the following criteria
for the definition of high-risk participants: (1) aged ≥ 45 years and (2) participants who were smoking one
packet or more of cigarettes each day (either at the time of entry into the screening programme or during
the preceding year).
The characteristics of the screening programmes are shown in Appendix 5. In the trial by Kubík and Haerting105
CXR was performed at baseline, 6-monthly during years 1–3, and then at years 3–6 of follow-up. In the Mayo
trial, CXR was conducted 4-monthly. This trial defined positive scans as those with an abnormality identified
(it was at the discretion of the single radiograph reader whether or not further investigation was required,
i.e. no second reading or central review). However, the Mayo trial106 did not report the definition of a positive
scan. In terms of imaging evaluation and interpretation strategy, both trials reported that double-reading by
chest physician and chest radiologist was used; if there was disagreement, the final decision was based on
consensus (third experienced physician arbitrated disagreements).
We included the PLCO trial (NLST eligible subgroup only) for sensitivity analysis (see Table 13), as the PLCO
trial was not an included trial because it did not meet inclusion criteria. This trial recruited the general
population (including both high- and low-risk participants), with a sample size of 154,901. In our sensitivity
analysis, we used only the data of the NLST eligible subgroup (n = 30,321) from the PLCO trial over the
6-year follow-up period because this subgroup (including high-risk participants) was more relevant to our
research question. However, it should be noted that the results of this subgroup were based on post hoc
analyses. This trial compared CXR screening with usual care (no-screening) only. The PLCO trial performed
four screening arounds (annually), with duration of follow-up of 3 years. Further details of this trial are
shown in Appendix 5.
Network meta-analysis results
Overall analysis
The overall network meta-analysis included six trials: three trials comparing LDCT with usual care, one trial
comparing LDCT with CXR and two trials comparing CXR with usual care. Figure 18 presents the network
of available intervention comparisons for lung cancer mortality.
Figure 19 presents the cumulative probability of three screening strategies (LDCT, usual care and CXR)
for the lung cancer mortality outcome. The estimated RR of LDCT compared with usual care was 0.95
(95% CI 0.82 to 1.11). LDCT was ranked first according to the estimated surface under the cumulative
ranking curve values, with a 74.8% probability of being the best intervention in terms of lung cancer
mortality reduction. Usual care had a 74.7% probability of being the second best strategy among the
three interventions. However, CXR screening had a 99.7% probability of being the worst intervention in
terms of lung cancer mortality reduction.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
Base case
Sensitivity analysis
Best
0
50
100
Second
Rank
C
u
m
u
la
ti
ve
 p
ro
b
ab
ili
ty
 (
%
)
Worst
(a)
Base case
Sensitivity analysis
Best
0
50
100
Second
Rank
C
u
m
u
la
ti
ve
 p
ro
b
ab
ili
ty
 (
%
)
Worst
(b)
Best
0
50
100
Second
Rank
C
u
m
u
la
ti
ve
 p
ro
b
ab
ili
ty
 (
%
)
Worst
Base case
Sensitivity analysis
(c)
FIGURE 19 Rankogram for the outcome of lung cancer mortality. Ranking indicates the probability of being the
best treatment, the second best, and so on, among the different interventions under evaluation. Sensitivity analysis
includes NLST-eligible subpopulation from PLCO. (a) Usual care; (b) LDCT; and (c) CXR.
B
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C
A  Usual care
B  LDCT
C  CXR
FIGURE 18 Network map. The size of nodes is proportional to the number of individuals randomised to each
intervention and the thickness of each line is proportional to the number of direct comparisons in trials.
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effective intervention for the outcome of lung cancer mortality compared with other screening strategies
(usual care and CXR).
Both consistency and inconsistency models were fit for lung cancer mortality data. By applying the design-
by-treatment model, we did not find any evidence of inconsistency. The global test for inconsistency gives
a p-value of 0.29, indicating no evidence of inconsistency.
Sensitivity analysis
Sensitivity analysis was performed by including data of the NLST eligible subgroup from another large trial
(PLCO) comparing CXR with usual care.107 The sensitivity analysis showed similar results to the overall
analysis: LDCT was ranked as the most effective strategy and CXR screening was ranked as the worst
strategy in terms of lung cancer mortality outcome.
Figure 19 presents the results of sensitivity analysis of cumulative probability of three screening strategies
for the lung cancer mortality outcome. The estimated RR of comparing LDCT with usual care from the
sensitivity analysis of network meta-analysis was 0.93 (95% CI 0.76 to 1.14). Based on the estimated
surface under the cumulative ranking curve values, LDCT screening was ranked first: it had a 75.3%
probability of being the best intervention in terms of lung cancer mortality reduction. Usual care had a
68.3% probability of being the second best strategy among the three interventions. Similarly, CXR screening
had a 87.7% probability of being the worst intervention in terms of the lung cancer mortality outcome.
For sensitivity analysis, both consistency and inconsistency models were also fit for lung cancer mortality
data. By applying the design-by-treatment model, we did not find any evidence of inconsistency. The global
test for inconsistency gives a p-value of 0.18, suggesting that there was no evidence of inconsistency.Discussion
The results of network meta-analysis showed that LDCT screening was ranked as the most effective
intervention for the outcome of lung cancer mortality compared with both CXR screening and usual care,
according to the estimated surface under the cumulative ranking curve values. The CXR was ranked as
the worst screening strategy for the lung cancer mortality outcome. We performed sensitivity analysis by
including data of the NLST eligible subgroup from the PLCO trial (comparing CXR with usual care).107 This
sensitivity analysis demonstrated consistent results.107 Both consistency and inconsistency models were fit
for data and we did not find any evidence of inconsistency.
To date, no research has been conducted to establish the relative efficacy between three screening
strategies (LDCT, usual care and CXR screening). The current network meta-analysis provides insight into
the relative effectiveness of LDCT, usual care and CXR screening for lung cancer mortality outcomes in
high-risk populations. It suggests that it may not be appropriate to consider lung cancer screening with
CXR as equivalent in effectiveness to usual care with no systematic screening. This reinforces concern
about whether or not the largest of the RCTs in the systematic review, NLST, truly reflects the effectiveness
of LDCT relative to no screening, the comparison best reflecting the policy decision in question in this
report. If the effectiveness of CXR screening is truly worse than no screening, the results of NLST will
overstate the magnitude of the effectiveness of LDCT screening. Whether or not this is true will be
confirmed or refuted as new mortality data on RCTs that have compared LDCT with no screening data,
such as NELSON, emerge.
The findings demonstrated that LDCT screening was ranked as the best screening strategy in terms of lung
cancer mortality reduction. Compared with CXR screening, LDCT scans are able to detect smaller pulmonary
abnormal nodules, thus leading to better precision of diagnosis. Therefore, the finding from the network
meta-analysis may be partly explained by improved diagnostic abilities associated with LDCT screening.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
NETWORK META-ANALYSIS OF LUNG CANCER SCREENING RANDOMISED CONTROLLED TRIALS
68In conclusion, the findings of this network meta-analysis provide robust evidence supporting LDCT to be
the most effective screening strategy on lung cancer mortality reduction in high-risk populations. It also
introduces uncertainty about whether or not the effectiveness of LDCT measured in NLST accurately
captures the size of the effect of introducing LDCT screening relative to no screening. To date, no research
has been conducted to establish the relative efficacy between three screening strategies (LDCT, usual care
and CXR screening) (see Appendix 6 for an overview of relevant systematic reviews). The current network
meta-analysis provides insight into the relative effectiveness of LDCT, usual care and CXR screening for
lung cancer mortality outcomes in high-risk populations.
Individual participant data meta-analysis on this topic is a necessary next step to find target populations for
different screening interventions and would allow a more personalised screening strategy for early lung
cancer detection in high-risk populations.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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cost-effectiveness evidenceMethods
Identification of studies
The search strategy included searching the following electronic databases:l
l
l
l
l
l
l
© Qu
Healt
journ
be ad
Park,MEDLINE (via Ovid)
MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
EMBASE (via Ovid)
HMIC (Health Management Information Consortium) (via Ovid)
Web of Science (via Clarivate Analytics)
NHS EED (NHS Economic Evaluation Database) and HTA (via The Cochrane Library)
EconLit (via EBSCOhost).The searches were developed and run by an information specialist (SR) in January 2017. Search filters were
used to limit the searches to economic studies as appropriate. Searches for economic studies were limited
to 2004 onwards and searches for health utilities studies were limited to the English language. An update
search was carried out in April 2017 and limited to economic studies. The search strategies for each
database are detailed in Appendix 1.
The database search results were exported to, and deduplicated using, EndNote (X7) [Clarivate Analytics
(formerly Thomson Reuters), Philadelphia, PA, USA]. Deduplication was also performed using manual checking.
Records were screened for eligibility on the basis of title and abstract by one reviewer (TS). Full texts
were retrieved for potentially eligible studies and were assessed for eligibility by one reviewer (TS). Studies
included by any identified systematic reviews of economic evaluations were also retrieved as full texts and
assessed for eligibility.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were decided before records were screened for eligibility and are shown in
Table 14.
Data abstraction and quality assessment
Trial- and model-based evaluations
Simple data abstraction templates were developed in advance of study selection.
Data were abstracted by one reviewer (TS) based on main publications (i.e. without referring to any
supplementary materials).
The quality of studies was assessed using the Consensus on Health Economic Criteria (CHEC)-list for
economic evaluations,109 with certain modifications/guidelines for assessment (see Appendix 7).
Only the main publication was examined for quality assessment (i.e. supplementary materials were
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TABLE 14 Inclusion and exclusion criteria for the review of existing cost-effectiveness evidence
Criteria Include Exclude
Screening population People at risk of lung cancer People with existing cancer, including lung
cancer
People with clinically suspected lung cancer
People with hereditary cancer syndromes
Target condition Lung cancer
Intervention(s) LDCT (single or multiple screen)
Comparator(s) No screening or screening with another
imaging modality (e.g. X-ray)
No comparator
Screening with non-imaging modality
(e.g. sputum culture, breath analysis)
Study design Cost–utility analysis
Cost-effectiveness analysis
Cost–benefit analysis
Cost–consequences analysis
NHS cost analysis
Cost-minimisation analysis
Non-NHS cost analysis
Studies not presenting incremental analyses or
allowing for their calculation
Non-systematic reviews
Editorials/comments/letters
Methodology Trial based
Model based
Systematic review of economic evaluations
Other Abstracts (when not linked to an included
full-text paper)
Non-English-language papers without an
official translation
SYSTEMATIC REVIEW OF EXISTING COST-EFFECTIVENESS EVIDENCE
70Systematic reviews of economic evaluations
Simple data abstraction templates were developed in advance of study selection.
Data were abstracted by one reviewer (TS) based on main publications (i.e. without referring to any
supplementary materials).
No quality assessment was conducted of systematic reviews of economic evaluations.
Methods of data synthesis
Synthesis was by tabulation of characteristics and results and narrative synthesis by one reviewer (TS).Results
A total of 3004 citations were considered, which ultimately led to the identification of 19 trial- and
model-based analyses (reported in 21 publications55,110–129) and five systematic reviews (reported in
six publications54,130–134), as shown in Figure 20.NIHR Journals Library www.journalslibrary.nihr.ac.uk
Records identified through database searching
(n = 3001)
Records after duplicates removed
(n = 2290)
Records screened
(n = 2290)
Records selected for full-text retrieval
(n = 71)
Full-text articles retrieved
(n = 61)
Trial- and model-based evaluations
• Publications, n = 21
   • Studies, n = 19
• Full-text article could not
   be retrieved, n = 1
• Abstracts only, n = 14
Full-text articles excluded
(n = 34)
• Comparator, n = 3
• Population, n = 1
• Study design, n = 29
• Language, n = 1
Citations from systematic reviews
(n = 5)
• New citations, n = 3
• Previously excluded at title/abstract, n = 2
Systematic reviews
• Publications, n = 6
   • Studies, n = 5
Records excluded
(n = 2214)
FIGURE 20 The PRISMA flow diagram for systematic review of existing cost-effectiveness evidence.
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Tables 49 and 50, Appendix 7, present the characteristics and results of the included trial- and model-based
studies, respectively.
Table 51, Appendix 7, presents the characteristics and results of the included systematic reviews.
Quality assessment
The results of the quality assessment are shown in Appendix 7.
Most studies failed to perform sufficient sensitivity analyses, and a significant number of studies did not
estimate quality-adjusted life-years (QALYs). Only five studies (reported in six publications110–115) were
judged to have used an economic study design appropriate to the stated objective. The other studies relied
on sources at a high risk of bias (e.g. cohort studies) or unsupported assumptions.
No studies clearly failed to include the three necessary cost items (LDCT scans, follow-up tests and lung cancer
costs), although some studies did not report adequately in the main publication to make a judgement.
Narrative synthesis
Trial- and model-based analysis
A common theme in the study results is that LDCT screening is more costly and more effective than no
screening. Studies had sharply diverging conclusions about the cost-effectiveness of screening. There is
some evidence that studies based on the Early Lung Cancer Action Project (ELCAP) cohort study135 predict
improved cost-effectiveness for screening117–119,122,125,127,128 versus studies based on NLST110–113,115,124,127 or
lung cancer natural history models.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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72Three different natural history models have been used to predict the cost-effectiveness of LDCT screening.
The Lung Cancer Policy Model was used by McMahon et al.114 and suggested that LDCT would not be
cost-effective. The Cancer Risk Management Model (renamed OncoSim) was used by Goffin et al.112,113
and suggested that biennial LDCT would be cost-effective. The Microsimulation Screening Analysis
(MISCAN) – Lung model was used by ten Haaf et al.115 and suggested that annual LDCT would be
cost-effective.
Many studies identified that the cost of LDCT scans, the effectiveness of screening (identifying early-stage
lung cancers) and the prevalence and incidence of lung cancer are key factors affecting the cost-effectiveness
of screening. A number of studies considered age and smoking history and found these to be influential also.
Some studies incorporated smoking cessation as an adjunct intervention, but these studies did not generally
consider the cost-effectiveness of screening versus smoking cessation, or screening with smoking cessation
versus smoking cessation and, therefore, were not appropriate evaluations of lung cancer screening.
Systematic reviews of economic evaluations
Existing systematic reviews found significant variation in methodology and results of economic evaluations.
Earlier economic evaluations did not have access to good-quality estimates of clinical effectiveness, and
the studies that incorporated the results of NLST produced ICERs of < US$100,000 per QALY. More recent
economic evaluations were generally more methodologically robust (see Table 51, Appendix 7).
The reviews concentrated on the cost-effectiveness of screening versus no screening, without any
significant attention being paid to the impact of frequency of screening.Discussion
Key findings
Although a number of economic evaluations of LDCT screening for lung cancer have been conducted, they
have not produced consistent results in terms of the cost-effectiveness of screening, and few commented
on the generalisability of their findings.
Previous systematic reviews have identified that there is significant heterogeneity in the results of economic
evaluations of lung cancer screening, and that this makes it difficult to draw conclusions about its
cost-effectiveness, particularly when considering an individual setting.
Two economic evaluations were conducted in the UK setting,55,116,117 both led by Professor David Whynes.
Both concluded that LDCT screening could be cost-effective in the UK. The more recent of these evaluations55,116
included a comparison with an economic evaluation based on NLST,110,111 highlighting the likely reasons why
the latter had found a less favourable estimate of the cost-effectiveness of LDCT screening. However, these
UK-based economic evaluations have not been based on high-quality evidence (although they have produced
somewhat consistent results in terms of incremental QALYs compared with studies that are based on high-
quality evidence).
Certain factors regularly appeared as significant in determining cost-effectiveness:
1. the cost of a LDCT scan
2. the risk of lung cancer (prevalence, and incidence for studies evaluating more than a single screen)
in the screened cohort
3. the effectiveness of LDCT screening in broad terms (e.g. achieving a stage shift without significant
overdiagnosis, extending lung cancer survival beyond lead time, reducing lung cancer mortality).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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interventions (e.g. establishing specialist centres for high-throughput LDCT screening). The second and
third points are intertwined, as the effectiveness as measured will depend on the population being
investigated. Nevertheless, it is well within the bounds of possibility to estimate with some accuracy the
risk of lung cancer, and to restrict screening to those with the greatest need or potential benefit.
Relation to existing work
Other systematic reviews of economic evaluations included six studies we have not included (three because
they considered CXR rather than LDCT, one because it considered whole-body CT, two because they did
not present an incremental analysis), as shown in Appendix 7, Table 53.
This review included 21 publications of trial- and model-based economic evaluations of lung cancer
screening by LDCT, reporting results of 19 studies. Seven of these publications have not been identified by
existing systematic reviews (see Appendix 7, Table 54).
Strengths and limitations
Comprehensive searches were designed and conducted by an experienced information specialist (SR).
Other systematic reviews have not identified any studies eligible for inclusion that were not identified in
these searches.
Other aspects of the review (study selection, data abstraction, quality assessment and narrative synthesis)
were performed by a single reviewer with experience of reviews of economic evaluations (TS), but were
not independently performed or checked by another reviewer. It is therefore possible that relevant studies
could have been excluded (although no such studies were identified by other systematic reviews) and that
errors could have been made in data abstraction or quality assessment.
Additionally, the review only included English-language publications and there was no quality assessment
of systematic reviews.
Areas of uncertainty
Significant uncertainty remains as to the cost-effectiveness of LDCT screening for lung cancer. The wide
range of results from existing studies makes it challenging to draw conclusions, and the evolving clinical
effectiveness literature has significantly affected the economic evaluation literature. Many studies were
conducted without access to high-quality estimates of the effectiveness of screening and most studies
were conducted in countries other than the UK.
It is important to establish estimates for the cost-effectiveness of LDCT screening in the UK based on
high-quality data, and for these estimates to cover a broad range of possible interventions to minimise
the possibility of rejecting LDCT screening on cost-effectiveness grounds despite the existence of a
cost-effective alternative configuration, which is not explored.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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Owing to the lack of an existing economic evaluation in the UK that allows for exploration of multiplealternatives, an independent economic evaluation was conducted based on a new decision model.
The layout of this chapter is based on the Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) checklist.136Methods
An individual patient simulation model was developed in Microsoft Excel® 2013 (Microsoft Corporation,
Redmond, WA, USA) using a discrete event simulation (DES) framework.
Individual patients were sampled across a spectrum of baseline characteristics and their outcomes
concurrently simulated across different intervention strategies (i.e. the number of CT screening rounds and
the time between rounds) and a control arm representing current practice (no screening). A large number
of individual patients sampled together defined a cohort.
Different population strategies were modelled at the cohort level, which were defined in terms of age
criteria for entry (minimum and maximum age) and a risk threshold. Simulated individuals meeting the
criteria in the population strategy would receive an intervention strategy, while individuals not meeting
the criteria would receive no screening.
Lifetime costs and QALYs were estimated for each combination of population and intervention strategy.
Modelling approach
Target population and subgroups
The target population was people who are at higher risk of lung cancer relative to the general population.
Specifically, the model considered people aged between 55 and 80 years with a history of smoking
(i.e. current or former smokers).
Subgroups in this population are identified by further restricting the age range and by imposing a
minimum threshold on the predicted risk of lung cancer for an individual to be eligible for screening.
Setting and location
The setting was the NHS in the UK.
Initial invitations to screening may be sent from primary care (as initial identification of people who may
be at high risk could be from primary care records). Screening CT scans are performed in secondary and
tertiary settings. Cancer care is performed in secondary and tertiary settings. Palliative care may be
delivered in secondary settings, in the community or in hospices.
Study perspective
The perspective on costs was NHS and Personal Social Services (PSS). The economic evaluation therefore
did not include any effect on tax revenue, pensions, productivity or out-of-pocket expenses for affected
individuals (e.g. transport).
Direct health effects on individuals who were contacted through a screening programme were included.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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76No direct health effects on family or carers were included as no good-quality evidence was found to
support their inclusion.
Although some screening studies have shown an impact on the smoking behaviour of participants
(e.g. Clark et al.90), and despite it being very likely that increased quitting reduces the risk of lung cancer
mortality, no attempt has been made to model smoking behaviour in the model.
Comparators
Four screening programme designs were compared with no screening in 12 population alternatives,
thereby creating 48 intervention strategies and one control (no screening programme) strategy that
represents current practice.
Chest X-ray was not considered as a comparator as it is not considered a relevant policy option (the
briefing note for this project lists only no screening as a comparator) and because RCT evidence has shown
that CXR is not expected to be clinically effective.107
Discount rate
Costs and QALYs were discounted at 3.5% per year. These are the conventional discount rates for
technology appraisal in England,137 Scotland138 and Wales139 (Northern Ireland typically endorses NICE
technology appraisals) and are derived from the UK Treasury discount rate.140
Time horizon
Individuals are modelled until death. Most simulated individuals are dead by 100 years of age (e.g. 98.9%
of women simulated from the age of 80 years die before the age of 100 years).
Choice of health outcomes
The primary health outcomes were HRQoL and life-years attained in each strategy, expressed in QALYs, as
is the preference in UK cost-effectiveness decision analyses.137 In the incremental analysis, the outcome
was QALYs gained versus no screening.
In addition, secondary health outcomes were:l
l
l
l
l
l
l
l
l
NIHRscreening programme sensitivity
number of lung cancers diagnosed per 100,000 entrants
interval cancers diagnosed per 100,000 entrants
mortality per 100,000 entrants
5-year survival from diagnosis of lung cancer
substage distribution
average age at diagnosis, death from lung cancer, death from other
lead time.Analysis methods
The economic evaluation employed a cost-effectiveness (cost–utility) analysis, in which the costs and QALYs
for each alternative (combination of population and intervention strategies) are estimated and then a
cost-effectiveness frontier is constructed by eliminating strategies that are dominated or extendedly
dominated. The cost-effectiveness of each alternative is then assessed using the incremental cost-effectiveness
ratio (ICER), the ratio of incremental costs to incremental QALYs.Main analysis: cost-effectiveness analysis of all alternatives, in which the ICER is calculated both versus
the most effective alternative on the cost-effectiveness frontier that is less effective than the current
option, and versus current practice (no screening).Journals Library www.journalslibrary.nihr.ac.uk
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(e.g. a cost-effectiveness of four intervention strategies and no screening assuming a minimum
age at entry of 60 years, a maximum age at entry of 75 years and a minimum risk of 4%).
Net monetary benefit (NMB) maximisation (at willingness to pay of £20,000 per QALY) conducted
for each intervention strategy to identify the optimal choice of age limits and predicted risk
thresholds.eThese analyses are conducted in the base-case analysis (in which all parameters are fixed at their base-case
values and a large cohort of patients is simulated).
Sensitivity analyses are also conducted:Deterministic sensitivity analysis: main analysis conducted with deterministic changes to parameter
values (the results remain stochastic as individual patients continue to be simulated).
Probabilistic sensitivity analysis (PSA): multiple cohorts simulated, each with a single set of parameter
values sampled probabilistically from suitable distributions reflecting parameter uncertainty. A main
analysis was conducted and cost-effectiveness acceptability curves were produced.Software
The model was implemented in Microsoft Excel. Supporting analyses were conducted in Stata 14.2,
R 3.3.3 (The R Foundation for Statistical Computing, Vienna, Austria), and JAGS 4.2 (Martyn Plummer,
Lyon, France).141
Model structure
Overview
A cohort of individuals is simulated with a range of baseline characteristics (including age and predicted
risk of lung cancer). The age range of simulated individuals is 55–80 years, as no screening programmes
are being evaluated that would include individuals outside this age range.
Each individual is concurrently simulated with four screening intervention arms and a control (no screening)
arm. By simulating the individuals concurrently through all arms there is a reduction in stochastic variation.
The costs, QALYs and other outcomes for each full programme (combination of population strategy
and intervention) are estimated using a decision tree. Costs of administering the screening programme
(sending letters with questionnaires, analysing the questionnaires to estimate the lung cancer risk, sending
invitations to those at high risk) are accumulated through the decision tree, and long-term costs and
QALYs are estimated at the leaves of the decision tree by identifying appropriate individuals simulated in
the cohort and assigning them appropriately either to the screening intervention (if they meet all criteria
and join the screening programme) or to no screening.
It was assumed that the two uptake probabilities (relating to a person completing a risk questionnaire and
agreeing to join the programme after being informed they are at high risk) are independent of age and
sex, although gender has been identified as a potential factor influencing the decision to participate in a
lung cancer screening programme (see Chapter 7).
Figure 21 shows how age thresholds and the risk threshold are used to identify individuals at high risk of
lung cancer and map them to screening interventions.Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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78Simulating individuals
The DES modelling framework was employed, but without interactions between individuals (i.e. no queues
or shared resources). This method of simulation involves sampling times to future events according to the
current state of the individual (and any relevant history). The earliest of these events is modelled as occurring
and the model ‘clock’ advances to that event. Times to events are then either reduced by the amount the
clock has advanced or are resampled (as appropriate). Figure 22 provides a diagram of the model.No lung cancer
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FIGURE 22 Model diagram for simulating individuals. LC, lung cancer.
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lung cancer.
A natural history model of lung cancer was utilised to generate outcomes for individuals in the absence
of screening (see Natural history). The action of lung cancer screening is to identify preclinical (occult,
asymptomatic) lung cancer earlier than it would be clinically diagnosed. The sensitivity of the screening
test affects the likelihood that a cancer will be detected at the time of screening.
If a lung cancer is detected by screening in an earlier stage than it would have presented clinically, then
the time to lung cancer mortality (i.e. survival) is extended, as survival is related to stage. If a lung cancer
is detected by screening in the same stage as it would have presented clinically, the time to lung cancer
mortality is extended by the lead time. In any case, the age at lung cancer mortality is modelled as never
being earlier when a cancer is screen detected than if the cancer had presented clinically.
In the base case it is assumed that there is no heterogeneity between patients in the rate at which their
cancers progress or present, but in a scenario analysis a random effect is included for each simulated
individual across their rates of progression, as shown in Equation 1:
log(λk→k+1i ) = log(λ
k→k+1) + ϵi ϵi∼N (0, σ2p). (1)
In this equation, λk→k+1i is the rate of progression from state k to state k + 1 for individual i. ϵi is the error
term for between-individual variability in the log-rate of progression, with variance σ2p. Note that the
variance is assumed to be the same for all progression rates.
Note that in the base case there is no lung cancer mortality from the preclinical lung cancer states. This is
justified in Natural history. Note also that there is no explicit modelling of cancer progression after diagnosis,
as the costs and outcomes are intended to be averaged across lung cancers diagnosed in each stage.
The model does not include incidental findings resulting from screening. It is likely that such findings
would lead to increased health-care resource use in the short term (although these could in some cases
be offset by savings in the long term), and could lead to improved QoL if the disease has been causing
reduced QoL and treatment is effective.
Five screening programme designs were developed following consultation with the expert advisory group.
These varied according to the target number of screens, the interval time between screens and the
duration of the programme (Table 15). UKLS55 adopted a single-screen design; the NLST and NELSON trials
adopted a triple screen design, with increasing screening intervals in NELSON.TABLE 15 Screening programme design
Design name Design features
No screening Patients are not screened: diagnosis by clinical presentation only
Single screena One-off screen shortly following entry into programme
Triple screenb First screen shortly following entry, then a second at 12 months and a third at 24 months
Annual repeated screenc First screen shortly following entry, then screens repeating 12-monthly from the date of
entry until 80th birthday
Biennial repeated screen First screen shortly following entry, then screens repeating 24-monthly from the date of
entry until 80th birthday
a The UKLS protocol.55
b The NLST protocol.71
c The US Preventive Services Task Force recommendations.142
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80Twelve population subgroups combining age at entry (minimum ages 55 and 60 years, maximum ages
75 and 80 years) and predicted risk (minimum risk 3%, 4% and 5%) were specified. Only patients in the
starting cohort whose age and risk profiles met the criteria of these populations were included in the
respective strategy analyses.
Starting characteristics
Each individual was simulated with the following random starting characteristics:l
l
l
l
NIHRage
sex
baseline disease state
risk score.In the base case, the age distribution of individuals was estimated from UKLS for the participants returning
a questionnaire.55 Truncated normal regression was performed on the age of participants with cut-off
points at 50 years and 76 years using the Stata command truncreg. The estimated age [mean and standard
deviation (SD)] was 61.94 years (SD 9.00 years). The ages were sampled using a truncated normal
distribution but with cut-off points at 55 years and 80 years to reflect the widest range of eligibility criteria.
A scenario analysis was conducted using an age distribution fitted to the approximate age distribution of
smokers in the UK143,144 (aged 55–80 years) and using least squares regression to estimate an underlying
normal distribution of 61.62 (SD 15.19) years. This scenario predicts a similar mean age but a greater spread.
The sex distribution of individuals was similarly estimated from UKLS participants returning a questionnaire,
producing an estimate of 48.2% being men.
The baseline disease state was estimated by sampling the age at preclinical lung cancer incidence and
the age at entry to the programme. If the age at preclinical lung cancer incidence was less than the age
at entry to the programme, then the stage of preclinical lung cancer was estimated using probabilities
inversely proportional to the expected time spent in each stage in the absence of screening. If the age at
preclinical lung cancer incidence was greater than the age at entry to the programme, then the individual
started with no lung cancer.
The risk score was estimated as detailed in Effectiveness estimates.
Model parameters
Details of model parameters are given throughout this chapter and Appendix 9 provides a full listing of
model parameters, their base-case values and their PSA distributions.
Natural history
A Bayesian Markov chain Monte Carlo (MCMC) analysis was conducted to calibrate a natural history
model of lung cancer to the NLST RCT71 and the incidence of lung cancer (International Classification of
Diseases, Tenth Edition,145 C33–C34) in England in 2014 according to sex and age (5-year age groups),1
adjusted for the population attributable fraction due to smoking143 and the estimated smoking (current
and former) population.143
The analysis was performed using JAGS141 and the rjags and coda146 packages in R.
The natural history model assumes progression through the stages of lung cancer (IA, IB, . . ., IV) in the
absence of treatment. Clinical presentation or identification through screening lead to clinical lung cancer.Journals Library www.journalslibrary.nihr.ac.uk
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1. Natural history model fitted to NLST data.
2. Preclinical progression and clinical presentation parameters fixed to their expected values from step 1, and
preclinical incidence parameters fitted to English estimates of the incidence of lung cancer among smokers.
A log-normal distribution was assumed for preclinical incidence of lung cancer. In step 1, this was assumed
to be the same for men and women, whereas in step 2 it was assumed that the location (µ) parameter
would vary between men and women.
The natural history model assumed exponential distributions for the time to preclinical progression (from stage IA
to stage IB, from stage IB to stage IIA, etc.) and the time to clinical presentation (according to the stage).
In the base case, no heterogeneity in the overall speed of cancer progression was included, whereas in a
scenario analysis, heterogeneity was included, as described in Equation 1.
As shown in Figure 23, the rate of clinical presentation is significantly lower at all stages than the expected
time to progression, which is why most lung cancers are identified only in the latest stage. At the expected
values of the parameters, the expected stage distribution is 10.3%, 4.7%, 10.4% and 74.6% for stages I,
II, III and IV, respectively.
The calibrated incidence curves demonstrate somewhat higher incidence for men than for women, with
very little incidence before the age of 50 years.
Further details of the calibration are given in Appendix 8, including example JAGS code and the model-run
characteristics.
Lung cancer survival
Survival from lung cancer was estimated according to the stage of lung cancer at diagnosis. The key data source
was the International Association for the Study of Lung Cancer (IASLC) study used to develop the TNM Seventh
Edition,24 which provides mature survival estimates based on a significant number of patients. The drawback
of this data set is that the patients are primarily not from the UK, although they were drawn from 46 sources
across 19 countries.– 2
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FIGURE 23 Rates of progression and clinical presentation for each stage of lung cancer.
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82Kaplan–Meier curves for survival according to clinical stage were extracted and annual values up to 10 years
were isolated. A Weibull plot was constructed by plotting cumulative hazard (logarithmic scale) versus time
(logarithmic scale). The lines were close to straight and close to parallel and, therefore, a proportional
hazards Weibull model was judged to be appropriate. A weighted linear regression was performed on log
(cumulative hazard) with log(time) and stage as independent variables. Each point was weighted by the
number of patients diagnosed in the stage multiplied by Kaplan–Meier survival (as an approximation of the
number of patients contributing to the data point).
The resulting survival curves closely match the extracted survival data, as shown in Figure 24.
To reduce unnecessary variability between intervention arms and to achieve a consistent improvement in
survival when a stage shift is achieved, a single quantile was sampled randomly per lung cancer and used
to sample all survival times for the different stages of the lung cancer.
Mortality from undiagnosed lung cancer
The rate of death from preclinical lung cancer is a highly uncertain quantity, as it is believed that most
individuals dying from lung cancer will do so with a diagnosis of lung cancer (i.e. they will have clinically
presented). This suggests that the rate of death from preclinical lung cancer should be much lower than
the rate of clinical presentation, even if this is significantly lower than the mortality rate for clinical lung
cancer, or even close to zero. This appears paradoxical, as diagnosing lung cancer should not accelerate
mortality, as the aim of treatment is (in many cases) to prolong life expectancy. The paradox is resolved by
not assuming that the time to clinical presentation and lung cancer mortality are independent, but in fact
that individuals would present shortly before dying from a previously undiagnosed lung cancer.0.0
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FIGURE 24 Comparison of survival data and Weibull fit. (a) Extracted Kaplan-Meier data; and (b) Weibull fit.
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post diagnosis, it is reasonable to estimate the rate of clinical presentation assuming a very low probability
of dying from lung cancer prior to diagnosis.
In the base case it is assumed that there is no hazard of dying from preclinical lung cancer, but as soon as
an individual is diagnosed with lung cancer, they then face the hazard of death from lung cancer.
Other cause mortality
Individuals at high risk of lung cancer are likely to be at a higher risk of mortality from other causes as well
(e.g. cardiovascular disease, other respiratory disease, other cancers).
We estimated the risk of death from causes other than lung cancer for smokers in the following ways:l
l
l
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We estimated and removed the proportion of the mortality rate attributable to lung cancer.
We fitted a parametric (Gompertz) model to the resulting mortality profile from age 30 years.The baseline risk of death was taken from the interim life tables for England and Wales based on data for
the years 2010–12.147
The adjustment for the risk of death caused by smoking was taken from the Institute and Faculty of
Actuaries ‘00’ tables,148 which allow comparison of the mortality rates in male and female smokers versus
males and females generally. The population here is individuals with permanent life assurance policies,
which may mean that the data are not wholly representative, but we used the estimates after the ‘select
period’ (during which individuals are at a lower risk of mortality because of selection bias), and these
estimates were only used to adjust the life tables for England and Wales, which are based on national
data. The adjustment was performed by estimating the mortality rate ratio between smokers and the
general population for each year of age from 30 years, and then applying this to the England and Wales
life tables.
The proportion of mortality caused by lung cancer was estimated using cause of death data from the Office
for National Statistics,149 estimating the number of lung cancers attributable to smoking for each age group
using population attributable fractions of 86.3% and 72.2% for men and women, respectively,143 using
estimates of smoking prevalence (current smokers and former smokers) in each age group143 to estimate the
population size in each age group, and finally dividing the number of lung cancers attributable to smoking
by the population size of smokers in each age group to obtain a mortality rate from lung cancer in smokers.
The mortality rate from lung cancer in smokers was subtracted from the overall mortality rate in smokers
to produce a final estimate of the risk of death from causes other than lung cancer (Figure 25).
Graphical inspection of the mortality profiles (log-hazard versus time) demonstrated exponential growth in
the mortality rate from age 30 years, suggesting that a Gompertz model would be appropriate. Gompertz
models were fitted separately for men and women using least squares regression on log-hazard for ages
30–100 years.
In the model, the age at death from other causes is sampled conditionally on the individual being alive at
the start of the simulation as shown in Equation 2, where λ and γ are the Gompertz parameters, U is a
uniform random variable between 0 and 1 and t0 is the age of the individual at the start of the simulation:
T =
ln − ln Uexp −λeγt0
   
− lnλ
γ
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Uptake of screening
The probability of an individual responding to an initial letter regarding lung cancer screening with a
lung cancer risk questionnaire was estimated from UKLS,55 as this included contacting a significant
number of people in two qualitatively different areas and included a risk questionnaire. In this trial,
247,354 individuals were sent invitation letters, of whom 75,958 responded positively with a completed
questionnaire. Therefore, it was assumed that 30.7% of individuals would respond to an initial letter and
complete a risk questionnaire.
The probability of an individual meeting all criteria for entry to a screening programme (having initially responded
and completed a risk questionnaire) was also estimated from UKLS.55 In this trial, 8729 individuals were classified
as high risk, of whom 4061 individuals subsequently gave informed consent to participate in the trial. Therefore,
it was assumed that 46.5% of individuals would join a programme if invited.
The model also assumes that once an individual takes up screening, that they are 100% compliant
(i.e. there are no missed screens).
Risk prediction
To achieve a favourable balance of benefits, harms and costs, it is necessary to target screening towards
individuals at high risk of lung cancer. The ability to accurately discriminate between individuals at low and
high risk is a key component of the effectiveness of a screening programme.
In the model it is assumed that the Liverpool Lung Project (version 2) (LLPv2) risk prediction tool150 will be
used, as this is the only risk prediction tool that has been used to select a population for a RCT of lung
cancer screening (in UKLS55). Other risk prediction tools are available and may have different data
requirements and different performance in terms of discriminatory ability. The choice of the LLPv2 tool
does not represent an endorsement.
Rather than estimating the performance of LLPv2 from the case–control study in which it was developed150
or the validation studies,151 we instead considered its performance among responders to an invitation to
screening, that is, in the UKLS population.55
In UKLS, 41 lung cancers were detected in the baseline screen out of 1994 individuals scanned.55 A further
nine lung cancers were detected within 3 years of follow-up in these individuals (Professor John K Field
and Dr Michael Marcus, University of Liverpool, 2017, personal communication).
However, the lung cancer outcomes are unknown in individuals:l
l
l
l
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not being randomised
not meeting the risk threshold
not replying to the questionnaire.It is therefore not possible to directly estimate the sensitivity and specificity of the LLPv2 at any particular
threshold, or to construct a receiver operating characteristic curve.
We were provided with data from UKLS on certain baseline characteristics, the risk prediction score and
their lung cancer outcome (if known).
We then sought to estimate a statistical model for the risk score according to those baseline characteristics
and the lung cancer outcome. As our model simulates individuals for their lifetime through different
screening programmes, we are easily able to identify whether or not a simulated individual developseen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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86clinical lung cancer within a certain duration of follow-up, and then to ‘back-estimate’ their risk prediction
score. In this way, simulated individuals who have a baseline lung cancer or develop clinical lung cancer
early in the model will have a higher predicted risk score if the risk prediction tool is effective.
Equation 3 describes the statistical model we sought to fit, which is a linear regression on the logit of the
risk score:
log
ri
1−ri
 
= β(r)0 + β
(r)
x xi + β
(r)
y yi + ϵi ϵi ∼N (0, σ2r ), (3)
where r1 is the predicted risk for individual i, β(r)0 is the intercept term, β(r)x are the coefficients for baseline
characteristics xi (age, sex, smoking status), β(r)y is the coefficient for the outcome yi (lung cancer or not) and
ϵi is an error term with variance σ2r.
All analyses in this section were conducted using Stata version 14.2.
Fitting this model to only individuals for whom all data are available (i.e. individuals receiving a baseline
screen) is expected to produce inefficient and biased estimates of the coefficients, because these
individuals are not representative (they have been selected because of their high risk). The results of this
regression are given in Table 16 and suggest that increasing age, being male, being a current or former
smoker (vs. having never smoked) and developing lung cancer all predict a higher risk score, although the
coefficient for smoking status is not statistically significant (as very few individuals received a CT scan who
were not smokers, i.e. there is a lack of power).TABLE 16 Completed-case and multiple imputation regressions for logit(ri)
Coefficient Estimate 95% CI
Completed-case regressiona
Age (years) 0.0267 0.0214 to 0.0320
Male 0.170 0.121 to 0.220
Current/former smoker 0.360 –0.313 to 1.03
Lung cancer 0.157 0.0221 to 0.292
(Intercept) –4.74 –5.50 to –3.98
Root-mean-squared error 0.485
Multiple imputation regressionb
Age (years) 0.0899 0.0891 to 0.0906
Male 0.306 0.296 to 0.315
Current/former smoker 1.46 1.45 to 1.47
Lung cancer 0.335 0.0307 to 0.639
(Intercept) –11.4 –11.4 to –11.4
Root-mean-squared error 0.629
a Based on data from 1994 individuals receiving a baseline CT scan.
b Based on data from 70,457 individuals with 50 separate imputations of the lung cancer outcome; root-mean-squared
error derived as the SD of prediction residuals produced from each imputation.
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available, multiple imputation was employed. The lung cancer outcome was imputed using logistic
regression on the age, sex, logit risk score and smoking variables and 50 imputations were performed.
The linear regression on logit risk score was then conducted again using the imputed data sets.
Table 16 gives the results of the multiple imputation regression. This shows stronger effects for all predictors,
and they are all now statistically significant. The error term also now has increased variance. The central
estimate for the lung cancer outcome coefficient is approximately half the root-mean-squared error, so there
will be significant overlap in the predicted risks for individuals developing and not developing lung cancer.
Accuracy of low-dose computed tomography
In the model it was assumed that LDCT tests would be imperfect, and that sensitivity and specificity would
both be < 100%.
Sensitivity was included in the model as the probability that an individual with preclinical lung cancer
would be diagnosed with lung cancer following CT screening. If an individual is not diagnosed with lung
cancer following CT screening, their preclinical disease may continue to progress until they present
clinically or are diagnosed in a subsequent screening round.
Specificity was included in the model as the probability that an individual without preclinical lung cancer
would receive a result that required further testing.
It was assumed that follow-up tests would be perfect (e.g. nobody receiving a false-positive result by
LDCT screening would go on to receive treatment).
The sensitivity of LDCT screening was estimated in the calibration exercise described in Natural history as
70.9% in the base case, but 97.3% in the scenario analysis in which heterogeneity was included.
The specificity of LDCT screening was estimated from UKLS to be 62.4%.55 This is lower than the 78%
estimated in the calibration exercise based on NLST and, therefore, could be a conservative estimate, but
it was judged that a UK-based estimate would be more relevant, as specificity can be relatively accurately
estimated (compared with sensitivity) with reference standards that can be employed in trials.
Impact on survival
Numerous studies have shown that survival is higher for screen-detected cancers than non-screen-detected
cancers, including those of the same stage (we have confirmed this for NLST using the data on which the
natural history model is calibrated), but there are three significant reasons why these survival estimates
would be biased:l
l
l
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Park,Lead time bias – the screen-detected cancers are detected earlier and, therefore, even if the age at
death is unchanged, the duration from date of diagnosis to date of death is extended.
Length bias – if some cancers are more aggressive than others, these are less likely to be detected
by screening, as they spend less time in the preclinical stage before reaching advanced stages and
being diagnosed.
Overdiagnosis (an extreme form of length bias) – some slow-growing cancers may never be clinically
relevant for a patient in the absence of screening because the patient dies from another cause.On this basis, it was decided that the model should assume the same survival for lung cancer in each
stage, whether screen detected or clinically presenting, with the following caveat: the age of lung cancer
mortality should not be brought forward by screening and, therefore, there is a lower bound on survival
of A + B, where A is the expected survival in the later stage (in which the cancer would have presented
absent screening) and B is the lead time. This also applies if the lung cancer is screen detected in the same
state as it would have clinically presented.een’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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88Figure 26 illustrates the approach through three examples: (a) lung cancer is detected significantly earlier
and in a substantially earlier stage in the screening arm (shown in green), resulting in a predicted age of
lung cancer mortality beyond that in the control arm; (b) lung cancer is detected somewhat earlier and in a
somewhat earlier stage in the screening arm – the predicted survival in the earlier stage would lead to an
earlier age of mortality and, therefore, survival is extended in the screening arm to match the age of lung
cancer mortality in the control arm; and (c) lung cancer is detected slightly earlier but in the same stage in
the screening arm – the predicted survival is extended exactly by the lead time to match the age of lung
cancer mortality in the control arm.
This modelling approach directly translates a stage shift into a reduction in lung cancer mortality, but NLST
is the only RCT thus far to report a positive result for this outcome.70 To explore the possibility that lung
cancer mortality may not be reduced (or may only be reduced a small amount), we also performed two
scenario analyses. In the first, there was assumed to be no effect on lung cancer mortality from screening
(i.e. the predicted age of lung cancer mortality is insensitive to whether or not patients receive screening).
In this instance, it is still possible for screening to lead to benefits for patients, as HRQoL is better for
earlier-stage detected cancers (see Measurement and valuation of preference-based outcomes). In the
second scenario, the potential effect on lung cancer mortality is halved (i.e. if, in the base case, a lung
cancer patient would be predicted to live x years longer in the screening arm than in the control arm,
in the scenario they are modelled as living x/2 years longer).
Measurement and valuation of preference-based outcomes
A literature review was conducted to identify appropriate utility values. EQ-5D was the preferred tool to
measure HRQoL, and the preferred valuation was the UK time trade-off (TTO) value set derived from a
sample of the general population.152 These were chosen as they are recommended in the NICE reference
case for economic evaluations.137 When such values were not available, generic health measures were
preferred, with utility values either obtained by mapping to EQ-5D and valuing with the UK TTO value set,
or obtained through TTO, standard gamble or discrete choice experiment. VASs were not accepted as
valuations of health states.
Searches of the published literature were conducted for HRQoL and utility outcomes relating to lung
cancer (see Appendix 1). The search terms were broad but the retrieved records were screened specifically
for EQ-5D primary and secondary studies. Any primary studies in lung cancer patients measuring HRQoL
with EQ-5D were eligible for inclusion unless they were lung cancer patients experiencing specific adverse
events or symptoms. Secondary studies were only eligible if they were systematic reviews and included
EQ-5D studies.
Screening
We identified two studies84,153 that reported EQ-5D measures relating to screening for lung cancer.
Mazzone et al.153 reported on the impact of lung cancer screening by CXR with computer-aided detection
versus placebo screening in a RCT. They used US population values elicited using the TTO method.154Time
(a)
(b)
(c)
Preclinical lung cancer
progression
Clinical presentation
Screen detection
Lung cancer mortality
FIGURE 26 Illustration of approach to modelling lung cancer survival.
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blinded) but that EQ-5D utility dropped significantly following notification that a lung nodule was detected
(from 0.940 to 0.877).
Reporting results from the NELSON study, van den Bergh et al.84 described patient-reported outcomes
for individuals in the LDCT screening arm who did not receive a positive result (i.e. received negative or
indeterminate results). The authors did not report EQ-5D utility values, but instead VAS scores and a
number of anxiety and distress measures. These measures suggested that across all participants there was
a worsening in patient-reported measures between giving consent and 1 week prior to CT scan, although
this was reversed shortly after receiving their CT scan (prior to receiving results). They also suggest that
participants receiving an indeterminate result had worse patient-reported outcomes after receiving their
result and before receiving a follow-up scan. The generic QoL SF-12 showed no statistically significant
difference over time (between those receiving an indeterminate and negative result) in the physical or
mental component scales.
We judged that it was important to include some estimate of the impact of screening on HRQoL as there
was some evidence to support it.
We therefore assumed that lung cancer screening itself would be associated with a small, temporary
disutility of 0.01 (based on VAS drop from 79.3 to 78.8 in NELSON84) lasting for 2 weeks (i.e. a loss of
0.01 × 2/52 = 0.00038 QALYs). This is probably a negligible loss for a single participant, but considering
that in screening very few patients benefit, the average benefit from screening may also be considered
‘negligible’.
We also assumed that receiving a false-positive result (the nearest representation of an indeterminate result
in the model) would result in a temporary disutility of 0.063 (based on EQ-5D drop in Mazzone et al.153) that
would last for 3 months (it is anticipated that within 3 months an individual would have had some follow-up
to give them reassurance). This corresponds to a loss of 0.063 × 3/12 = 0.0158 QALYs. As this represents
a significant loss of utility (greater than the base-case disutility owing to stage IV lung cancer) and because
the study is of CXR rather than LDCT, a scenario analysis was conducted in which this disutility is not
included at all.
General (smokers)
All individuals included in the economic evaluation are current or former smokers. It is therefore important
to note that such individuals are unlikely to be at perfect health, or even at the same average health of
the population.
We estimated the impact of smoking (current or previously regular) on EQ-5D utility from the Health
Survey for England 2014: Health, Social Care and Lifestyles. Summary of Key Findings,155 controlling for
sex and age. Linear regression was conducted with appropriate weighting and stratification based on the
survey design.
The effect of smoking was estimated to be –0.048. Men had slightly higher utility values (+0.029) and an
age profile was observed in which utilities generally declined with age.
For the baseline age category (75–84 years), the estimated utility for female smokers was 0.753 and for
male smokers was 0.782. These utility values were used for women and men in the model regardless of
the current smoking status (which was not modelled) and age. It would have been possible to model utility
as a function of age, but it was judged that this additional complexity would not greatly affect results and,
therefore, it was decided to focus on other aspects of the economic evaluation.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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90Lung cancer
The ideal study to inform utility values relating to lung cancer would include lung cancer patients as well as
matched patients without lung cancer (matched on at least age, sex and smoking history) and would estimate
the effect of the stage of lung cancer as well as the effect of different treatments and time-dependent effects
(e.g. time before death). In addition, EQ-5D utilities measured in patients and valued by a representative sample
of the UK population using the TTO method would be preferred to be in line with the NICE reference case,137
which is used for the vast majority of economic evaluations of health technologies in the UK.
Unfortunately, no such study was found in our review of the literature.
It was decided, therefore, to focus on studies that gave evidence of the effect of lung cancer stage on
utility values.
Only one such study, by Chouaid et al.,156 explicitly measured HRQoL in UK patients (among patients from
other countries) using EQ-5D and valued using a UK population TTO tariff. This study included 255 NSCLC
patients with stage IIIB or stage IV lung cancer and produced utility estimates of 0.77 and 0.70 for these
stages, respectively.
Another study, by Grutters et al.,157 used the UK population TTO tariff but measured HRQoL in 245 NSCLC
Dutch patients. Only two patients with stage IV lung cancer were included. The study estimated utility
values of 0.77, 0.74, 0.70 and 0.86 for stages I, II, III and IV, respectively.
Three studies158–160 utilised a TTO tariff elicited from a US population sample.154 Jang et al.158 measured
HRQoL in 172 NSCLC patients in Canada and produced utility estimates of 0.80, 0.78, 0.73 and 0.75 for
stages I to IV, respectively. Yang et al.160 measured HRQoL in 518 NSCLC patients in Taiwan and produced
utility estimates of 0.85, 0.83 and 0.83 for operable stage I, II and III, respectively, and 0.72 and 0.75 for
inoperable stage III and IV NSCLC. Tramontano et al.159 measured HRQoL in 2396 lung cancer patients in the
US and produced utility estimates of 0.81, 0.77, 0.77 and 0.76 for stages I to IV, respectively. This study
also used the Short Form questionnaire-6 Dimensions (SF-6D) and UK population value set161 (derived using
standard gamble) and estimated utility values of 0.71, 0.68, 0.67 and 0.66 for stages I to IV, respectively.
In addition to differences in the population valuing the health states (USA vs. UK) and the valuation method
(TTO vs. standard gamble), the EQ-5D asked patients to rate their health today, whereas the SF-6D asked
patients to recall their health for the previous 4 weeks.
Of all these studies, the study by Tramontano et al.159 is by far the largest and is the only study to not
restrict to NSCLC. As such, we believe this is the best study with which to estimate lung cancer utility
values according to stage, despite it using a US value set rather than a UK value set.
All of the studies identified will have been at some risk of bias for a number of reasons. First, as lung cancer can
be associated with particularly poor HRQoL, it is possible that patients with worse HRQoL are underrepresented
as they will be less likely to participate in studies or to be able to complete health questionnaires. Second, most
of these estimates do not account for other differences between patients besides their cancer stage. It may be
that late-stage cancer is associated with other factors that affect HRQoL, such as age, sex, income and other
respiratory conditions.
It is also possible that generic health measures (such as EQ-5D and SF-6D) are not sensitive to aspects of
lung cancer that negatively affect HRQoL, such as shortness of breath and fatigue.
It is notable that the identified studies did not produce a large difference in the utility of stage IV lung
cancer versus earlier stages, the largest difference (0.07) being measured by Chouaid et al.156 for stage IV
versus stage IIIB NSCLC. This contrasts with a systematic review by Sturza that aimed to estimate utility
values associated with lung cancer.162 Using meta-regression across a large number of studies using a
variety of HRQoL measures and valuation methods, Sturza estimated a difference in utility value of 0.25NIHR Journals Library www.journalslibrary.nihr.ac.uk
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may be inflated, for example because it relies on meta-regression rather than investigation within a study
population, because it includes estimates not derived using EQ-5D and because it includes multiple
methods of valuation.
In the base-case analysis, it was decided that the utility values from Tramontano et al.159 would be used to
estimate the disutility for later stages of lung cancer versus stage I, whereas in a scenario analysis, a disutility
of 0.252 for stage IV would be applied based on the estimate by Sturza.162
It was further assumed that individuals with stage I cancers (mostly asymptomatic) would have the same
utility as smokers without lung cancer. This was judged to be a pragmatic approach as the average utility
for smokers without lung cancer estimated above is lower than the utility estimated for stage I lung
cancer, and it would lack face validity to increase the utility for individuals with lung cancer versus
individuals without lung cancer.
The utility values are applied for the remainder of the lung cancer patient’s life according to their stage at
diagnosis. This is a simplifying assumption as lung cancer often progresses despite treatment, and HRQoL
is likely to decline as patients approach death.
It was also assumed that individuals with preclinical lung cancer would experience some disutility as a
result of lung cancer symptoms. The same utility values for clinical lung cancer of a particular stage were
applied to the preclinical lung cancer stage also (i.e. it is assumed that a diagnosis of lung cancer does not
intrinsically affect HRQoL).
Resources and costs
The approach to the measurement and costing of resource consumption followed that recommended by
NICE in the Guide to the Methods of Technology Appraisal.137 Costs to the NHS and PSS were included
so as to assume the health and social care payer perspective, and NHS Reference Costs were the primary
source of unit costs.163 Reference costs for the financial year running 2015 to 2016 were standardised from
financial returns from 237 NHS providers delivering £64.2B.163 They used Healthcare Resource Group (HRG)
currency version 4+ for NHS acute care in England, and include the direct, indirect and overhead costs for
admitted patient care, outpatients and emergency care. Other unit costs were inflated when needed to the
adopted price year, 2016.
Costs from outside the UK were converted using the Campbell and Cochrane Economics Methods Group
(CCEMG) – Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-Centre) Cost
Converter using International Monetary Fund (IMF) purchasing power parity data.
Health and social care resources were categorised according to whether they related directly to the screening
programme, referral, diagnosis, treatment, follow-up (‘hospital costs’), or care at the end of life. Whenever
possible, the estimates of resource utilisation were determined at the substage cancer level described by
the Union for International Cancer Control Seventh Edition staging system.23,24 The screening cost category
considered the marginal cost of programme administration and, if selected, the LDCT examination(s) of
programme joiners. Transactional costs relating to programme establishment were not included. The hospital
costs category included referral, diagnosis, treatment and follow-up, although the relatively small cost of referral
is borne by the primary care budget. The end-of-life cost category captured the palliative resource use in NHS
and social care prior to lung cancer mortality, and did not include the contribution of charitable or informal care.
Directly applicable individual patient-level resourcing information was not available within the timeframe
of the study, so a literature search of the MEDLINE database was conducted (January 2017) to identify
resourcing and/or costing evaluations that might inform input parameters at summary level. The economic
evaluation search criteria were adapted by excluding the screening, Markov model and cost-effectiveness
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92were returned and a review of titles and abstracts identified six studies of interest, of which four were
included for input parameter estimation.115,164–166 Two studies were rejected on the grounds of limitations in
outcomes reported167 and inferior applicability168 (Vinod et al.168 reported estimates for a non-screening
population). One additional study was identified from the clinical effectiveness systematic review and two
reference texts were used for sourcing the unit costs of standard resources in England.55,163,169
The included sources of evidence that inform the resource utilisation and cost parameters used in the
model are given in Table 17.
Screening programme costs
Screening programme costs included programme administration around participation as well as LDCT
examinations for subsequent joiners (Table 18). Administration comprised the postal invitation to self-assess
to all potentially high-risk candidates, the scoring of responder questionnaires and a subsequent follow-up
letter of invitation or decline. These costs were allocated appropriately using the decision tree described
in Model structure and probability of uptake described in Effectiveness estimates. Since the probability of
uptake (a product of the probability of responding and then the probability of joining the programme) in
the base case was based on a trial population and may not accurately predict real-world uptake, scenario
analyses tested lower and high rates of uptake, as described in Deterministic sensitivity analyses.
The LDCT screening examinations were the same unit cost whether they were the first or subsequent
examination, and were assumed to be of the kind directly accessed in NHS secondary and tertiary care
settings (currency code RD20A).163 In scenario analyses, the base-case unit cost of LDCT was varied up and
down according to the upper and lower quartile values of the HRG currency code distribution. As it could
be presumed direct access would be preceded by clinical consultation, as is not the case via invitation,
this was added as an associated cost equating to 15 minutes with a band 5 hospital nurse.169TABLE 17 Sources of evidence for resource and cost estimates
Study, year of
publication Resource category Use in model
ten Haaf et al.,
2017115
Screening programme Cost of invitations, questionnaires, scoring of questionnaires and follow-up
administration. Based on the health-care system of ON, Canada
Field et al., 201655 Screening programme,
hospital costs
Rate of positive response to invitation to screening, and rate of programme
uptake. Based on UK experience from the pilot screening programme.
Resource use following a false-positive screen
Department of
Health and Social
Care, 2016163
Screening programme,
hospital costs
Unit cost estimates including LDCT and diagnostic procedures following a
false-positive screen
Curtis and Burns,
2016169
Screening programme,
hospital costs
Cost of GP referral and clinical staffing of screening assessment
Kennedy et al.,
2016164
Hospital costs Direct hospital costs in the first year. Based on the presentation of 3274
patients at a single large English teaching hospital between January 2008
and October 2013
McGuire et al.,
2015165
Hospital costs Direct hospital costs after the index year. Based on the 2-year treatment
cost profile of NSCLC in England using Hospital Episode statistics for
20,081 patients in the index year 2007/8
Round et al.,
2015166
End-of-life care Cost of care at the end of life for patients with lung cancer. Based on the
cost of health and social care for people with lung cancer in England and
Wales from the start of strong opioid treatment to death, 2013/14 tariff
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 18 Unit costs of the screening programme
Item Base-case unit cost (£) Scenario analysis
Initial postal invitation and questionnaire 2.90
Scoring of questionnaire 18.54
Follow-up letter 1.74
Nurse consultation 6.25
LDCT scan 98.80 70.39, 120.76a
a Upper and lower quartile values of the HRG currency code distribution.
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Following a referral, secondary care is the setting for most of the NHS expenditure on people with lung
cancer (83% in 2012/13).164 In order to incorporate the burden of referral and symptom management on
primary care, an average of two GP consultations was assumed per clinical presentation (unit cost £36169)
and included in this category. The cost of symptomatic referrals suspicious for lung cancer that are
subsequently found to be negative for lung cancer was not included.
The rate of resource consumption for the hospital-based aspects of the care pathway, namely the diagnosis,
treatment and clinical follow-up, was based on a retrospective 1-year cohort study of all emergency, inpatient
and outpatient costs (not palliative) from the records of 3274 lung cancer patients between January 2008
and October 2013.164 This study was limited to the experience of a single English teaching hospital, so may
not reflect nationwide variation in disease management, but was not limited to NSCLC as was the study by
McGuire et al.165 Summary costs at 90 days were chart extracted by substage at diagnosis and attributed to
all true diagnoses, whether clinical presentations or true-positive screen detections, irrespective of survival
time with lung cancer as many of these costs are quickly accrued (more than half of first-year costs come in
the first 90 days). People surviving beyond 90 days were attributed further costs in the first year proportionate
to their survival up to a limit of 2 years. Second-year costs were adjusted downwards from index year costs
using the rate of change observed between year 1 and year 2 in a separate retrospective cohort study of NHS
lung cancer resource consumption.165 Two years was judged a reasonable cut-off point for disease costs in
the base case, given the front-loaded nature of resourcing following a lung cancer diagnosis. McGuire et al.165
estimated that second-year costs were just 13% of first-year costs. However, in a scenario analysis the
subsequent year costs were maintained at a flat rate for survivors up to 5 years.
A summary of hospital costs by substage of cancer and period post presentation is given in Table 19.
People who received a false-negative screen were zero cost until a true diagnosis of lung cancer, whereupon
costs accrued as described above. Those who received a false-positive screen were resourced as observed
in UKLS.55 Of 951 false-positive cases, there were 72 resultant cancer MDTs, 1466 outpatient CT scans,
seven needle biopsies, 13 PET scans, one endobronchial ultrasound bronchoscopy and 21 follow-up outpatient
consultations. The cost of investigative resourcing following a false-negative screen was £184.63. A breakdown
of the unit costs and their consumption is given in Table 20.
End-of-life costs
In the literature search, we identified a recent and directly applicable study of the cost of caring for people
with cancer in England and Wales.166 In this study, the average per-patient cost of palliative resourcing over
an average period of 180 days from the start of strong opioid treatment was £4589, based on 68,340
hospital episodes relating to lung cancer. The personalised social services component of this figure (£1380)
was included in the base case but excluded in a scenario analysis in which the payer perspective was© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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TABLE 20 Unit cost and unit consumption of investigative resourcing following a false-negative screen
Resource item Unit cost (£)163
Unit consumption
per FP case55 Weighted cost (£)
Cancer MDT meeting 107.35 0.0757 8.13
Outpatient CT scan 102.50 1.5415 158.00
Elective inpatient percutaneous biopsy of lesion of,
lung or mediastinum
994.59 0.0074 7.32
Outpatient endobronchial ultrasound examination
of mediastinum
562.87 0.0011 0.59
Outpatient PET-CT scan 573.91 0.0137 7.85
Non-admitted face-to-face attendance, follow-up
with clinical oncology
124.01 0.0221 2.74
Total cost of a FN screen 184.63
FN, false negative; FP, false positive.
TABLE 19 Cost of diagnosis, treatment and follow-up by cancer substage and period post presentation
Substage at presentation
Cost (£)
90-days Index yeara Second yearb
IA 5558 11,406 1438
IB 6412 11,771 1484
IIA 7279 12,917 1628
IIB 6558 13,073 1648
IIIA 6512 11,927 1503
IIIB 6047 10,365 1306
IV 5442 8229 1037
a The Index year includes costs from the first 90 days.
b Index year cost in Kennedy et al.164 adjusted downwards for second-year cost according to trend in McGuire et al.165
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94limited to health care. In a further scenario analysis, the end-of-life cost attributed to lung cancer mortality
was excluded altogether in order to reflect the possibility that other deaths in this population could be
equally costly owing to the preponderance of comorbidity in people with a history of smoking.
Key modelling assumptions
We have attempted to list the key assumptions in the model in Table 21, and to indicate (if possible) the
anticipated impact of the assumptions made on the cost-effectiveness of screening programmes versus no
screening, and to indicate whether the assumptions are explored in scenario or sensitivity analyses.
Of the 19 assumptions listed, nine have an unclear impact on cost-effectiveness, six may have improved
cost-effectiveness (i.e. tended to be optimistic assumptions) and four may have worsened cost-effectiveness
(i.e. been conservative assumptions). Thirteen are not explored in scenario or sensitivity analyses, while,
of the six that are explored (or partially explored), three are assumptions with an unclear anticipated impact
and the other three may have been optimistic assumptions.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 21 Key assumptions in our model
Assumption
Anticipated impact (on cost-effectiveness of screening
vs. no screening vs. likely true cost-effectiveness)
Explored in scenario or
sensitivity analyses
Changes in smoking
behaviour are not modelled
Possibly worsened; screening may encourage some to quit
smoking, but evidence is mixed
No
Uptake will be similar in
real life to that in UKLS
Unclear; on the one hand trials tend to recruit healthier
volunteers, but on the other hand invitations to participate
in a trial contain substantially different information to
invitations to participate in a screening programme
Yes
Full concordance with
screening programme (i.e.
no missed appointments)
Improved; missed appointments lead to wasted resources
and missed opportunities for patients to benefit from
screening
No
HRQoL similar for
preclinical and diagnosed
lung cancer (stratified by
stage)
Unclear; a diagnosis of lung cancer may lead to heightened
anxiety, and treatments for lung cancer may lead to reduced
HRQoL. However, with a diagnosis patients may also receive
better support to manage their symptoms
No
HRQoL similar for clinically
presenting and screen-
detected lung cancer of the
same stage
Unclear No
HRQoL for diagnosed lung
cancer is constant until
death
Worsened; one would expect HRQoL to diminish over time
as the disease progresses despite treatment, and this would
be particularly acute in those dying from lung cancer (and
there are more of these without screening)
No
Natural history of lung
cancers is similar across all
included individuals
Improved; length bias and overdiagnosis are not fully
addressed in the base-case analysis, both of these
phenomena undermine effectiveness
Yes
Lung cancers progress
through stages in
numerical order without
skipping any stages
Unclear; if lung cancers do skip stages in significant
proportion then the natural history model calibrated to NLST
data may not be appropriate
No
Sensitivity of LDCT
independent of patient
and tumour characteristics
Unclear; sensitivity may be expected to be worse for earliest-
stage cancers (people who could potentially benefit the
most from screening), but this would also have a significant
impact on overdiagnosis
No
Lung cancer mortality
methodology
Unclear; the methodology establishes a lower bound on
effectiveness (so that screening cannot be less effective than
no screening), but it is possible that survival is underestimated
when a stage shift is achieved, since there is some evidence
(though at high risk of bias) that screen-detected cancers
have improved survival vs. non-screen-detected cancers
Partially; there are scenario
analyses in which the impact
on mortality is eliminated or
attenuated, but no scenario
analysis in which the impact
on mortality is strengthened
Mortality from preclinical
lung cancer assumed to be
negligible
Worsened; if there is significant mortality from preclinical
(occult) lung cancer in the population, then screening would
potentially be able to reduce this
No
Lung cancer incidence in
participating population
similar to incidence in
general smoking (current
and former) population
Possibly improved; respondents are likely to be healthier
than general smoking population and, therefore, may have
reduced incidence; however, the use of a risk prediction
model should substantially mitigate this
Partially (through univariate
sensitivity analyses)
Survival in participating
population similar to
survival in general
population (stratified by
stage)
Improved; it is more likely that a participating population
would be healthier and less deprived than the general
population of smokers and would therefore have improved
survival, potentially benefiting less from screening
Partially (through univariate
sensitivity analyses)
continued
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TABLE 21 Key assumptions in our model (continued )
Assumption
Anticipated impact (on cost-effectiveness of screening
vs. no screening vs. likely true cost-effectiveness)
Explored in scenario or
sensitivity analyses
Incidental findings not
modelled
Unclear; incidental findings may be of clinical value (i.e. it
may be possible to offer treatment or management that
improves patient outcomes) but may also significantly
increase costs
No
True-positive results lead to
immediate diagnosis and
treatment
Improved; there is expected to be a delay between
screening and diagnosis, during which lung cancer could
progress further, thereby reducing the benefit of screen
detection
No
False-positive and
indeterminate results are
treated equivalently
Unclear; indeterminate results typically result in less intensive
follow-up than false-positive results, but the model assumes
a weighted average of these results according to UKLS
No
Non-attendance of
screening was not explicitly
modelled
Unclear; NHS Reference Costs163 include costs of missed
appointments as overheads within unit costs, but it is not
clear whether or not the unit cost chosen will include a
representative overhead for non-attendance in a
hypothetical screening programme
Partially (through sensitivity
analyses on the unit cost of
LDCT)
Additional cancers caused
by radiation exposure not
modelled
Improved; additional cancers would lead to increased costs
and decreased QALYs
No
Risk prediction is
dependent only on
prevalence of occult lung
cancer or short-term
incidence (within 3 years)
Worsened (especially for annual and biennial strategies); in
the model the value of risk prediction is limited to the first
3 years, such that individuals who would develop lung
cancer > 3 years later have no higher predicted risk on
average than individuals who would not develop lung
cancer beyond 3 years
No
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96Quality assurance
Quality assurance of the economic model was conducted by three modellers:
1. The lead modeller (EG) conducted developer testing and incorporated a number of automatic model
checks to highlight any possible errors as the model was developed.
2. One member of the team (TS), who had contributed only a small quantity towards the implementation
of the model itself, conducted two rounds of quality assurance on the model (one on the version for
the draft report and one on the final version) and signed off corrections of errors identified through this
quality assurance. Methods of quality assurance included formula review and parallel build.
3. A member of Peninsula Technology Assessment Group (PenTAG) not working on the project
(Dr Irina Tikhonova, Research Fellow in Health Economic Modelling) conducted quality assurance on
the version of the model used for the draft report.Results
Throughout this section a naming convention is used for the different potential screening programmes
(Box 1).
Base case
Forty-eight hypothetical screening programmes were modelled, as well as a no-screening comparator arm,
representing current practice.NIHR Journals Library www.journalslibrary.nihr.ac.uk
BOX 1 Naming convention for screening programmes
Naming convention= frequency–lower age limit–upper age limit–risk threshold
Where frequency is S (single screen), T (three screens), A (annual screening to age 80 years) or B (biennial
screening to age 80 years).
For example, S–55–75–5% refers to a screening programme for which people aged 55–75 years are sent
questionnaires, and those with a predicted risk of ≥ 5% are invited to a single CT screening round.
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69These analyses are conducted by simulating a cohort of 20,000 individuals, as cost and QALY predictions
appear to be very stable after 15,000 simulations.
The different population selection criteria produced a wide range of proportions of smokers joining
screening programmes (from 1.2% for 60–75–5% to 4.0% for 55–80–3%), as shown in Table 22. The
predominant reasons for smokers not joining screening programmes were not responding to the initial
invitation and not being invited (as outside the age limit).
Main analysis
Cost-effectiveness
Four of the modelled screening strategies were on the cost-effectiveness frontier (i.e. strategies that can
give the maximum NMB for at least one choice of the cost-effectiveness threshold) and ‘no screening’ was
also on the frontier (the least costly and least effective option).TABLE 22 Proportion of smokers joining and not joining screening
Population criteria
Proportion of smokers aged 55–80 years (%)
Joiner
Non-joiner
Decline Low risk No response Not invited
No screening – – – – 100.0
55–80–3% 4.0 4.6 22.1 69.3 –
55–80–4% 2.6 3.0 25.1 69.3 –
55–80–5% 1.7 2.0 27.0 69.3 –
60–80–3% 3.8 4.4 14.5 51.3 26.0
60–80–4% 2.5 2.9 17.3 51.3 26.0
60–80–5% 1.7 2.0 19.0 51.3 26.0
55–75–3% 3.2 3.7 21.8 64.8 6.5
55–75–4% 1.9 2.2 24.6 64.8 6.5
55–75–5% 1.2 1.4 26.1 64.8 6.5
60–75–3% 3.1 3.5 14.2 46.8 32.4
60–75–4% 1.9 2.2 16.7 46.8 32.4
60–75–5% 1.2 1.4 18.2 46.8 32.4
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98Table 23 gives key results for strategies on the cost-effectiveness frontier. In this analysis, none of the
screening strategies would be considered cost-effective versus no screening at a threshold of £20,000 per
QALY. At a threshold of £30,000 per QALY, S–60–75–3% would be cost-effective versus no screening
(ICER £28,169 per QALY), as would S–55–75–3% (ICER £28,784 per QALY), but in a fully incremental
analysis only S–60–75–3% would be cost-effective with a threshold of £30,000 per QALY.
Figure 27 presents the cost-effectiveness plane with all strategies, and Figure 28 shows the strategies on
the cost-effectiveness frontier.
A summary of selected clinical outcomes is presented for the screening strategies on the cost-effectiveness
frontier in Table 24.TABLE 23 Base-case cost-effectiveness results
Strategy Costs (£) QALYs
ICER (vs. no
screening) (£)
Incremental costs
(vs. previous) (£)
Incremental QALYs
(vs. previous)
ICER (vs.
previous) (£)
No screening 1103 8.502
S–60–75–3% 1126 8.503 28,169 23 0.0008 28,169
S–55–75–3% 1129 8.503 28,784 3 0.0001 35,453
S–55–80–3% 1135 8.503 30,821 6 0.0001 44,087
T–55–80–3% 1151 8.503 40,034 17 0.0002 95,292
Only strategies on the cost-effectiveness frontier are shown. All strategies were predicted to lead to health benefits (vs. no
screening), ranging from 0.0003 to 0.0012 QALYs per person. Although such gains would not generally be considered
significant, these gains are concentrated in people who join the screening programme (ranging from 1.2% to 4.0% of the
population), and are diagnosed with lung cancer at an earlier stage and, therefore, receive more substantial health benefits.
For example, individuals participating in the S–60–75–3% screening programme are predicted to gain an average 0.054 life-years
(≈3 weeks)/0.027 discounted QALYs compared with no screening, and to die from lung cancer 0.16 years (≈8 weeks) later.
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TABLE 24 Clinical outcomes for participants of strategies on the cost-effectiveness frontier
Screening programme strategy
Strategy
S–60–75–3% S–55–75–3% S–55–80–3% T–55–80–3%
Per participant
Number of screens 1.00 1.00 1.00 2.70
Number of false positives 0.33 0.33 0.33 0.95
Lead time (years) 0.299 0.299 0.295 0.395
Life-years gained 0.0537 0.0568 0.0524 0.0762
Additional lung cancer survival (%) 0.80 0.45 0.43 0.64
Additional 5-year lung cancer survival (%) 16.1 16.4 16.1 21.0
Additional survival time with lung cancer (years) 1.87 1.89 1.85 2.44
Change in age at lung cancer diagnosis –1.70 –1.69 –1.62 –2.03
Change in age at death from any cause 0.05 0.06 0.05 0.08
Change in age at death from lung cancer 0.16 0.20 0.23 0.41
Per 100,000 participants
Proportion of diagnoses arising from screening (%) 44.4 44.3 47.1 62.5
Number of screen-detected cases 1710 1785 2335 3185
Number of interval cancers 0 0 0 215
Additional lung cancer diagnoses 295 300 450 590
Lung cancer deaths averted 170 100 120 180
Life-years gained 0.2683 0.2839 0.2621 0.3809
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Lung cancer mortality reduction
The average number of lung cancer deaths (per 100,000 participants) was 15,200, 15,100, 14,600 and
15,000 for the single, triple, annual and biennial strategies, respectively, with a comparable 15,800 for
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100Across the different screening programmes a reduction in lung cancer mortality of 2.9% to 8.7% was
predicted (RR) among the participating individuals versus no screening. The results for the strategies on the
cost-effectiveness frontier are shown in Table 25.
The average lung cancer mortality reduction for single-screen strategies was 4.2%, while for triple screen
strategies it was 4.4%, for annual strategies it was 7.7% and for biennial strategies it was 5.2%.
Lung cancer stage and survival
Screening strategies were associated with an increased probability of lung cancer being diagnosed in the
early stages (I and II) versus later stages (III and IV). The average ORs of early diagnosis (geometric mean)
were predicted to be 2.44, 3.29, 5.62 and 3.83 for single, triple, annual and biennial screening
programmes, respectively.
Table 26 presents the average stage distributions for screening programmes by frequency of screening.
As can be seen, the most significant impact is seen in the increase in lung cancers detected at stage IA
and the decrease in lung cancers detected at stage IV.
As would be expected, lung cancer survival was predicted to be higher in the screening arms. Lung cancer
survival at 5 years was predicted to be 20.3%, 26.2%, 32.3% and 29.1% for single, triple, annual and
biennial screening programmes (on average) versus a comparable average of 4.7% for no screening.
Lung cancer diagnoses
Lung cancer screening programmes led to increased lung cancer diagnoses across the lifetime of participants
(i.e. what would be considered overdiagnosis) versus no screening. The average RRs of a lung cancer
diagnosis were 1.11, 1.15, 1.20 and 1.18 for single, triple, annual and biennial screening programmes
(geometric mean), respectively.TABLE 25 Lung cancer mortality reduction in strategies on the cost-effectiveness frontier
Strategy
Lung cancer deaths
in simulation (n)
Comparison (no screening
in same individuals) (n) RR
S–60–75–3% 624 658 0.948
S–55–75–3% 669 689 0.971
S–55–80–3% 796 820 0.971
T–55–80–3% 780 820 0.951
TABLE 26 Average stage distributions for screening programmes (by frequency of screening)
Screening programme
Lung cancer stage
IA IB IIA IIB IIIA IIIB IV
No screening 0.06 0.01 0.02 0.02 0.06 0.03 0.80
Single 0.13 0.03 0.03 0.03 0.06 0.03 0.69
Triple 0.17 0.04 0.03 0.03 0.06 0.03 0.64
Annual 0.27 0.05 0.03 0.04 0.05 0.02 0.54
Biennial 0.19 0.04 0.03 0.04 0.06 0.04 0.60
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Per 100,000 participants, there were on average 19,200 lung cancers diagnosed in the single-screening
arms, 19,700 in the triple screening arms, 20,600 in the annual screening arms and 20,300 in the biennial
screening arms. The comparable figure for no screening was 17,200.
On average, 47.7% of lung cancer diagnoses in the single-screen programmes were screen detected,
compared with 64.2%, 80.6% and 72.1% for triple, annual and biennial strategies, respectively (these
could be considered the screening programme sensitivities). Interval cancers accounted for 3.9%, 5.6%
and 11.8% of diagnoses in the triple, annual and biennial strategies, respectively.
Number of screening tests and false positives
Screening programmes were associated with an average of 1.00, 2.68, 8.03 and 4.55 LDCT screens per
participant for single, triple, annual and biennial screening programmes, respectively, and with 0.32, 0.93,
2.96 and 1.60 false-positive or indeterminate results.
Average ages at events
The average age at diagnosis of lung cancer was lower in the screening arms (which would be expected
unless there was significant overdiagnosis in older participants). The average ages at diagnosis were 74.6,
74.1, 73.6 and 73.9 years for single, triple, annual and biennial programmes, respectively, versus a
comparable 76.2 years in the absence of screening.
The average age at death from lung cancer was higher in the screening arms. The average ages at death
from lung cancer were 77.6, 77.8, 78.0 and 77.9 years for single, triple, annual and biennial programmes,
respectively, versus a comparable average of 77.5 years for no screening.
The average age at death from other causes was not significantly affected (around 82 years), but was slightly
higher in the screening arms. The only explanation for this in the model is that some lung cancer patients
were dying from other causes in the screening arms, whereas they died from lung cancer in the no-screening
arm, and that these patients were on average older at time of death than the people already dying from
other causes.
Lead time is calculated in the model as the difference between the age at which an individual is diagnosed
with lung cancer in the no-screening arm (or dies from other causes, whichever is earlier) and the age at
which the individual is diagnosed with lung cancer in the screening arm. Lead time is therefore time spent
by the individual with a known diagnosis of lung cancer that they would not have had in the absence of
screening. The average lead time in the single-screening arms was 0.32 years, whereas it was 0.44 years in
the triple screening arms. The average lead time in annual screening arms was 0.58 years, whereas it was
0.20 years in the biennial screening arms.
Costs
The costs per participant relating to LDCT screening ranged from £104 (single-screen programmes) to
£603–794 (annual screening programmes).
Lung cancer costs (excluding end of life) also generally rose in line with the frequency of screening. If there
are savings in the cost of treating some screen-detected cancers because they were detected at an earlier
stage, these are outweighed by the increased number of lung cancers diagnosed (i.e. overdiagnosis).
The costs of end-of-life care are decreased as the frequency of screening increases, because there is a
reduction in the number of people dying of lung cancer (the model assumes end-of-life costs only for
individuals dying of lung cancer, not for those dying of other causes with lung cancer).
The costs for the screening programmes on the cost-effectiveness frontier are shown in Table 27. The
programmes are predicted to lead to population lifetime cost increases of £299M to £634M for a relevant
population of 13 million smokers aged 55–80 years. The costs of running the screening programme© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101
TABLE 27 Costs for programmes on the cost-effectiveness frontier
Costs
Strategy
No screening S–60–75–3% S–55–75–3% S–55–80–3% T–55–80–3%
Costs for each participant (£)
LDCT screening 104 104 104 275
Lung cancer costs (excluding end
of life)
1458 1445 1469 1724
End of life 534 530 515 505
Total cost 2097 2080 2088 2504
Population of 13 million smokers aged 55–80 years (lifetime costs, £M)
Screening administration 0 80.16 110.97 118.66 118.66
LDCT screening 0 41.42 43.53 54.06 142.48
Lung cancer costs (excluding end
of life)
9355 9540 9547 9610 9742
End of life 4979 4972 4971 4970 4965
Total cost 14,334 14,633 14,673 14,753 14,968
Additional cost vs. no screening 299.1 338.8 418.5 634.2
INDEPENDENT ECONOMIC ASSESSMENT
102(invitations, risk scoring, LDCT scans) make up less than half of the increased cost, with the rest being
attributable to increased costs associated with lung cancer (excluding end-of-life care).
Secondary analyses
Cost-effectiveness of different screening frequencies in fixed populations
We evaluated the cost-effectiveness of the four different screening frequencies (and no screening) within
the 12 fixed populations.
Table 28 gives the results of these analyses, and demonstrates the following:l
l
l
l
l
NIHRAnnual and biennial screening were dominated by triple screening in all populations.
Triple screening was always on the cost-effectiveness frontier and always gave the most QALYs.
The ICERs of triple screening were always in excess of £36,000 per QALY.
Single screening was sometimes on the cost-effectiveness frontier and was sometimes extendedly
dominated by no screening and triple screening.
The ICERs of single screening (when not extendedly dominated) were < £30,000 (but well > £20,000)
per QALY for 55–75–3% and 60–75–3%, and > £30,000 per QALY for other populations.Optimisation analysis
An optimisation analysis was performed for each screening frequency to identify the optimal choice of age
limits and predicted risk thresholds. A simple grid optimisation approach was taken, in which minimum
age was varied in 1-year steps from 55 to 75 years, maximum age was varied in 1-year steps from 65 to
80 years, and the risk threshold was varied in 1% steps from 0% to 10%. Grid points where the minimum
age was not less than the maximum age were removed, and a pragmatic minimum of 200 patients (1% of
the simulated cohort) had to meet all criteria. The quantity to be maximised was the incremental net
monetary benefit (INMB) versus no screening with a willingness to pay of £20,000 per QALY.Journals Library www.journalslibrary.nihr.ac.uk
TABLE 28 Cost-effectiveness of different screening frequencies within fixed populations
Population Screening frequency Costs (£) QALYs
ICER vs. no
screening (£) ICER (£)
55–80–3% No screening 1103 8.50215
Annual 1188 8.50294 108,405 D
Biennial 1164 8.50306 66,985 D
Single 1135 8.50319 30,821 30,821
Triple 1151 8.50337 40,034 95,292
55–80–4% No screening 1103 8.50215
Annual 1160 8.50274 97,461 D
Biennial 1145 8.50275 70,934 D
Single 1128 8.50285 36,315 36,315
Triple 1139 8.50309 38,574 45,121
55–80–5% No screening 1103 8.50215
Biennial 1135 8.50256 79,242 D
Single 1124 8.50261 46,378 ED
Annual 1144 8.50264 85,031 D
Triple 1131 8.50283 42,254 42,254
60–80–3% No screening 1103 8.50215
Annual 1182 8.50290 104,759 D
Biennial 1159 8.50301 65,627 D
Single 1132 8.50311 30,485 30,485
Triple 1148 8.50329 39,719 88,019
60–80–4% No screening 1103 8.50215
Biennial 1142 8.50273 67,880 D
Annual 1156 8.50274 91,335 D
Single 1125 8.50281 34,432 34,432
Triple 1136 8.50305 37,066 44,278
60–80–5% No screening 1103 8.50215
Biennial 1132 8.50252 79,341 D
Single 1121 8.50257 44,569 ED
Annual 1141 8.50260 84,714 D
Triple 1129 8.50279 40,615 40,615
55–75–3% No screening 1103 8.50215
Annual 1178 8.50282 112,853 D
Biennial 1155 8.50298 63,129 D
Single 1129 8.50306 28,784 28,784
Triple 1142 8.50318 38,375 106,423
continued
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TABLE 28 Cost-effectiveness of different screening frequencies within fixed populations (continued )
Population Screening frequency Costs (£) QALYs
ICER vs. no
screening (£) ICER (£)
55–75–4% No screening 1103 8.50215
Annual 1151 8.50260 108,804 D
Biennial 1138 8.50266 69,054 D
Single 1123 8.50271 35,890 35,890
Triple 1131 8.50289 38,131 44,930
55–75–5% No screening 1103 8.50215
Biennial 1129 8.50251 73,225 D
Single 1119 8.50251 45,239 ED
Annual 1137 8.50253 89,986 D
Triple 1125 8.50268 41,617 41,617
60–75–3% No screening 1103 8.50215
Annual 1171 8.50278 108,778 D
Biennial 1150 8.50293 61,342 D
Single 1126 8.50297 28,169 28,169
Triple 1139 8.50310 37,859 95,963
60–75–4% No screening 1103 8.50215
Annual 1148 8.50260 100,793 D
Biennial 1135 8.50264 65,367 D
Single 1120 8.50267 33,475 33,475
Triple 1128 8.50286 36,181 43,829
60–75–5% No screening 1103 8.50215
Biennial 1126 8.50247 72,679 D
Single 1117 8.50248 42,796 ED
Annual 1134 8.50250 90,039 D
Triple 1122 8.50264 39,437 39,437
D, dominated; ED, extendedly dominated.
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104The results of these analyses are shown in Table 29. They demonstrate that it is possible (post hoc) to
identify an appropriate cohort for whom screening is cost-effective (vs. no screening) for any frequency
except annual. The INMB for the single screen versus no screening is £3.24.
The results of these analyses should be treated with significant caution. First, they are based on a particular
microsimulation and results may change for newly simulated cohorts (although the number of simulations
was chosen to give some degree of stability). Second, these are post hoc identified cohorts and the results
may not generalise. Third, this is based only on the base-case analysis and optimal cohorts may differ
substantially in a probabilistic analysis or under other scenario and sensitivity analyses.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 29 Results of optimisation analyses
Screening frequency
£20,000 per QALY
Age limit (years) Risk threshold (%) ICER vs. no screening (£)
Single 64 to 67 2 13,631
Triple 65 to 66 3 10,303
Annual 65 to 66 3 20,589
Biennial 65 to 66 3 17,291
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Deterministic sensitivity analyses
Univariate sensitivity analyses
Univariate sensitivity analyses were conducted by rerunning the base case with a single parameter
increased or decreased by 10% of its base-case value or by log(1.1) (≈0.095) depending on whether or
not it could change sign and/or was estimated on a logarithmic scale.
Each run of the model simulated 6000 individuals and, therefore, it is possible that stability was not
reached for strategy mean costs and QALYs; however, the results should still be indicative of the likely
direction and magnitude of the impact on cost-effectiveness from changing each parameter.
The impact on cost-effectiveness was assessed by evaluating the INMB of the strategy S–60–75–3% (the
optimal screening strategy in the base case, although not cost-effective) versus no screening (at £20,000
per QALY) and comparing it to the base-case value (–£7).
When the INMB is > £0, it indicates that S–60–75–3% is cost-effective with no screening at £20,000
per QALY.
The results of the univariate sensitivity analysis are presented in a tornado diagram in Figure 29.
Four out of the five most influential parameters relate to the natural history for smokers (lung cancer
survival, other cause mortality, preclinical lung cancer incidence). The cost of LDCT screens (c_LDCT; see
Appendix 9 for parameter labels) is fairly influential and, as would be expected, screening is expected to be
more cost-effective when the cost is lower.
There appears to be some asymmetry in the tornado diagram, which may suggest non-linearity in a
number of the parameters. For some parameters, the resulting range of INMB does not include the base
case. This may be due to Monte Carlo variation, or may be a result of non-linearities.
The specificity of screening (sens_LDCT) appears to be more influential than the sensitivity (spec_LDCT),
but in both cases improved diagnostic performance leads to better cost-effectiveness. Likewise, the
performance of the risk prediction (risk_lungcancer) positively affects cost-effectiveness, as would
be expected.
It should be noted that parameters were all varied by approximately the same degree, regardless of how
precisely they were estimated, and that no correlation between parameters has been incorporated. These
issues are both addressed within the PSA (see Probabilistic sensitivity analysis).© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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FIGURE 29 Tornado diagram for univariate sensitivity analyses. Parameters sorted by range of INMB produced
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A number of scenario analyses were conducted, in which changes to the structure or sets of parameter
values were made. For each scenario analysis 10,000 individuals were simulated and the impact of the
scenario analysis is assessed by presenting the INMB of S–60–75–3% versus no screening, as well as for up
to two alternative screening strategies: (1) the strategy giving the highest INMB versus no screening of all
screening strategies, and (2) the strategy on the cost-effectiveness frontier giving the highest INMB versus
no screening of all screening strategies.
The results of these scenario analyses are presented in Table 30 and discussed in detail below.
Very few scenario analyses led to any screening strategy being predicted to be cost-effective versus no
screening at a threshold of £20,000 per QALY (this happened only if false-positive and indeterminate
results were predicted to have no effect on HRQoL, or if there was no discounting).
Age distribution
In this scenario the age distribution of responders was presumed to match the age distribution of smokers
in the UK population, as described in Model structure.TABLE 30 Results of scenario analyses
Scenario
INMB vs. no screening (£) Alternative screening strategy
S–60–75–3% 1 2 1: highest NMB
2: highest NMB
on frontier
Base case –7
Age distribution –14 –12 –17 S–60–75–5% S–60–80–3%
Risk prediction accuracy –9 –5 T–60–75–5%
Programme uptake (low) –15 –9 –14 S–60–80–5% S–60–80–3%
Programme uptake (high) –17 –12 –22 S–60–75–5% T–60–75–3%
Heterogeneity in tumour progression –35 –19 –30 S–60–75–5% S–60–80–5%
Mortality impact (removed) –46 –28 N/A S–60–75–5% N/A
Mortality impact (halved) –20 –10 S–60–75–5%
Short-term impact on utility from lung
cancer diagnosis
–8 –1 S–60–75–5%
Alternative (significantly higher) disutility
for stage IV lung cancer
–3
No screening anxiety after first screen –10 –10 S-60–75–5%
No change in HRQoL for false-positive
result
4
Follow-up care for up to 5 years –10 –5 S–60–75–5%
PSS costs for end of life not included –10 –7 –12 S–60–75–4% S–60–80–3%
End-of-life costs excluded –9 –6 –8 S–60–75–5% S–60–80–4%
Lower unit cost of LDCT –10 –8 S–60–75–5%
Higher unit cost of LDCT –10 –5 –6 S–60–75–5% S–60–75–4%
10-year time horizon –9 –5 S–60–75–5%
No discounting 2 8 T–60–75–4%
N/A, not applicable.
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108In this scenario, S–60–75–3% was extendedly dominated, and there were two screening strategies on the
cost-effectiveness frontier: S–60–80–3% (ICER £36,526 per QALY) and T–60–80–3% (£69,956 per QALY).
Risk-prediction accuracy
The accuracy of risk prediction was increased by changing the risk_lungcancer parameter in the risk model.
In this scenario, S–60–75–3% was dominated and there were three screening strategies on the
cost-effectiveness frontier: T–60–75–5% (£25,056 per QALY), T–60–75–3% (£51,077 per QALY) and
T–55–75–3% (£13M per QALY).
Programme uptake
In one scenario analysis the uptake of the screening was halved. In this scenario, S–60–75–3% was
dominated and there were three screening strategies on the cost-effectiveness frontier: S–60–80–3%
(£41,040 per QALY), T–60–80–3% (£97,030 per QALY) and B–60–80–3% (£263,700 per QALY).
In another scenario analysis the uptake of the screening was increased. In this scenario, S–60–75–3% was
dominated and there were three screening strategies on the cost-effectiveness frontier: T–60–75–3%
(£49,409 per QALY), T–60–80–3% (£84,823 per QALY) and T–55–80–3% (£382,200 per QALY).
Incorporating heterogeneity in lung cancer progression
In this scenario analysis, the natural history model was recalibrated assuming heterogeneity between
patients in the rate of lung cancer progression. This also affected the estimated sensitivity of LDCT
screening (increasing it substantially).
In this scenario, S–60–75–3% was dominated and there was one screening strategy on the cost-
effectiveness frontier: S–60–80–5% (£167,136 per QALY).
Impact on mortality
In one scenario analysis, the survival benefit from early detection was eliminated (i.e. the survival is
extended only by the lead time because of screening). In this scenario all screening strategies were
dominated by no screening.
In another scenario analysis, the survival benefit from early detection was halved. In this scenario,
S–60–75–3% was dominated and there were two strategies on the cost-effectiveness frontier:
S–60–75–5% (£74,157 per QALY) and T–60–75–5% (£121,200 per QALY).
Impact on health-related quality of life
In the first of these scenario analyses, it was assumed that there would be a short period of disutility
following a lung cancer diagnosis. In this scenario, S–60–75–3% was dominated and there were four
screening strategies on the cost-effectiveness frontier: S–60–75–5% (£22,190 per QALY), S–60–75–4%
(£50,776 per QALY), S–55–75–3% (£58,040 per QALY) and S–55–80–3% (£113,800 per QALY).
In the second of these scenario analyses, a substantial disutility was assumed for stage IV lung cancer. In
this scenario, five screening strategies were on the cost-effectiveness frontier: S–60–75–3% (£22,496 per
QALY), S–60–80–3% (£34,254 per QALY), A–60–75–3% (£66,781 per QALY), A–60–80–3% (£93,480 per
QALY) and A–55–80–3% (£120,200 per QALY).
In the third of these scenario analyses, it was assumed that there would be no impact on HRQoL in the
run-up to subsequent screens (as participants would have ‘acclimatised’ to screening). In this scenario
analysis, there were three screening strategies on the cost-effectiveness frontier: S–60–75–3% (£36,680
per QALY), S–60–80–3% (£44,784 per QALY) and S–55–80–3% (£1M per QALY).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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result of false-positive or indeterminate results. In this scenario analysis there were four screening strategies
on the cost-effectiveness frontier: S–60–75–3% (£16,759 per QALY), B–55–75–3% (£33,577 per QALY),
A–55–75–3% (£63,262 per QALY) and A-55–80–3% (£105,800 per QALY).
Cost of follow-up care
In this scenario analysis, follow-up costs for lung cancer were included for up to 5 years (compared with
2 years in the base case). S–60–75–3% was extendedly dominated and there were three screening strategies
on the cost-effectiveness frontier: S–60–75–5% (£31,086 per QALY), S–60–80–3% (£39,648 per QALY)
and S–55–80–3% (£67,566 per QALY).
End-of-life costs
In the first of these scenario analyses, PSS costs were excluded from the cost of the end of life (reducing
the cost from £4589 to £3209). S–60–75–3% was extendedly dominated and there were two screening
strategies on the cost-effectiveness frontier: S–60–80–3% (£35,003 per QALY) and T–60–80–3%
(£76,903 per QALY).
In the second of these scenario analyses, end-of-life costs were eliminated completely (which gives an
approximation to the case in which end-of-life costs are included for other cause mortality at the same
cost as for lung cancer mortality). In this scenario analysis S–60–75–3% was extendedly dominated and
there were five screening strategies on the cost-effectiveness frontier: S–60–80–4% (£31,014 per QALY),
S–55–80–4% (£31,485 per QALY), S–55–80–3% (£37,778 per QALY), T–55–80–4% (£244,500 per QALY)
and T–55–80–3% (£751,000 per QALY).
Computed tomography screening costs
In the first of these scenario analyses, the cost of a LDCT scan was taken from the lower quartile cost across
trusts in the NHS reference costs (£70 vs. £99 in the base case).163 In this scenario, there were two screening
strategies on the cost-effectiveness frontier: S–60–75–3% (£39,303 per QALY) and S–60–80–3% (£74,212
per QALY). These results appear anomalous, as it would be expected that cost-effectiveness would be
improved by reducing the cost of LDCT (and this was confirmed in the univariate sensitivity analysis). The
scenario analysis has not been reconducted as this would potentially introduce bias into the results.
In the second of these scenario analyses, the cost of a LDCT scan was taken from the upper quartile cost
across trusts (£121 vs. £99 in the base case). In this scenario, S–60–75–3% was extendedly dominated and
there were four screening strategies on the cost-effectiveness frontier: S–60–75–4% (£31,607 per QALY),
S–60–80–4% (£45,210 per QALY), T–60–80–4% (£61,927 per QALY) and T–60–80–3% (£230,700
per QALY).
Time horizon
When a time horizon of 10 years was used (compared with a lifetime time horizon in the base case),
there were five screening strategies on the cost-effectiveness frontier: S–60–75–5% (£31,290 per QALY),
S–60–75–3% (£33,307 per QALY), S–60–80–3% (£45,075 per QALY), B–60–80–3% (£143,900 per QALY)
and B–55–80–3% (£383,100 per QALY).
Discount rate
When costs and QALYs are not discounted, S–60–75–3% is dominated and there are five strategies
on the cost-effectiveness frontier: T–60–75–5% (£15,001 per QALY), T–60–75–4% (£15,160 per QALY),
T–60–75–3% (£63,533 per QALY), B–60–75–3% (£254,200 per QALY) and B–55–75–3% (£477,400
per QALY).
Probabilistic sensitivity analysis
A PSA was conducted with 200 separate samples of parameter values and cohorts of 3000 individuals
sampled for each set of parameter values for a total of 600,000 simulations. With cohort sizes of 3000,© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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110it is likely that stability was not reached for strategy mean costs and QALYs for each parameter value, and
that Monte Carlo variability affects the apparent variability in the PSA results. Nevertheless, there should be
adequate exploration of the parameter space with 200 samples and, with a total of 600,000 simulations,
the mean total costs and QALYs should be estimated with good precision.
Deterministic and probabilistic results were compared. As shown in Figure 30, there was very good
agreement between deterministic and probabilistic costs (although probabilistic costs are slightly lower on
average), which is expected as a large proportion of the costs relate to screening and are less affected by
outcomes for individuals.
Figure 31 shows that there was less correlation between deterministic and probabilistic QALYs, with
evidence that the range of probabilistic QALYs was compressed compared with deterministic QALYs.
The incremental economic value of the strategies was consistently estimated across the deterministic and
probabilistic analyses (Figure 32).y = 1.0143x – 62.522
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frontier (S–60–75–3%, S–60–80–3% and S–55–80–3%) and no screening was also on the
cost-effectiveness frontier (Table 31).
To determine whether the difference between the results in the base case and the PSA are genuine or a
result of poor convergence, the INMB of S–60–75–3% at a willingness to pay of £28,169 per QALY (the
base-case ICER) was plotted against PSA iteration number (Figure 33). This demonstrates that it is highly
unlikely that the PSA and base-case results would converge with further iterations, and that the PSA results
should be preferred as there is the suggestion of non-linearities.
Decision uncertainty was characterised by the 95% credible interval (CrI) of the INMB for each strategy
(vs. no screening) at a willingness to pay of £20,000 per QALY.
The 95% CrI of INMB was fully below £0 (i.e. unlikely to be cost-effective vs. no screening) for:l
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A–60–75–5%.The 95% CrI was not fully above £0 (i.e. likely to be cost-effective vs. no screening) for any screening
strategies. For other strategies, the 95% CrI of INMB contained £0.
The screening strategy with the highest mean INMB was S–60–75–5% (mean –£7, 95% CrI –£18 to £7).
The strategy with the next highest probability of being cost-effective was S–60–75–4% (mean INMB –£8,
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TABLE 31 Cost-effectiveness results from PSA
Strategy Costs (£) QALYs ICER vs. no screening, £ (95% CrI) Full ICER, £ (95% CrI)
No screening 1056 8.489
S–60–75–3% 1078 8.490 35,595 (12,000 to > 500,000) 35,595 (14,000, NE)
S-60–80–3% 1084 8.490 36,710 (13,000 to > 500,000) 41,630 (16,000, NE)
S–55–80–3% 1087 8.490 39,191 (14,000 to > 500,000) 104,506 (46,000, NE)
CrI, credible interval; NE, not estimable.
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112Figure 34 shows the cost-effectiveness acceptability curves for four strategies on the cost-effectiveness
frontier. As can be seen, no screening has a higher probability of being cost-effective than the other
strategies for thresholds ≤ £50,000 per QALY, although S–60–75–3% and S–60–80–3% are expected to
be cost-effective at thresholds below £50,000 per QALY.Discussion
Key findings
Lung cancer screening programmes are predicted to lead to health benefits for participants compared with
no screening, but they are also predicted to lead to increased costs.
In the base-case analysis it is predicted that the lung cancer screening programmes modelled would not be
considered a cost-effective use of limited NHS resources using a cost-effectiveness threshold of £20,000
per QALY.
If a higher cost-effectiveness threshold of £30,000 per QALY is used, then a single screen offered to people
aged 60–75 years with a predicted risk of lung cancer ≥ least 3% is predicted to be cost-effective.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Lung cancer screening is estimated to lead to a reduction in mortality from lung cancer ranging from 4.2%
to 7.7% depending on the frequency (this is in good agreement with the estimated 5% reduction in lung
cancer mortality estimated in the network meta-analysis in Chapter 4), but also to result in increased lung
cancer diagnoses (i.e. overdiagnosis) and increased costs relating to lung cancer.
A PSA showed that, at a threshold of £20,000 per QALY, no screening has a > 70% chance of being
cost-effective, while it has a 50% chance of being cost-effective at a threshold of £30,000 per QALY.
However, at £30,000 per QALY there are a number of LDCT screening strategies that could potentially be
cost-effective and, therefore, the probability of any one strategy being cost-effective is low.
One-way sensitivity analyses showed that a 10% variation in any single parameter is unlikely to result in
LDCT screening being cost-effective at £20,000 per QALY (this was the case for < 20% of parameters),
and that the results were particularly sensitive to the natural history of lung cancer, the cost of treating
lung cancer and the cost of LDCT scans.
Scenario analyses demonstrated that the impact of false-positive and indeterminate screening results on
HRQoL was important in determining cost-effectiveness, as was the discount rate. Although anxiety and
distress from screening results may be studied, as well as potentially affected by a variety of interventions,
the discount rate is something that is considered across a range of interventions and there is little reason
to believe that the discount rate that applies to lung cancer screening should be different from that
applied to other screening interventions. The health effects of lung cancer screening do not lag significantly
behind the costs, as survival is generally poor, so benefits are accrued relatively soon after costs are incurred.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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involvement
A patient and public involvement (PPI) exercise was undertaken at the request of the report funders.In this chapter (and for the rest of the report) we use the term ‘patient’ to mean specific members of
the public (smokers and former smokers) who might be invited to undertake the lung cancer screening
technology assessed in this report. This term does not include general members of the public. We undertook
workshop meetings with both patients and general members of the public and the views elicited in these
consultations, that were judged to be relevant to this HTA, are presented and explored in relation to
existing literature.Methods
In response to a request to undertake PPI as part of feedback on the draft protocol for this HTA, we worked
with our institution’s source of advice on PPI [the PPI team in Collaboration for Leadership in Applied
Health Research and Care South West Peninsula (PenCLAHRC)] to design a feasible approach to collecting
observations and views about the introduction of a possible lung cancer screening programme in the UK.
In a joint strategy developed between PenTAG and the PPI team, we aimed to elicit views from a range of
participants, with a particular focus on smokers/former smokers currently without symptoms of lung cancer
who may be considered at ‘high risk’ of lung cancer and, hence, a potential priority target group for a UK
national lung cancer screening programme. Given the high prevalence of ‘high-risk’ smokers in underprivileged
populations of the UK, views were particularly sought from smokers/former smokers living in local deprived
areas. Three workshop meetings were arranged targeting three different groups of smokers and former
smokers. One group consisted of smokers/former smokers (and included close relatives of people dying from
smoking-related conditions) from PenCLAHRC’s Peninsula Public Involvement Group (PenPIG), one group
consisted of smokers/former smokers (and included one person whose father had died from a smoking-related
condition) recruited through GP practices located in deprived areas and one group consisted of former
smokers/non-smokers (and included people who had lost relatives to smoking-related conditions) recruited
from Beacon Heath Community Centre/Food Bank located in the most deprived ward of Exeter. In addition to
these workshop meetings, an unrestricted drop-in session at Beacon Heath community centre was conducted
in order to capture a wide range of public views from people of a variety of ages and a range of smoking
statuses.
All workshop meetings were specifically tailored to meet the needs of this lung cancer screening HTA,
with each workshop meeting consisting of three sessions over 2 hours. One session consisted of a general
introduction to HTA (using a video specifically designed for this purpose). A second session focused on the
‘impact’ from introducing or not introducing lung cancer screening. People were asked to discuss positive
and negative aspects with each scenario (screening is/is not introduced). A third session focused specifically
on the ‘impact’ of receiving an invitation to lung cancer screening. Workshop participants were asked to
imagine how they (or smokers from deprived areas) might feel if they received an invitation to lung cancer
screening and to consider the barriers and facilitators that may affect decisions to attend for lung cancer
screening. At the end of the session, workshop participants were asked to comment on the findings of a
recent study that investigated attitudes towards lung cancer screening in socioeconomically deprived and
heavy-smoking communities.170
The first workshop meeting, held at South Cloisters, University of Exeter Medical School, involved nine
members of PenPIG comprising eight females and one male (four smokers and five ex-smokers).© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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116The second workshop meeting, held at South Cloisters, University of Exeter Medical School, involved five
members of the public consisting of three females and two males (two smokers and three ex-smokers)
recruited from GP surgeries located in more deprived areas of Exeter.
The third workshop meeting, held in a private meeting space at The Beacon Community Centre and
Food Bank Centre, involved four members of the public consisting of three males and one female (two
ex-smokers and two non-smokers). Two of the meeting participants also attended the Food Bank Centre.
A drop-in session was conducted at Beacon Health during a community drop-in morning (unrestricted).
In addition, a public representative who participated in the first PenPIG workshop meeting attended,
and contributed to, the clinical experts’ meeting.
All three workshop meetings were audio-recorded and transcribed, with transcripts checked back against
the original audio-recordings for accuracy and to aid familiarisation. NVivo software (version 11; QSR
International, Warrington, UK) was used to analyse the transcripts. An inductive thematic analysis was
performed across all workshop meetings, with analysis procedures used for coding and theme development
following the approach proposed by Braun and Clarke.171 Textual data, reduced into themes, were then
interpreted into an analytical framework consisting of seven main categories. Views gathered from the
unrestricted drop-in session that confirmed, refuted or extended the identified themes were included in the
final analysis. The interpretive analytical framework was checked by PPI researchers, HTA researchers and a
PPI representative involved in the workshop meetings, and transferability confirmed by clinical experts
during a stakeholder meeting.People’s views on impact from a lung cancer screening programme
The key themes arising from the qualitative thematic analysis of workshop transcripts are summarised in
the seven categories in Table 32 and are expanded on in the full thematic analysis (see Appendix 11).
Key associations and core dynamics between themes arising from public consultation in all three tailored
workshop meetings, together with the community/food bank centre drop-in session, have been presented
in Figure 35 as a concept map (with accompanying narrative summary) in order to provide an explanatory
model of contextual ‘real-world’ perspectives through which to view our clinical effectiveness analysis and
economic model. The chapter concludes with a reflection on the issues raised that reinforce those arising
from other perspectives, but particularly issues that have not been raised elsewhere or where the views
raised conflicted with generally accepted perspectives.
Narrative summary to accompany explanatory model of patient and public views
The explanatory model explores relationships between patient and public views expressed around
decisions to attend a national lung cancer screening programme together with views on the broader
cultural and societal influences that may influence such decisions.
At the centre of the explanatory model (highlighted in light blue in Figure 35) is the core dynamic arising
from the consultation process that highlights the tension between feeling motivated/unmotivated to attend
for screening and presents associated factors that may be influential in decisions to attend/not attend a
national lung cancer screening programme. This core dynamic may be viewed within the context of current
prevailing views and influences in the UK that were expressed during our PPI consultations (highlighted
in mid-blue in Figure 35). In our PPI discussions, poor public awareness around potential treatments and
survival benefits resulting from early detection as well as a culture of stigma and blame associated with
smoking were acknowledged and thought to be influential on decisions to attend for screening.
Factors associated with poor motivation/barriers to attend for lung cancer screening are highlighted in
mid-green on the right-hand side of Figure 35. Influences of poor life circumstances, gender, current
smoking status and implications of being targeted as a smoker were discussed. It was thought thatNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 32 Analytical framework and themes from PPI involvement meetings
Engagement/facilitators Disengagement/barriers
Financial
costs/funding Culture/environment
Treatment/care
pathway
QoL/mental
well-being
Responsibility
and risk
Universal vs. targeted approach
Other benefits of screening
(detection of other lung diseases)
Invitation to screening (content/
format)
Planning
Work
Motivation to quit smoking
Support
Poor access to screening/
support
Worry/denial/fear of
knowing
Fatalism; believe will die;
‘damage is done’
Invitation to screening
(content/format)
Work/lifestyle
Gender
Age
Public stigma
Blame from health
professionals
No motivation to quit
smoking
To NHS
Insurance premiums
Tax revenue from
cigarettes
Cost of travel to
screening/additional
tests
Cost of travel to hospital
for carers
Cost of private screening
Missed appointments
Cultural norms
Government and
media influence
Inequity/deprivation
Detection
l early
l late
Treatment/no
treatment
Repeat testing
Coping
Anxiety/worry
QoL and diagnosis
QoL and treatment
Reduced QoL
attributable to
effects of treatment
Support (lack of)
Empowerment
Disempowerment
Family history
(of lung cancer)
Smoking history
Passive smoking
Information
(about risk)
Environmental risk
Exposure to
radiation
(technology)
Perception of risk
Themes from workshop 1 thematic analysis.
Themes added after workshop 2 thematic analysis.
Themes added after workshop 3 thematic analysis.
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Suggested core dynamics in
explanatory model
Associations expressed by
workshop meeting participants
Factors/dynamics associated
with QoL
Factors/dynamics associated
with attending lung cancer
screening programme
Factors/dynamics associated
with not attending funded lung
cancer screening programme
Factors/dynamics associated
with smoking cessation
Factors/dynamics associated
with cultural norms and societal
views
Solutions to overcoming barriers
offered by participants in
workshop meetings
Factors/dynamics associated
with screening invitations
Societal views and influence
Culture of acceptance/no blame
Older individuals brought up in culture in which
smoking was the norm; in which health benefits
were promoted (‘good for the nerves’) and
when health risks were not widely publicised
Culture of blame
      Barriers to responding to screening invitation
Stigma towards smokers from health professionals
and non-smokers in society regarding lung cancer
being self-inflicted through smoking behaviour
• Concerns about increased life insurance
   premiums if invitation is targeted to smokers
• Invitation promotes lifestyle change or
   smoking cessation
• Anxiety/fear about lung cancer diagnosis
Current smokers (who do not want to
give up); men; older people (’I die when
I die’)
Deprivation/low SES
• Unsupportive/uninspiring environment
• Expected lack of engagement/apathy
Coping
• with mental illness
• poor life circumstances
• Reduced QoL
• Increased (but acceptable)
   fear and anxiety on
   receiving invitation
Motivated to
give up smoking
• Former smokers
• Family (influence)
Motivated to make lifestyle changes
Attend screening programme
Unmotivated
to give up
smoking
Motivated
to give up
smoking
Other lung diseases
diagnosis Repeat testing
• Radiation 
   risk thought
   acceptable
   considering
   survival 
   benefits
False-positive
diagnosis
• Thought
   acceptable
   considering
   survival
   benefits
Early
lung
cancer
diagnosis
Late
lung
cancer
diagnosis
Effect on QoL
Motivated to
attend for
screening
Unmotivated
to give up
smoking
Improved reassurance if know
protocols are in place to ensure
prompt treatment after positive
diagnosis
Reduced short-term QoL
QoL improved by support
after diagnosis, e.g. good
(face-to-face)
communication from health 
professionals
Improved long-term QoL;
feeling empowered
• More time to come to terms with
   shock of diagnosis (for patients
   and carers)
• More time for planning and
   making best use of time
   remaining
Unmotivated
to attend for
screening
Development
of targeted
invitations
Unreliable patient
records relating to
current smoking
status
Common view that lung cancer is incurable
Barriers to attending screening
Poor access because of: location 
(e.g. rural vs. urban); poor access 
to transport; low SES (e.g. cannot
afford travel to screening centre)
Anxiety: may make appointment
to attend but change mind at last
minute
Solutions to overcome barriers
• Provide mobile clinics
• Reimburse public transport
   costs
Solutions to overcome 
barriers
• Screening invitation
   content maximised
   for engagement
• Improve public
   awareness of
   survival benefits
   with early detection
Motivated to
attend for
screening
Negative
diagnosis
Do not attend
screening
programme
Receive lung cancer
screening invitation
FIGURE 35 Explanatory model of patient and public views arising from workshop meetings.
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69smokers may generally be less willing to engage with a lung cancer screening programme than former
smokers because of the social stigma associated with smoking (from both members of the public and
health professionals) and particularly unwilling to engage if they have no intention of giving up smoking.
It was thought that people living with poorer life circumstances (e.g. people with low SES or people living
with mental illness) may be more dependent on smoking in order to cope with general life stress and
may be less willing to give up smoking/engage with a cancer screening programme. Participants said that
some people would be cautious about accepting an invitation to attend for lung cancer screening as it
would identify them as ‘high risk’ and may have implications for insurance (e.g. life insurance premiums).
It was acknowledged that feelings of fear and anxiety associated with a potential positive diagnosis may
be difficult to talk about and may cause some people (especially men) to avoid attending lung cancer
screening. It was thought that smokers may be put off responding to an invitation to attend screening if
the invitation promoted lifestyle change or smoking cessation. In addition, older people who consider
themselves too old to benefit were thought less likely to be motivated to attend. Solutions offered in
meetings to overcome such barriers included suggestions to modify invitation content in order to improve
engagement (e.g. including information about ‘what to expect’ and safety information that encouraged
informed choice) as well as increasing general public awareness of the benefits of lung cancer screening
with regard to early detection and increased survival. It was thought that the use of GP records to identify
and target smokers could be unreliable, as smokers may be less inclined to be honest about their smoking
status in order to avoid public stigma/being judged and blamed by their GP. Participants acknowledged
that some would hold the view that lung cancer was self-inflicted and should not be funded by the NHS.
However, most participants felt that it was inappropriate to blame current/former smokers currently at
high risk of lung cancer who began smoking when smoking was the cultural norm, when health benefits of
smoking were promoted (smoking was ‘good for the nerves’) and when health risks were not widely publicised.
Factors associated with motivation for/facilitators to attend lung cancer screening are highlighted in
Figure 35 in dark blue. Influences of smoking status, other family members and access to screening were
discussed. It was suggested that wider family members may be influential in the decision to attend for lung
cancer screening (e.g. unmotivated individuals may decide to attend for the sake of their children). It was
recognised that some people may not be eligible to access a targeted national screening programme but
might consider themselves at risk [e.g. because of environmental exposure (to passive smoking or asbestos)
or because they have a family history of lung cancer]. Individuals eligible and motivated to attend lung
cancer screening may be unable to do so because of poor access (e.g. as a consequence of living in a
deprived or rural location with poor public transport or inability to afford public transport). Solutions to
such barriers that were put forward by workshop meeting participants included provision of mobile
screening clinics and reimbursement of public transport travel costs. It was also recognised that feelings
of anxiety arising on receiving an invitation could mean that some motivated individuals may make an
appointment, but then change their mind at the last minute and so fail to turn up.
Factors associated with treatment pathways for eligible motivated people able to access screening are
highlighted in dark blue on the left-hand side of Figure 35. Implications of repeat testing and diagnosis
were discussed. The radiation risk from repeat testing and potential anxiety caused by false-positive
diagnosis were considered acceptable because of the potential survival benefits associated with early
detection and successful treatment of lung cancer. It was thought that incidental findings of other lung
diseases occurring during the screening process may motivate some people to give up smoking and that
an invitation containing wording about lung screening (rather than lung cancer screening) would be less
stigmatising and potentially more acceptable to smokers. Participants said that although receiving a negative
lung cancer screening result may motivate some smokers to change their lifestyle, others receiving a negative
screening result may become complacent and unmotivated to quit smoking.
Factors associated with QoL resulting from introducing a lung cancer screening programme are highlighted
in dark green in Figure 35. Influences of receiving an invitation to attend lung cancer screening and
influence of diagnosis were discussed. Given the survival benefits associated with lung cancer screening,
participants thought that any feelings of anxiety and fear arising on receiving an invitation were acceptable.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
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120In addition, it was suggested that some people may become more motivated to give up smoking on
receiving an invitation to attend lung cancer screening and that receiving a negative screening result may
motivate individuals to make lifestyle changes. Although it was acknowledged that receiving a diagnosis of
lung cancer would have an impact on QoL in the short term, it was suggested that this could be moderated
by good face-to-face communication from health professionals. Reassurance could also be gained from
knowing that protocols were in place to ensure prompt treatment after a positive diagnosis. A workshop
participant who, as a child, lost his father (a smoker) to a lung disease (emphysema) suggested a link between
lung cancer diagnosis and improved QoL for both patients and family/carers in the longer term. The view
was expressed that an early diagnosis of untreatable lung cancer could lead to feelings of empowerment
and increased QoL arising from having more time to deal with the shock of diagnosis (for both patients and
family/carers) as well as more time to plan for the future (e.g. write a will) and make the best use of time
remaining with family and friends.Discussion
Lung cancer prevalence is higher in lower-SES communities, in which lifelong smokers are both
over-represented172 and more tobacco dependent.173 It is widely accepted that, for a lung cancer screening
programme to be effective, it must achieve a positive benefit–harm ratio, which in turn depends on
attracting the higher-risk and hard-to-reach lower-SES individuals in a population. Increasing the risk profile
of participants has the potential to reduce avoidable invasive follow-up tests and the number needed to
screen (NNS)174 and, hence, improves the cost-effectiveness and efficacy of a screening programme as well
as reducing lung cancer inequalities. However, enrolment to screening programmes offered within the trial
context has been extremely low and biased towards former smokers, rather than current smokers, and
towards higher-SES individuals.75,175 Lower-SES smokers are less likely to engage with an offer of screening
or see it through, a tendency observed across other screening programmes176–178 and health-care services.179,180
As part of our PPI workshop format, we invited workshop participants to comment on the findings of a
recent study that investigated attitudes towards lung cancer screening in socioeconomically deprived
and heavy-smoking communities.170 The study found that, although participants were supportive of lung
cancer screening in principle, many did not feel that screening could offer a long-term survival benefit for
‘heavy smokers’. Quaife et al.181 found that a belief that lungs are not a treatable organ appeared to be
a common lay explanation for poor survival and undermined the potential value of screening. Perceived
blame and stigma around lung cancer as a self-inflicted smoker’s disease were described by study
interviewees as important social deterrents of screening participation and this perspective also emerged
during our consultations. The study suggested targeting invitation strategies to this high-risk SES group
to achieve equitable participation in screening. Such invitation targeting is currently being investigated in
the Lung Screen Uptake Trial (LSUT) (October 2013 to September 2017).181 The study targets those aged
60–75 years who have been recorded as a smoker in the previous 5 years by their GP. Intervention
invitation materials are targeted for (and in consultation with) high-risk and ‘hard-to-reach’ groups prior
to the hospital appointment for assessment and LDCT screening (if eligible), with the primary outcome
measure being uptake of hospital appointments for assessment/screening. Based on previously published
research,182–186 targeted content was developed for this study (Box 2).
Although most smoking/ex-smoking participants in all three of our PPI discussion workshops said that they
would respond to a targeted invitation to lung cancer screening, some participants said that they would
not respond to an invitation to lung cancer screening if it was specifically targeted at smokers/ex-smokers
because of the stigma associated with smoking. They said that they would be more likely to respond to a
universal invitation that did not specifically mention smoking and lung cancer, but that offered screening
for general lung diseases or offered a universal programme based, for example, on age. A view was
elicited relating to the unreliability of people’s willingness to be honest about their smoking status with
their GP, so bringing into question the reliability of health records for targeting purposes, and this view was
strongly expressed by our PPI representative during our initial HTA researcher/clinician stakeholder meeting.NIHR Journals Library www.journalslibrary.nihr.ac.uk
BOX 2 Design of a targeted intervention invitation from Quaife et al.181
[. . .] to minimise fear [of a positive diagnosis], fatalism, stigma and blame around lung cancer by:
i) emphasising a supportive and non-judgemental service, ii) providing a lay explanation for how early detection
of lung cancer can work (using a diagram to illustrate that the lung is a treatable organ which need not be
completely removed because early treatment can be focused within a lobe), iii) acknowledging that the invited
generation were previously not informed of the risks of smoking, iv) avoiding mention of smoking, smoking
cessation, and risk where possible at the screening invitation stage, v) emphasising the salience for older adults,
and vi) normalising the offer so as to not implicate the reason for invitation as being that lung cancer is
suspected or that the recipient is being singled out.
Reproduced from Quaife et al.181 © Quaife et al. 2016. This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were
made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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intervention) were inevitable and that radiation risks from LDCT technology were acceptable considering
the survival benefits resulting from early detection of lung cancer. Participants thought that raising public
awareness about lung cancer screening and providing information about safety (radiation) and the likely
physical sensations of the screening process in the screening invitation would be helpful to alleviate
people’s worry and encourage participation in screening.
The research literature reports poorer HRQoL and increased anxiety among current smokers, those with a
longer smoking history and individuals with a lower level of education in the NELSON84,85 and Pittsburgh
Lung Screening Study (PLuSS)187 screening cohorts. Although it is recognised that there is potential for
distress at any point along the lung cancer screening pathway, the psychological impact of screening
may depend largely on the nature of the screening result that they receive (and any ensuing tests or
surveillance) and psychosocial characteristics.188 Higher perceptions of risk189 and guilt about smoking190
have been shown to predict higher screening-related distress. Research indicates screening-induced stress
is short term (< 6 months).191,192 However, it is recognised that there are important differences between
trial and real-world contexts, and there is evidence from other screening programmes of long-term
psychological distress associated with cancer screening.193 Participants in our PPI workshop meetings
recognised that smokers with low SES status, who would potentially benefit the most from a UK lung
cancer screening programme, may face particular psychosocial challenges associated with poor life
circumstances. Participants acknowledged the higher prevalence of smoking in these members of society,
together with people living with mental illness, as a way of coping with general life pressures. During our
PPI workshop meetings, participants recognised the importance of the impact of a lung cancer screening
programme on QoL/mental well-being at all lung cancer screening stages. PPI workshop meeting
participants said psychological/mental well-being would be affected just by the introduction of the
screening programme, both positively and negatively, and that they thought psychological well-being
should be an outcome assessed in this HTA review.
The importance of good communication from health professionals when delivering screening results,
as reported in qualitative literature,194 arose as a point of discussion in our PPI workshop meetings.
Brain et al.86 and Quaife and Janes195 acknowledged the importance of preparing individuals
psychologically for abnormal screening results so that they are fully informed, and the views elicited during
our PPI workshop meetings are in agreement with this stance.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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122Some of our PPI workshop meeting participants described how important it would be to have access to
information about the likelihood of survival after a diagnosis during the lung cancer screening process in
order to minimise reduced QoL following a positive lung cancer diagnosis. This perspective is corroborated
by a multicentre survey conducted in the USA that found that 23% of patients diagnosed with incidental
pulmonary nodules who received information on lung cancer risk from their clinician provider were more
likely to find this information reassuring than scary.196
Incidental findings are often viewed as a negative aspect of CT screening, but their detection may also
provide an opportunity to rectify other conditions that threaten QoL or survival. The NLST reported a 6.7%
reduction in all-cause mortality, which may be explained by detection of clinical and radiological findings
in the process of screening, and by the improved access to health care brought about by screening that
may prompt intervention for non-lung cancer comorbidities.197 During our PPI discussions, it was
recognised that other diseases (e.g. pneumonia or fungal infections) may be detected incidentally during
lung cancer screening and treated with consequent improvements in health.
The impact of lung cancer screening on smoking cessation remains unclear. Several studies have reported
increased smoking cessation in trial participants compared with the background population. However, no
statistically significant differences in outcomes between the screened and control groups have been noted,
suggesting that trial participants may be a more motivated group.73,81,88,198–201 During our PPI discussions,
some participants said that they thought that receiving an invitation for screening would act as a motivator
to quit smoking and that receiving a lung disease diagnosis could similarly motivate people to give up
smoking. Quaife and Janes195 propose that similar positive responses could be researched and capitalised
on to promote smoking cessation.
The use of mobile CT scanners versus dedicated screening centres was discussed in our PPI workshop
meetings. It was acknowledged that, if screening was not offered at a local hospital, then certain members
of society would find it more difficult to access screening because of their location, poor access to transport
and caring responsibilities. It was thought that the impact from these factors would be accentuated if people
had little support or low income or lived in more deprived areas. Participants in two meetings suggested that
access might be improved by providing mobile screening clinics in the community, similar to those already
provided for breast screening. Although the cost of various methodologies that can be used in the screening
process, such as the use of mobile CT scanners versus dedicated screening centres, needs to be evaluated,
during an initial researcher/clinician HTA stakeholder meeting the view was aired that the cost of funding
mobile lung cancer screening clinics would be prohibitive. One low-SES community drop-in participant
(who was accessing the food bank centre) expressed the view that people, including himself, would be
willing to travel long distances using public transport to attend screening if they were financially reimbursed.Summary
Views expressed during our PPI workshop meetings were broadly in agreement with currently accepted
perspectives based on research findings from published trial and qualitative research literature. Our PPI
participants discussed the challenges of engaging higher-risk individuals (low-SES smokers) and recognised
that people living in deprived areas (as well as people living with mental health issues) are more likely to
smoke in order to cope with poor life circumstance and associated stress. The importance of overcoming
barriers to access screening, particularly for low-SES individuals who may not have their own transport,
was discussed during our PPI workshop meetings and novel solutions offered. One low-SES community
drop-in participant (who was accessing the food bank centre) expressed the view that people, including
himself, would be willing to travel long distances using public transport to attend screening if they were
financially reimbursed. Our PPI participants made some suggestions regarding screening invitation content
to improve uptake [e.g. increase informed consent by providing information in screening invitation about
safety (radiation) of LDCT screening technology and provide details of the likely physical experience of
the screening process and subsequent potential treatment pathways]. PPI participants suggested that anNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69invitation that did not specifically mention smoking and lung cancer, but that offered screening for general
lung diseases, would be less stigmatising and more engaging for smokers. Incidental findings are often
viewed as a negative aspect of CT screening, but it is currently recognised that their detection during lung
cancer screening can reduce all-cause mortality.
Some PPI participants thought that a targeted screening invitation that promoted lifestyle change or
offered help to give up smoking would be disengaging for smokers. A view was also expressed relating to
smoking-related stigma and the unreliability of people’s willingness to be honest about their smoking
status with their GP, thereby bringing into question the reliability of health records for targeting purposes.
During our PPI workshop discussions, participants recognised the potential impact of a lung cancer screening
programme on QoL/mental well-being at all lung cancer screening stages and felt strongly that psychological
well-being should be considered as an outcome in this HTA review. Many participants acknowledged that
they would expect to experience feelings of fear on receiving an invitation to attend lung cancer screening
but said that they would want to attend screening despite this. It was, however, acknowledged that people
could change their mind at the last minute and fail to attend for screening because of anxiety, even after
initially accepting the invitation. Interestingly, our PPI participants did not think that the distress and anxiety
caused by false positives were problematic given the benefits of a lung cancer screening programme for
survival. Participants expressed the view that, because all tests are fallible, some misdiagnosis is inevitable and
it is an unfortunate but acceptable consequence of performing a test. Equally, PPI participants said that any
anxiety experienced while waiting for test results was acceptable given the potential for early treatment and
improved survival that lung cancer screening offers. Although the trial research literature reports short-term
psychological distress associated with diagnosis during lung cancer screening, our PPI participants said that
there may be some potential QoL gains in the longer term for people diagnosed with terminal lung cancer
relating to empowerment, both for the patient (in planning and spending their remaining time wisely) but
also for their family and carers (to plan for life after their loved one has died).
The impact of lung cancer screening on smoking cessation remains unclear in the research literature.
During our PPI discussions, some participants said that they thought that receiving an invitation for
screening would act as a motivator to quit smoking and that receiving a lung disease diagnosis could
similarly motivate people to give up smoking. Quaife and Janes195 have proposed that similar positive
responses could be researched further and capitalised on to promote smoking cessation.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
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NHS and other partiesResource implications
A lung cancer screening programme could potentially entail significant resource implications.
Although a significant number of costs were not included in the economic evaluation (particularly those
related to the set-up and evaluation of a programme), it was still estimated that screening could result in
additional costs on the order of hundreds of millions of pounds (see Table 27).
The current capacity of radiology departments will be of concern when considering the implementation of
a lung cancer screening programme. If around 3.1% of 13 million smokers all received a single LDCT scan,
this alone would represent 400,000 LDCT scans (not including a significant number of follow-up scans
that would be necessary. The NHS Reference Costs 2015 to 2016163 (England) indicate that around two
million CT scans are conducted per year (not including PET-CT), so that an additional 400,000 scans would
represent a 20% increase in workload.
A lung cancer screening programme could be implemented incrementally by specifying a single year of age
for screening eligibility, such that screening would be delayed for those younger than the year of age
chosen, while those older than the year of age chosen would never become eligible. This would reduce the
immediate burden on radiology services by a factor of 10–25, but would also mean significantly reduced
benefits. Economic modelling should be capable of identifying the most cost-effective year of age for such
a programme.Identification of suitable populations
A key factor in the potential value of a lung cancer screening programme is the ability of a programme to
effectively and efficiently identify individuals meeting the criteria for the programme. There are issues
of sensitivity (minimising the number of people who should be included but are missed) and specificity
(minimising the number of people contacted about screening who are in fact ineligible) to consider.
The economic analysis in Chapter 6 assumes that it is possible to identify all (or a clear majority of) smokers
within a certain age range, and that this can be done at minimal cost compared with other costs associated
with screening.
It is supposed that there are data of sufficient quality held by GPs to identify people with a history of ever
smoking, although the data are not considered of suitable quality to estimate a more detailed smoking
history (e.g. how long has each individual smoked, do they currently smoke, with what intensity have
they smoked). A GP in the Expert Advisory Group for the project indicated that data on ever smoking
would likely be of sufficient quality to accurately identify ever-smokers within a given age range, although
concerns were raised about how time-consuming it would be to interrogate the data, whether or not GPs
would be expected to improve the quality of these data using clinic time, and whether or not invitations
would need to be sent by the GPs or if their names and reputations would be co-opted as part of a
programme. On the other hand, views were raised in the PPI workshops that GP records may be unreliable
as smokers may be less inclined to be honest about their smoking status in order to avoid stigma,
judgement and blame.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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ASSESSMENT OF FACTORS RELEVANT TO THE NHS AND OTHER PARTIES
126The UK-based RCT of lung cancer screening (UKLS) did not use primary care-based recruitment of
participants55 and so such a technique for recruitment to a screening programme may need to be
demonstrated in a pilot study.
There is also a consideration to make that smokers are not the only group who are at risk of lung cancer,
as there are certain occupations that increase the risk of lung cancer.Equity, societal and ethics considerations
Lung cancer is a disease particularly affecting those with lower SES, with incidence being higher and
survival poorer in the most deprived regions compared with the most affluent.202 Data also demonstrate
that men are at higher risk of lung cancer incidence and have poorer survival.
Interventions that reduce the morbidity and mortality from lung cancer have the potential to reduce health
inequalities, if these interventions are equally available and taken up by individuals with lower SES.
A lung cancer screening programme based on risk stratification can arguably legitimately target screening
more towards men and individuals with lower SES as these groups are more likely to be at high risk of
lung cancer, as it will still target women and more affluent individuals if they are in fact at high risk.
Importantly, though, groups at a high risk of lung cancer also face significant barriers to screening.
Transport and time off work to attend screening may be more difficult to obtain for such groups, and
there may also be a higher risk of other significant health issues, including mental health issues, which may
make screening attendance more challenging. Current smokers are at particular risk of lung cancer, but
may be deterred from attending screening if they are resistant to lifestyle change and believe that
screening is in part designed to get them to quit smoking.
There is a risk with screening that the worried-well will be disproportionately represented. An accurate risk
prediction algorithm can partly counter this, but it will rely on accurate representations of smoking histories
from potential participants.
The majority of people diagnosed with lung cancer are above retirement age. Although our review and
economic evaluation have not considered costs and benefits from a societal (including productivity costs/
gains) or governmental (including tax and pensions) perspective, nevertheless the potential for economic
and patient benefit from a NHS perspective is concentrated in the lower ages at which people are routinely
diagnosed with lung cancer (60–75 years). Two NICE Citizens Council meetings have considered the issue
of age in terms of trading off equity (treating people of all ages the same) and efficiency (maximising
the value obtained by spending money).203,204 In one it was considered legitimate by most members to
differentiate on the basis of age when age is an indicator of risk, and when certain age groups are more
likely to benefit from a treatment,203 while in the other meeting it was considered that consideration of
age is a circumstance when it is difficult to unpick the tensions between equity and efficiency.
Acceptability is an additional concern for mass screening programmes. In particular, here we can consider
the acceptability to those receiving screening (including distress and anxiety, comfort during the scan, etc.),
those deemed ineligible owing to low risk (potential to be reassured about risk level vs. concern about
not receiving screening), and the wider public who are funding the screening. Concerns that there may
be issues of public acceptance of a lung cancer screening programme on the basis that lung cancer is
‘self-inflicted’ can be somewhat allayed by the unanimous conclusion of a Citizens Council that such
factors should not be considered when determining clinical need.205NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Clinical effectiveness
Twelve RCTs were included in the systematic review of clinical effectiveness (see Table 1). Only six of
these contributed to the key outcomes (see Table 4). Most studies were conducted in European countries
but some studies were conducted in the USA (see Table 1), including by far the largest, NLST,70,71 with
over 50,000 participants. One trial, UKLS,55 was conducted in the UK. Most RCTs started between 2001
to 2010 (see Table 4), and so many are just maturing. The majority of included trials were judged to
be of moderate to high quality, but two trials64,69 were judged to be of poor quality including one that
contributed mortality data.69 There was variation between the LDCT programmes, but typically they
involved three to five rounds of screening over 3 to 6.5 years. UKLS,55 a pilot trial, had only one screening
round. The nature of high-risk participants also varied but was usually defined in terms of age and current
and past smoking. Of the trials, NLST70,71 stands apart, not just in terms of size, but by being compared
with CXR screening rather than no screening.
Concerning mortality, only four of the RCTs, including NLST, currently contribute (see Figure 2). Meta-analysis
of these showed that LDCT screening was associated with a non-statistically significant decrease in lung cancer
mortality (pooled RR 0.94, 95% CI 0.74 to 1.19) with up to 9.80 years of follow-up when compared with
controls (usual care/best available care). A moderate level of heterogeneity was observed in the magnitude of
effects (I2= 43.3%), given which the results should be treated with caution.
A range of potential sources for heterogeneity was investigated. When removing the poor-quality trial
(MILD69), sensitivity analysis demonstrated a statistically significant decrease in lung cancer mortality (pooled
RR 0.85, 95% CI 0.74 to 0.98) in favour of LDCT screening compared with controls. A considerable
reduction in heterogeneity was observed (I2 = 6.9%).
The findings from this review also showed that, compared with controls (usual care/best available care),
LDCT screening demonstrated a non-statistically significant increase on all-cause mortality outcome
(pooled RR 1.01, 95% CI 0.87 to 1.16) with up to 9.80 years of follow-up. Likewise, given the substantial
heterogeneity (I2 = 57.0%) detected between studies, the results from this pooled analysis should be
treated with caution. We also investigated the potential sources of heterogeneity. When removing the
low-quality trial (MILD69), sensitivity analysis showed that LDCT screening demonstrated a non-statistically
significant decrease in all-cause mortality (pooled RR 0.95, 95% CI 0.89 to 1.00) compared with controls.
The level of heterogeneity was also considerably reduced (I2 = 0%), suggesting that variation in trial
quality could be a potential source of heterogeneity between studies.
Number needed to screen is often advised as a way to improve the interpretation of clinical effectiveness data.
This is more difficult for LDCT screening because of varying time periods over which events are taking place
and variation in the baseline event rates. However, for a pooled RR for reducing lung cancer deaths of 0.94
(95% CI 0.74 to 1.19), we have cautiously calculated that this is equivalent to a NNS of 357 to avoid one lung
cancer death [95% CI 82 to –113 (screening increases lung cancer deaths)]. This illustrates the impact of the
very low frequency of the events in question even in a population selected to be at high risk. A number of
assumptions for the NNS must be specified. First, it assumes a typical screening programme as used in
LDCT-screening RCTs (five annual screens in a population of smokers and ex-smokers) over an 8-year period
(5 years of screening followed by 3 further years of observation). Second, it assumes a baseline risk of lung
cancer death without intervention of 4.7 lung cancer deaths per 100 persons over an 8-year period as found
in the DANTE RCT,61 which identified the highest lung cancer risk of death in the RCTs contributing data on
mortality. If lower baseline risks were used, the NNS would be higher.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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128Network meta-analysis (including six RCTs61,63,69,71,105,106) was performed to assess the relative effectiveness
of LDCT, usual care and CXR screening. The results showed that LDCT was ranked as the best screening
strategy, with a 74.8% probability of being the best intervention in terms of lung cancer mortality
reduction. Usual care (no screening) had a 74.7% probability of being the second best strategy. However,
CXR screening had a 99.7% probability of being the worst intervention on lung cancer mortality outcome.
Concerning numbers of lung cancers detected, compared with controls (usual care/best available care), LDCT
screening was associated with a statistically significantly increase in lung cancer detection rate (pooled RR
1.38, 95% CI 1.02 to 1.86) with at least 5 years of follow-up. Although there was heterogeneity (I2 = 79.7%),
all included studies individually showed statistically significant increases in the numbers of cancers detected in
the LDCT group (see Figure 8).
Our findings further demonstrated a clear benefit of LDCT screening on the shift in stage distribution
towards earlier stages for detection of lung cancers. LDCT screening was associated with statistically
significantly increases in early stage (I and II) cancer detection (pooled RR 1.73, 95% CI 1.27 to 2.37), when
compared with controls (usual care/best available care). LDCT screening was associated with a statistically
significant reduction in the risk of late stage lung cancer compared with controls (RR 0.85, 95% CI 0.73 to
1.00), although this effect was not observed when only trials comparing LDCT to no screening were included
(RR 1.00, 95% CI 0.75 to 1.34), despite these trials still finding an increased probability of lung cancers
being early stage. This is consistent with overdiagnosis being a significant factor in the trials.
Based on the randomised data from four included trials (see Table 9), there were consistently no
statistically significant differences in HRQoL or psychological consequences between the LDCT screening
group and control groups during the trials.
The data from three included trials (one reported as two subcomponents) showed mixed results with
regard to the effect of a LDCT screening programme on participants’ smoking behaviour (see Table 10).
The data within trial arms sometimes indicated positive associations between smoking cessation and the
presence of an abnormality on LDCT. However, this is inconsistent with the evidence comparing trial arms
that did not show a consistent pattern favouring LDCT’s effect on smoking behaviour between trial arms.
Cost-effectiveness
Systematic review
Lung cancer screening programmes are predicted to lead to health benefits for participants compared with
no screening, but also increased costs. Study estimates of cost-effectiveness differed substantially, and
there are a number of key parameters in existing studies that may not be generalisable to the UK setting.
Independent economic evaluation
Forty-eight lung cancer screening strategies were considered, each representing a unique combination of
frequency (single, triple, annual or biennial), minimum age for entry (55 or 60 years), maximum age for
entry (75 or 80 years) and threshold for predicted risk (3%, 4% or 5%).
Lung cancer screening programmes are predicted to lead to health benefits for participants compared with
no screening (including potential anxiety impacts as a result of screening), but they are also predicted to
lead to increased costs (including increased costs associated with lung cancer).
Participants in lung cancer screening are estimated to have a reduction in lung cancer mortality of
4.2–7.7% (depending on the frequency of screening), but also to receive more lung cancer diagnoses than
in the absence of screening (i.e. lung cancer is overdiagnosed).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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undergo screening (depending on the population criteria), as a significant number would not respond to
an invitation to screening, and another significant proportion would not meet the threshold for lung
cancer risk.
Lung cancer screening with a single LDCT scan for smokers aged 60–75 years with a ≥ 3% risk of lung
cancer is predicted to be cost-effective at a threshold of £30,000 per QALY (the upper end of thresholds
commonly considered in the UK for non-ultra-orphan, non-end-of-life treatments), but not at a threshold
of £20,000 per QALY (the lower end of thresholds commonly considered in the UK). This screening
programme was estimated to cost £28,000 per QALY gained. However, when the probable range of
inputs is considered in a PSA, there were no screening strategies that were cost-effective at thresholds of
£20,000 or £30,000 per QALY.
Annual and biennial screening programmes are not estimated to be cost-effective at any threshold, and
this appears to be mostly as a consequence of the presumed detrimental impact of false-positive and
indeterminate results on HRQoL.
Patient and public involvement
An explanatory model was constructed detailing the key contextual associations and core dynamics arising
from our PPI meetings. The model details views expressed in our workshop meetings around smokers’/
former smokers’ decisions to attend a potential national lung cancer screening programme together with
views on the broader cultural and societal influences that may influence such decisions. Lung cancer
prevalence is higher in lower-SES communities, where lifelong smokers are both over-represented172 and
more tobacco dependent than higher-SES communities.173 It is widely accepted that for a lung cancer
screening programme to be effective, it must attract higher-risk and hard-to-reach lower-SES individuals
in a population. Increasing the risk profile of participants has the potential to reduce avoidable invasive
follow-up tests and the NNS174 and, hence, improve the cost-effectiveness and efficacy of a screening
programme, as well as reduce lung cancer inequalities.
Our PPI participants discussed the challenges of engaging higher-risk individuals (low-SES smokers) and
recognised that people living in deprived areas (as well as people living with mental health issues) are more
likely to smoke in order to cope with poor life circumstance and associated stress. The importance of
overcoming barriers (e.g. practical or financial) to access screening, particularly for low-SES individuals who
may not have their own transport, was discussed. Our PPI participants made some suggestions regarding
screening invitation content to improve uptake and discussed the potential impact of a lung cancer screening
programme on QoL/mental well-being at all lung cancer screening stages, including empowerment at end of
life. PPI participants held discussions around the impact of a lung cancer screening programme on smoking
cessation as well as discussions about the psychological impact of false-positive results and radiation risks
from screening. The importance of good communication from health professionals when delivering
screening results arose as a point of discussion in our PPI workshop meetings.
In addition to personal views around uptake and implementation, the potential impact of wider societal
and cultural contexts on decisions to attend for lung cancer screening was discussed. Poor public
awareness about potential effective treatments for lung cancer and survival benefits resulting from early
detection of lung cancer was acknowledged, as was a culture of stigma and blame associated with
smoking. There was a general recognition that smokers aged ≥ 55 years, who would potentially be
eligible for a national lung cancer screening programme, belonged to a generation that were previously
ill-informed of the risks of smoking.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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130Strengths and limitations of the assessment
Clinical effectiveness
Extensive literature searches were conducted in an attempt to identify potentially relevant studies. We
performed electronic searches of a range of bibliographic databases as well as screening of clinical trial
registers. Conference proceedings were also searched to identify unpublished studies. The review process
followed recommended methods to minimise any potential errors and biases. The quality of included
studies was assessed in detail at outcome level and accounted for when interpreting the findings.
Appropriate synthesis approaches were employed by taking into account the heterogeneity of study
characteristics, and the meta-analyses adhered to a pre-defined analytic strategy.
In terms of limitations, only English-language studies were included; therefore, some potentially relevant
non-English-language studies may have been missed. There was some evidence of inconsistency in the
meta-analysis of mortality outcomes. A range of potential sources of heterogeneity were further explored.
The observed heterogeneity may be explained by variations in trial quality, different risk profiles of
populations at baseline, and variations in the CT parameters used in included trials. In addition, there were
wide variations in definitions of a positive scan on the lung nodule detection across trials.
Cost-effectiveness
This is a model developed independently by an experienced research group, free from potential conflicts
of interest. It is also, we believe, the first economic evaluation of lung cancer screening to include a risk
prediction component with a variable threshold (but, for example, ten Haaf et al.115 have used risk proxies
in the form of smoking histories).
The independent economic assessment evaluates the cost-effectiveness of a wide range of potential
screening programmes, through the use of a natural history model (which allows for evaluation of
hypothetical screening programmes that have not been evaluated in clinical trials). This natural history
model is based on high-quality evidence from the large NLST RCT71 and UK national sources.1 The
assessment also includes recent estimates of the costs of screening, and somewhat recent estimates of
the cost of lung cancer. A clear description of the assumptions underpinning the assessment has been
given. The economic evaluation seems to suggest with some robustness that screening is unlikely to be
cost-effective at a threshold of £20,000 per QALY.
A number of assumptions were made in the construction of the economic model and some of these
were explored in scenario or sensitivity analyses. No modelling of smoking behaviour was included, and
incidental findings were not modelled. By using the DES framework, there has been no need to artificially
restrict the model states or distributions for event times, or to consider a homogeneous cohort.
The model does not take the impact on mortality as an input, but produces it as an output resulting from the
natural history model and the screening programme design. If additional mortality benefit (above what the
model currently predicts) needs to be incorporated in an economic evaluation (i.e. if it is demonstrated in
future data from trials), new assumptions and parameters will need to be introduced. This could be based on,
for example, an acceleration factor applied to lead time. The current model predicts that the cost-effectiveness
of screening is closely linked to the RR of lung cancer mortality (Figure 36), which suggests that, with a RR
of 0.935, single screening of individuals aged 60–75 years with ≥ 3% risk of lung cancer would become
cost-effective at £20,000 per QALY (although this is based on extrapolation and is therefore subject to
significant uncertainty).
As a DES was used, greatly increasing the computational resource requirements for analyses, there is the
risk that results are affected by Monte Carlo error because no inbuilt convergence checks were used, and
certain analyses were conducted with a number of simulations known to be short of the apparent number
required for stability.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The diversity of perspectives and issues expressed by participants in discussions during our PPI consultations
were audio-recorded and all meeting transcripts were analysed thematically to ensure an accurate and
comprehensive record of our PPI consultation process for consideration in this and future related HTAs.
A key strength of performing a thematic analysis of all workshop transcripts and constructing an explanatory
model to reflect participant perspectives was that it ensured that these views were preserved throughout the
research process and enabled efficient and accurate communication of PPI perspectives between PenTAG
researchers, the majority of whom were not present at any of the PPI meetings. PenTAG researchers were
consequently able to consider a variety of patient and public perspectives during the HTA process, particularly
issues and concerns relevant to ‘at-risk’ asymptomatic smokers/former smokers recruited locally from deprived
areas. Patient and public views relating to the psychological impact of screening and HRQoL were referred
to by PenTAG modellers while running scenario analyses and provided further assurance that the economic
model analysis had face validity.
Conducting PPI meetings with a tailored workshop format designed specifically for this HTA ensured that
views expressed in our PPI meetings were relevant to our HTA and the variety of perspectives and issues
discussed reflect the complexity of real-world situations that could potentially affect uptake and
implementation of a potential UK lung cancer screening programme.
A key strength of our approach was that we were able to capture the perspectives of a range of patient
and public members, with a particular focus on smokers/former smokers currently without symptoms of
lung cancer who may be considered ‘high risk’ and, hence, a potential priority target group for a UK
national lung cancer screening programme. Views were particularly sought from smokers/former smokers
recruited from local deprived areas. Our consultations were extended to include the views of non-smokers
during a visit to a community centre/food bank in the most deprived ward in Exeter. At the end of each PPI
workshop meeting, all participants were asked to comment on the findings of a recent qualitative study
that investigated attitudes towards lung cancer screening in socioeconomically deprived and heavy-smoking
communities.170 However, we acknowledge that many patients and members of the public have an interest
in this HTA and we were not able to include everyone. Owing to practical limitations (e.g. a notable lack
of local established support groups for lung cancer patients/carers in our local Exeter area), we took the
decision not to specifically recruit lung cancer patients/carers. However, people who lost close relatives to
cancer (including lung cancer) and other smoking-related diseases were involved in our workshop meetings,
as were people who had a family history of lung cancer.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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DISCUSSION
132Areas of uncertainty
Clinical effectiveness
The overall effectiveness of LDCT screening depends on a complex interplay between its individual effects on
screening programme participants, and it is often unclear how opposing effects interact. Thus, it can be
difficult to judge, for example, how better outcomes arising from earlier treatment because a cancer is
identified at stage I or II (as opposed to stage III or IV) are offset by the need for many participants to
undergo further investigation of suspicious lung nodules that ultimately turn out to be benign. However,
these are only two of many different effects that might be operating in LDCT screening for lung cancer.
In this situation, when available, outcomes that capture the net effect of the screening programme are
particularly helpful in gauging its overall clinical effectiveness. This is why emphasis has been placed on lung
cancer mortality and overall mortality in this report.
The report shows that LDCT screening may be clinically effective in reducing lung cancer mortality but that
there is considerable uncertainty. This arises from:l
l
l
l
NIHRthe imprecision of the pooled estimate with wide 95% CIs compatible with both an improvement and
a worsening of lung cancer mortality
the heterogeneity between the results of the included studies, with different included studies indicating
different effects on lung cancer mortality
the fact that the key RCT, NLST, compares LDCT against CXR screening rather than no screening
the finding from our network meta-analysis that screening with CXR may be associated with worse
outcomes than no screening.To these could be added concerns about whether or not results in the USA are generalisable to European
health-care settings and whether or not newer LDCT techniques will help avoid unnecessary investigation
without compromising the ability to identify lung cancers early. The strong possibility of overdiagnosis
suggested by an excess of lung cancers identified by LDCT in the included RCTs is another very important
uncertainty, and the nature of the additional cancers needs to be characterised.
Cost-effectiveness
A number of factors lead to uncertainty in the cost-effectiveness of lung cancer screening.
This economic evaluation assumes zero cost to identify individuals aged 55–80 years with a history of
smoking from GP records.
The cost of lung cancer treatment is a critical factor in cost-effectiveness because of overdiagnosis and
stage shift effects of screening, but has been estimated only from a single-centre study conducted in
2008–13 and, therefore, may not be fully generalisable to the whole of the UK at present (because of
changes in clinical practice, the introduction of additional technologies and any significant changes in drug
acquisition prices, e.g. expiry of market exclusivity). If the costs of lung cancer have increased since they
were estimated for early lung cancer stages, then the estimated cost-effectiveness of screening will be
biased in favour of screening, because the costs of overdiagnosis will not be fully represented. On the
other hand, if costs have increased for later lung cancer stages then the estimates will be biased against
screening because stage shift is then even more desirable because of the potential to avoid large costs.
The National Lung Cancer Audit found that there was quite limited use of very expensive targeted
treatments for patients diagnosed in 2015,18 but uptake may be expected to increase.
The economic evaluation assumes response rates to invitations observed in UKLS,55 but response rates may
be lower outside the context of a clinical trial, or higher if the literature is able to claim significant benefits
from lung cancer screening.Journals Library www.journalslibrary.nihr.ac.uk
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much smaller impact on HRQoL than other studies have, and, although we believe we have used the
best-quality data available, it is possible that a high-quality mapping study could be conducted to
incorporate QoL measurements using a number of different instruments. If HRQoL is significantly worse in
reality than assumed in the model, then lung cancer screening will be more cost-effective than predicted.
The economic evaluation currently assumes that only the stage of lung cancer is clinically relevant, in that
it affects survival. The model does not currently assume any relationship between the stage of lung cancer
and the performance of LDCT (which may be unreasonable as small nodules in early-stage lung cancer are
likely to be more challenging to identify). The model also does not consider whether or not lung cancer
type (non-small-cell vs. small-cell vs. mixed) affects performance of screening, costs or survival. Likewise,
the model does not consider the impact of location of the lung cancer (central vs. peripheral) on these aspects.
Patient and public involvement
The perspectives and views elicited during our PPI discussions are from one PPI exercise consisting of a
number of people recruited from our local Exeter area and it is uncertain if different issues and perspectives
would be represented if our PPI meetings were repeated with different people in a different geographical
location. We specifically targeted certain groups most likely to be prioritised for a national lung cancer
screening programme, with a strong focus on smokers/former smokers, especially from deprived areas, and
it is uncertain whether or not the issues and perspectives represented in this report are generalisable to other
potentially important groups, such as patients who have experienced treatment for lung cancer or people
exposed to environmental risks such as asbestos. Given the uncertainties around the evidence for HRQoL
experienced by people with lung cancer described in this report, and the implications for the economic
evaluation outlined above, patient-based evidence (i.e. qualitative evidence synthesis of individual research
studies conducted to understand the experience of lung cancer patients) could contribute scientific context-
sensitive evidence to this area of uncertainty in a future report.Other relevant factors
The presumed method of recruitment for a lung cancer screening programme – through primary care
records – may not work as well in practice as assumed in the model. It may be inaccurate and carry
significant costs.
Many individuals at high risk of lung cancer are also likely to face barriers to participating in screening
(e.g. because of other health issues). It is possible that screening uptake would be disproportionately high
in people with higher SES and at lower risk of lung cancer.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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The LDCT screening may be clinically effective in reducing lung cancer mortality but there is considerableuncertainty. This arises from the imprecision of the pooled estimate, the heterogeneity between the
results of the included studies, the fact that the key RCT compares LDCT against CXR screening and the
finding from our network meta-analysis that screening with CXR may be associated with worse outcomes
than no screening.
Beyond mortality, the review confirms the theoretical basis of LDCT by showing that more lung cancers are
diagnosed in the earlier stages and fewer in the later stages. However, it also confirms that more lung
cancers are detected in the LDCT trial arms many years after completion of the screening programmes,
indicating an element of overdiagnosis.
It seems unlikely that LDCT screening leads to major differences in psychological consequences and
HRQoL, and the effect on smoking behaviour continues to be uncertain.
Evidence from economic modelling suggests that LDCT screening for lung cancer may not be cost-effective,
depending on the cost-effectiveness threshold used. Thresholds of £20,000 to £30,000 per QALY are
commonly used in the UK, and screening is estimated in the base-case analysis to be cost-effective with the
higher threshold, but not with the lower. However, when the probable range of input values is considered,
cost-effectiveness is no longer demonstrated at either threshold.
Economic modelling suggests that screening would result in a reduction in lung cancer mortality, but also an
increase in lung cancer diagnoses. Lung cancer screening is predicted to be more effective than no screening
on balance, but to result in additional costs. One screening strategy that was investigated provided a ratio of
additional costs to benefits that was towards the upper limit of what would conventionally be considered
cost-effective, while other screening strategies were outside the normal range of cost-effectiveness.
Screening strategies with annual or biennial scans (once every 2 years) are not expected to be cost-effective,
regardless of the amount one is willing to pay for benefits.Implications for service provision
If lung cancer screening using LDCT is implemented as a national screening programme, evidence suggests
that it may reduce the number of people dying from lung cancer and the number of people diagnosed in
the latest stages of lung cancer. Evidence also suggests that more people overall will be diagnosed with
lung cancer, and that NHS spending on lung cancer would increase overall. Lung cancer screening
programmes would also result in a significant increase in workload for radiology services.
It is estimated that ≤ 4% of individuals contacted as part of a screening programme could end up
participating. As there are an estimated 13 million smokers aged 55–80 years, this could result in an
additional half a million CT screens per year compared with an estimated two million CT screens currently
conducted each year (in England). It is unlikely that such an increase in the burden on radiography services
would be accommodated without significant recruitment and/or service reconfiguration.Suggested research priorities
Update assessment with anticipated future trial data
Clinical effectiveness and cost-effectiveness estimates should be updated with the anticipated results from
several ongoing RCTs (particularly NELSON). This is likely to resolve many current uncertainties within a
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136In the longer term, another large trial of lung cancer screening is currently being conducted in Asia
(based in Shanghai) that will further explore the generalisability of the initial trial results to populations
with different ethnicities.
Overdiagnosis
Further investigation on the extent and nature of possible overdiagnosis in LDCT screening would
be extremely helpful in elucidating the degree to which this may or may not influence the clinical
effectiveness and cost-effectiveness of LDCT screening overall.
Quality of included randomised controlled trials
One included RCT, MILD,69 was revealed to have major problems with its randomisation on quality
assessment (see Chapter 3, Risk of bias of included studies, and Table 8). These problems could be severe
enough to challenge whether or not it was a true RCT. If it was not a true RCT it should not be included
in the meta-analysis, with the effect of reducing the heterogeneity in the meta-analysis results. Further
investigation of the quality of currently included trials would thus be useful. This could be achieved by
further enquiry of the original investigators and should be done systematically and symmetrically across all
included studies (to avoid introducing bias into a review). It should also include ongoing RCTs that may
be included in systematic reviews of LDCT in future. Only if studies currently thought to be RCTs are not so
on further investigation would it be appropriate to exclude them from future systematic reviews on the
effectiveness of LDCT.
Detailed costing of lung cancer
The (lifetime) cost of lung cancer (diagnosis, staging, treatment, follow-up and palliative care) should be
estimated according to key characteristics of the patient and tumour (e.g. age, sex, lung cancer stage
and type), based on nationally representative data. This is because the estimates used in the economic
modelling may be outdated and are from a single centre.
Health-related quality of life in lung cancer
Further consideration should be given to the HRQoL of patients with lung cancer. The economic modelling
currently uses fixed disutilities according to the stage at diagnosis, taken from a single study.159 Evidence
from other studies could be considered to arrive at alternative parameter values, and structural changes
could also be considered, such as estimating the HRQoL according to time since diagnosis, time before
death, current treatment and current disease stage.
Further developments of economic model
We have acknowledged a number of assumptions in the economic model for this interim report that have
not been explored through scenario or sensitivity analyses. In addition to collecting and incorporating
better-quality parameters (the research recommendations above), some of these assumptions should be
explored or relaxed through further developments of the economic model. A comparison of the methods
and results of the economic model to other economic evaluations could also be made to identify common
findings as well as discrepancies.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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2004–January 2012, no comparator, low-dose computed tomography
only, randomised controlled trial filter
First clinical effectiveness search, MEDLINE
Database: MEDLINE.
Host: Ovid.
Data parameters: 1946 to December week 1 2016.
Date searched: 9 January 2017.
Searcher: SR.
Hits: 183.
Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
© Que
Health
journa
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Park, Sexp Lung Neoplasms/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3
exp Tomography, X-Ray Computed/
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
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10 or 11 or 12
randomized controlled trial.pt.
controlled clinical trial.pt.
randomized.ab.
placebo.ab.
drug therapy.fs.
randomly.ab.
trial.ab.
groups.ab.
11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
exp animals/ not humans.sh.
19 not 20
4 and 9 and 13 and 24
(200407* or 200408* or 200409* or 200410* or 200411* or 200412* or 2005* or 2006* or 2007*
or 2008* or 2009* or 2010* or 2011* or 201201*).ed.
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156First clinical effectiveness search, MEDLINE In-Process & Other Non-Indexed Citations
Database: MEDLINE In-Process & Other Non-Indexed Citations.
Host: Ovid.
Data parameters: December 30 2016.
Date searched: 9 January 2017.
Searcher: SR.
Hits: 9.
Search strategy1.
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3.
4.
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7.
8.
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10.
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15.
1.
2.
3.
4.
NIHR((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
(tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.
4 or 5 or 6
((low$ adj3 dos$) or LDCT).ti,ab,kw,ot.
((ultralow$ or ultra-low$) adj3 dos$).ti,ab,kw,ot.
(low-dos$ or ultralow-dos$).ti,ab,kw,ot.
10 or 11 or 12
3 and 7 and 11
(200407* or 200408* or 200409* or 200410* or 200411* or 200412* or 2005* or 2006* or 2007*
or 2008* or 2009* or 2010* or 2011* or 201201*).ed.
12 and 13
limit 14 to English language and yr=“2004-”First clinical effectiveness search, EMBASE
Database: EMBASE.
Host: Ovid.
Data parameters: 1974 to 2016 December 30.
Date searched: 9 January 2017.
Searcher: SR.
Hits: 82.
Search strategyexp lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3Journals Library www.journalslibrary.nihr.ac.uk
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
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Park, Sexp computer assisted tomography/
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
(tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.
5 or 6 or 7 or 8
((low$ adj3 dos$) or LDCT).ti,ab,kw,ot.
((ultralow$ or ultra-low$) adj3 dos$).ti,ab,kw,ot.
(low-dos$ or ultralow-dos$).ti,ab,kw,ot.
10 or 11 or 12
4 and 9 and 13
(200407* or 200408* or 200409* or 200410* or 200411* or 200412* or 2005* or 2006* or 2007*
or 2008* or 2009* or 2010* or 2011* or 201201*).dd.
14 and 15
limit 16 to english language and yr=“2004-”First clinical effectiveness search, Health Management Information Consortium
Database: Health Management Information Consortium.
Host: Ovid.
Data parameters: 1979 to November 2016.
Date searched: 9 January 2017.
Searcher: SR.
Hits: 15.
Search strategyexp Lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).tw.
(NSLC or NSCLC or SLC or SCLC).tw.
1 or 2 or 3
((CT or CAT) adj3 (scan$ or screen$)).tw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).tw.
(tomogra$ or helix or helical or spiral$ or spiro$).tw.
5 or 6 or 7
((low$ adj3 dos$) or LDCT).ti,ab,kw,ot.
((ultralow$ or ultra-low$) adj3 dos$).ti,ab,kw,ot.
(low-dos$ or ultralow-dos$).ti,ab,kw,ot.
10 or 11 or 12
4 and 8 and 12
limit 13 to yr=“2004 - 2011”First clinical effectiveness search, PsycINFO
Database: PsycINFO.
Host: Ovid.
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Searcher: SR.
Hits: 28.
Search strategy
exp Lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).tw.
(NSLC or NSCLC or SLC or SCLC).tw.
1 or 2 or 3
((CT or CAT) adj3 (scan$ or screen$)).tw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).tw.
(tomogra$ or helix or helical or spiral$ or spiro$).tw.
5 or 6 or 7
((low$ adj3 dos$) or LDCT).ti,ab,kw,ot.
((ultralow$ or ultra-low$) adj3 dos$).ti,ab,kw,ot.
(low-dos$ or ultralow-dos$).ti,ab,kw,ot.
10 or 11 or 12
4 and 8 and 12
limit 13 to yr=“2004 – 2011”
First clinical effectiveness search, Web of Science
Database: Web of Science [Science Citation Index (SCI) and Conference Proceedings Citation Index –
Science (CPCI-S)].
Host: Clarivate Analytics.
Data parameters: not applicable.
Date searched: 9 January 2017.
Searcher: SR.
Hits: 332.
Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
NIHRTS=((lung* or bronch* or pulmon*) near/2 (cancer* or neopla* or tumor* or tumour* or carcinoma*
or adenocarcinoma* or “small cell” or squamous))
TS=(NSLC or NSCLC or SLC or SCLC)
TS=((CT or CAT) near/2 (scan* or screen*))
TS=((computer* near/2 tomogram*) and (scan* or screen*))
TS=(tomogram* or helix or helical or spiral* or spiro*)
#1 or #2
#3 or #4 or #5
TS=(“low-dos*” or “ultralow-dos*”)
TS=((ultralow* or ultra-low*) near/2 dos*)
TS=((low* near/2 dos*) or LDCT)
#8 or #9 or #10
#6 and #7 and #11Indexes=SCI-EXPANDED, CPCI-S Timespan=2004-2011.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69First clinical effectiveness search, The Cochrane Library
Database: The Cochrane Library.
Host: Cochrane Collaboration.
Data parameters: CDSR: Issue 1 of 12, January 2017; HTA: Issue 4 of 4, October 2016; CENTRAL: Issue 11
of 12, November 2016.
Date searched: 9 January 2017.
Searcher: SR.
Hits: 56.
Search strategy
#1 MeSH descriptor: [Lung Neoplasms] explode all trees
#2 ((lung* or bronch* or pulmon*) near/3 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)):ti,ab,kw
#3 (NSLC or NSCLC or SLC or SCLC):ti,ab,kw
#4 #1 or #2 or #3
#5 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#6 ((CT or CAT) near/3 (scan* or screen*)):ti,ab,kw
#7 ((computer* near/3 tomogra*) and (scan* or screen*)):ti,ab,kw
#8 (tomogram* or helix or helical or spiral* or spiro*):ti,ab,kw
#9 #5 or #6 or #7 or #8
#10 ((low* near/3 dos*) or LDCT):ti,ab,kw
#11 ((ultralow* or ultra-low*) near/3 dos*):ti,ab,kw
#12 (low-dos* or ultralow-dos*):ti,ab,kw
#13 #10 or #11 or #12
#14 #4 and #9 and #13 Publication Year from 2004 to 2011
First clinical effectiveness search, CINAHL
Database: CINAHL.
Host: EBSCOhost.
Data parameters: not applicable.
Date searched: 4 January 2017.
Searcher: SR.
Hits: 1275.
Search strategy1.
2.
3.
4.
5.
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journa
be add
Park, S(MH “Lung Neoplasms+”)
TX (lung* or bronch* or pulmon*) N2 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)
TX (NSLC or NSCLC or SLC or SCLC)
S1 OR S2 OR S3
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6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
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NIHR
160TX (CT or CAT) N2 (scan* or screen*)
TX (computer* N2 tomogra*) and (scan* or screen*)
TX (tomogram* or helix or helical or spiral* or spiro*)
S5 OR S6 OR S7 OR S8
((low* near/3 dos*) or LDCT):ti,ab,kw
((ultralow* or ultra-low*) near/3 dos*):ti,ab,kw
(low-dos* or ultralow-dos*):ti,ab,kw
S10 and S11 and S12
S4 AND S9 and S13
(MH “Clinical Trials+”)
PT Clinical Trial
TX clinic* n1 trial*
TX (singl* n1 blind*) or (singl* n1 mask*)
TX (doubl* n1 blind*) or (doubl* n1 mask*)
TX (tripl* n1 blind*) or (tripl* n1 mask*)
TX (trebl* n1 blind*) or (trebl* n1 mask*)
TX randomi* control* trial*
(MH “Random Assignment”)
TX random* allocat*
TX placebo*
(MH “Placebos”)
(MH “Quantitative Studies”)
TX allocat* random*
S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 or S25 or S26 or
S27 or S28
S14 AND S29
Limit to 2004-2011Summary
TABLE 33 Number of hits per database and in total (first clinical effectiveness search)DatabaseJournals Library www.journalslibrary.nihr.ac.ukHitsMEDLINE 124MEDLINE in Process & Other Non-Indexed Citations 9EMBASE 82HMIC 25PsycINFO 28Web of Science (SCI and SCCI) 332Cochrane 56CINAHL 167Total records 823Duplicates 230Total unique records 593
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Lung cancer screening searches: clinical effectiveness 2, 2012–current,
all computed tomography scan doses, X-ray comparator, randomised
controlled trial filter
Second clinical effectiveness search, MEDLINE
Database: MEDLINE.
Host: Ovid.
Data Parameters: 1946 to December week 1 2016.
Date Searched: 10 January 2017.
Searcher: SR.
Hits: 2074.
Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
© Que
Health
journa
be add
Park, Sexp Lung Neoplasms/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3
exp Tomography, X-Ray Computed/
exp Radiography, Thoracic/
(x ray or xray or x-ray or CXR or radiograph$).ti,ab,ot,kw.
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
(tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.
5 or 6 or 7 or 8 or 9 or 10
4 and 11
(2012* or 2013* or 2014* or 2015* or 2016* or 2017*).ed.
randomized controlled trial.pt.
controlled clinical trial.pt.
randomized.ab.
placebo.ab.
drug therapy.fs.
randomly.ab.
trial.ab.
groups.ab.
14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
exp animals/ not humans.sh.
22 not 23
12 and 13 and 24
limit 25 to english language and yr=“2012-Current”Second clinical effectiveness search, MEDLINE In-Process & Other Non-Indexed Citations
Database: MEDLINE In-Process & Other Non-Indexed Citations.
Host: Ovid.
Data parameters: 30 December 2016.en’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
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162Date searched: 10 January 2017.
Searcher: SR.
Hits: nine.
Search strategy
1. ((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
2. (NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
3. 1 or 2
3. (x ray or xray or x-ray or CXR or radiograph$).ti,ab,ot,kw.
4. ((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
5. ((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
6. (tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.
7. 4 or 5 or 6 or 7
8. 3 and 7
9. (2012* or 2013* or 2014* or 2015* or 2016* or 2017*).ed.
10. randomized controlled trial.pt.
11. controlled clinical trial.pt.
12. randomized.ab.
13. placebo.ab.
14. drug therapy.fs.
15. randomly.ab.
16. trial.ab.
17. groups.ab.
18. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
19. exp animals/ not humans.sh.
20. 18 not 19
21. 8 and 9 and 20
22. limit 21 to english language and yr=“2012 - Current”
Second clinical effectiveness search, EMBASE
Database: EMBASE.
Host: Ovid.
Data parameters: 1974 to 30 December 2016.
Date searched: 10 January 2017.
Searcher: SR.
Hits: 2061.
Search strategy1.
2.
3.
4.
NIHRexp lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3Journals Library www.journalslibrary.nihr.ac.uk
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
1.
2.
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Park, Sexp computer assisted tomography/
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
(tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.
exp thorax radiography/
(x ray or xray or x-ray or CXR or radiograph$).ti,ab,ot,kw.
5 or 6 or 7 or 8 or 9 or 10
4 and 11
Clinical trial/
Randomized controlled trial/
Randomization/
Single blind procedure/
Double blind procedure/
Crossover procedure/
Placebo/
Randomi?ed controlled trial$.tw.
Rct.tw.
Random allocation.tw.
Randomly allocated.tw.
Allocated randomly.tw.
(allocated adj2 random).tw.
Single blind$.tw.
Double blind$.tw.
((treble or triple) adj blind$).tw.
Placebo$.tw.
Prospective study/
or/13-30
Case study/
Case report.tw.
Abstract report/ or letter/
32 or 33 or 34
31 not 35
12 and 36
limit 37 to english language and yr=“2012 –Current”Second clinical effectiveness search, Health Management Information Consortium
Database: Health Management Information Consortium.
Host: Ovid.
Data parameters: 1979 to November 2016.
Date searched: 10 January 2017.
Searcher: SR.
Hits: seven.
Search strategyexp Lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).tw.en’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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9.
10.
11.
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164(NSLC or NSCLC or SLC or SCLC).tw.
1 or 2 or 3
((CT or CAT) adj3 (scan$ or screen$)).tw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).tw.
(tomogra$ or helix or helical or spiral$ or spiro$).tw.
(x ray or xray or x-ray or CXR or radiograph$).tw.
5 or 6 or 7 or 8
4 and 9
limit 10 to yr=“2012 -Current” and englishSecond clinical effectiveness search, PsycINFO
Database: PsycINFO.
Host: Ovid.
Data parameters: 1806 to December Week 4 2016.
Date Searched: 10 January 2017.
Searcher: SR.
Hits: 42.
Search strategyexp Lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).tw.
(NSLC or NSCLC or SLC or SCLC).tw.
1 or 2 or 3
((CT or CAT) adj3 (scan$ or screen$)).tw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).tw.
(tomogra$ or helix or helical or spiral$ or spiro$).tw.
(x ray or xray or x-ray or CXR or radiograph$).tw.
5 or 6 or 7 or 8
4 and 9
limit 10 to yr=“2012 -Current” and englishSecond clinical effectiveness search, Web of Science
Database: Web of Science (SCI and CPCI-S).
Host: Clarivate Analytics.
Data parameters: not applicable.
Date searched: 10 January 2017.
Searcher: SR.
Hits: 1216.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
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Park, STS=((lung* or bronch* or pulmon*) near/2 (cancer* or neopla* or tumor* or tumour* or carcinoma*
or adenocarcinoma* or “small cell” or squamous))
TS=(NSLC or NSCLC or SLC or SCLC)
TS=((CT or CAT) near/2 (scan* or screen*))
TS=((computer* near/2 tomogram*) and (scan* or screen*))
TS=(tomogram* or helix or helical or spiral* or spiro*)
TS=(x ray or xray or x-ray or CXR or radiograph*)
#1 or #2
#3 or #4 or #5 OR #6
#7 and #8
TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR
TS=controlled trial* OR TS=follow-up stud* OR TS=prospective stud* OR TS=random* OR
TS=placebo* OR TS=(single blind*) OR TS=(double blind*)
#9 and #10Indexes=SCI-EXPANDED, CPCI-S Timespan=2012–2017; Language: English
Second clinical effectiveness search, The Cochrane Library
Database: The Cochrane Library.
Host: Cochrane.
Data parameters: CDSR: Issue 1 of 12, January 2017; HTA: Issue 4 of 4, October 2016; CENTRAL: Issue 11
of 12, November 2016.
Date searched: 10 January 2017.
Searcher: SR.
Hits: 457.
Search strategy
#1 MeSH descriptor: [Lung Neoplasms] explode all trees
#2 ((lung* or bronch* or pulmon*) near/3 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)):ti,ab,
#3 (NSLC or NSCLC or SLC or SCLC):ti,ab,kw
#4 #1 or #2 or #3
#5 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#6 ((CT or CAT) near/3 (scan* or screen*)):ti,ab,kw
#7 ((computer* near/3 tomogra*) and (scan* or screen*)):ti,ab,kw
#8 (tomogram* or helix or helical or spiral* or spiro*):ti,ab,kw
#9 MeSH descriptor: [Radiography, Thoracic] explode all trees
#10 (x ray or xray or x-ray or CXR or radiograph*):ti,ab,kw
#11 #5 or #6 or #7 or #8 or #9 or #10
#12 #4 and #11 Publication Year from 2012 to 2017en’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
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166Second clinical effectiveness search, CINAHL
Database: CINAHL.
Host: EBSCOhost.
Data parameters: not applicable.
Date searched: 10 January 2017.
Searcher: SR.
Hits: 403.
Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
NIHR(MH “Lung Neoplasms+”)
TX (lung* or bronch* or pulmon*) N2 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)
TX (NSLC or NSCLC or SLC or SCLC)
S1 OR S2 OR S3
(MH “Tomography, X-Ray Computed+”)
TX (CT or CAT) N2 (scan* or screen*)
TX (computer* N2 tomogra*) and (scan* or screen*)
TX (tomogram* or helix or helical or spiral* or spiro*)
TX (x ray or xray or x-ray or CXR or radiograph*)
(MH “Radiography, Thoracic+”)
S5 and S6 and S7 and S8 and S9
S4 AND S11
(MH “Clinical Trials+”)
PT Clinical Trial
TX clinic* n1 trial*
TX (singl* n1 blind*) or (singl* n1 mask*)
TX (doubl* n1 blind*) or (doubl* n1 mask*)
TX (tripl* n1 blind*) or (tripl* n1 mask*)
TX (trebl* n1 blind*) or (trebl* n1 mask*)
TX randomi* control* trial*
(MH “Random Assignment”)
TX random* allocat*
TX placebo*
(MH “Placebos”)
(MH “Quantitative Studies”)
TX allocat* random*
S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 or S25 or S26 or
S27 or S28
S12 AND S27
Limit to 2012-2017 and EnglishJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Summary
TABLE 34 Number of hits per database and in total (second clinical effectiveness search)1
1
1
©
H
j
b
PDatabase1.
2.
3.
4.
5.
6.
7.
8.
9.
0.
1.
2.
Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of Stat
ealth and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in pro
ournals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction
e addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampto
ark, Southampton SO16 7NS, UK.HitsMEDLINE 2074MEDLINE in Process & Other Non-Indexed Citations 213EMBASE 2061HMIC 7PsycINFO 42Web of Science (SCI and SCCI) 1216Cochrane 457CINAHL 403Total records 6473Duplicates 1929Total unique records 4544Lung cancer screening cost-effectiveness searches
Cost-effectiveness search, MEDLINE
Database: MEDLINE.
Host: Ovid.
Data parameters: 1946 to December Week 1 2016.
Date searched: 5 January 2017.
Searcher: SR.
Hits: 999.
Search strategyexp Lung Neoplasms/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3
exp Tomography, X-Ray Computed/
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
(tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.
5 or 6 or 7 or 8
4 and 9
exp Economics/
Economics, Medical/e for
fessional
should
n Science
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13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
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168Economics, Nursing/
Economics, Pharmaceutical/
exp Economics, Hospital/
(economic$ or price or prices or pricing or priced or discount or discounts or discounted or discounting
or ration$ or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$ or pharmaco-
economic$).ti,kf.
exp “Fees and Charges”/
(fee or fees or charge$ or preference$).tw.
(fiscal or funding or financial or finance).tw.
exp “Costs and Cost Analysis”/
exp Health Care Costs/
(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.
(value adj2 (money or monetary)).ti,ab,kf.
exp Decision Support Techniques/
exp Models, Economic/
economic model*.ab,kf.
markov$.tw.
Markov Chains/
monte carlo.tw.
Monte Carlo Method/
(decision adj2 (tree$ or analy$ or model$)).ti,ab,kf.
exp Decision Theory/
(survival adj3 analy$).tw.
“Deductibles and Coinsurance”/
exp Health Expenditures/
Uncertainty/
exp Budgets/
or/11-37
Animals/ not human.sh.
38 not 39
(200407* or 200408* or 200409* or 200410* or 200411* or 200412* or 2005* or 2006* or 2007*
or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017*).ed.
10 and 40 and 41Cost-effectiveness search, MEDLINE In-Process & Other Non-Indexed Citations
Database: MEDLINE In-Process & Other Non-Indexed Citations.
Host: Ovid.
Data parameters: 30 December 2016.
Date searched: 5 January 2017.
Searcher: SR.
Hits: 74.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
1.
2.
3.
4.
5.
6.
7.
8.
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Park, S((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
(tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.
4 or 5 or 6
3 and 7
(economic$ or price or prices or pricing or priced or discount or discounts or discounted or discounting
or ration$ or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$ or pharmaco-
economic$).ti,kf.
(fee or fees or charge$ or preference$).tw.
(fiscal or funding or financial or finance).tw.
(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.
(value adj2 (money or monetary)).ti,ab,kf.
economic model*.ab,kf.
markov$.tw.
monte carlo.tw.
(decision adj2 (tree$ or analy$ or model$)).ti,ab,kf.
(survival adj3 analy$).tw.
or/9-18
(200407* or 200408* or 200409* or 200410* or 200411* or 200412* or 2005* or 2006* or 2007*
or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017*).ed.
8 and 19 and 20Cost-effectiveness search, EMBASE
Database: EMBASE.
Host: Ovid.
Data parameters: 1974 to 30 December 2016.
Date searched: 5 January 2017.
Searcher: SR.
Hits: 1314.
Search strategyexp lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3
exp computer assisted tomography/
((CT or CAT) adj3 (scan$ or screen$)).ti,ab,ot,kw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).ti,ab,ot,kw.
(tomogra$ or helix or helical or spiral$ or spiro$).ti,ab,ot,kw.en’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
1.
2.
3.
4.
5.
6.
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1705 or 6 or 7 or 8
4 and 9
Economics/
Cost/
exp Health Economics/
Budget/
budget*.ti,ab,kw.
(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or
pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or
finances or financed).ti,kw.
(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or
pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or
finances or financed).ab. /freq=2
(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kw.
(value adj2 (money or monetary)).ti,ab,kw.
Statistical Model/
economic model*.ab,kw.
Probability/
markov.ti,ab,kw.
monte carlo method/
monte carlo.ti,ab,kw.
Decision Theory/
Decision Tree/
(decision* adj2 (tree* or analy* or model*)).ti,ab,kw.
or/11-28
10 and 29
(200407* or 200408* or 200409* or 200410* or 200411* or 200412* or 2005* or 2006* or 2007*
or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017*).dd.
30 and 31
limit 32 to english languageCost-effectiveness search, Health Management Information Consortium
Database: Health Management Information Consortium.
Host: Ovid.
Data parameters: 1979 to November 2016.
Date searched: 5 January 2017.
Searcher: SR.
Hits: 22.
Search strategyexp Lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).tw.
(NSLC or NSCLC or SLC or SCLC).tw.
1 or 2 or 3
((CT or CAT) adj3 (scan$ or screen$)).tw.
((computer$ adj3 tomogra$) and (scan$ or screen$)).tw.Journals Library www.journalslibrary.nihr.ac.uk
7.
8.
9.
10.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
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Park, S(tomogra$ or helix or helical or spiral$ or spiro$).tw.
5 or 6 or 7
4 and 8
limit 9 to yr=“2004 - Current”Cost-effectiveness search, Web of Science
Database: Web of Science (SCI and CPCI-S).
Host: Clarivate Analytics.
Data parameters: not applicable.
Date searched: 5 January 2017.
Searcher: SR.
Hits: 302.
Search strategyTS=((lung* or bronch* or pulmon*) near/2 (cancer* or neopla* or tumor* or tumour* or carcinoma*
or adenocarcinoma* or “small cell” or squamous))
TS=(NSLC or NSCLC or SLC or SCLC)
TS=((CT or CAT) near/2 (scan* or screen*))
TS=((computer* near/2 tomogram*) and (scan* or screen*))
TS=(tomogram* or helix or helical or spiral* or spiro*)
#1 or #2
#3 or #4 or #5
#6 and #7
TS=((pharmacoeconomic* or socioeconomics or economic* or pric* or cost* or cba or cea or cua or
“health utilit*” or “value for money”))
#9 and #8Indexes=SCI-EXPANDED, CPCI-S Timespan=2004–2017.
Cost-effectiveness search, NHS Economic Evaluation Database and Health
Technology Assessment
Database: NHS EED and HTA.
Host: The Cochrane Library.
Data parameters: HTA: Issue 4 of 4, October 2016; NHS EED: 2 of 4, April 2015.
Date searched: 5 January 2016.
Searcher: SR.
Hits: HTA: 17; NHS EED: 32 = total 49.en’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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172Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
NIHRMeSH descriptor: [Lung Neoplasms] explode all trees
((lung* or bronch* or pulmon*) near/3 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)):ti,ab,kw
(NSLC or NSCLC or SLC or SCLC):ti,ab,kw
#1 or #2 or #3
MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
((CT or CAT) near/3 (scan* or screen*)):ti,ab,kw
((computer* near/3 tomogra*) and (scan* or screen*)):ti,ab,kw
(tomogram* or helix or helical or spiral* or spiro*):ti,ab,kw
#5 or #6 or #7 or #8
#4 and #9 Publication Year from 2004 to 2017Cost-effectiveness search, EconLit
Database: EconLit.
Host: EBSCOhost.
Data parameters: not applicable.
Date searched: 5 January 2017.
Searcher: SR.
Hits: 99.
Search strategy
1. TX (lung* or bronch* or pulmon*) N2 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)
2. TX (NSLC or NSCLC or SLC or SCLC)
3. S1 OR S2
4. Limit to 2004-2017
Summary
TABLE 35 Number of hits per database and in total (cost-effectiveness search)DatabaseJournals Library www.journalslibrary.nihr.ac.ukHitsMEDLINE 999MEDLINE in Process & Other Non-Indexed Citations 74EMBASE 1314HMIC 22Web of Science (SCI and SCCI) 358Cochrane – HTA and NHS EED 49EconLit 99Total records 2915Duplicates 692Total unique records 2223
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Lung cancer screening utilities searchesUtilities search, MEDLINE
Database: MEDLINE.
Host: Ovid.
Data parameters: 1946 to December Week 1 2016.
Date searched: 24 January 2017.
Searcher: SR.
Hits: 1102.
Search strategy1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
1.
2.
3.
4.
5.
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be add
Park, Sexp Lung Neoplasms/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3
(HRQOL or HRQL or QOL or QALY$).tw.
(EQ-5D or EQ-5D-3L or EQ-5D-5L).tw.
quality-adjusted life years/
(euroqol or euro qol or eq5d or eq 5d).tw.
health utilit$.tw.
disutil$.tw.
5 or 6 or 7 or 8 or 9 or 10
4 and 11
limit 14 to english languageUtilities search, MEDLINE In-Process & Other Non-Indexed Citations
Database: MEDLINE In-Process & Other Non-Indexed Citations.
Host: Ovid.
Data parameters: January 20 2016.
Date searched: 24 January 2017.
Searcher: SR.
Hits: 258.
Search strategy((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2
(HRQOL or HRQL or QOL or QALY$).tw.
(EQ-5D or EQ-5D-3L or EQ-5D-5L).tw.en’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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NIHR
174(euroqol or euro qol or eq5d or eq 5d).tw.
health utilit$.tw.
disutil$.tw.
4 or 5 or 6 or 7 or 8
3 and 9
limit 10 to english languageUtilities search, EMBASE
Database: EMBASE.
Host: Ovid.
Data parameters: 1974 to 2017 January 20.
Date searched: 10 January 2017.
Searcher: SR.
Hits: 709.
Search strategyexp lung cancer/
((lung$ or bronch$ or pulmon$) adj3 (cancer$ or neopla$ or tumor$ or tumour$ or carcinoma$ or
adenocarcinoma$ or small cell or squamous)).ti,ab,ot,kw.
(NSLC or NSCLC or SLC or SCLC).ti,ab,ot,kw.
1 or 2 or 3
(HRQOL or HRQL or QOL or QALY$).ti.
(EQ-5D or EQ-5D-3L or EQ-5D-5L).ti.
quality adjusted life year/
(euroqol or euro qol or eq5d or eq 5d).ti.
health utilit$.ti.
disutil$.ti.
5 or 6 or 7 or 8 or 9 or 10
4 and 11
limit 14 to english languageUtilities search, NHS Economic Evaluation Database
Database: NHS EED.
Host: The Cochrane Library.
Data parameters: NHS EED: 2 of 4, April 2015.
Date searched: 24 January 2017.
Searcher: SR.
Hits: 59.
Search strategyMeSH descriptor: [Lung Neoplasms] explode all trees
((lung* or bronch* or pulmon*) near/3 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)):ti,ab,kwJournals Library www.journalslibrary.nihr.ac.uk
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
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Health
journa
be add
Park, S(NSLC or NSCLC or SLC or SCLC):ti,ab,kw
#1 or #2 or #3
descriptor: [quality-adjusted life years] explode all trees
(HRQOL or HRQL or QOL or QALY*):ti,ab,kw
(EQ-5D or EQ-5D-3L or EQ-5D-5L):ti,ab,kw
(euroqol or euro qol or eq5d or eq 5d):ti,ab,kw
health utilit*:ti,ab,kw
disutil*:ti,ab,kw
#5 or #6 or #7 or #8 or #9 or #10
#4 and #11Utilities search, School of Health and Related Research Utilities Database
Website: School of Health and Related Research Health Utilities Database (ScHARRHUD).
Date searched: 24 January 2017.
Searcher: SR.
Hits: nine.
Utilities search, Health Economics Research Centre
Website: Health Economics Research Centre (HERC) Oxford.
Date searched: 24 January 2017.
Searcher: SR.
Hits: seven.
Website: EQ-5D EuroQol.
Date searched: 24 January 2017.
Searcher: SR.
Hits: 60.
Summary
TABLE 36 Number of hits per database and in total (utilities search)Databaseen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of Stat
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176Backward citation chasing
Citation chasing yielded 1246 further references (after deduplicating and checking against already
screened papers).
Update searches
The cost-effectiveness searches were updated on 11 April 2017 with following results.TABLE 37 Results of update searches for cost-effectivenessNDatabaseIHR Journals Library www.journalslibrary.nihr.ac.ukHitsMEDLINE 7MEDLINE in Process & Other Non-Indexed Citations 13EMBASE 57HMIC 0Web of Science (SCI and SCCI) 9Cochrane – HTA and NHS EED 0EconLit 0Total records 86Duplicates 18Total unique records 68Ongoing trials
Registers searched: ClinicalTrials.gov and Controlled Trials (ISRCTN).
Search terms: Lung cancer AND screening.
Ongoing trials all phases.
Date limit was 2012 onwards.
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Appendix 2 Included trials with linked citationsTABLE 38 Included trials in systematic review of clinical effectiveness
Study Extracted data Citation
DANTE Yes Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al. A randomized
study of lung cancer screening with spiral computed tomography: three-year results
from the DANTE trial. Am J Respir Crit Care Med 2009;180:445–53
Yes Infante M, Chiesa G, Solomon D, Morenghi E, Passera E, Lutman FR, et al. Surgical
procedures in the DANTE trial, a randomized study of lung cancer early detection with
spiral computed tomography: comparative analysis in the screening and control arm.
J Thorac Oncol 2011;6:327–35
Yes Infante MV, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Passera E, et al. Preliminary
five-year results from a randomized study of lung cancer screening with spiral CT
(the DANTE trial). J Thorac Oncol 2011;6:S351–S352
Yes Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al. Long-term
follow-up results of the DANTE trial, a randomized study of lung cancer screening
with spiral computed tomography. Am J Respir Crit Care Med 2015;191:1166–75.
https://doi.org/10.1164/rccm.201408-1475OC
Yes Infante MV, Cavuto S, Lutman FR, Passera E, Chiesa G, Brambilla G, et al. The DANTE
trial, a randomized study of lung cancer screening with spiral CT: 7-year results. J Thorac
Oncol 2013;8:S147–S148
Yes Infante MV, Fabio LR, Cavuto S, Brambilla G, Chiesa G, Passera E, et al. DANTE:
a randomized study on lung cancer screening with low-dose spiral CT (LDCT): end of
accrual and preliminary results. CHEST J 2006;130:114
Yes Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E, et al. Lung cancer
screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer
2008;59:355–63
Depiscan Yes Blanchon T, Bréchot JM, Grenier PA, Ferretti GR, Lemarié E, Milleron B, et al. Baseline
results of the Depiscan study: a French randomized pilot trial of lung cancer screening
comparing Low Dose CT scan (LDCT) and Chest X-Ray (CXR). Lung Cancer 2007;58:50–8
Repeat Milleron B. Screening for Lung Cancer: Feasibility Study of a Randomized Trial
Comparing Low Dose Spiral CT and Chest X-Ray. Chicago, IL: Annual Meeting
Proceedings of the American Society of Clinical Oncology; 31 May–3 June 2014
Repeat Milleron B. Screening for lung cancer: feasibility study of a randomized trial comparing
low dose spiral CT and chest x-ray. J Clin Oncol 2004;22(Suppl. 14):7183
DLCST Yes Aggestrup LM, Hestbech MS, Siersma V, Pedersen JH, Brodersen J. Psychosocial
consequences of allocation to lung cancer screening: a randomised controlled trial.
BMJ Open 2012;2:e000663. https://doi.org/10.1136/bmjopen-2011-000663
Yes Ashraf H, Saghir Z, Thomsen LH, Dirksen A, Dossing M, Pedersen JH, Tonnesen P.
Smoking habits in the Danish Lung Cancer Screening Trial (DLCST): final results after
5-year screening program. Am J Respir Crit Care Med 2012;185:A2585
Yes Ashraf H, Saghir Z, Dirksen A, Pedersen JH, Thomsen LH, Døssing M, Tønnesen P.
Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT:
final results after a 5-year screening programme. Thorax 2014;69:574–9. https://doi.org/
10.1136/thoraxjnl-2013-203849
No Ashraf H, Tønnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Døssing M. Effect of CT
screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening
Trial (DLCST). Thorax 2009;64:388–92. https://doi.org/10.1136/thx.2008.102475
Yes Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish
randomized lung cancer CT screening trial – overall design and results of the prevalence
round. J Thorac Oncol 2009;4:608–14. https://doi.org/10.1097/JTO.0b013e3181a0d98f
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TABLE 38 Included trials in systematic review of clinical effectiveness (continued )
Study Extracted data Citation
Yes Pedersen JH, Wille MW, Dirksen A. The Danish lung cancer screening trial: results
5 years after last CT screening. J Thorac Oncol 2015;10:S191
Yes Petersen RH, Hansen HJ, Dirksen A, Pedersen JH. Lung cancer screening and video-
assisted thoracic surgery. J Thorac Oncol 2012;7:1026–31. https://doi.org/10.1097/
JTO.0b013e31824fe942
Yes Rasmussen JF, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences in
the Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer
2015;87:65–72. https://doi.org/10.1016/j.lungcan.2014.11.003
Yes Saghir Z, Ashraf HG, Dirksen, Tønnesen P, Hansen H, Bach KS, et al. Danish Lung
Cancer Screening Trial (DLCST): preliminary results after five annual screening rounds
with low dose CT. Am J Respir Crit Car Med 2011;83:A6103
Yes Saghir Z, Dirksen A, Ashraf HG, Tonnesen P, Bach KS, Hansen H, et al. CT screening of
lung cancer brings forward early disease. The Danish Lung Cancer Screening Trial
(DLCST): status after five years of CT screening. J Thorac Oncol 2011;6:S350–1
No Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening
for lung cancer brings forward early disease. The randomised Danish Lung Cancer
Screening Trial: status after five annual screening rounds with low-dose CT. Thorax
2012;67:296–301. https://doi.org/10.1136/thoraxjnl-2011-200736
No data Saghir Z, Dirksen A, Rasmussen JF, Heleno BM, Brodersen J, Pedersen JH. In lung cancer
screening by CT incidental findings are frequent and often of clinical importance. Am J
Respir Crit Car Med 2012;185:A5072
No data Saghir Z, Dirksen A, Pedersen JH. Predictors of nodule malignancy in the Danish lung
cancer screening trial (DLCST). J Thorac Oncol 2013;8:S678
Yes Wille MM, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the
randomized Danish Lung Cancer Screening Trial with focus on high-risk profiling. Am J
Respir Crit Care Med 2016;193:542–51. https://doi.org/10.1164/rccm.201505-1040OC
Garg Yes Garg K, Keith RL, Byers T, Kelly K, Kerzner AL, Lynch DA, Miller YE. Randomized controlled
trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary
results. Radiology 2002;225:506–10. https://doi.org/10.1148/radiol.2252011851
ITALUNG No Conti B, Aquilini F, Pistelli F, Santis M, Tavanti L, Cini S. Lung function in a group of
smokers or ex-smokers enrolled in a Randomized Controlled Trial (RCT) with low-dose
Computed Tomography (CT) for lung cancer screening (ITALUNG-CT Study). Barcelona:
European Respiratory Society Annual Congress;18–22 September 2010
Yes Gonfiotti A, Santini P, Pegna AL, Esposito I, Paci E, Mussi A, Janni A. Results of thoracic
surgical operations in the italung trial for lung cancer screening. Interactive
Cardiovascular and Thoracic Surgery 2009;9:S83
Yes Lopes Pegna A, Picozzi G, Falaschi F, Carrozzi L, Falchini M, Carozzi FM, et al. Four-year
results of low-dose CT screening and nodule management in the ITALUNG trial.
J Thorac Oncol 2013;8:866–75. https://doi.org/10.1097/JTO.0b013e31828f68d6
Yes Mascalchi M, Mazzoni LN, Falchini M, Belli G, Picozzi G, Merlini V, et al. Dose exposure in
the ITALUNG trial of lung cancer screening with low-dose CT. Br J Radiol 2014;85:1134–9
Yes Mascalchi M, Belli G, Zappa M, Picozzi G, Falchini M, Della Nave R, et al. Risk-benefit
analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial.
AJR Am J Roentgenol 2006;187:421–9
No Mascalchi M, Picozzi G, Falchini M, Vella A, Diciotti S, Carrozzi L, et al. Initial LDCT
appearance of incident lung cancers in the ITALUNG trial. Eur J Radiol 2014;83:2080–6.
https://doi.org/10.1016/j.ejrad.2014.07.019
Yes Lopes Pegna A, Picozzi G, Mascalchi M, Maria Carozzi F, Carrozzi L, Comin C, et al. Design,
recruitment and baseline results of the ITALUNG trial for lung cancer screening with
low-dose CT. Lung Cancer 2009;64:34–40. https://doi.org/10.1016/j.lungcan.2008.07.003
No Picozzi G, Mascalchi M, Falaschi F, Paci E. Initial appearance of LDCT screen-detected
lung cancers in the ITALUNG trial. J Thorac Imaging 2014;29:3
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TABLE 38 Included trials in systematic review of clinical effectiveness (continued )
Study Extracted data Citation
Yes Picozzi G, Falaschi F, Mascalchi M, Paci E. Four years results of low dose CT screening
and nodule management in the ITALUNG trial. J Thorac Imaging 2014;29:W26–W7
LSS-PCLO Yes Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P, et al. Baseline
findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs
chest radiograph: the lung screening study of the National Cancer Institute. Chest
2004;126:114–21. https://doi.org/10.1378/chest.126.1.114
Yes Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, et al. Final
results of the Lung Screening Study, a randomized feasibility study of spiral CT versus
chest X-ray screening for lung cancer. Lung Cancer 2005;47:9–15
Yes Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS. Cumulative incidence of
false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med
2010;152:505–12, W176–80. https://doi.org/10.7326/0003-4819-152-8-201004200-
00007
lungSEARCH Yes Spiro SG, Hackshaw A, LungSEARCH Collaborative Group. Research in progress –
LungSEARCH: a randomised controlled trial of surveillance for the early detection of
lung cancer in a high-risk group. Thorax 2016;71:91–3. https://doi.org/10.1136/
thoraxjnl-2015-207433
Yes Spiro SG, Hackshaw A, Shah P, Novelli M, Kocjan G, Shaw P, et al. Research in
progress – LungSEARCH: a randomised controlled trial of surveillance for the early
detection of lung cancer in a high-risk group. Thorax 2015;71:91–3
LUSI Yes Becker N, Motsch E, Gross ML, Eigentopf A, Heussel CP, Dienemann H, et al. Randomized
Study on early detection of lung cancer with MSCT in Germany: results of the first 3 years
of follow-up after randomization. J Thorac Oncol 2015;10:890–6. https://doi.org/
10.1097/JTO.0000000000000530
Yes Becker N, Motsch E, Gross ML, Eigentopf A, Heussel CP, Dienemann H, et al.
Randomized study on early detection of lung cancer with MSCT in Germany:
study design and results of the first screening round. J Cancer Res Clin Oncol
2012;138:1475–86. https://doi.org/10.1007/s00432-012-1228-9
Yes Eigentopf A, Becker N, Motsch E, Gross ML. Interim results from the German
randomized lung screening trial LUSI. Oncology Research and Treatment
2014;37:34–35
Yes Eigentopf A, Motsch E, Gross ML, Becker N. Results of all 5 screening rounds of the
randomized study on the early detection of lung cancer LUSI. Oncology Research and
Treatment 2016;39:27–8
No Sommer G, Tremper J, Koenigkam-Santos M, Delorme S, Becker N, Biederer J, et al.
Lung nodule detection in a high-risk population: comparison of magnetic resonance
imaging and low-dose computed tomography. Eur J Radiol 2014;83:600–5. https://doi.org/
10.1016/j.ejrad.2013.11.012
MILD Yes Pastorino U, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, et al. Annual
or biennial CT screening versus observation in heavy smokers: 5-year results of
the MILD trial. Eur J Cancer Prev 2012;21:308–15. https://doi.org/10.1097/
CEJ.0b013e328351e1b6
No Pozzi P, Munarini E, Bravi F, Rossi M, La Vecchia C, Boffi R, Pastorino U. A combined
smoking cessation intervention within a lung cancer screening trial: a pilot observational
study. Tumori 2015;101:306–11. https://doi.org/10.5301/tj.5000282
No data Sverzellati N, Guerci L, Randi G, Calabrò E, La Vecchia C, Marchianò A, et al. Interstitial
lung diseases in a lung cancer screening trial. Eur Respir J 2011;38:392–400. https://doi.org/
10.1183/09031936.00201809
No data Sverzellati N, Cademartiri F, Bravi F, Martini C, Gira FA, Maffei E, et al. Relationship and
prognostic value of modified coronary artery calcium score, FEV1, and emphysema
in lung cancer screening population: the MILD trial. Radiology 2012;262:460–7.
https://doi.org/10.1148/radiol.11110364
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TABLE 38 Included trials in systematic review of clinical effectiveness (continued )
Study Extracted data Citation
No Sverzellati N, Silva M, Calareso G, Galeone C, Marchianò A, Sestini S, et al. Low-dose
computed tomography for lung cancer screening: comparison of performance between
annual and biennial screen. Eur Radiol 2016;26:3821–9. https://doi.org/10.1007/
s00330-016-4228-3
NELSON No Bunge EM, van den Bergh KA, Essink-Bot ML, van Klaveren RJ, de Koning HJ. High
affective risk perception is associated with more lung cancer-specific distress in CT
screening for lung cancer. Lung Cancer 2008;62:385–90. https://doi.org/10.1016/
j.lungcan.2008.03.029
Repeat van de Wiel JC, Wang Y, Xu DM, van der Zaag-Loonen HJ, van der Jagt EJ, van Klaveren RJ,
Oudkerk M, NELSON study group. Neglectable benefit of searching for incidental findings
in the Dutch-Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT.
Eur Radiol 2007;17:1474–82. https://doi.org/10.1007/s00330-006-0532-7
No data Gietema HA, Schilham AM, van Ginneken B, van Klaveren RJ, Lammers JW, Prokop M.
Monitoring of smoking-induced emphysema with CT in a lung cancer screening setting:
detection of real increase in extent of emphysema. Radiology 2007;244:890–7
No data Gietema HA, Zanen P, Schilham A, van Ginneken B, van Klaveren RJ, Prokop M,
Lammers JW. Distribution of emphysema in heavy smokers: impact on pulmonary
function. Respir Med 2010;104:76–82. https://doi.org/10.1016/j.rmed.2009.08.004
No data Heuvelmans MA, Oudkerk M, de Bock GH, de Koning HJ, Xie X, van Ooijen PM, et al.
Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT
lung cancer screening reduces false-positive referrals. Eur Radiol 2013;23:1836–45.
https://doi.org/10.1007/s00330-013-2799-9
No data Heuvelmans MA, Oudkerk M, de Jong PA, Mali WP, Groen HJ, Vliegenthart R.
The impact of radiologists’ expertise on screen results decisions in a CT lung cancer
screening trial. Eur Radiol 2015;25:792–9. https://doi.org/10.1007/s00330-014-3467-4
Yes (abstract) Horeweg N, Van Der Aalst CM, Vliegenthart R, Zhao YR, Xie X, Scholten ET, et al.
Participants’ results of three rounds of the randomised Dutch-Belgian lung cancer
screening trial; a volumetry-based computer tomography screening strategy. Am J Respir
Crit Care Med 2013;187:A2344
Yes Horeweg N, Scholten ET, de Jong PA, van der Aalst CM, Weenink C, Lammers JW, et al.
Detection of lung cancer through low-dose CT screening (NELSON): a prespecified
analysis of screening test performance and interval cancers. Lancet Oncol
2014;15:1342–50. https://doi.org/10.1016/S1470-2045(14)70387-0
Yes Horeweg N, van der Aalst CM, Thunnissen E, Nackaerts K, Weenink C, Groen HJ, et al.
Characteristics of lung cancers detected by computer tomography screening in the
randomized NELSON trial. Am J Respir Crit Care Med 2013;187:848–54. https://doi.org/
10.1164/rccm.201209-1651OC
Yes Horeweg N, van der Aalst CM, Vliegenthart R, Zhao Y, Xie X, Scholten ET, et al.
Volumetric computed tomography screening for lung cancer: three rounds of the
NELSON trial. Eur Respir J 2013;42:1659–67. https://doi.org/10.1183/09031936.
00197712
No data Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R,
Scholten ET, et al. Lung cancer probability in patients with CT-detected pulmonary
nodules: a prespecified analysis of data from the NELSON trial of low-dose CT
screening. Lancet Oncol 2014;15:1332–41. https://doi.org/10.1016/S1470-2045(14)
70389-4
Yes Oudkerk M, Heuvelmans MA. Screening for lung cancer by imaging: the NELSON study.
J Belg Soc Radiol 2013;96:163–6
No data Takx RA, Isˇgum I, Willemink MJ, van der Graaf Y, de Koning HJ, Vliegenthart R, et al.
Quantification of coronary artery calcium in nongated CT to predict cardiovascular
events in male lung cancer screening participants: results of the NELSON study.
J Cardiovasc Comput Tomogr 2015;9:50–7. https://doi.org/10.1016/j.jcct.2014.11.006
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TABLE 38 Included trials in systematic review of clinical effectiveness (continued )
Study Extracted data Citation
No data Takx RA, Vliegenthart R, Mohamed Hoesein FA, Isˇgum I, de Koning HJ, Mali WP, et al.
Pulmonary function and CT biomarkers as risk factors for cardiovascular events in male
lung cancer screening participants: the NELSON study. Eur Radiol 2015;25:65–71.
https://doi.org/10.1007/s00330-014-3384-6
yes van den Bergh KA, Essink-Bot ML, Bunge EM, Scholten ET, Prokop M, van Iersel CA,
et al. Impact of computed tomography screening for lung cancer on participants in a
randomized controlled trial (NELSON trial). Cancer 2008;113:396–404. https://doi.org/
10.1002/cncr.23590
Yes van den Bergh KA, Essink-Bot ML, Borsboom GJ, Th Scholten E, Prokop M, de Koning HJ,
van Klaveren RJ. Short-term health-related quality of life consequences in a lung cancer
CT screening trial (NELSON). Br J Cancer 2010;102:27–34. https://doi.org/10.1038/
sj.bjc.6605459
Yes van den Bergh KA, Essink-Bot ML, Borsboom GJ, Scholten ET, van Klaveren RJ,
de Koning HJ. Long-term effects of lung cancer CT screening on health-related quality
of life (NELSON). Eur Respir J 2010;38:154–61
No van den Bergh KA, Essink-Bot ML, van Klaveren RJ, de Koning HJ. Informed participation
in a randomised controlled trial of computed tomography screening for lung cancer.
Eur Respir J 2009;34:711–20. https://doi.org/10.1183/09031936.00098908
Yes van der Aalst CM, de Koning HJ, van den Bergh KA, Willemsen MC, van Klaveren RJ.
The effectiveness of a computer-tailored smoking cessation intervention for participants
in lung cancer screening: a randomised controlled trial. Lung Cancer 2012;76:204–10.
https://doi.org/10.1016/j.lungcan.2011.10.006
No van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ.
Lung cancer screening and smoking abstinence: 2 year follow-up data from the
Dutch-Belgian randomised controlled lung cancer screening trial. Thorax
2010;65:600–5. https://doi.org/10.1136/thx.2009.133751
Yes van der Aalst CM, van Klaveren RJ, van den Bergh KA, Willemsen MC, de Koning HJ. The
impact of a lung cancer computed tomography screening result on smoking abstinence.
Eur Respir J 2011;37:1466–73. https://doi.org/10.1183/09031936.00035410
Yes van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, et al.
Risk-based selection from the general population in a screening trial: selection criteria,
recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT
screening trial (NELSON). Int J Cancer 2007;120:868–74. https://doi.org/10.1002/
ijc.22134
Yes Xu DM, Gietema H, de Koning H, Vernhout R, Nackaerts K, Prokop M, et al. Nodule
management protocol of the NELSON randomised lung cancer screening trial. Lung
Cancer 2006;54:177–84
No van Klaveren RJ, Oudkerk M, Prokop M, Yankelevitz DF, Reeves AP, Kostis WJ, et al.
Management of lung nodules detected by volume CT scanning. N Engl J Med
2010;362:757–9
Yes van’t Westeinde SC, Horeweg N, De Leyn P, Groen HJ, Lammers JW, Weenink C, et al.
Complications following lung surgery in the Dutch-Belgian randomized lung cancer
screening trial. Eur J of Cardiothorac Surg 2012;42:420–9
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TABLE 40 Characteristics of study populations [LDCT vs. usual care (no screening)]
Study
identifier Arm
Country and number
of centres
Number of patients
approached
Number of patients
randomised
Number of patients
screened at
baseline (n/N, %)
Characteristics of patients at baseline
Median age (years),
(range)
Male,
n/N (%)
Current
smokers,
n/N (%)
Former
smokers,
n/N (%)
Family
history of
LC n/N (%)
DANTE61 LDCT Italy, 3 centres 2811 2811 (1403 vs. 1408) 1276 64.3 (64.0–64.7) 1276/1276
(100)
714/1276
(56)
562/1276
(44)
Control 1196 64.6 (64.3–64.9) 1196/1196
(100)
681/1196
(56.9)
515/1196
(43.1)
DLCST63 LDCT Denmark, 1 centre 561 4104 2052 57.9± 4.8 (49–71) 1147/2052
(55.9)
1545/2052
(75.3)
507/2052
(24.7)
Control 2052 57.8± 4.8 (49–71) 1120/2052
(54.6)
1579/2052
(76.9)
473/2052
(23.1)
Garg et al.
200264
LDCT USA, 1 centre 304 239 92 (55 high risk,
37 medium risk)
68.1± 6.2 (high risk)
63.3± 6.6 (medium risk)
185/190 NR NR NR
Control 98 (47 high risk,
51 medium risk)
67.4± 8.2 (high risk)
62.1± 7.6 (medium risk)
NR NR NR
ITALUNG72 LDCT Italy, 3 centres (urban) 71,232 letters were
sent. There were
17,055 (23.9%)
responders
3206 Recruited: 55–69 years
55–59 years, n= 734
60–65 years, n= 580
> 65 years, n= 299
1035/1613
(32.28)
432/1406
(13.47)
146/1406
(4.55)
Control Recruited: 55–69 years
55–59 years, n= 670
60–65 years, n= 626
> 65 years, n= 297
1039/1593
(32.41)
406/1593
(12.66)
148/1593
(4.62)
Lung
SEARCH67
LDCT UK, 10 centres (urban) NR 785 > 90% of screened
subjects provided
sputum in year 1
63 (mean age) (52) (56) (44)
Control 783
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Study
identifier Arm
Country and number
of centres
Number of patients
approached
Number of patients
randomised
Number of patients
screened at
baseline (n/N, %)
Characteristics of patients at baseline
Median age (years),
(range)
Male,
n/N (%)
Current
smokers,
n/N (%)
Former
smokers,
n/N (%)
Family
history of
LC n/N (%)
LUSI68 LDCT Germany, (NR, but 5
study areas)
292,440 4052 2029 50–54 years, n= 942
55–59 years, n= 518
60–64 years, n= 344
65–69 years, n= 225
1315/2029
(64.8)
1259/2029
(62.1)
770/2029
(37.9)
NR
Control 2023 50–54 years, n= 932
55–59 years, n= 528
60–64 years, n= 341
65–69 years, n= 222
1307/2023
(64.6)
1247/2023
(64.6)
775/2023
(38.3)
NR
MILD55 LDCT (annual) Italy, 1 centre 4099 1190 1190 57 814/1190
(68.4)
820/1190
(68.9)
370/1190
(31.1)
LDCT (biannual) 1186 1186 58 813/1186
(68.5)
810/1186
(68.3)
376/1186
(31.7)
Control 1723 1723 57 1090/1723
(63.3)
1546/1723
(89.7)
177/1723
(10.3)
NELSON57 LDCT The Netherlands and
Belgium, 4 centres
606,409 15,822 7915 58.0 (IQR 54.0–62.0) 6328/7582
(83.5)
4215/7582
(55.6)
3367/7582
(44.4)
Control 7907 57.0 (IQR 8.0) 6275/7453
(84.2%)
4077/7434
(54.8)
3357/7434
(45.2)
377/7396
(4.7)
UKLS55 LDCT UK, 2 centres 247,354 sent
questionnaire; 8729
eligible
2028 1994 67 (67.1± 4.1) 1529/2028
(75.4)
777/2028
(38.3)
1249/2028
(61.6)
498/2028
(24.6)
Control 2027 2027 67 (66.9± 4.1) 1507/2027
(74.3)
791/2027
(39.0)
1236/2027
(61.0)
554/2027
(27.3)
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TABLE 41 Characteristics of study populations (LDCT vs. CXR)
Study
identifier Arm
Country and
number of
centres
Number of patients
approached
Number of
patients
randomised
Number of
patients
screened at
baseline
(n/N, %)
Characteristics of patients at baseline
Median age (years),
(range) Male, n/N (%)
Current smokers,
n/N (%)
Former smokers,
n/N (%)
Family history
of lung canerr,
n/N (%)
Depiscan
62
LDCT France, 14 centres 830 765 385 56 (47–75) 274/385 (71) 238/385 (65) 129/385 (35) NR
CXR 380 56 (47–76) 267/380 (70) 224/380 (64) 127/380 (36) NR
LSS-PLCO
66
LDCT USA, 6 centres 653,417 mailed;
12,270 contacted;
4828 eligible
3318 1660 50–59 years, n= 616
60–64 years, n= 514
65–69 years, n= 337
70–74 years, n= 193
965/1660 (58.1) 961/1660 (57.9) 699/1660 (42.1) NR
CXR 1658 50–59 years, n= 624
60–64 years, n= 500
65–69 years, n= 3448
70–74 years, n= 186
965/1658 (59.0) 947/1658 (57.1) 711/1658 (42.9) NR
NLST
71
LDCT USA, 33 centres NR 53,454 26,722 < 55 years, n= 2
55–59 years, n= 11,440
60–64 years, n= 8170
65–69 years, n= 4756
70–74 years, n= 2353
> 74 years, n= 1
15,770/26,722 (59.0) 12,862/26,722 (48.1) 13,860/26,722 (51.8) 5815/26,723 (21.8)
CXR 26,722 < 55 years, n= 4
55–59 years, n= 11,420
60–64 years, n= 8198
65–69 years, n= 4762
70–74 years, n= 2345
> 74 years, n= 3
Missing, n= 1
15,762/26,732 (59.0) 12,900/26,722 (48.3) 13,832/26,732 (51.7) 5806/26,733 (21.7)
a
NR, not reported.
a Reported in Aberle et al.,
75
which includes two participants inadvertently twice randomised.
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Characteristics of recruitment and adherence
TABLE 42 Characteristics of recruitment and adherence
Study identifier Method of recruitment
Definition of high-risk individuals at
baseline Exclusion criteria Initial adherence to screening
DANTE61 Via family doctors, large-scale
mailings, media, internet, hospital
boards and leaflets. Only males
recruited
Aged 60–74 years; current or former
smokers (≥ 20 pack-years; quit
< 10 years before recruitment)
Other disease with < 5 years’ life
expectancy; < 5 years’ disease-free
laryngeal and non-melanoma skin
cancer; treatment of other cancer in the
last 10 years; unable to engage with
follow-up protocol
Did not provide consent (post
randomisation): 91/1403 vs. 166/1408
Non-adherence to baseline screening:
97% (1264/1300) vs. 96% (1186/1232)
Proportion attending all five CT scans
(of those with a baseline scan): 93%
(1184/1264)
Depiscan62 Via family and occupational doctors
(selection and enrolment);
information was provided, consent
obtained and randomisation
performed across two study
appointments. Males and females
recruited
Aged 50–75 years; current or former
smokers (≥ 15 cigarettes per day for
≥ 20 years; quit < 15 years before
recruitment)
History of other cancer; disease that
would hinder or prevent thoracic surgery
or diagnostic procedure, including
pulmonary infections; congestive heart
failure/recent myocardial infarction;
heavy exposure to asbestos; prior disease
that may look radiologically similar to
lung cancer; current symptoms
Non-adherence to baseline screening:
144 (19%) across both arms,
significantly lower in the CT arm
(55/385 vs. 89/380) and in older
participants
DLCST63 Via local and regional media (free
newspapers). Males and females
recruited
Aged 50–70 years; current or former
smokers (≥ 20 pack-years; quit at
> 50 years of age and < 10 years
before recruitment)
Other disease with < 10 years’ life
expectancy; history of treatment for lung
or breast cancer, malignant melanoma,
or hypernephroma; disease-free < 5 years
for other cancers and < 2 years for
tuberculosis; CT scan ≤ 1 year ago; body
weight > 130 kg; current symptoms; FEV2
of ≤ 30% of normal; not able to climb
36 steps without stopping
Non-adherence to baseline screening:
low in both arms, higher in the CT arm
(5/2052 vs. 0/2052). Mean participation
rates across all study time-points:
significantly higher in the CT arm
(95.5% vs. 93.0%)
continued
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TABLE 42 Characteristics of recruitment and adherence (continued )
Study identifier Method of recruitment
Definition of high-risk individuals at
baseline Exclusion criteria Initial adherence to screening
Garg et al. 200264 Via medical centre for veterans and
associated clinics. Mostly males
recruited
Aged 50–80 years; current or former
smokers (≥ 30 pack-years)
High-risk group also had airflow
obstruction diagnosed in a sputum
cytology cohort study. Moderate-risk
group were randomly selected but met
above risk criteria
Other disease with < 6 months’ life
expectancy; thoracic CT scan ≤ 3 years
ago; pregnancy; not able to provide
consent or engage with follow-up
protocol
Moderate-risk group only: symptomatic
COPD; airflow obstruction;
non-compliance with inhalers
Adherence not reported
ITALUNG65 Via letter from family doctors.
Males and females recruited
Aged 55–69 years; current or former
smokers (≥ 20 pack-years; quit
< 10 years before recruitment)
History of other cancer (except
non-melanoma skin cancer); unable to
engage with follow-up protocol involving
thoracic surgery
Adherence to baseline screening: 87%
(1406/1613). Proportion attending
four CT scans: 79%
LSS-PLCO66 Via large-scale mailings, clinician
recommendations, media adverts
and posters. Males and females
recruited
Aged 50–74 years; current or former
smokers (≥ 30 pack-years; quit
< 10 years before recruitment)
History of lung cancer; current treatment
for other cancer (except non-melanoma
skin cancer); thoracic or lung CT scan
≤ 2 years ago; previous lung resection;
participation in other cancer trials
(except smoking cessation)
Adherence to baseline screening:
higher in CT arm, 96% (1586/1660)
vs. 93% (1550/1658)
Proportion attending at 1 year:
higher in CT arm, 85.8% vs. 79.9%;
adherence significantly lower in those
with positive screens at baseline
LungSEARCH67 Via family doctors and hospital
clinics. Males and females recruited
Current or former smokers
(≥ 20 pack-years; smoked ≥ 20 years;
quit < 8 years before recruitment); COPD
No history of cancer Adherence to baseline screening not
reported
LUSI68 Via large-scale mailings to
participants identified through
population registers in the local
area. Males and females recruited
Aged 50–69 years; current or former
smokers (≥ 15 cigarettes per day for
≥ 25 years or ≥ 10 cigarettes per day
for ≥ 30 years; quit < 10 years before
recruitment)
Other disease with < 10 years’ life
expectancy; cancer diagnosis ≤ 5 years
ago, unable to engage with surgical
treatment
Adherence to baseline screening: high
(99.9%) in both arms 2028/2029 vs.
2022/2023, and similar in both arms
across five screening rounds
MILD69 Via media (newspaper, television)
adverts. Males and females
recruited
Aged ≥ 49 years; current or former
smokers (≥ 20 pack-years; quit
< 10 years before recruitment)
History of cancer ≤ 5 years ago Proportion attending at ≥ 1 CT scan:
97% in both screening groups
(1149/1186 biennial; 1152/1190 annual)
Proportion of participants adhering over
the study: 96.1% annual 95.1%
biennial
A
PPEN
D
IX
4
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
206
Study identifier Method of recruitment
Definition of high-risk individuals at
baseline Exclusion criteria Initial adherence to screening
NELSON56,57 Via population registries across two
countries (the Netherlands and
Belgium). Males only to start with,
recruitment later expanded to
females
Aged 50–75 years; current or former
smokers (≥ 15 cigarettes per day for
≥ 25 years or ≥ 10 cigarettes per day
for ≥ 30 years; quit < 10 years before
recruitment)
Lung cancer diagnosis < 5 years ago or
≥ 5 years ago with current treatment;
history of melanoma, hypernephroma,
renal or breast cancer; history of
other cancers (unless curatively treated
> 5 years ago without recurrence);
pneumonectomy; thoracic CT scan
< 1 year ago; body weight ≥ 140 kg;
moderate/bad health (self-report) and
not able to climb two flights of stairs
Adherence to first screening round:
95.5% (7557/7915)
Proportion attending at ≥ 1 CT scan:
95.8% (7582/7915)
NLST70,71 Via targeted mailings, media
adverts (local radio and
newspapers, television, websites,
internet adverts), health fairs,
unions, local branches of the
American Cancer Society, and
community groups. Recruitment
included strategies to improve
access to the study for minority
groups. Males and females
recruited
Aged 55–74 years; current or former
smokers (≥ 30 pack-years; quit
< 15 years before recruitment)
History of lung cancer; haemoptysis;
thoracic CT scan < 18 months ago;
unexplained weight loss (> 6.8 kg
in last year)
Adherence to first screening round:
high across both arms 98% (52,344/
53,439), 98.5% (26,309/26,715) in the
CT arm vs. 97.4% (26,035/26,724) in
the control arm
UKLS55 Via letter, sent by a data
management company on behalf
of the recipient’s PCT. Letter
recipients of the correct age, living
in six PCTs around Liverpool and
Cambridgeshire, were randomly
selected using NHS PCT records.
Males and females recruited
Aged 50–75 years; using the LLPv2 risk
prediction model, ≥ 5% 5-year risk of
lung cancer
Other disease that would prevent
screening or lung cancer treatment;
thoracic CT scan < 1 year ago; not able
to lie flat; not able to provide consent
Adherence to baseline screening:
98.3% (1994/2028)
PCT, primary care trust.
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Characteristics of screening programmes
TABLE 43 Characteristics of screening programmes
Study
identifier
(country)
Screening programme
comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
DANTE (Italy)61 LDCT
(and baseline CXR and
sputum cytology testing)
vs.
No screening
(and baseline CXR and sputum
cytology testing)
LDCT
Positive if one or more of the
following was evident: ≥ 10-mm
diameter non-calcified nodule,
non-calcified nodule with speculated
margins, hilar mass, focal ground
glass opacities, major atelectasis,
endobronchial lesions, mediastinal
adenopathy, pleural effusion or mass
Baseline CXR
Positive if one or more of the
following evident: non-calcified
shadow, hilar mass, enlarged
mediastinum, pleural effusion/
thickening or lytic bone lesion
LDCT
Whole lungs scanned at full
inspiration (following single breath hold)
Independent double-reading of images
by experienced chest radiologists.
Decision based on consensus (local
co-ordinator arbitrated disagreements)
Baseline CXR
Read by radiologists who were blind
to the CT scan results
LDCT
Flexible follow-up protocol (guidance only)
Step 1 (2–4 weeks): course of oral antibiotics
followed by high-resolution CT scan
Step 2 (dependent on results of step 1):
l Benign calcifications (or regression) – LDCT at
1 year
l Smooth lesion of < 10mm – LDCT at 3, 6 and
12 months; if stable, LDCT at 1 year
l Non-smooth lesion of ≥ 6mm but < 10mm –
re-do step 1; if no regression make clinical
decision regarding the next step
l Lesions of ≥ 10mm but ≤ 20mm – re-do step 1;
if no regression PET scan. Positive PET scan
followed with tissue diagnosis, negative PET
scan followed closely
l Lesions of ≥ 20mm: re-do step 1 or standard
contrast-enhanced CT. PET scan. Positive PET
scan followed with tissue diagnosis, negative
PET scan followed closely
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Study
identifier
(country)
Screening programme
comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
Depiscan
(France)62
LDCT
vs.
CXR
LDCT
Positive (requiring follow-up) if
non-calcified nodules evident
CXR
Positive (requiring follow-up) if
non-calcified nodules evident
LDCT
Whole lungs scanned at full
inspiration (following single breath-hold)
Independent double-reading of images
by radiologists. Decision based on
consensus
CXR
Not reported
LDCT
Follow-up protocol (recommended)
l Nodule of ≤ 5 mm – LDCT at 1 year
l Nodule of > 5 mm but < 10mm – LDCT
at 3 months; if stable, LDCT at 6, 12 and
24 months. If enlargement noted then
histological diagnosis
l Nodule of ≥ 10mm – CT with injection, PET
scan, and/or histological diagnosis. Results
discussed by team of study personnel that
included a pulmonary oncologist, radiologist
and thoracic surgeon
CXR
Follow-up protocol
l Suspected non-calcified nodule – LDCT scan,
following the same recommended protocol as
in the LDCT arm
DLCST
(Denmark)63
LDCT
(and PFT and < 5-minute
cessation counselling)
vs.
No screening
(and PFT and < 5 minute
cessation counselling)
LDCT
Positive if one or more of the
following was evident: ≥ 5 mm
diameter (note that nodules ≥ 5mm
but ≤ 15mm indeterminate); nodules
increasing in volume by 25%; nodules
with suspicious morphology
LDCT
Whole ribcage and upper abdomen at
full inspiration
Read by two experienced chest
radiologists. Decision based on
consensus
LDCT
Follow-up protocol implemented after referral
(decided by pulmonologist and radiologist)
l Indeterminate LDCT screen – LDCT at 3 months,
often followed up with PET-CT
l Positive LDCT screen – CT with contrast,
followed by individual plan, which could involve
more invasive procedures; VATS used in
most cases
continued
D
O
I:10.3310/hta22690
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.69
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Snow
sillet
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
209
TABLE 43 Characteristics of screening programmes (continued )
Study
identifier
(country)
Screening programme
comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
Garg et al.
(USA)64
LDCT
vs.
No screening
LDCT
Positive (requiring follow-up) if
between one and six non-calcified
nodules evident
LDCT
30-cm scan of lungs and diaphragm
inspiration at inspiration (during two
breath-holds performed after
hyperventilation)
Read by one experienced chest
radiologist; some systematically
selected scans also read by a second
experienced chest radiologist
LDCT
Follow-up protocol
l Positive LDCT screen – thin-section CT for
diagnostic purposes
ITALUNG (Italy)65 LDCT
(and invitation to smoking
prevention programme)
vs.
No screening
(and invitation to smoking
prevention programme)
LDCT
Positive if one or more of the
following was evident: ≥ 5-mm
diameter non-calcified nodule,
≥ 10-mm non-solid nodule, part-solid
nodule, nodules increasing by ≥ 1-mm
mean diameter, increase in solid part
of a nodule from one scan to the
next, several nodules indicative of
inflammatory disease
LDCT
Independent double-reading of
images by experienced radiologists.
Decision based on consensus
LDCT
Follow-up protocol at each centre for positive LDCT
scans
l No nodule growth (or regression) – LDCT at
1 year
l Solid nodules of ≥ 8mm and ≤ 10mm –
FDG-PET, followed by FNAB if positive or LDCT
at 3 months if negative. If FNAB not positive
then LDCT at 3 months
l Non-calcified nodules of ≥ 5mm and ≤ 7mm
(solid or part solid) – LDCT at 3 months
l Growing nodules (peripheral) – FDG-PET or
CT-guided FNAB
l Growing nodules (deep) – FDG-PET or FBS
l Airway abnormalities – sometimes followed up
using FBS
l Nodules indicative of inflammatory disease –
antibiotics followed by LDCT at 1 month
l Partial resolution – LDCT at 2 months
If FNAB indicated lung cancer, a staging CT scan
was performed
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Study
identifier
(country)
Screening programme
comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
LSS-PLCO
(USA)66
LDCT
vs.
CXR
LDCT
Positive at T0 if one or more of the
following was evident: ≥ 4 mm
diameter non-calcified nodule, any
other abnormality considered
suspicious by radiologist
After T0 the criteria changed so that
results were considered positive if one
or more of the following was evident:
≥ 4 mm diameter non-calcified
nodule, ≤ 3 mm diameter spiculated
nodule, focal parenchymal opacities,
endobronchial lesions, other
abnormality considered suspicious by
radiologist
CXR
Positive if one or more of the
following was evident (list not
exhaustive): any nodule or mass,
infiltrate/consolidation, alveolar
opacity, enlargement of hilar or
mediastinal lymph nodes (not
calcified), lung/lobe collapse or closure
LDCT
Read by one radiologist; some scans
also independently read by a second
radiologist
CXR
Single, posteroanterior view CXR
LDCT
Follow-up (referral) for positive screening results
were conducted on request of patients, according
to clinic recommendations (i.e. no specific follow-up
protocol and details at each centre not reported).
Data on diagnoses were collected
CXR
As with LDCT
LungSEARCH
(UK)67
LDCT
(and sputum surveillance and
AFB)
vs.
No screening
(and exit CXR at 5 years)
LDCT
Positive if ≥ 9-mm abnormal nodule
LDCT
Not reported
LDCT
Follow-up of positive LDCT (or AFB) decided by
clinicians, but includes an enhanced screening
protocol (with more frequent AFB) for pre-invasive
lesions
continued
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TABLE 43 Characteristics of screening programmes (continued )
Study
identifier
(country)
Screening programme
comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
LUSI (Germany)68 LDCT
(and cessation counselling)
vs.
No screening
(and cessation counselling)
LDCT
Positive if one or more of the
following was evident: new nodules
≥ 5mm, nodules with VDT ≤ 600 days
LDCT
Read by radiologists, with special
training for the study
LDCT
Follow-up protocol for positive LDCT results
l Nodules of ≥ 5mm and ≤ 7mm – LDCT at
6 months
l Nodules of ≥ 8mm and ≤ 10mm – LDCT at
3 months
l VDT of ≥ 400 days and ≤ 600 days – LDCT at
3–6 months, depending on nodule size
l Nodules of > 10 mm diameter – antibiotics
followed by CT, PET or immediate biopsy, as
decided by pulmonologist
l VDT of ≤ 400 days – antibiotics followed by CT,
PET or immediate biopsy, as decided by
pulmonologist
MILD (Italy)69 LDCT – annual
(and cessation programme,
pulmonary function test and
blood sample)
vs.
LDCT – biennial
(and cessation programme,
pulmonary function test and
blood sample)
vs.
No screening
(and cessation programme,
pulmonary function test and
blood sample)
LDCT
Positive if one or more of the
following was evident: nodules
of ≥ 60mm3, i.e. approximately
5 mm diameter (note that nodules
of ≥ 60mm3 but ≤ 250mm3
indeterminate), hilar/mediastinal
lymphadenomegaly (non-calcified),
atelectasis, consolidation, other
indicative pleural findings, nodules
increasing in volume by 25% in
3 months
LDCT
Whole lungs scanned at deep
inspiration (following single breath
hold, no use of contrast)
Independent double-reading of
images by trained radiologists (third
radiologist arbitrated disagreements)
LDCT
Follow-up protocol for positive LDCT results
l Volume of ≥ 60mm3 but ≤ 250mm3
(indeterminate) – LDCT at 3 months
l All positive results (not indeterminate) –
follow-up could include PET-CT,
contrast-enhanced CT or biopsy
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Study
identifier
(country)
Screening programme
comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
NELSON (the
Netherlands
and Belgium)56,57
LDCT
vs.
No screening
LDCT
Positive if one or more of the
following was evident: solid nodules
(or solid component) of ≤ 50 mm3, i.e.
4.6 mm diameter (note that nodules
of ≥ 50 but ≤ 500mm3 indeterminate),
non-solid nodule of > 8 mm diameter,
VDT of ≤ 600 days (≥ 400 days but
≤ 600 days indeterminate)
LDCT
Scan from posterior recess to apex of
the lung, no use of contrast
Independent double-reading of
images by experienced radiologists,
except the last two rounds (read by
a single, experienced radiologist)
LDCT
Follow-up protocol for positive LDCT results
l Indeterminate results – LDCT at 3–4 months
l Positive results – follow-up and diagnosis by
pulmonologist, standardised protocol used,
which could involve physical examination,
contrast-enhanced CT, FDG-PET, bronchoscopy
NLST (USA)70,71 LDCT
vs.
CXR
LDCT
Positive if one or more of the
following was evident: non-calcified
nodule ≥ 4 mm diameter, other
abnormalities could be classified as
positive or suspicious
CXR
Positive if any non-calcified nodule or
mass was evident
LDCT
Read by experienced radiologists,
images also compared with previous
LDCT screens
CXR
Single-view posteroanterior X-rays,
read by experienced radiologists
LDCT
Follow-up protocol for positive LDCT results
(guidelines only, details not reported), radiologists
could use discretion and make recommendations for
diagnostic follow-up
continued
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TABLE 43 Characteristics of screening programmes (continued )
Study
identifier
(country)
Screening programme
comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
UKLS (UK)55 LDCT
vs.
No screening
LDCT
Probably benign (‘negative’ with
regard test accuracy; but requiring
follow-up) if one or more of the
following was evident: solid nodule of
15–49mm3, solid or non-solid nodule
of 3–4.9 mm diameter, part-solid
nodule with solid component
< 15mm3 or < 3 mm diameter
Positive (potentially malignant) if one
or more of the following was evident:
solid intraparenchymal nodule of
50–500mm3, solid pleural/juxtapleural
nodule of 5–9.9-mm diameter,
non-solid or part-solid nodule with
ground glass component of > 5 mm
Positive (more likely malignant) if one
or more of the following was evident:
solid intraparenchymal nodule or
ground glass component of non-solid
or part-solid nodule of > 500mm3,
solid pleural/juxtapleural nodule or
ground glass component of non-solid
or part-solid nodule of ≥ 10mm,
growth on follow-up CT
LDCT
Scan from lung apices to bases,
suspended inspiration (following
single breath hold), no use of contrast
Double-reading of images by
experienced chest radiologists.
Decision based on consensus (third
radiologist arbitrated disagreements)
LDCT
Follow-up protocol for LDCT results
l Probably benign – LDCT at 12 months
l Potentially malignant – LDCT at 3 months
and 12 months
l More likely malignant – MDT assessment
AFB, autofluorescence bronchoscopy; FBS, optical fibrobrochoscopy; FNAB, fine-needle aspiration biopsy; PFT, pulmonary function test; VATS, video-assisted thoracic surgery;
VDT, volume doubling time.
Bold font highlights the characteristics of the different screening arms.
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Lung cancer mortality and all-cause mortality data
TABLE 44 Mortality (lung cancer specific and all cause)
Study identifier
Comparator
Mortality
Lung cancer All-cause
Usual care
Number of
events in the
LDCT group
Total number
of participants
in the LDCT
group
Number of
events in the
control group
Total number
of participants
in the control
group
Number of
events in the
LDCT group
Total number
of participants
in the LDCT
group
Number of
events in
the control
group
Total number
of participants
in the control
group
DANTE78 Usual care 59 1264 55 1186 180 1264 176 1186
DLCST79 Usual care 39 2052 38 2052 165 2052 163 2052
MILD (annual)69 Usual care 12 1190 7 1723 31 1190 20 1723
MILD (biannual)69 Usual care 6 1186 20 1186
NLST70 CXR 356 26,722 443 26732 1877 26,722 2000 26,732
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APPENDIX 4
216Evidence from single study arms: health-related quality of life and
psychological consequences
NEderlands Leuvens Longkanker Screenings ONderzoer
The NELSON trial84 evaluated longitudinal trends comparing indeterminate with negative screening results.
These participants received four questionnaires at four time points: before randomisation (T0), 1 week
before the baseline screening (T1), 1 day after the screening (T2) and 2 months after the screening results
but before the 3-month follow-up CT (T3). At the time point of T3, there was a clinically relevant increase
in the measure of lung-cancer-specific distress (the IES scores) but with a significant decrease in this
measure among participants with a negative result. The results from this trial showed that trial participants
receiving an indeterminate result experienced increased level of lung-cancer-specific distress compared with
those who receiving a negative baseline screening result. However, these results were less robust as they
were not based on randomised evidence.
Another NELSON trial85 reported that there was a temporary increase in lung-cancer-specific distress
(the IES scores) after receiving an indeterminate baseline result at time point of T1 (mean score 7.8, 95% CI
6.5 to 9.0) compared with time point of T0 (mean score 4.0, 95% CI 2.8 to 5.3).85 It should be noted
that unfavourable short-term effects due to an indeterminate baseline screening result had resolved over
long-term follow-up. The findings from this NELSON trial85 also showed that there was no significant impact
of an indeterminate result at the second screening round on patients’ QoL measure at long-term follow-up.
The NELSON trials84,85 reported that generic anxiety scores (STAI-6) (mean score of 34.1 at baseline), which
was measured in a subsample of 324 participants, were comparable to the Dutch general population.
The results showed that STAI-6 scores were found to differ significantly over time between different rounds
(p < 0.01). The mean score of STAI-6 was 34.1 measured at one day before screening, 32.7 measured 1 week
after screening and 34.3 measured 6 months after screening. Furthermore, the NELSON trial also showed that
waiting for the CT scan results was reported to be discomforting by approximately half of the participants.84
Among a total of 351 participants who had an appointment for a baseline CT scan and were asked to
complete questionnaires regarding their experienced discomfort, approximately half reported discomfort in
connection with having to wait for the results of the CT scan and expressed feeling of anxiety at waiting for
those results. Therefore, minimising waiting time for the screening test results is recommended.
National Lung Screening Trial
The NLST74 assessed the impact of lung cancer screening results (abnormal findings) on patients’ HRQoL
among a total of 2812 participants. These participants were asked to complete the SF-36 to assess the
effect of screening with LDCT or CXR in the short (1 month) and long term (6 months). False positives
were defined as those who were lung cancer free at 1 year, whereas those with true-positive results
were not. Of the total participants, there were 1024 (36.4%) participants receiving false-positive results,
63 (2.2%) receiving true-positive results, and 1381 (49.1%) receiving negative results.
The results from NLST74 showed that HRQoL measures at short- and long-term follow-up did not differ
significantly between participants with false-positive and negative screens; participants receiving a
false-positive screen result did not experience significant difference in HRQoL measures at the 1-month
follow-up or at the 6-month follow-up compared with those receiving a negative result.
However, NLST74 showed that there were lower scores in HRQoL for participants receiving
true-positive results at both short-term (1 month) and long-term (6 months) follow-up, compared with
those participants receiving false-positive results and negative screening results. At 1 month post CT scan,
the mean SF-36 physical component measure was 44.50 for those with true positive results, 47.7 for
those with false-positive results and 47.6 for those with negative results. At 6 months post CT scan, the
mean SF-36 physical component measure was 38.3 for those with true-positive results, 47.1 for those with
false-positive results and 47.9 for those with negative results.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69A similar pattern was also observed in SF-36 mental component score in the NLST.74 At 1 month post
CT scan, the mean SF-36 mental component measure was 44.1 for those with true-positive results 50.6 for
those with false-positive results and 51.3 for those with negative results. At 6 months post CT scan, the
mean SF-36 mental component measure was 46.3 for those with true-positive results, 50.4 for those with
false-positive results and 51.4 for those with negative results.
UK Lung Cancer Screening Trial
The UKLS55 found statistically significant differences in T1 lung cancer distress among groups with different
test results. Participants who were positive for MDT referral (major lung abnormality) were significantly
more distressed than each of the other result groups [negative mean difference 0.36 (p < 0.001), positive
for repeat scan mean difference 0.24 (p < 0.001)]. Lung cancer distress scores for the MDT group approached
the thresholds of clinical significance. Participants who were positive for a repeat scan reported significantly
greater T1 cancer distress than those receiving a normal (negative) result (mean difference 0.12; p < 0.001)
in the UKLS.55
In terms of T1 general anxiety, participants who were referred to MDT reported significantly greater
anxiety than those receiving any other result [negative mean difference 0.36 (p < 0.001), positive for
repeat scan mean difference 0.31 (p = 0.003)]. It should be noted that their scores were within the
low/normal range. There were no statistically significant differences in depression scores between any of
the screening result groups.
Summary of the evidence from single study arms
The evidence from single study arms showed that among participants randomised to LDCT, HRQoL or
psychological consequences for participants receiving different test results may differ at both short- and
long-term follow-up.
It is tempting to extrapolate these findings to suggest that HRQoL and psychological consequences might be
greater in LDCT. However, this is inconsistent with direct evidence from the randomised comparisons that,
as reported in the earlier section, show no difference between LDCT and no screening/CXR screening. The
evidence from these randomised comparisons is less open to bias and includes all patients (as opposed to
screening arm results subgroups, some of which were very small). So our conclusion remains that there are
no differences between LDCT and no screening/CXR screening and were not modified by the evidence from
the screening arms of the trials analysed in isolation.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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Characteristics of study populations
TABLE 45 Characteristics of study populations (CXR vs. usual care)
Study identifier Arm
Country;
number of
centres
Number of
patients
approached
Number of
patients
randomised
Number of
patients
screened at
baseline
Characteristics of patients at baseline
Age (years)
Male, n/N
(%)
Current
smokers,
n/N (%)
Former
smokers,
n/N (%)
Family
history of
LC, n/N (%)
Czech105 CXR Czech Republic;
six districts
6364 6346 3172 40–44: n= 487
45–49: n= 716
50–54: n= 923
55–59: n= 582
60–64: n= 464
3172/3172
(100)
3172/3172
(100)
NR NR
Control 3174 40–44: n= 499
45–49: n= 710
50–54: n= 926
55–59: n= 584
60–64: n= 455
3174/3174
(100)
3174/3174
(100)
NR NR
Mayo106 CXR USA; NR NR 10,933 screened;
9211 randomised
4618 < 50: n= 1159
50 to < 55: n= 1102
55 to < 60: n= 1042
60 to < 65: n= 811
65 to < 70: n= 483
≥ 70: n= 21
4618/4618
(100)
NR/NR (90) NR/NR (10) NR
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Study identifier Arm
Country;
number of
centres
Number of
patients
approached
Number of
patients
randomised
Number of
patients
screened at
baseline
Characteristics of patients at baseline
Age (years)
Male, n/N
(%)
Current
smokers,
n/N (%)
Former
smokers,
n/N (%)
Family
history of
LC, n/N (%)
Control 4593 < 50: n= 1154
50 to < 55: n= 1135
55 to < 60: n= 1019
60 to < 65: n= 784
65 to < 70: n= 469
≥ 70: n= 32
4593/4593
(100)
NR
PLCO (for
sensitivity analysis
only)107
CXR USA; 10 centres 154,901 77,445 15,183 NR 9252/15,183
(60.9)
6146 (40.5) NR NR
Control 77,456 15,138 NR 9110/15,138
(60.2)
6069/15,138
(40.1)a
NR NR
LC, lung cancer; NR, not reported.
a Calculated from raw data, differs from PLCO107 for which % is reported as 40.3%.
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Characteristics of recruitment and adherence
TABLE 46 Characteristics of recruitment and adherence: CXRs
Study
identifier Method of recruitment
Definition of high-risk individuals
at baseline Exclusion criteria Initial adherence to screening
Czech105 Via general health examination of
middle-aged males only
Aged 40–64 years; current smokers
(approximate lifetime consumption
> 150,000 cigarettes)
History of pulmonary disease. Likely
inability to participate over 3 years due
to serious disease or other reasons
Adherence to screening over 3 years
in screening arm 92.5% vs. control
arm 94.7%
Mayo106 Via ‘smoking survey’ completed by
outpatients at a general medical
examinations by the Mayo Clinic
If questionnaire categorised as ‘high-risk’
males only were referred to the study
Aged > 45 years; current or former
smokers (at least one pack per day at
time of recruitment or within previous
year)
History of known or suspected cancer
of the respiratory tract (except
roentgenographically occult cancer);
< 5 years’ life expectancy; unable to
tolerate pulmonary resection; failure to
complete general medical examination;
insufficient mental capacity for study
cooperation
Adherence to testing schedule over
6 years of screening averaged 75%
PLCO (for
sensitivity
analysis only)107
Via mass mailing of general population.
A subset of entire PLCO population in
line with population characteristics of
NLST were used for this analysis. Males
and females recruited
Aged 55–74 years; current or former
smokers (≥ 30 pack-years; quit
< 15 years before recruitment)
History of prostate, lung, colorectal or
ovarian cancer, or current cancer
treatment or removal of one lung
Adherence to baseline screening,
screening arm 85.9% (13,035/15,183)
Overall adherence to expected
screens, screening arm 81.4%
(48,330/15,183)
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TABLE 47 Characteristics of screening programmes: CXRs
Study identifier
(country) Screening programme comparison
Definition of a positive scan for
lung cancer
Imaging evaluation and
interpretation strategy
Diagnostic follow-up for suspicious
abnormality finding
Kubík et al.
(Czech Republic)105
CXR
(at baseline, 6-monthly during years
1–3, and then at years 3, 4 and 5 and
6, screening also included sputum
cytology testing)
vs.
No screening
(+ CXR at baseline, years 3, 4, 5 and
6, included sputum cytology testing at
same times as CXR)
CXR
Positive if abnormality identified
(reader decision whether or not
further investigation was required)
Other
Also sent for further investigation if
one or more of the following was
evident: patient approached with
symptoms, cancer or atypical cells
from sputum testing, bloody sputum
CXR
Chest photofluorogram,
posteroanterior view
Double-reading by chest physician and
chest radiologist. Decision based on
consensus (third experienced physician
arbitrated disagreements)
CXR
Follow-up protocol
Positive CXR – referral to specialist
diagnostic hospital ward (if sputum
signs – recommendation for inpatient
stay), fibre-optic animation, additional
CXR, (including whole-lung CXR),
otorhinolaryngological examination
(for exclusion purposes)
Mayo (USA)106 CXR
(4-monthly, screening also included
sputum cytology testing, medical
history review)
vs.
Usual care
(annual CXR and sputum cytology
testing)
CXR
Not clear
CXR
Stereo chest roentgenograms,
standard size
Double-reading by chest physician
and radiologist. Decision based on
consensus (another chest physician
arbitrated disagreements)
CXR
Follow-up protocol
Positive CXR, suggesting lung cancer –
review of clinical data
Positive CXR, new or growing
abnormality – work-up could include
additional CXR and sputum testing,
bronchoscopy (with or without
fluoroscopic guidance)
PLCO (USA)107 CXR
(at baseline, annually up to 4 years)
vs.
No screening
CXR
Positive if the readers felt that one
of the following was evident and
suspicious: any nodule, mass, infiltrate
or other abnormality
CXR
Posteroanterior CXR
CXR
No study follow-up protocol, positive
CXR follow-up was decided by patients
and their health-care providers
Characteristics of screening programmes
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clinical effectiveness
Usman Ali et al.206 found that LDCT was more effective for reducing mortality (both lung-cancer-specificand all-cause mortality) than CXR (with or without smoking cessation) in one large RCT (NLST),
whereas three smaller RCTs showed no benefit of screening in reducing mortality. However, LDCT
screening was also found to be associated with important harms including overdiagnosis, false positives
and consequences of false-positive screening results. Invasive follow-up procedures performed as a result
of positive screening tests were associated with deaths and patients experiencing major complications.
This reviews’ overall findings are similar to other systematic reviews evaluating the benefits of lung cancer
screening (see Manser et al.52 and Humphrey et al.207).
Bach208 considered evidence from 21 studies (8 RCTs and 13 cohort trials) comparing LDCT with no
screening/usual care and CXR for individuals at an elevated risk of developing lung cancer because of age
and smoking history. One large RCT (NLST) showed a significant reduction in mortality using LDCT
compared with CXR over 6.5 years of follow-up, with no benefit on mortality observed in two smaller
RCTs comparing LDCT with usual care (DANTE61 and DLST). The authors208 concluded that LDCT screening
can lead to harm. They report that screening identified a relatively high percentage of individuals with
nodules (average of ≈20%), the vast majority of which are benign. The authors highlight the radiation
exposure associated with additional imaging of these nodules. They also highlight the variability in the
rates of surgical biopsy as well as surgical procedures performed for benign disease, although they also
state that complications in those with benign lesions were rare.
Black et al.54 performed a systematic review to assess effectiveness of CT screening for lung cancer in a mass
population screening programme. The review’s narrative synthesis consisted of 12 studies of lung cancer CT
screening, two of which were RCTs. Both RCTs were pilot studies and had too short a follow-up period
(1 year) to assess lung cancer mortality and total mortality. None of the 12 studies reported disease-specific
or total mortality compared with no screening and only one study provided survival data, leading the authors
to conclude they were unable to assess whether or not CT screening for lung cancer is clinically effective in
reducing mortality. Observational studies provided data on the screening process, the natural history of the
detected nodules and survival. The authors concluded that their review found evidence that CT detects a
greater number of non-calcified nodules and other suspicious chest abnormalities than screening with CXR,
and that smaller non-calcified nodules are detected by CT than by CXR. Among the detected tumours, a high
proportion were stage I (both baseline and incidence) or resectable. CT screening was associated with high
false-positive rates. Reporting of adverse events, psychological effects of receiving false-positive test results
or effects on QoL were universally poor across studies. The authors reported that receiving positive CT
examinations were associated with a higher motivation to quit smoking.
It is likely that this systematic review by Black et al.209 is linked to the systematic review by Black et al.54
As above, this review reported that none of the 12 studies reported disease-specific or total mortality
compared with no screening and the two pilot RCTs were of too short duration (1 year) to draw firm
conclusions about the clinical effectiveness of CT screening for lung cancer in terms of a reduction in
mortality. The authors reported that the proportion of people with abnormal CT findings varied between
studies, as did the prevalence of lung cancer detected. The authors reported that incidence of lung cancer
was lower with screening and that among the detected tumours, a high proportion were stage I or
resectable tumours.
Chang et al.210 performed a systematic review of seven studies (including two RCTs with short follow-up
periods) to summarise findings on the early detection of lung cancer and the diagnostic accuracy of
FDG-PET in high-risk individuals. The authors reported limited information regarding whole-body scanning© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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APPENDIX 6
226using PET for lung cancer screening. The authors reported high sensitivity for the detection of T1 lung
cancers, with detection being lower for carcinoid tumours, adenocarcinoma and bronchoalveolar cell
carcinomas and concluded that a combination of FDG-PET and LDCT may improve screening for lung
cancer in high-risk patients. The authors acknowledged and highlighted limitations in data pertaining
to survival benefits from PET screening in high-risk individuals.
Chien et al.211 provided a summary of evidence regarding the role of PET specifically for lung cancer
screening. Identified papers were placed in two categories: studies that reported findings in lung cancer CT
screening programmes with selective PET, and studies focusing on primary PET screening for cancer. The
systematic review found high diagnostic performance (sensitivity and specificity) of selective PET screening,
while the detection rate of lung cancer using primary PET was low (0.18%). The authors concluded that
selective PET could be used as a selective screening modality (i.e. for diagnosing lung cancer in patients
with a pulmonary nodule found using CT screening). None of included studies evaluated the efficacy of
primary PET screening specific to lung cancer.
Coureau et al.212 summarised evidence from 10 RCTs (completed and ongoing) on the impact of lung
cancer screening by LDCT in populations highly exposed to tobacco. The review aimed to evaluate
effectiveness and the disadvantages and risks associated with screening. Two of the 10 identified trials
were pilot studies, one had recently started, five were ongoing and two had published main results. The
authors noted the inconsistency in choice of control arm across trials and methods employed (e.g. trial
participants, the definition of a positive screen and indeterminate nodules, number of screening rounds
and follow-up durations differed between trials). Of the five trials that published results on mortality,
only one (NLST) reported a significant 16% decrease in disease-specific mortality (with 6.5 years of median
follow-up) and a 7% decrease in all-cause mortality with LDCT screening when compared with CXR
screening. DANTE61 provided non-significant results in favour of LDCT screening. Two trials observed a
higher mortality rate for subjects undergoing LDCT screening (significant for MILD69 and non-significant for
DLCST63). The authors reported that harms of screening (e.g. secondary effects of false-positive results in
the short term, psychological distress and the effect of repeated irradiation in the long term) were rarely
reported, were inconsistent and that overdiagnosis was rarely addressed and used non-standardised
calculation methods. The authors concluded that despite the positive effect on mortality found in NLST,
no study identified in the review provides all elements necessary to document the risk–benefit balance.
Fu et al.213 presented a systematic review and meta-analysis of nine RCTs comparing LDCT and CXR or
usual care (no screening) in individuals at high risk of lung cancer (aged > 49 years and who had been
exposed to smoking). The results from the review show LDCT screening is associated with detection of a
significantly higher number of stage I lung cancers (OR 2.15, 95% CI 1.88 to 2.47) and a higher number
of total lung cancers (OR 1.31, 95% CI 1.20 to 1.43) than the control. These results are generally similar to
the meta-analysis of Gopal et al.,214 which showed that LDCT is more sensitive in discovering more stage I
lung cancers and all cancers than CXR or no screening. The review findings, similar to Humphrey et al.,207
also showed that LDCT screening could reduce lung-cancer specific mortality (OR 0.84, 95% CI 0.74 to 0.96)
but not all-cause mortality (OR 0.96, 95% CI 0.90 to 1.02) compared with control. The meta-analysis by
Fu et al.213 indicated that screening with LDCT is associated with higher false-positive rates than the control.
Gopal et al.214 presented findings from a meta-analysis for six RCTs of LDCT screening for lung cancer
in a high-risk population. The authors reported a significantly higher number of stage I lung cancers, a
higher number of total NSCLCs and higher total lung cancers. They also report that screening resulted in
increased detection of false-positive nodules and an increased number of unnecessary thoracotomies for
benign lesions. The authors concluded that their analysis offers no compelling evidence in favour of LDCT
screening for lung cancer.
Humphrey et al.207 performed a systematic review of RCTs and cohort studies in high-risk current/former
smokers. The authors restricted their analysis of effectiveness of LDCT screening to for RCTs. The authors
reported that one good-quality large RCT (NLST) was associated with significant reductions in lung cancerNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69(20%) and all-cause (6.7%) mortality. The authors reported that three small European trials (DANTE,61
DLCST63 and MILD69) showed no benefit of screening in reducing mortality. The authors reported harms
including radiation exposure, overdiagnosis and a high rate of false-positive findings that typically were
resolved with further imaging. They also reported that smoking behaviour was not affected and that
incidental findings were common.
Manser et al.52 identified nine trials investigating LDCT screening, CXR screening or sputum testing to
detect lung cancer. The authors reported that the evidence included in their review suggested that
screening with annual plain chest radiography screening in smokers and ex-smokers is not effective at
reducing lung cancer mortality. The authors identified a large trial (NLST) that showed LDCT screening
reduced lung cancer mortality in high-risk current/former smokers when compared with usual care. They
conclude that annual LDCT screening is associated with a reduction in lung cancer mortality in high-risk
smokers. The authors also concluded that there is no evidence to support early screening for lung cancer
with chest radiography or sputum cytology.
Piñeiro et al.215 report findings of a narrative synthesis of three RCTs and three observational single-arm
studies evaluating smoking cessation interventions for patients undergoing LDCT screening. The authors
included two RCTs evaluating self-help smoking cessation interventions, and one pilot RCT evaluating
the timing (before/after the LDCT scan) of a combined (counselling and pharmacotherapy) smoking
cessation intervention. The authors reported that efficacy results across all studies were modest at best
and that findings based on non-randomised and pilot studies in the review demonstrate that combined
(counselling + pharmacotherapy) smoking cessation interventions can be successfully implemented in
screening settings and that they may promote smoking cessation. The authors concluded that the review
findings suggested that participation in LDCT screening promotes smoking cessation and may represent a
teachable moment to quit smoking.
Seigneurin et al.216 aimed to identify the LDCT technique associated with low recall rates, a low number of
invasive procedures and high positive predictive values without substantially decreasing detection rate.
They conducted a systematic review and meta-regression analysis of 10 RCTs and six observational studies
to determine whether or not some characteristics of LDCT lung cancer screening programmes such as the
number of readers, the use of a cut-off size to define the positive nodules that required further assessment
and the use of volumetric assessment software could modify the operating characteristics (recall rates,
detection rates and positive predictive values). Only lung cancer screening programmes based on slices that
were < 5 mm thick were included because of the progression towards the standard use of multidetector
CT scanners worldwide. The authors reported that the results of their meta-analysis highlighted the value
of cut-off size at prevalent screens and confirm the relevance of the 5-mm value commonly used in LDCT
screening programmes. They reported that volumetry software analysis at incident screens seems to
decrease recall rates without a significant decrease in detection rates, whereas the number of readers did
not have a great influence. The authors suggested the presence of PET in the work-up protocol may be
associated with lower rates of surgical procedures for benign findings.
Slatore et al.217 conducted a narrative systematic review of five RCTs (detailing DLCST,63 NELSON56,57 trials)
and one cohort study (PLuSS) evaluating psychosocial consequences among asymptomatic adults at high
risk of lung cancer undergoing LDCT lung cancer screening. The authors reported an association between
lung cancer screening with LDCT and short-term psychological discomfort in many individuals, but did not
find an association of LDCT screening with distress, worry or HRQoL. False-positive results were found to
be associated with short-term increases in distress that returned to levels that were similar to those among
people with negative results. Negative results were associated with short-term decreases in distress.
The authors concluded that clinicians may want to consider tailoring communication strategies that can
decrease the distress associated with these results.
Slatore et al.217 conducted a narrative synthesis of two RCTs (DLCST63 and NELSON56,57 trials) and three
cohort studies (ELCAP, Mayo CT and PLuSS trials) to evaluate the effect of LDCT screening on smoking© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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APPENDIX 6
228abstinence. Overall, the authors reported that the results from the included RCTs suggested that
LDCT screening itself does not influence smoking behaviours and that evidence from these trials and
cohort studies suggest that participants who received positive results relating to lung cancer had higher
abstinence rates than those with scans without such findings. The authors reported that this association
between positive screening results and abstinence may have a dose–response relationship in terms of the
number of abnormal CT scans as well as the seriousness of the finding. The authors concluded that
clinicians should consider tailoring LDCT result communication in order to maximise the potential for
smoking behaviour change and long-term abstinence.
In the systematic review and meta-analysis by Wang et al.,218 the authors reported results showing that
> 70% of NSCLC patients whose cancer was detected using CT were at pathological stage I, and that
there is a tendency for this proportion to increase as screening continues. The authors reported that,
relative to CXR screening and usual care, the proportion of stage I cancers detected using CT is higher by
> 12% and 45%, respectively. The authors stated that almost all types of NSCLC can increasingly be
detected at an early stage in a CT rather than a CXR screening, but acknowledge that evidence is lacking
regarding this advantage in SCLC patients.
Wu et al.192 performed a narrative synthesis of 13 studies, 10 of which were derived from three large
RCTS assessing efficacy of lung cancer screening (NELSON,56,57 NLST71 and DLCST63) in order to evaluate the
evidence pertaining to psychological burden associated with lung cancer screening. Three studies reported
psychological outcomes in smaller cohorts who underwent lung cancer screening (PLuSS, asbestos workers,
individuals with lung cancer family history). The authors reported that, taken collectively, the evidence
suggests that lung cancer screening has the potential to cause short-term (< 6 months after screen)
psychological burden in individuals with an indeterminate scan result but that effects do not appear to
persist long term (> 6 months after screen). The authors concluded that lung cancer screening might be
associated with short-term adverse psychological burden, particularly after a false-positive result, but that
these adverse effects diminish over time.
Yau et al.219 performed a systematic review to assess the operating characteristics (including sensitivity and
specificity) associated with baseline LDCT screening for lung cancer. In addition, the stage distribution of
LDCT-detected cancers from baseline scans was analysed. The authors reported that their review found that
screening with LDCT detected a greater number of cancerous nodules. They also reported that, on average,
80% of lung cancers detected by baseline LDCT screening were categorised as stage I cancers. The authors
conclude that, given the operating characteristics at baseline LDCT screening and the relatively high
proportion of stage I cancers detected, screening for lung cancer with LDCT may potentially be effective.
However, the authors acknowledged that the lack of established trial data for morbidity and mortality
available to them preclude a full assessment of LDCT lung cancer screening. The authors concluded that one
of the key findings from their review is that the clinical assessment of the false-negative rate is vital to the
accurate determination of the operating characteristics of LDCT screening and has not been well reported
among published trials.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 48 Overview of systematic reviews
Author, year, title (number
of included studies)
Participants (P), interventions (I)
and comparators (C) Outcomes Design Results Comment
Usman Ali, 2005,206 Screening
for lung cancer: a systematic
review and meta-analysis
(34 RCT studies)
P: adults, average to high risk of
lung cancer, not suspected to
have lung cancer
I: CXR (with or without SC);
LDCT
C: no screening, usual care or
head-to-head comparison
Benefits of screening: lung cancer
mortality, all-cause mortality, stage
at diagnosis, smoking cessation
rate, incidental findings
Harms of screening and invasive
follow-up testing: overdiagnosis,
death, major complications or
morbidity requiring hospitalisation
or medical intervention, false
positives and their consequences,
negative consequences of
incidental findings, anxiety, QoL,
infection of bleeding from invasive
follow-up testing
RCTs Authors report no benefit of CXR
screening (with or without SC) for
lung cancer mortality. Three small
trials (pooled) found no statistically
significant benefits of LDCT for lung
cancer mortality and all-cause
mortality compared with usual care
Authors report that one large trial
found statistically significant
reductions in lung cancer mortality
(20%) for LDCT screening compared
with CXR alone over a follow-up of
6.5 years and 15% over 7.4 years.
The same trial found statistically
significant relative reduction (6%) for
all-cause mortality for LDCT over
7.4 years compared with CXR
Authors conclude that there is no
survival benefit when screening with
CXR (with or without SC) but that in
selected high-risk individuals, LDCT
screening significantly reduced lung
cancer mortality and all-cause
mortality
Authors note that LDCT was
associated with overdiagnosis, deaths
and major complications in patients
undergoing invasive follow-up
procedures
Authors performed a
meta-analysis if possible
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TABLE 48 Overview of systematic reviews (continued )
Author, year, title (number
of included studies)
Participants (P), interventions (I)
and comparators (C) Outcomes Design Results Comment
Bach, 2012,208 Benefits and
harms of CT screening for lung
cancer: a systematic review
(21 studies, 8 RCTs and
13 cohort studies)
P: people with elevated risk of
developing lung cancer due to
age and smoking history
I: LDCT (screening in one arm of
an RCT or non-comparative
cohort of LDCT screening)
C: NR
Mortality (lung cancer and
all-cause), nodule detection rate,
frequency of additional imaging,
frequency of invasive diagnostic
procedures, complications from
the evaluation of suspected lung
cancer, and the rate of smoking
cessation or reinitiation
RCTs and
non-comparative
cohort studies
Authors report that LDCT was
associated with a statistically
significant reduction in mortality
compared with control for one large
RCT (NLST), with no benefit on
mortality observed in for two smaller
RCTs (DANTE61 and DLSCT63). Authors
conclude that LDCT screening may
benefit individuals at an elevated risk
for lung cancer
Authors conclude that LDCT
screening can lead to harm with 20%
diagnosed with nodules, but only 1%
had lung cancer. They report marked
heterogeneity in this finding and
in the frequency of follow-up
investigations, biopsies and the per
cent of surgical procedures performed
in those with benign lesions
Black, 2006,54 The clinical
effectiveness and
cost-effectiveness of computed
tomography screening for lung
cancer: systematic reviews
(12 studies, including 2 RCTs)
P: no restriction based on age,
sex or smoking history or risk
status
I: CT screening for lung cancer
was the main theme of the
paper
C: no screening
Lung cancer and all-cause
mortality, positive CT
examinations, investigations and
follow-up, detection of lung cancer
(prevalence and incidence, stage,
resectability), lung cancer survival,
follow-up requirements, QoL,
adverse events
RCTs and cohort
studies
Authors report that none of the
12 studies provided data to assess
lung-cancer-specific or total mortality
compared with no screening and the
two RCTs were too short in duration
(1 year) to draw firm conclusions
about the clinical effectiveness of CT
screening
Authors conclude there is no
evidence that screening with LDCT
improves survival or reduces mortality
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Author, year, title (number
of included studies)
Participants (P), interventions (I)
and comparators (C) Outcomes Design Results Comment
Black, 2007,209 Population
screening for lung cancer
using computed tomography,
is there evidence of clinical
effectiveness? A systematic
review of the literature
(12 studies, including 2 RCTs)
P: no restriction based on age,
sex or smoking history or risk
status
I: CT screening for lung cancer
was the main theme of the
paper
C: no screening NR
Lung cancer and all-cause
mortality, nodule detection,
histology, survival, follow-up
requirements, QoL, adverse events
RCTs and cohort
studies
Authors report that none of the
12 studies provided data to assess
lung-cancer-specific or total mortality
compared with no screening and the
two RCTs were too short in duration
(1 year) to draw firm conclusions
about the clinical effectiveness of CT
screening
Authors conclude that there is no
evidence that screening with LDCT
improves survival or reduces mortality
Chang, 2013,210 The value of
positron emission tomography
in early detection of lung cancer
in high-risk population: a
systematic review
[7 studies, 5 original articles
(2 RCTs) and 2 SRs]
P: high-risk patients (current/
former smokers, > 50 years,
> 20 pack-years smoking
history)
I: PET or PET+ LDCT (PET/CT)
C: observation
Screening or early detection of
lung cancer
RCTs, cohorts
and case control
studies
Authors conclude that PET or PET/CT
may be useful for early detection of
lung cancer tumours in high-risk
individuals. Authors conclude that
there is insufficient trial data to
determine survival benefits
RCTs had small patient numbers
and did not have long enough
follow-up duration
Chien, 2013,211 [(18)F]
fluorodeoxyglucose-positron
emission tomography screening
for lung cancer: a systematic
review and meta-analysis
(12 studies, including 1 RCT)
P: no restrictions
I: studies focusing on PET
screening (including PET/CT
Screening)
C: primary PET studies and
selective PET studies
Detection rates for all types of
cancer including lung cancer
All single-arm
studies, with
exception of one
RCT
Authors report that lung cancer
screening programmes with selective
PET have high sensitivity and
specificity and could be used as a
selective screening modality (i.e. for
diagnosing lung cancer in patients
with a pulmonary nodule found using
CT screening)
All identified primary PET
screening studies were
conducted in Far East Asian
countries (Japan, Taiwan, and
Korea), whereas all the identified
selective PET studies were
conducted in Europe
Coureau, 2016,212 Low-dose
computed tomography
screening for lung cancer in
populations highly exposed
to tobacco: a systematic
methodological appraisal of
published RCTs
(10 RCT studies)
P: individuals highly exposed to
tobacco
I: LDCT
C: any other intervention
Mortality, positive LDCTs and
cancer incidence, false positives,
surgery, complications, QoL,
overdiagnosis and cost-effectiveness
RCTs Authors report that from five RCTs
reporting mortality results, only one
(NLST) found a significant decrease
of disease-specific and all-cause
mortality with LDCT screening
compared with CXR screening.
None of the studies provided all the
information needed to document
the risk–benefit balance. Authors
conclude that LDCT screening should
not be recommended in subjects
highly exposed to tobacco
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TABLE 48 Overview of systematic reviews (continued )
Author, year, title (number
of included studies)
Participants (P), interventions (I)
and comparators (C) Outcomes Design Results Comment
Fu, 2016,213 A meta-analysis:
is low-dose computed
tomography a superior method
for risky lung cancers screening
population?
(9 RCT studies)
P: high-risk population for
lung cancer. Smoking history
> 15 years or ex-smokers with
quit year < 10 years, average
50–60 years old and average
smoking history 20–30 pack-years
I: LDCT
C: CXR and no screening
Number of stage I lung cancers,
number of total lung cancers,
lung-cancer-specific or all-cause
mortality, and false-positive rates
RCTs Authors report using LDCT to screen
for lung cancer (compared with
CXR or no screening) in high-risk
individuals resulted in a significantly
higher number of stage I cancers,
total lung cancers and lower lung-
cancer-specific mortality. Authors
report that LDCT screening does not
decrease all-cause mortality and is
associated with a higher false-positive
rate
Authors present a funnel plot
analysis, which showed no
symmetry and suggest
publication bias towards trials
showing positive results for LDCT
screening
Gopal, 2010,214 Screening for
lung cancer with low-dose
computed tomography: a
systematic review and meta-
analysis of the baseline findings
of RCTs (structured abstract)
(6 RCT studies)
P: high-risk population; average
50–60 years old, average
smoking history 20–30 pack
years
I: LDCT
C: CXR or no screening
Number of stage I NSCLC, number
of total NSCLC and total lung
cancers, false-positive results and
unnecessary treatments
RCTs Authors report significantly higher
number of stage I lung cancers,
number of total NSCLC and higher
total lung cancers. LDCT screening
resulted in increased detection of
false-positive nodules and number of
unnecessary thoracotomies for benign
lesions. Authors conclude that there is
no compelling evidence in favour of
LDCT screening for lung cancer
Humphrey, 2013,207 Screening
for lung cancer with low-dose
computed tomography:
a systematic review to update
the US Preventative services
task force recommendation
[20 studies, including 7 RCTs
and 13 cohort studies; (analysis
limited to 4 RCTs)]
P: asymptomatic current and
former smokers
I: LDCT
C: CXR and usual care
Lung cancer mortality and
all-cause mortality
Outcomes reported by all seven
RCTs and cohort studies included
radiation exposure, false-positive
findings/follow-up evaluation;
false-negative findings,
overdiagnosis, psychological
consequences, smoking behaviour,
incidental findings
RCTs or cohort
studies
Authors report from four RCTs, one
good-quality, large RCT (NLST) was
associated with significant reductions
in lung cancer (20%) and all-cause
(6.7%) mortality. Authors report that
three smaller RCTs (DANTE61, DLCST63
and MILD69) showed no benefit of
screening for reducing mortality
Harms included radiation exposure,
overdiagnosis and a high rate of
false-positive findings that typically
were resolved with further imaging.
Authors report smoking behaviour
was not affected and incidental
findings were common
Authors limited their analysis
to four out of seven RCTs
that reported results in the
intervention and control groups.
Authors present forest plots to
display mortality findings and
performed a narrative synthesis,
but did not perform a meta-
analysis because of heterogeneity,
follow-up intervals and the quality
of the trials
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Author, year, title (number
of included studies)
Participants (P), interventions (I)
and comparators (C) Outcomes Design Results Comment
Manser, 201352 Screening for
lung cancer
(9 studies, including 8 RCTs and
1 CCT)
P: adult smokers, former
smokers, non-smokers
I: sputum examinations, CXR
screening or CT screening
C: not specified
Disease-specific mortality,
compliance, lung cancer incidence,
5-year survival, stage at diagnosis,
resection rate, postoperative
deaths, harms of screening, costs,
all-cause mortality, QoL, test
performance, smoking behaviour
RCTs and CCTs Authors report their meta-analysis
found no convincing evidence to
support screening for lung cancer
with chest radiography or sputum
cytology. There was evidence of an
association between annual LDCT
screening and a reduction in lung
cancer mortality in high-risk smokers
Authors performed an intention-
to-screen meta-analysis
Piñeiro, 2016,215 Smoking
cessation interventions within
the context of low-dose
computed tomography lung
cancer screening: a systematic
review
(6 studies including 3 RCTs)
P: people undergoing LDCT
I: smoking cessation
intervention programmes
C: not specified
Reported smoking-related
outcomes
RCTs and
observational
studies
Authors included two RCTs that
evaluated self-help smoking cessation
interventions, and one pilot RCT
evaluating the timing (before/after
the LDCT scan) of a combined
(counselling and pharmacotherapy)
smoking cessation intervention.
Authors report efficacy results across
all studies were modest at best.
Authors report that findings based on
non-randomised and pilot studies in
the review demonstrate that combined
(counselling+ pharmacotherapy)
smoking cessation interventions can be
successfully implemented in screening
settings and that they may promote
smoking cessation
Seigneurin, 2014,216 A
systematic review of the
characteristics associated with
recall rates, detection rates and
PPVs of computed tomography
screening for lung cancer
(16 studies including 10 RCTs
and 6 observational studies)
P: smokers (current or former)
or general population
I: LDCT screening programmes
based on slices < 5-mm thick
C: not specified
Number of positive LDCT results,
cancers detected, number of
surgical procedures for benign
findings
RCTs and
observational
studies
Authors report that the results of
their meta-analysis highlight the value
of cut-off size at prevalent screens
and confirm the relevance of the
5-mm value commonly used in LDCT
screening programmes. Volumetry
software analysis at incident screens
decreased recall rates without a
significant decrease in detection rates,
whereas the number of readers (1 or
≥ 2) did not have a great influence.
The authors suggest that presence of
PET in the work-up protocol may be
associated with lower rates of surgical
procedures for benign findings
Authors carried out a
metaregression analysis to relate
the recall rate, detection rate
and PPV to one or more
characteristics of the studies
involved
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TABLE 48 Overview of systematic reviews (continued )
Author, year, title (number
of included studies)
Participants (P), interventions (I)
and comparators (C) Outcomes Design Results Comment
Slatore, 2014217 Smoking
behaviours among patients
receiving computed
tomography for lung cancer
screening. Systematic review in
support of the U.S. preventative
services task force
(5 studies including 2 RCTs and
3 cohort studies)
P: adult asymptomatic current
and former smokers
I: LDCT lung cancer screening
C: not specified
Smoking behaviours (cessation;
relapse; abstinence)
RCTs and cohort
studies
Authors report that LDCT screening
itself does not influence smoking
behaviours however, participants who
received positive lung cancer results
had higher abstinence rates than
those without. Authors suggest that
this association between positive
screening results and abstinence may
have a dose–response relationship in
terms of the number of abnormal CT
scans as well as the seriousness of the
finding
Authors report that trial results
were not able to be pooled
because of heterogeneity of
outcome measures, hence a
narrative synthesis was
undertaken
Slatore, 2014,191 Patient-centred
outcomes among lung cancer
screening recipients with
computed tomography:
a systematic review
(6 studies including 2 RCTs
(from 5 citations) and 1 cohort
study)
P: asymptomatic adults at a
high risk of lung cancer because
of smoking behaviours
I: LDCT lung cancer screening
C: no screening
Patient-centred outcomes of QoL,
distress and anxiety
RCTs and cohort
studies
Authors report that following LDCT
lung cancer screening there was
an association with short-term
psychological discomfort, but no
effects for distress, worry or HRQoL.
Short-term increases in distress
followed false-positive results, which
returned to levels similar to those
among people with negative results.
Negative results were associated with
short-term decreases in distress
Authors report that trial results
were not able to be pooled
because of heterogeneity of
outcome measures, hence a
narrative synthesis was
undertaken
Wang, 2016218 Can CT
screening give rise to a
beneficial stage shift in lung
cancer patients? Systematic
review and meta-analysis
(24 studies including 8 RCTs
and 16 cohort studies)
P: natural populations (wide
geographical distribution) of
any age
I: CT lung cancer screening
C: not specified
Stage and pathology-specific stage
information concerning both lung
cancer patients and nodules
RCTs and cohort
studies
Authors conclude that CT has
superiority over CXR and usual care
for detecting a higher proportion of
early stage NSCLC, including a
number of indolent cancers. Authors
acknowledge that evidence is
currently lacking for the same
beneficial stage shift of the more
aggressive SCLCs
Authors performed a meta-analysis.
They state that their study focused
on the topic of the first ‘detection
step’ because of the current paucity
of mortality outcome evidence in
CT screening
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Author, year, title (number
of included studies)
Participants (P), interventions (I)
and comparators (C) Outcomes Design Results Comment
Wu, 2016192 Psychological
burden associated with lung
cancer screening: a systematic
review
(13 studies, including 3 RCTs
(from 10 citations) and 3 cohort
studies)
P: not specified
I: LDCT lung cancer screening
C: not specified
Patient self-report of psychological
burden and related outcomes
(e.g. HRQoL, psychological distress,
depression)
RCTs and cohort
studies
Authors report that lung cancer
screening did not have substantial
long-term (> 6 months) effects on
psychological burden, but potential
short-term (< 6 months) psychological
burden
Authors report heterogeneity in
outcome measures used to
capture psychological burden and
conducted a narrative synthesis
of the evidence
Most outcome measures were
general rather than condition
specific
Yau, 2007219 Systematic review
of baseline low-dose CT lung
cancer screening
(15 studies, including 2 RCTs)
P: former or current smokers
I: LDCT screening
C: not specified
Number of lung cancers found RCTs an cohort
studies
Authors report that their initial
assessment of LDCT screening
demonstrated good sensitivity and
specificity of the technology and a
high proportion of early-stage lung
cancer detection. However, the
authors acknowledge that these
findings are derived mainly from
observational studies and that there is
a lack of long-term mortality data
CCT, controlled clinical trial; NR, not reported; PPV, positive predictive value; SC, smoking cessation; SR, systematic review.
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DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Appendix 7 Methods and results of the
systematic review of existing cost-effectiveness
evidenceMethods
Quality assessment
The following modifications to the CHEC list and guidelines for assessment were used in the
quality assessment:l
l
l
l
l
l
l
l
l
© Qu
Healt
journ
be ad
Park,General – ‘unclear’ was additionally allowed as a judgement for all items.
Study design – an appropriate study design was an economic evaluation principally based on a RCT of
lung cancer screening without significant unsupported assumptions.
Perspective – health service and third-party payer perspectives were allowed as appropriate perspectives
(in addition to a societal perspective), and other perspectives were allowed if appropriately justified.
Resource use identification – a full identification of all important and relevant costs required all of the
following (note that there are other costs that may be considered important for an economic
evaluation in this area, such as the cost of identifying an eligible population):¢
¢
¢
¢
¢
¢
¢
een’s
h and
als pro
dress
Southscreening scan costs
costs of follow-up tests for all positive or indeterminate screening scans
costs of diagnosing, staging and treating lung cancer.eResource use measurement – ‘lung cancer’ was judged to be an acceptable physical unit.
Resource valuation – sources should be clearly given and should be fair approximations of opportunity
costs, well-established reference costs and tariffs with minimal inbuilt incentives are acceptable.
Outcome identification – since lung cancer is a disease with a significant effect on the quantity and
QoL, a full identification of all important and relevant outcomes required all of the following:lung cancer diagnoses
lung cancer deaths
life-years
QALYs.Outcome valuation – valuation includes estimation of health state utility values (for calculation of QALYs)
or determination of an appropriate cost-effectiveness threshold or willingness to pay for non-QALY
outcomes.
Incremental analysis – all studies conducted at least a partial incremental analysis as this was an
inclusion criterion for the review, so for this quality measure only a fully incremental analysis (including
all relevant combinations of compatible interventions, e.g. screening with smoking cessation) was
judged to be acceptable.Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
vided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
d to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
ampton SO16 7NS, UK.
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Results
Characteristics of included studies
TABLE 49 Characteristics of included trial- and model-based studies
Study author and
year of publication
Form of
economic
evaluation
Location, currency
and price year Population Intervention(s) Comparator(s) Methodology
Marshall, 2001118 CEA and CUA USA, 1999 US$ ‘High-risk’ adults aged 60–74 years Annual LDCT for 5 years No screening Decision tree model
Marshall, 2001119 CEA USA, 1999 US$ General smokers aged 60–74 years Single LDCT screen No screening Decision tree model
Chirikos, 2002120 CEA USA, 2000 US$ Adult smokers aged 45–74 years Annual LDCT for 5 years No screening Cohort model
Mahadevia, 2003121 CUA USA, 2001 US$ 60-year-old heavy smokers (current and
former, > 20 pack-years)
Annual LDCT to age 80 years No screening Markov model
Wisnivesky, 2003122 CUA USA, 2000 US$ Adults aged ≥60 years with ≥10 pack-year
smoking history
Single LDCT screen No screening Decision tree model
Manser, 2005123 CEA and CUA Australia, 2002 AU$ Male current smokers aged 60–64 years Annual LDCT for 5 years No screening Markov model
Whynes, 2008117 CUA UK, 2004 GBP Men aged 61 years at high risk Single LDCT screen No screening Decision tree model
McMahon, 2011114 CUA USA, 2006 US$ Current and former smokers ≥20 pack-years
smoking history
Annual LDCT screening
Smoking cessation
No intervention Patient-level
microsimulation
model
Goulart, 2012124 CEA USA, 2011 US$ Those eligible for NLST, i.e. smokers
aged 55 to 74 years
LDCT screening (frequency
unclear)
No screening Decision tree model
Pyenson, 2012125 CEA USA, 2012 US$ Current and former smokers aged
50 years with ≥ 30 pack-year smoking
history
Annual LDCT from age
50–64 years
No screening Cohort model
Shmueli, 2013126 CUA Israel, 2011 US$ Adults aged ≥45 years with ≥10 pack-year
smoking history
Single LDCT screen No screening Decision tree
Villanti, 2013127 CUA USA, 2012 US$ High-risk adults aged 50 years Annual LDCT screening to age
64 years
Screening plus smoking
cessation
No screening Cohort model
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Study author and
year of publication
Form of
economic
evaluation
Location, currency
and price year Population Intervention(s) Comparator(s) Methodology
Black, 2014111 and
2015110
CEA and CUA USA, 2009 US$ NLST cohort (aged 55–74 years with
≥ 30 pack-year smoking history)
Annual LDCT for 3 years
Annual CXR for 3 years
No screening Decision tree model
Pyenson, 2014128 CEA USA, 2014 US$ Adults aged 55–80 years with
≥ 30 pack-year smoking history
Annual LDCT No screening Cohort model
Tabata, 2014129 CEA Japan, JPY (¥; price
year unclear)
Smokers aged 55–74 years Annual LDCT Annual CXR Decision tree model
Goffin, 2015112 CUA Canada, 2008 CA$ Smokers aged 55–74 years with
≥ 30 pack-year history
Annual LDCT for 3 years with
smoking cessation
Annual LDCT to age 75 years
with smoking cessation
No intervention Microsimulation
model
Field, 2016,55 2016116 CEA and CUA UK, 2011–12 GBP Adults aged 50–75 years Risk prediction followed by
single LDCT screen
No intervention Decision tree model
Goffin, 2016113 CUA Canada, 2008 CA$ Smokers aged 55–74 years with
≥ 30 pack-year history
Biennial LDCT screening for
20 years with/without smoking
cessation
Annual LDCT
screening for
20 years with/
without
smoking
cessation
Microsimulation
model
ten Haaf, 2017115 CEA Canada, 2015 CA$ Adult smokers (current or former)
aged 46–75
Eligibility criteria and annual or
biennial LDCT screening
No screening Microsimulation
model
CEA, cost-effectiveness analysis; CUA, cost–utility analysis; GBP, Great British pounds; JPY, Japanese yen.
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TABLE 50 Results of included trial- and model-based studies
Study author and
year of publication
Source of effectiveness
estimates
Measurement of
health outcomes
Time horizon and
discount rate Base-case findings
Results of sensitivity and scenario
analyses
Marshall, 2001118 ELCAP (LDCT cohort study,
n = 1000)
Life-years, QALYs 5 years, 3% LDCT more expensive and more
effective than no screening, ICER
US$19,533/QALY
1-year decrease in assumed survival
benefit → ICER US$50,783/QALY
Also sensitive to incidence of lung
cancer and cost of LDCT scan
Marshall, 2001119 ELCAP Life-years 5 years, 3% LDCT more expensive and more
effective than no screening, ICER
US$23,100/LYG
In ‘very high-risk’ cohort, ICER
US$5940/LYG
Cost-effectiveness improved as
prevalence of lung cancer increased
Cost-effectiveness worsened if
adjusted for lead time bias
Cost-effectiveness improved for higher
specificity
Cost-effectiveness sensitive to cost of
CT scans
Chirikos, 2002120 Hypothetical stage shift Life-years 15 years, 7.5% LDCT more expensive and more
effective than no screening, ICER
US$33,557–90,022/LYG depending
on achieved stage distribution
Proportion diagnosed in earlier stage
key factor of cost-effectiveness
Higher discount factor leads to small
improvement in cost-effectiveness
Mahadevia, 2003121 Hypothetical stage shift QALYs 40 years (to age
100), 3%
LDCT more expensive and more
effective than no screening, ICER
US$116,300/QALY
Degree of stage shift: 50%→ 91%
in current smokers results in ICER
US$50,000/QALY
No stage shift achieves ICER
US$50,000/QALY for quitting and
former smokers
Favourable scenario ICER US$42,500/
QALY
Wisnivesky, 2003122 ELCAP Life-years Unclear, 3% LDCT more expensive and more
effective than no screening, ICER
US$2,500/LYG
Sensitive to cost of LDCT, probability
of overdiagnosis and prevalence of
lung cancer
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Study author and
year of publication
Source of effectiveness
estimates
Measurement of
health outcomes
Time horizon and
discount rate Base-case findings
Results of sensitivity and scenario
analyses
Manser, 2005123 Diagnostic performance of LDCT
based on ‘weighted averages of
six studies’
Life-years, QALYs 15 years, 3% LDCT more expensive and more
effective than no screening, ICER
AU$57,325/LYG or AU$105,090/QALY
Sensitive to performance of LDCT
(proportion diagnosed in stage I,
diagnostic performance and mortality
impact), cost of LDCT, prevalence and
incidence of lung cancer
Whynes, 2008117 ELCAP QALYs Unclear (perhaps
40 years), 3.5%
LDCT more expensive and more
effective than no screening, ICER
£13,910/QALY (for men)
If testing in women only, ICER
£11,710/QALY
Low prevalence significantly worsens
cost-effectiveness
McMahon, 2011114 Natural history model calibrated
to tumour registry data and
validated against screening
studies
QALYs Lifetime, 3% LDCT more expensive and more
effective than no screening
ICERs for screening consistently above
US$100,000/QALY unless positive
impact on smoking cessation included
Screening dominated by smoking
cessation if screening has no impact
on quit rates
Goulart, 2012124 NLST (LDCT RCT, n = 53,454) Lung cancer deaths Unclear (possibly
1 year), no
discounting
LDCT more expensive and more
effective than no screening, ICER
US$240,000 per lung cancer death
avoided
No sensitivity analyses of
cost-effectiveness results
Pyenson, 2012125 ELCAP Life-years 15 years, no
discounting
LDCT more expensive and more
effective than no screening, ICER
US$18,862/LYG
Scenario analyses produced range of
ICERs from US$11,708 to US$26,016/
LYG
Shmueli, 2013126 Single-centre Israeli cohort study QALYs Lifetime, 3% LDCT more expensive and more
effective than no screening, ICER
US$1,464/QALY
Sensitive to overdiagnosis, PPV of
LDCT, cost of stage IV lung cancer,
although ICERs ranged from US$155
to $3187/QALY
PSA suggests that ICER very likely to
be below US$20,000/QALY
continued
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TABLE 50 Results of included trial- and model-based studies (continued )
Study author and
year of publication
Source of effectiveness
estimates
Measurement of
health outcomes
Time horizon and
discount rate Base-case findings
Results of sensitivity and scenario
analyses
Villanti, 2013127 ELCAP and NLST QALYs 15 years, no
discounting
LDCT more expensive and more
effective than no screening, ICER
US$28,240/QALY (ELCAP) or
US$47,115/QALY (NLST)
Adding smoking cessation nearly
doubled QALY gain from screening
alone and had lower ICER
Sensitive to screening costs and
resulting stage distribution from
screening
Black, 2014111 and
2015110
NLST (assume same outcomes
for no screening as CXR)
Life-years, QALYs Lifetime, 3% LDCT screening more costly and more
effective than CXR and no screening,
ICER (vs. no screening) US$81,000/
QALY
CXR dominated by no screening
Sensitive to sex (more cost-effective
for women), age, smoking status, risk
of lung cancer, cost of LDCT
Pyenson, 2014128 ELCAP Life-years 20 years, no
discounting
LDCT screening more costly and more
effective than no screening, ICER
US$18,452/LYG
Sensitive to sex (more cost-effective
for women), cost of lung cancer
treatment, cost of LDCT, effectiveness
of stage shift
Tabata, 2014129 Anti-Lung Cancer Association
(ALCA), Japanese case–control
study
Life-years Unclear LDCT screening more costly and more
effective than CXR, ICERs ranging
from ¥983,000 to ¥1942/LYG
depending on sex and age
Sensitive to sex (more cost-effective
for men) and age, the cost of LDCT,
screening interval and proportion of
cancer diagnosed in early stages
Goffin, 2015112 Natural history model, partially
calibrated to NLST
QALYs 20 years (lifetime),
3%
LDCT screening more costly and more
effective than CXR
ICER of triple screen (vs. no screening)
CA$74,000/QALY
ICER of annual screening (vs. no
screening) CA$52,000/QALY
ICER of annual screening vs. triple
screen [estimated; not reported by
authors] CA$21,000/QALY (triple
screening extendedly dominated)
Sensitive to smoking history of
participants, impact on smoking and
LDCT cost
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Study author and
year of publication
Source of effectiveness
estimates
Measurement of
health outcomes
Time horizon and
discount rate Base-case findings
Results of sensitivity and scenario
analyses
Field, 2016,55 2016116 UKLS and estimates of lead time Life-years, QALYs Lifetime, 3.5% LDCT screening more costly and more
effective than no screening, ICER
£8466/QALY
If certain nodules not pursued further,
cost-effectiveness is improved
Goffin, 2016113 Natural history model partially
calibrated to NLST
QALYs Lifetime, 3% Biennial LDCT screening cheaper and
less effective than annual LDCT
screening
ICER of annual vs. biennial ranged
from CA$54,000 to CA$4.8M/QALY
Sensitive to stage distributions
ten Haaf, 2017115 Natural history model calibrated
to NLST
Life-years Lifetime, 3% 576 screening scenarios evaluated
LDCT screening more expensive and
more effective than no screening
11 screening scenarios and no
screening on the efficient frontier
At CA$50,000/LYG threshold, it is
cost-effective to screen annually in
55- to 75-year-olds with ≥ 40 pack-year
smoking history (quit ≤ 10 years ago if
former smoker), ICER CA$41,136/LYG
Sensitive to cost of LDCT and smoking
criteria
LYG, life-year gained; PPV, positive predictive value.
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TABLE 51 Characteristics and results of included systematic reviews
Study author and
year of publication
Population, interventions and
comparators Eligible study designs
Date range for
searches Key findings
Klittich, 2002130 Any population
Any lung cancer screening
Costs, CUA September 1998 to
September 2001
Seven studies included
Economic evaluations mostly ad hoc (adjunct to clinical trials)
and/or methodologically weak
Two studies methodologically robust and evaluated annual
screening (one with CXR, one with low-dose CT). Both concluded
screening would be cost-effective. One study found results were
sensitive to the prevalence of lung cancer
Black, 200654 Population screening using CT Full economic evaluations,
CEA
1994 to January 2005 Six studies included
Lack of clinical effectiveness data made it difficult to assess
suitability of approaches. Reporting was poor
Interventions ranged from single CT screens to annual CT screens
over 20 years. Four studies focused on high-risk individuals
ICER (cost per QALY) ranged from US$19,500 to > US$2M
Four studies concluded screening would be cost-effective, one
study concluded insufficient evidence, another study concluded
screening would not be cost-effective
Several limitations were present across all studies
CADTH, 2006131,132 Population lung cancer screening
by CTa
Full economic evaluations 2000 to November 2005 Five studies included
Studies ranged in quality. One study was higher quality than
the rest, in which authors concluded screening is unlikely to be
cost-effective. Other studies of lower quality concluded screening
was likely to be or could be cost-effective
Economic evaluations of lung cancer were most hypothetical of
studies across all indications reviewed
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Study author and
year of publication
Population, interventions and
comparators Eligible study designs
Date range for
searches Key findings
Puggina, 2016133 LDCT screening for lung cancer
in high-risk individuals (in terms
of smoking history)
CEA (cost per life-year
gained), CUA (cost per QALY)
To March 2015 Nine studies included
Wide variation in results. With threshold of US$50,000 per
QALY, five of nine studies found lung cancer screening to be
cost-effective, increasing to seven and nine as the threshold is
raised to US$100,000 and US$150,000 per QALY, respectively.
Two studies found that smoking cessation rates strongly influence
the cost-effectiveness of screening
Most of the studies failed to include actual clinical evidence and
failed to adopt a true societal perspective
Raymakers, 2016134 Lung cancer screening using
LDCT
CEA January 2000 to
December 2014
Thirteen studies included
Ten studies focused on high-risk populations. Most studies
evaluated annual screening, four evaluated single screen. Four
studies included smoking cessation with annual screening
Cost-effectiveness estimates varied substantially. Costs per QALY
varied from US$28,000 to US$243,000 for repeated screening.
Cost per QALY of a single screen estimated in one study as
US$1500 per QALY
Results were particularly sensitive to the prevalence of lung
cancer, cost of CT, achieved stage shift, lead time bias and
smoking cessation
CADTH, Canadian Agency for Drugs and Technologies in Health; CEA, cost-effectiveness analysis; CUA, cost–utility analysis.
a Review also included CT and magnetic resonance imaging screening for other target conditions; results reported here only for lung cancer screening.
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Quality assessment
The results of quality assessment are shown in Table 52.
TABLE 52 Quality assessment of included trial- and model-based economic evaluations
Study author and year
of publication
Question
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Marshall, 2001118 N Y N N N Y Y Y Y Y Y U Y Y N Y Y N N
Marshall, 2001119 N Y N N N Y Y Y Y N Y N Y Y N Y N N N
Chirikos, 2002120 N Y N N Y Y Y Y Y N Y N Y Y N Y N N N
Mahadevia, 2003121 Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y U N
Wisnivesky, 2003122 Y Y Y N U Y Y Y N N Y N Y Y N Y Y N N
Manser, 2005123 Y Y Y N Y Y Y Y Y Y Y U Y Y Y Y N U N
Whynes, 2008117 Y Y Y N U Y Y Y Y Y Y N Y Y N Y Y U N
McMahon, 2011114 Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y N U N
Goulart, 2012124 Y N N N N Y Y Y N N Y N Y N N Y N Y N
Pyenson, 2012125 Y Y Y N Y Y Y Y Y N Y Y Y N N U N N N
Shmueli, 2013126 Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y N U N
Villanti, 2013127 Y Y Y N Y Y Y Y Y Y Y Y N N N N N N N
Black, 2014111 and 2015110 Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y N N N
Pyenson, 2014128 Y Y Y N Y Y Y Y Y N Y Y Y N N Y N N N
Tabata, 2014129 Y Y Y N U U U U U N Y Y Y U N Y N N N
Goffin, 2015112 Y Y Y Y Y Y U U U Y Y U N Y N Y Y N N
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Study author and year
of publication
Question
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Field, 2016,55 2016116 Y Y Y N Y Y Y Y Y Y Y U Y Y N Y Y U N
Goffin, 2016113 Y Y Y Y Y U U U U Y Y U N Y N Y N U N
ten Haaf, 2017115 Y Y Y Y Y Y Y Y Y N Y Y Y Y N Y N U N
Questions (made freely available for research purposes by Evers et al.109
Q1 Is the study population clearly described?
Q2 Are competing alternatives clearly described?
Q3 Is a well-defined research question posed in answerable form?
Q4 Is the economic study design appropriate to the stated objective?
Q5 Is the chosen time horizon appropriate to include relevant costs and consequences?
Q6 Is the actual perspective chosen appropriate?
Q7 Are all important and relevant costs for each alternative identified?
Q8 Are all resources measured appropriately in physical units?
Q9 Are resources valued appropriately?
Q10 Are all important and relevant outcomes for each alternative identified?
Q11 Are all outcomes measured appropriately in physical units?
Q12 Are outcomes valued appropriately?
Q13 Is an incremental analysis of costs and outcomes performed?
Q14 Are all future costs and outcomes discounted appropriately?
Q15 Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis?
Q16 Do the conclusions follow from the data reported?
Q17 Does the study discuss the generalisability of the results to other settings and patient/client groups?
Q18 Does the article indicate that there is not potential conflict of interest of study researcher(s) and funder(s)?
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248Discussion
Relation to existing workTABLE 53 Studies included in other systematic reviews excluded in this systematic review
Citation
Included in
reviews Reason for exclusion
Beinfeld MT, Wittenberg E, Gazelle GS. Cost-effectiveness of whole-body
CT screening. Radiology 2005;234:415–22
Raymakers134 Intervention (whole-
body CT)
Caro JJ, Klittich WS, Strauss G. Could chest X-ray screening for lung
cancer be cost-effective? Cancer 2000;89:2502–5
Klittich130 Intervention (did not
include LDCT)
Okamoto N. Cost-effectiveness of lung cancer screening in Japan. Cancer
2000;89:2489–93
Klittich130; Black54;
CADTH131,132; and
Raymakers134
Study design (did not
include an incremental
analysis)
Baba Y, Takahashi M, Tominguchi S, Kiyota S. Cost-effectiveness
decision analysis of mass screening for lung cancer. Acad Radiol
1998;5(Suppl. 2):S344–6
Klittich130 Intervention (did not
include LDCT)
Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K,
et al. Peripheral lung cancer: Screening and detection with low-dose
spinal CT versus radiography. Radiology 1996;201:798–802
Klittich130 Study design (did not
include an incremental
analysis)
Eddy DM. Screening for lung cancer. Ann Intern Med 1989;111:232–7 Klittich130 Intervention (did not
include LDCT)
TABLE 54 Included studies in other systematic reviews
Study author and
year of publication
Study author and year of publication
Klittich, 2002130 Black, 200654 CADTH, 2006131,132 Puggina, 2016133
Raymakers,
2016134
ten Haaf, 2017115
Goffin, 2016113
Field, 2016,55 2016116
Goffin, 2015112
Black, 2014111 and 2015110 ✓ ✓
Tabata, 2014129
Pyenson, 2014128 ✓ ✓
Villanti, 2013127 ✓ ✓
Shmueli, 2013126 ✓ ✓
Pyenson, 2012125 ✓
Goulart, 2012124
McMahon, 2011114 ✓ ✓
Whynes, 2008117
Manser, 2005123 ✓ ✓
Wisnivesky, 2003122 ✓ ✓ ✓
Mahadevia, 2003121 ✓ ✓ ✓ ✓
Chirikos, 2002120 ✓ ✓ ✓
Marshall, 2001119 ✓ ✓ ✓ ✓
Marshall, 2001118 ✓ ✓ ✓ ✓
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A natural history model was constructed as shown in Figure 22, with exponential time-to-event
distributions (i.e. constant hazard) for all events except preclinical incidence of lung cancer, which had a
log-normal time-to-event distribution.
This model was represented by 15 states (1, no cancer; 7, preclinical lung cancer; 7, clinical lung cancer)
and a time-dependent transition rate matrix Q = qi,j, with the following properties:l
l
© Qu
Healt
journ
be ad
Park,qi,j is the rate of transitions from state i to state j
qi,i is equal to minus the sum of the transition rates qi,j, such that the row sums are all 0.Of the elements in the matrix, only q1,2 varies with time (this represents the transition from no lung cancer
to preclinical lung cancer, determined by a log-normal distribution). q1,2 was estimated as piecewise
constant each year of age (x) using the following equation:
q1, 2(x) =
Λ(x + δx) − Λ(x)
δx
. (4)
where δx = 1 year and:
Λ(x) = −ln 1−Φ
lnx−µ
σ
  
, (5)
(i.e. the cumulative hazard function for the log-normal distribution).
To fit to data from NLST, the participants of NLST were stratified into cohorts according to their age
(to the nearest year) and each cohort’s membership over time was simulated using a continuous time Markov
model approach,220 augmented with transition matrices applied at the time of screening (representing the
sensitivity and specificity of screening). The cohort membership was then used as the vector of probabilities
for a multinomial distribution, such that the number of cancer diagnoses in each stage for each year of the
study (screen detected, interval and post-screening cancers) were the data inputs.
A total of 26,719 participants were included (those randomised to LDCT screening rather than CXR).
To fit to incidence data, a single cohort was modelled from birth using a Markov model approach. An
additional parameter was included so that men and women could have a different location parameter for
preclinical incidence. The rates of preclinical progression and clinical presentation were fixed to the
expected values obtained by fitting to NLST data.
In the scenario analysis in which heterogeneity in the progression rate is included, this was achieved by
running the continuous-time Markov model repeatedly with different values of the heterogeneity
parameter each time. These values were sampled as evenly spaced quantiles of the distribution, with
p = 0.025, 0.075, . . . , 0.975 (i.e. 20 quantile samples), as shown in Figure 37.
The models were built and fitted in JAGS (software for Bayesian MCMC analysis, based on the BUGS
language), called from R using the rjags package. Sample code is given in Sample code. Owing to the
computational complexity of the model, it was not possible to run with extremely long burn-in periods oreen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
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FIGURE 37 Quantiles used to incorporate heterogeneity in progression rates.
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250thinning, but visual inspection of traces and auto-correlation plots satisfied that convergence had probably
been reached and adequate thinning had been conducted. Table 55 gives the setup parameters used in
the analyses. Prior distributions for parameters are presented alongside the posterior distributions
in Results.Results
In this section we present the posterior distributions of parameters in the form of their mean, SD, median
and 95% CrI.TABLE 55 Calibration setup parameters
Analysis
Number of
heterogeneity
quantiles
Number of
chains
Adaptation/burn-in/
samples (per chain)
Sample
thinning
Total
samples
NLST without heterogeneity N/A 6 1000/0/5000 50 600
Incidence without heterogeneity N/A 6 1000/4000/5000 50 600
NLST with heterogeneity 20 6 1000/0/5000 50 600
Incidence with heterogeneity 20 6 1000/4000/5000 50 600
N/A, not applicable.
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Parameter name Description Prior distributiona
Posterior distribution,
mean (SD) [median (95% CrI)]
Preclinical incidence
mu.p0_pIA Log-normal distribution parameter
(location) for preclinical incidence of
lung cancer
Normal(3, 0.1) 4.555 (0.020)
[4.554 (4.515 to 4.597)]
sigma.p0_pIA Log-normal distribution parameter
(shape) for preclinical incidence of
lung cancer
Uniform(0.001, 5) 0.266 (0.017)
[0.266 (0.232 to 0.302)]
Preclinical progression
lnlambda.pIA_pIB Preclinical progression rate from IA to
IB (log-scale)
Normal(0, 0.1) 0.004 (0.141)
[0.019 (–0.304 to 0.261)]
lnlambda.pIB_pIIA Preclinical progression rate from IB to
IIA (log-scale)
Normal(0, 0.1) 1.645 (0.201)
[1.643 (1.249 to 2.044)]
lnlambda.pIIA_pIIB Preclinical progression rate from IIA
to IIB (log-scale)
Normal(0, 0.1) 1.801 (0.206)
[1.792 (1.407 to 2.206)]
lnlambda.pIIB_pIIIA Preclinical progression rate from IIB
to IIIA (log-scale)
Normal(0, 0.1) 1.626 (0.238)
[1.646 (1.155 to 2.111)]
lnlambda.pIIIA_pIIIB Preclinical progression rate from IIIA
to IIIB (log-scale)
Normal(0, 0.1) 1.080 (0.262)
[1.090 (0.576 to 1.595)]
lnlambda.pIIIB_pIV Preclinical progression rate from IIIB
to IV (log-scale)
Normal(0, 0.1) 2.080 (0.374)
[2.053 (1.314 to 2.879)]
Clinical presentation
lnlambda.pIA_cIA Clinical presentation rate in Stage IA
(log-scale)
Normal(0, 0.1) –2.483 (0.175)
[–2.469 (–2.802 to –2.111)]
lnlambda.pIB_cIB Clinical presentation rate in Stage IB
(log-scale)
Normal(0, 0.1) –1.873 (0.261)
[–1.877 (–2.365 to –1.313)]
lnlambda.pIIA_cIIA Clinical presentation rate in Stage IIA
(log-scale)
Normal(0, 0.1) –1.651 (0.276)
[–1.634 (–2.187 to –1.164)]
lnlambda.pIIB_cIIB Clinical presentation rate in Stage IIB
(log-scale)
Normal(0, 0.1) –2.136 (0.322)
[–2.152 (–2.693 to –1.503)]
lnlambda.pIIIA_cIIIA Clinical presentation rate in Stage IIIA
(log-scale)
Normal(0, 0.1) –1.409 (0.272)
[–1.418 (–1.930 to –0.866)]
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TABLE 56 Prior and posterior distributions calibrating to NLST without progression heterogeneity (continued )
Parameter name Description Prior distributiona
Posterior distribution,
mean (SD) [median (95% CrI)]
lnlambda.pIIIB_cIIIB Clinical presentation rate in Stage IIIB
(log-scale)
Normal(0, 0.1) –0.881 (0.385)
[–0.884 (–1.625 to –0.072)]
lnlambda.pIV_cIV Clinical presentation rate in Stage IV
(log-scale)
Normal(0, 0.1) –1.403 (0.196)
[–1.415 (–1.780 to –0.993)]
Diagnostic performance
sensitivity Probability that an individual with
preclinical lung cancer (any stage)
will be diagnosed with lung cancer
as a result of screening
Uniform(0, 1) 0.706 (0.055)
[0.709 (0.578 to 0.806)]
specificity Probability that an individual without
preclinical lung cancer will receive a
false-positive or indeterminate result
from screening
Uniform(0, 1) 0.777 (0.001)
[0.777 (0.775 to 0.800)]
a Normal distribution parameters are µ and τ= 1/σ2.
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252With heterogeneityTABLE 57 Prior and posterior distributions calibrating to NLST with progression heterogeneity
Parameter name Description Prior distributiona
Posterior distribution,
mean (SD) [median (95% CrI)]
Preclinical incidence
mu.p0_pIA Log-normal distribution parameter
(location) for preclinical incidence of
lung cancer
Normal(3, 0.1) 4.550 (0.017)
4.545 (4.520 to 4.584)
sigma.p0_pIA Log-normal distribution parameter
(shape) for preclinical incidence of
lung cancer
Uniform(0.001, 5) 0.264 (0.016)
0.263 (0.237 to 0.297)
Preclinical progression
lnlambda.pIA_pIB Preclinical progression rate from IA to
IB (log-scale)
Normal(0, 0.1) 0.447 (0.351)
0.403 (–0.165 to 1.206)
lnlambda.pIB_pIIA Preclinical progression rate from IB to
IIA (log-scale)
Normal(0, 0.1) –0.245 (0.502)
–0.264 (–1.269 to 0.700)
lnlambda.pIIA_pIIB Preclinical progression rate from IIA
to IIB (log-scale)
Normal(0, 0.1) –1.260 (0.618)
–1.248 (–2.535 to –0.094)
lnlambda.pIIB_pIIIA Preclinical progression rate from IIB
to IIIA (log-scale)
Normal(0, 0.1) –2.556 (0.775)
–2.504 (–4.279 to –1.151)
lnlambda.pIIIA_pIIIB Preclinical progression rate from IIIA
to IIIB (log-scale)
Normal(0, 0.1) –4.498 (0.969)
–4.444 (–6.570 to –2.799)
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TABLE 57 Prior and posterior distributions calibrating to NLST with progression heterogeneity (continued )
Parameter name Description Prior distributiona
Posterior distribution,
mean (SD) [median (95% CrI)]
lnlambda.pIIIB_pIV Preclinical progression rate from IIIB
to IV (log-scale)
Normal(0, 0.1) –4.233 (1.161)
–4.130 (–6.603 to –2.167)
sigma.lnlambda.p Random effects on preclinical
progression standard deviation
Exponential(1) 5.611 (1.027)
5.540 (3.850 to 7.733)
Clinical presentation
lnlambda.pIA_cIA Clinical presentation rate in Stage IA
(log-scale)
Normal(0, 0.1) –2.583 (0.142)
–2.591 (–2.852 to –2.301)
lnlambda.pIB_cIB Clinical presentation rate in Stage IB
(log-scale)
Normal(0, 0.1) –2.120 (0.276)
–2.122 (–2.636 to –1.571)
lnlambda.pIIA_cIIA Clinical presentation rate in Stage IIA
(log-scale)
Normal(0, 0.1) –1.876 (0.293)
–1.878 (–2.408 to –1.288)
lnlambda.pIIB_cIIB Clinical presentation rate in Stage IIB
(log-scale)
Normal(0, 0.1) –2.299 (0.314)
–2.300 (–2.933 to –1.660)
lnlambda.pIIIA_cIIIA Clinical presentation rate in Stage IIIA
(log-scale)
Normal(0, 0.1) –1.302 (0.264)
–1.296 (–1.810 to –0.776)
lnlambda.pIIIB_cIIIB Clinical presentation rate in Stage IIIB
(log-scale)
Normal(0, 0.1) –0.518 (0.423)
–0.543 (–1.400 to 0.326)
lnlambda.pIV_cIV Clinical presentation rate in Stage IV
(log-scale)
Normal(0, 0.1) 0.084 (0.198)
0.067 (–0.290 to 0.464)
Diagnostic performance
sensitivity Probability that an individual with
preclinical lung cancer (any stage)
will be diagnosed with lung cancer
as a result of screening
Uniform(0, 1) 0.961 (0.028)
0.967 (0.895 to 0.999)
specificity Probability that an individual without
preclinical lung cancer will receive a
false-positive or indeterminate result
from screening
Uniform(0, 1) 0.778 (0.001)
0.778 (0.775 to 0.780)
a Normal distribution parameters are µ and τ= 1/σ2.
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
253
APPENDIX 8
254Sample code
NLST-cohort.jags NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
255
APPENDIX 8
256NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
257
APPENDIX 8
258NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22690 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 69Appendix 9 Summary of economic
model parametersTABLE 58 Summary of parameters in the independent economic evaluation
Label Description Base-case value PSA
Population
pop_size Number of smokers aged 55–80 13,000,000 Not varied
p_male Proportion of those receiving risk prediction
who are men
0.482 Beta(29393,31609)
pop_age_mean Population mean age 61.939 N(61.939,0.048)
pop_age_sd Population standard error 9.000 N(8.999,0.062)
pop_age_LL Quantile for lower age limit of whole
population and lower boundary of age at
entry distribution
0.220 Not varied
pop_age_UL Quantile for upper age limit of whole
population and upper boundary of age at
entry distribution
0.978 Not varied
Programme uptake
p_respond Probability someone responds to the initial
invite and returns the questionnaire
0.307 Beta(75958,171396)
p_join Probability someone joins screening
programme given they are eligible
0.465 Beta(4061,4668)
Natural history of disease
mu_AB Lognormal parameter (location) for
pre-clinical incidence of lung cancer
4.7470 Multivariate normal 1
delta_mu_AB_F Coefficient for women for lognormal
parameter (location) for pre-clinical
incidence of lung cancer
0.0358 Multivariate normal 1
sigma_AB Lognormal parameter (shape) for pre-clinical
incidence of lung cancer
0.3635 Multivariate normal 1
ln_lambda_pIA_pIB Log rate of pre-clinical progression from
stage Ia to Ib
0.0035 Multivariate normal 1
ln_lambda_pIB_pIIA Log rate of pre-clinical progression from
stage Ib to IIa
1.6451 Multivariate normal 1
ln_lambda_pIIA_pIIB Log rate of pre-clinical progression from
stage IIa to IIb
1.8006 Multivariate normal 1
ln_lambda_pIIB_pIIIA Log rate of pre-clinical progression from
stage IIb to IIIa
1.6258 Multivariate normal 1
ln_lambda_pIIIA_pIIIB Log rate of pre-clinical progression from
stage IIIa to IIIb
1.0797 Multivariate normal 1
ln_lambda_pIIIB_pIV Log rate of pre-clinical progression from
stage IIIb to IV
2.0803 Multivariate normal 1
ln_lambda_pIA_cIA Log rate of clinical presentation at stage Ia –2.4828 Multivariate normal 1
ln_lambda_pIB_cIB Log rate of clinical presentation at stage Ib –1.8726 Multivariate normal 1
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TABLE 58 Summary of parameters in the independent economic evaluation (continued )
Label Description Base-case value PSA
ln_lambda_pIIA_cIIA Log rate of clinical presentation at stage IIa –1.6507 Multivariate normal 1
ln_lambda_pIIB_cIIB Log rate of clinical presentation at stage IIb –2.1362 Multivariate normal 1
ln_lambda_pIIIA_cIIIA Log rate of clinical presentation at stage IIIa –1.4088 Multivariate normal 1
ln_lambda_pIIIB_cIIIB Log rate of clinical presentation at stage IIIb –0.8811 Multivariate normal 1
ln_lambda_pIV_cIV Log rate of clinical presentation at stage IV –1.4027 Multivariate normal 1
Survival from diagnosis
lambda_lcs_Ia Lambda constant for survival if diagnosed
and treated from stage Ia
0.214 N(0.214,0.011)
lambda_lcs_Ib Lambda constant for survival if diagnosed
and treated from stage Ib
0.274 N(0.274,0.014)
lambda_lcs_IIa Lambda constant for survival if diagnosed
and treated from stage IIa
0.330 N(0.33,0.016)
lambda_lcs_IIb Lambda constant for survival if diagnosed
and treated from stage IIb
0.475 N(0.475,0.024)
lambda_lcs_IIIa Lambda constant for survival if diagnosed
and treated from stage IIIa
0.588 N(0.588,0.029)
lambda_lcs_IIIb Lambda constant for survival if diagnosed
and treated from stage IIIb
0.909 N(0.909,0.045)
lambda_lcs_IV Lambda constant for survival if diagnosed
and treated from stage IV
1.423 N(1.423,0.071)
gamma_lcs_all_stages Gamma constant for survival if diagnosed
and treated at any stage
0.676 N(0.676,0.034)
lambda_ocm_F Lambda parameter (Gompertz distribution)
for other cause mortality in women
0.00019 N(0.000195,0.00001)
gamma_ocm_F Gamma parameter for above 0.1018 N(0.102,0.005)
lambda_ocm_M Lambda as above for men 0.00059 N(0.00059,0.00003)
gamma_ocm_M Gamma as above for men 0.0917 N(0.092,0.005)
Risk prediction
risk_age Risk prediction coefficient for age (years) 0.08985 N(0.090,0.00038)
risk_male Risk prediction coefficient for male sex 0.30562 N(0.306,0.005)
risk_smoker Risk prediction coefficient for current/former
smoker (vs. never smoker)
1.45929 N(1.459,0.005)
risk_lungcancer Risk prediction coefficient for lung cancer
(at baseline or within 3 years)
0.33488 N(0.335,0.152)
risk_intercept Risk prediction intercept –11.39758 N(–11.398,0.024)
risk_SD Risk prediction standard deviation (error
term)
0.62920 Gamma(25,0.025)
Screening effectiveness
sens_LDCT Sensitivity of LDCT test for lung cancer 0.709 Multivariate normal 1
spec_LDCT Specificity of LDCT test for lung cancer 0.624 Beta(740,445)
mu_ind_scrn_delay Mean time to index screening examination –2.823 Multivariate normal 2
sig_ind_scrn_delay Standard deviation of time to index
screening exam
0.820 Multivariate normal 2
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TABLE 58 Summary of parameters in the independent economic evaluation (continued )
Label Description Base-case value PSA
QoL
u_base_male Utility of male smoker in the UK general
population/occult lung cancer
0.7816 N(0.782,0.012)
u_base_female Utility of female smoker in the UK general
population/occult lung cancer
0.7531 N(0.753,0.11)
u_dis_sII Disutility of second stage cancer vs. first
stage
–0.04 N(–0.04,0.013)
u_dis_sIII Disutility of third stage cancer vs. first stage –0.04 N(–0.04,0.009)
u_dis_sIV Disutility of fourth stage cancer vs. first
stage
–0.05 N(–0.05,0.01)
u_dis_fp Disutility associated with a false-positive
screen
–0.063 N(–0.063,0.028)
u_dis_scr_anx Disutility associated with anxiety of a
screening event
–0.010 N(–0.01,0.007)
t_dis_fp Duration of disutility from false-positive
screen
3.00 Gamma(4,0.75)
t_dis_scrn_anx Duration of disutility from screening anxiety 2.00 Gamma(4,0.5)
Costs
c_invite Cost of initial invite and questionnaire £2.90 Gamma(25,0.116)
c_score Cost of scoring questionnaire and risk
stratefication
£18.54 Gamma(25,0.742)
c_letter Cost of follow-up letter and (if applicable)
LDCT appointment
£1.74 Gamma(25,0.07)
c_gp_ref Cost of GP consultations leading to lung
cancer referral
£72.00 Gamma(25,2.88)
c_LDCT Cost of low-dose CT scan £98.80 Gamma
(59.126,1.671)
c_scrn_nurse Cost of nurse-led screening consultation £6.25 Gamma(25,0.25)
c_false_pos Cost of resourcing following a false-positive
screen
£184.63 Gamma(25,7.385)
c_eol_lung Cost of end-of-life care for lung cancer
patient
£4589.04 Gamma(3.329,1378)
c_rdtf_sIa_ini Cost of initial diagnosis and treatment if dx
stage Ia
£5558.14 Gamma(25,222)
c_rdtf_sIb_ini Cost of initial diagnosis and treatment if dx
stage Ib
£6411.63 Gamma(25,256)
c_rdtf_sIIa_ini Cost of initial diagnosis and treatment if dx
stage IIa
£7279.07 Gamma(25,291)
c_rdtf_sIIb_ini Cost of initial diagnosis and treatment if dx
stage IIb
£6558.14 Gamma(25,262)
c_rdtf_sIIIa_ini Cost of initial diagnosis and treatment if dx
stage IIIa
£6511.63 Gamma(25,260)
c_rdtf_sIIIb_ini Cost of initial diagnosis and treatment if dx
stage IIIb
£6046.51 Gamma(25,242)
continued
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TABLE 58 Summary of parameters in the independent economic evaluation (continued )
Label Description Base-case value PSA
c_rdtf_sIV_ini Cost of initial diagnosis and treatment if dx
stage IV
£5441.86 Gamma(25,218)
c_rdtf_sIa_rem_ind_yr Cost of index year diagnosis, treatment and
follow-up if dx stage Ia
£5848.11 Gamma(25,234)
c_rdtf_sIb_rem_ind_yr Cost of index year diagnosis, treatment and
follow-up if dx stage Ib
£5359.21 Gamma(25,214)
c_rdtf_sIIa_rem_ind_yr Cost of index year diagnosis, treatment and
follow-up if dx stage IIa
£5637.60 Gamma(25,226)
c_rdtf_sIIb_rem_ind_yr Cost of index year diagnosis, treatment and
follow-up if dx stage IIb
£6514.78 Gamma(25,262)
c_rdtf_sIIIa_rem_ind_yr Cost of index year diagnosis, treatment and
follow-up if dx stage IIIa
£5415.46 Gamma(25,217)
c_rdtf_sIIIb_rem_ind_yr Cost of index year diagnosis, treatment and
follow-up if dx stage IIIb
£4318.07 Gamma(25,173)
c_rdtf_sIV_rem_ind_yr Cost of index year diagnosis, treatment and
follow-up if dx stage IV
£2787.31 Gamma(25,111)
c_rdtf_sIa_subyrs Cost of treatment and follow-up in
subsequent years if dx stage Ia
£1437.79 Gamma(25,58)
c_rdtf_sIb_subyrs Cost of treatment and follow-up in
subsequent years if dx stage Ib
£1483.75 Gamma(25,59)
c_rdtf_sIIa_subyrs Cost of treatment and follow-up in
subsequent years if dx stage IIa
£1628.19 Gamma(25,65)
c_rdtf_sIIb_subyrs Cost of treatment and follow-up in
subsequent years if dx stage IIb
£1647.88 Gamma(25,66)
c_rdtf_sIIIa_subyrs Cost of treatment and follow-up in
subsequent years if dx stage IIIa
£1503.45 Gamma(25,60)
c_rdtf_sIIIb_subyrs Cost of treatment and follow-up in
subsequent years if dx stage IIIb
£1306.49 Gamma(25,52)
c_rdtf_sIV_subyrs Cost of treatment and follow-up in
subsequent years if dx stage IV
£1037.31 Gamma(25,41)
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cost-effectiveness resultsTABLE 59 Listing of base-case cost-effectiveness results
Strategy Average costs per patient (£) Average QALYs per patient
No screening 1103 8.5021
S–55–80–3% 1135 8.5032
T–55–80–3% 1151 8.5034
A–55–80–3% 1188 8.5029
B–55–80–3% 1164 8.5031
S–55–80–4% 1128 8.5028
T–55–80–4% 1139 8.5031
A–55–80–4% 1160 8.5027
B–55–80–4% 1145 8.5027
S–55–80–5% 1124 8.5026
T–55–80–5% 1131 8.5028
A–55–80–5% 1144 8.5026
B–55–80–5% 1135 8.5026
S–60–80–3% 1132 8.5031
T–60–80–3% 1148 8.5033
A–60–80–3% 1182 8.5029
B–60–80–3% 1159 8.5030
S–60–80–4% 1125 8.5028
T–60–80–4% 1136 8.5031
A–60–80–4% 1156 8.5027
B–60–80–4% 1142 8.5027
S–60–80–5% 1121 8.5026
T–60–80–5% 1129 8.5028
A–60–80–5% 1141 8.5026
B–60–80–5% 1132 8.5025
S–55–75–3% 1129 8.5031
T–55–75–3% 1142 8.5032
A–55–75–3% 1178 8.5028
B–55–75–3% 1155 8.5030
S–55–75–4% 1123 8.5027
T–55–75–4% 1131 8.5029
A–55–75–4% 1151 8.5026
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TABLE 59 Listing of base-case cost-effectiveness results (continued )
Strategy Average costs per patient (£) Average QALYs per patient
B–55–75–4% 1138 8.5027
S–55–75–5% 1119 8.5025
T–55–75–5% 1125 8.5027
A–55–75–5% 1137 8.5025
B–55–75–5% 1129 8.5025
S–60–75–3% 1126 8.5030
T–60–75–3% 1139 8.5031
A–60–75–3% 1171 8.5028
B–60–75–3% 1150 8.5029
S–60–75–4% 1120 8.5027
T–60–75–4% 1128 8.5029
A–60–75–4% 1148 8.5026
B–60–75–4% 1135 8.5026
S–60–75–5% 1117 8.5025
T–60–75–5% 1122 8.5026
A–60–75–5% 1134 8.5025
B–60–75–5% 1126 8.5025
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public consultation workshop meetingsEngagement/facilitators
This category included themes relating to participants’ views on strategies most likely to improve lung
cancer screening invitation uptake as well as factors or approaches that would potentially have an impact
on willingness or capacity to engage with a lung cancer screening programme if offered.
Universal versus targeted approach
While acknowledging that it made sense to target screening to people most at risk of lung cancer
(e.g. smokers), there was concern from participants in all three meetings that such an approach would
exclude people who were also at (lower) risk of lung cancer (e.g. because of passive smoking or exposure
to asbestos). Although most smoking/ex-smoking participants in all three workshops said that they would
respond to a targeted invitation to lung cancer screening, some participants said that they would not
respond to an invitation to lung cancer screening if it was specifically targeted at smokers/ex-smokers
because of associated stigma. They said that they would be more likely to respond to a universal invitation
that did not specifically mention smoking and lung cancer, but which offered screening for general lung
diseases. A view was expressed that if lung cancer screening was the norm, more people would engage
with it. A view was expressed relating to the unreliability of people’s willingness to be honest about their
smoking status on health records, and implications for a screening programme targeted at smokers/ex
-smokers as opposed to a universal programme based, for example, on age. One participant from the
community drop-in session thought that people most at risk of lung cancer should be targeted for
screening because of the risk of false positives and the associated anxiety.
Other benefits of screening
It was recognised that during lung cancer screening it was possible that other lung diseases may be
identified. Views were expressed about the positives and negatives of this, with positives including the
potential to detect treatable lung diseases (e.g. pneumonia or fungal infections with a consequent
improvement in health), whereas negatives included the detection of more serious diseases with poor
prognosis such as pulmonary fibrosis.
Invitation to screening
Wording of the screening invitation was discussed in two meetings and it was suggested that an approach
similar to that taken in other national screening programmes should be taken. Participants in two meetings
highlighted the importance of informed choice when deciding whether or not to accept an invitation to
attend lung cancer screening. Participants thought it particularly important that the invitation addressed
possible consequences of attending screening (e.g. acknowledging the potential impact of a positive
screening result and providing details of potential treatments and treatment pathways that might then be
offered). It was thought important to acknowledge in the invitation that people may be worried about
attending lung cancer screening and that it would be beneficial to highlight any evidence of increased
likelihood of survival with early detection and treatment.
Planning
It was recognised that family, especially reliant family members such as older relatives and children, could
be influential on decisions whether or not to attend lung cancer screening, with participants from two
meetings saying that they would go for screening for the sake of their family but would not go if they just
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266Work
One participant described how potentially influential the workplace could be for increasing engagement
with lung cancer screening by illustrating how an older male relative went for a health check when
instructed to by his workplace, despite resisting going for health checks for years before.
Motivation to quit smoking
Some participants described how receiving an invitation for screening could act as a motivator to quit smoking
and thought that receiving a lung disease diagnosis could similarly motivate people to give up smoking.
Support
Participants at two meetings described how they thought that support from family and friends was
important, both in aiding decisions about whether or not to attend for lung cancer screening as well as
accompanying them to attend hospital appointments.Disengagement/barriers
This category included themes relating to participants’ views on strategies likely to reduce lung cancer
screening invitation uptake as well as factors or approaches that would potentially negatively affect
willingness or capacity to engage with a lung cancer screening programme if offered.
Poor access to screening/support
It was thought that a combination of worry and poor access to screening would contribute to poor
attendance for lung cancer screening. It was acknowledged that because screening probably would not
be offered at a local hospital, certain members of society would find it more difficult to access screening
because of their location, poor access to transport and caring responsibilities. It was thought that impact
from these factors would be accentuated if people had little support or low income or lived in more
deprived areas. It was also noted that people with caring responsibilities who had little support might
struggle to cope if they had a positive diagnosis and underwent chemotherapy. Participants in two meetings
suggested that access might be improved by providing mobile screening clinics in the community, similar
to those already provided for breast screening. One community drop-in participant (who also accessed the
food bank centre) thought that people on low incomes would be more likely to travel long distances to
attend screening if they were financially reimbursed.
Worry/denial/fear of knowing
Participants at all three workshops imagined that they would have feelings of anxiety, fear and worry
around obtaining results from a lung cancer screening test, and thought it likely that some people would
experience denial and avoid attending for lung cancer screening. One participant expressed the view that
fear of obtaining results may be more pronounced for people with a history of lung cancer in their family.
Participants expressed the view that denial may increase with age, with older people more likely to agree
that ‘ignorance is bliss’.
Fatalism
Participants thought that the general public perception of lung cancer was that it is incurable. Participants
described their own experience of knowing the risks of smoking, but feeling that ‘it was too late anyway’.
Invitation to screening
Some participants thought that using the screening invitation to promote lifestyle change or offering help
to give up smoking would act as a deterrent to smokers taking up the invitation to screening. Participants
at two meetings discussed fear of pain that they associated with mammogram screening and noted how
this affected their participation in the national breast cancer screening programme. One participant
described feeling worried about having a magnetic resonance imaging (MRI) scan because theyNIHR Journals Library www.journalslibrary.nihr.ac.uk
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screening and providing information about safety (radiation) and the likely physical sensations of the
screening process would be helpful to alleviate people’s worry and encourage participation in screening.
Work/lifestyle
Having to take time off work to attend screening was described as problematic both for people who were
self-employed and employees. Issues included hours (and money if self-employed) lost during the working
day, difficulties scheduling appointments outside working hours and experiencing docked pay if late for
work because of hospital delays.
Gender
Views were expressed in two workshops that men may be less likely to respond to an invitation to lung
cancer screening because they may feel unable to show or talk about experiences of fear relating to a
potential lung cancer diagnosis.
Age
Some participants thought that it would be harder for older people who have been smoking for a long
time to want or be able to quit smoking, making them less likely to engage with a lung cancer screening
programme. The view was shared by a community drop-in participant (aged 86 years) who said that he
would not engage with a lung cancer screening programme as he considered himself too old and would
‘die when I die’.
Public stigma
Participants from one meeting said that they would not feel judged for smoking if they received an
invitation targeted at smokers for lung cancer screening, but were concerned that non-smokers might
strongly feel that lung cancer screening should not be funded by the NHS, and the money allocated
elsewhere, because of the self-inflicted link between smoking and lung cancer. A light ex-smoker
attending the community centre drop-in session, who had family members employed by the NHS,
described feeling worried about the future of the NHS and questioned whether or not a screening
programme for a self-inflicted illness such as lung cancer should be funded by the NHS.
Blame from health professionals
Participants from two meetings described feeling blamed by a health-care professional for smoking.
One participant described visiting a health-care professional for a health condition unrelated to smoking,
only to be asked if they smoked and advised to give up. Another participant described feeling blamed by a
lung specialist who told them that ‘the damage was done’ despite having given up smoking 26 years
previously.
No motivation to quit smoking
Participants thought that a lack of readiness to give up smoking would result in smokers not accepting an
invitation to lung cancer screening.Financial costs/funding
This category included themes relating to participant’s views on costs and funding issues associated with
providing a national lung cancer screening programme.
To NHS
Views were expressed in all three workshops around cost. Views were expressed that if lung cancer
screening was offered, there would be more cases of treatable lung cancer detected and that this would
save the NHS money in the long term, with fewer hospital stays and less medication needed. Views were
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268the service and money would be saved through not offering early treatment (surgery). However, it was also
acknowledged that not offering screening would result in more cases of late treatment of lung cancer,
which might be more expensive than early treatment, with longer treatment times requiring more medical
interventions and medications, more time in hospital and more incapacity. The issue of the cost of follow-on
(palliative) care was also raised. A view was expressed by a community drop-in participant that money might
potentially be saved by the NHS if the introduction of screening was staggered (i.e. targeted lung cancer
screening was offered initially, and then, if successful, universal screening offered at a later date).
Insurance premiums
The fear of raised insurance premiums following participation in a national lung cancer screening
programme targeting people most at risk of lung cancer was discussed in two meetings. One participant
expressed concerns that people might feel that participating in a targeted lung cancer screening
programme would jeopardise their life insurance, making them less likely to engage with it.
Tax revenue
It was acknowledged in two meetings that the government benefited from tax revenue derived from the
sale of cigarettes, with some participants suggesting that explicit use of this revenue to fund a national
lung cancer screening programme targeted at smokers/ex-smokers might help overcome any associated
public stigma. One participant expressed the view that the association between smoking and lung cancer
has been established for 40 years but noted that the government had not banned the sale of cigarettes.
Another participant expressed the view that the government should take some responsibility for funding a
lung cancer national screening programme now because they had not deterred people from smoking in
the past and had benefited from cigarette tax revenue over many years.
Cost of travel to screening/additional tests
It was acknowledged by participants in two meetings that the cost of travel to hospital for screening and
additional tests would hinder access for less affluent people and people from rural areas who were
dependent on public transport.
Cost of travel to hospital for carers
Participants acknowledged the cost to carers of accompanying relatives to hospital for lung cancer
screening tests and for visiting hospital to support relatives during stays for treatment.
Cost of private screening
It was acknowledged in one workshop that if a national lung cancer screening programme was not
offered by the NHS, then the cost of private lung cancer screening would hinder access to lung cancer
screening for less-affluent people.
Missed appointments
In one meeting, participants shared their observations of the high prevalence of missed appointments in
primary care and their own struggles to make appointments to see their GP. It was acknowledged that
people may change their mind at the last minute to attend for screening, even after initially accepting the
invitation. One participant expressed the view that understanding the take-up rate and the reliability of
people turning up was important in deciding if a national lung cancer screening programme was
worth doing.Culture/environment
This category included themes relating to participants’ views on cultural influences and social perceptions
relating to smoking behaviour and the acceptability of a national lung cancer screening programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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There was acknowledgement in two meetings that it would be unfair to stigmatise smokers/ex-smokers
who began smoking in a past era when smoking was the cultural norm, when benefits of smoking were
promoted (e.g. smoking was ‘good for your nerves’) and health risks of smoking were not publicised.
Meeting participants compared this with the high prevalence of diabetes and cultural norms of obesity
occurring today despite public awareness of the associated health risks. A participant of the community
centre drop-in compared the past with the current situation and expressed the view that enough
information and public awareness now existed about the consequences of lifestyle choices, for example
diabetes and eating sugar, for people to take responsibility for their health. She described eating too much
sugar to deal with the stress of looking after young children even though she was informed about the
health consequences of this behaviour and acknowledged that people living in more deprived areas may
be exposed to more stress and that this would affect their behaviour in relation to smoking.
Government and media influence
Participants thought that raising public awareness before the introduction of a lung cancer screening
programme would aid screening uptake. Acknowledgement of the strong cultural influence of the media
in the glamorising of smoking in the past, and the resulting increase in uptake of smoking, was raised in
two meetings.
Inequity/deprivation
In two meetings, participants said that they did not think lack of money affected people’s smoking
behaviour, stating that smokers from more deprived areas prioritised purchasing cigarettes above other
things. It was acknowledged that smoking for some people may be prioritised in order to cope with poor
life circumstances. In both meetings, participants commented on lack of engagement/apathy of people
living in more deprived areas to access services in general, and said that they expected a similar lack of
engagement with a lung cancer screening programme.Treatment/care pathway
This category included themes relating to participants’ views on the potential impact of a lung cancer
screening programme relating to the screening process, lung cancer detection and potential treatment and
pathways of care.
Detection
Early
Participants thought that an early diagnosis of lung cancer would mean that potentially more treatment
options would be available and that the prognosis would be better.
Late
In one meeting, a view was elicited that treatment would be more intrusive if it was offered later.
Treatment/no treatment
The initial debilitating nature of treatment with chemotherapy was noted by participants in one meeting,
as was the perceived importance of being able to make informed choices about treatment options based
on prognosis and likelihood of survival. In one meeting, there were discussions around the use of protocols
to ensure that people would feel reassured that they would receive a prompt referral to treatment or
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270Repeat testing
In one meeting, the probable need for an increased frequency of repeat lung cancer screening compared
with other screening programmes was discussed. One participant in the community drop-in session raised
concerns about radiation exposure with repeat testing.Quality of life/mental well-being
This category included themes relating to participants’ views on the potential impact of a lung cancer
screening programme on QoL and mental well-being together with views on smoking behaviour in relation
to QoL and mental well-being.
One participant expressed the view that she would worry if she attended for lung cancer screening
and would worry if she did not. This view was shared by participants from two meetings who said that
psychological/mental well-being would be affected just by the introduction of the screening programme,
both positively and negatively, and that psychological well-being should be considered as an outcome in
this HTA.
Coping
Participants in two workshops thought that many people smoked in order to cope with stress and general
life pressures/poor life circumstances (e.g. caring for a partner who is an alcoholic). Participants from two
meetings said that they thought that people with mental health issues were likely to be dependent on
smoking as a way of coping with their illness.
Anxiety/worry
About the test
This was discussed in all three meetings. Participants thought that having information about the technology,
particularly safety, would be helpful to alleviate people’s worry and facilitate informed choice. One participant
described being unprepared for the physical sensations experienced when having a MRI scan and said that
having had information about what to expect in advance would have helped reduce worry.
Misdiagnosis
Participants in two meetings discussed the possibility of misdiagnosis, and expressed the view that all tests
were fallible and so some misdiagnosis was inevitable and that it was an unfortunate but acceptable
consequence of performing a test.
On receiving screening invitation
Many participants acknowledged that they would expect to experience feelings of fear on receiving an
invitation to attend lung cancer screening but that they would want to attend screening despite this.
Waiting for results and further tests
It was generally acknowledged that shorter waiting times between test/results was preferable, although
one participant described not caring how long he would have to wait for results as long as he had access
to lung cancer screening and the opportunity for early treatment of lung cancer that it might provide.
Quality of life and diagnosis
Participants from one meeting discussed how the benefits of early detection for self and family would include
having more time to come to terms with a lung cancer diagnosis. However, another view was expressed
that an early diagnosis of lung cancer, if not treatable, would result in a lowering of QoL. Other participants
described how important it would be to have access to information about likelihood of survival after a positive
diagnosis of lung cancer in order to ensure that QoL did not reduce further following a positive diagnosis.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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It was recognised that treatment with chemotherapy/radiotherapy was debilitating, but that it affected
individuals differently. It was also thought important to be informed of the likely chance of survival with
such treatment, in order to make an informed decision about whether or not to have it.
Support (or lack of support)
At home
One participant described the importance of ensuring support at home for people with caring
responsibilities undergoing treatment for lung cancer.
In care pathway
Participants from two meetings discussed the impact of receiving a positive diagnosis of lung cancer and
the need for support to minimise the impact on QoL. One participant thought that the impact of a positive
diagnosis on QoL would depend on how the news was communicated (face to face or by letter), the
communication skills of the health-care staff and their ability to clearly communicate about what would
happen next.
Empowerment
One participant described how she thought receiving an invitation to lung cancer screening would make
her think about giving up smoking and invoke feelings of taking control of her life.
Participants from two meetings expressed views on the benefits of having a lung cancer diagnosis
confirmed early. Participants thought an early diagnosis would provide time to adjust to the news and
reduce shock, both for patients and for their family/carers. Others described how knowing that they had
lung cancer would help them feel empowered to decide how to best spend their remaining time and
potentially change their lifestyle. Participants spoke of feeling how they would feel more in control of their
lives, how they could ‘put things in place’ (e.g. write wills and make funeral arrangements, spend time
wisely and create memories with their loved ones and feel more empowered to help their children to come
to terms with their diagnosis, e.g. make memory boxes). Participants described the benefits for family and
carers of knowing a relative had lung cancer as this knowledge could help them plan for their own lives
after their loved one had died. One participant described how such planning by carers/relatives could
benefit patients as they could be reassured that their family would be alright after they have died.
Disempowerment
In one meeting, there was discussion about expected levels of apathy from people from more deprived
areas regarding engaging with services such as a lung cancer screening programme. Participants felt that
this apathy may be linked to identity and self-esteem issues, and be affected by how people viewed
themselves/felt viewed by society. It was thought that such people may be experiencing higher levels of
stress and/or living in an unsupportive or uninspiring environment (e.g. social housing that is perceived by
others to be inhabited by ‘problem families’).Responsibility and risk
This category included themes relating to participants’ views on risks from lung cancer screening and
responsibility and risks associated with developing lung cancer.
Family history (of lung cancer)
Participants from two workshops described how their family history of lung cancer made them feel more
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272Smoking history
There was some deliberation between participants as to whether or not lung cancer screening should be
offered based on age or smoking history.
Passive smoking
Participants describe being aware of increased risk from passive smoking from public places and if brought
up in families in which either/both parents smoked.
Information (about risk)
In one meeting, a fatalistic view that once you have lung cancer ‘then that’s it’ was acknowledged as
being commonly held in society. It was thought that this societal view might be counteracted by providing
information in the screening invitation about how early detection of lung cancer can lead to successful
treatment. Another participant thought that it would be useful to provide information about the risk of
radiation during screening in case this would put some people off attending for lung cancer screening.
One community drop-in participant thought that information about test accuracy and the risk of
misdiagnosis was important.
Environmental risk
In two meetings, the topic of environmental risk, from asbestos and from vehicle fumes, was raised,
with participants acknowledging passive risks of lung cancer from such exposure.
Exposure to radiation (from technology)
Although participants from two workshops were aware of some potential increased risk from radiation
from the screening technology, none of these participants thought that the risk was unacceptably high or
said that their concerns about radiation would prevent them having a scan. One participant from the
community drop-in said that they would be anxious about participating in a lung cancer screening
programme if they had to have a succession of tests involving radiation.
Perception of risk
Participants from one meeting discussed how non-smokers who were perceived as being at a low risk of
lung cancer may still want to attend for lung cancer screening because of the risks from passive smoking,
especially if they were exposed to smoking from one or both parents as well as in public spaces while
they were growing up. Participants in one group discussed a feeling of a cultural shift when Roy Castle
got cancer, that society changed as people became more aware of the risks of passive smoking. One
participant expressed the view that it may send out mixed messages to the public about the risks of
passive smoking if lung cancer screening was not offered to all members of the public as it would appear
that the government/NHS thought that risks from passive smoking were sufficiently high for smoking to be
banned in public spaces, but not high enough for people exposed to passive smoking to be screened for
lung cancer.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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